data_2kmr_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2kmr _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 67.9 m . . . . . 0 CA--C 1.541 0.612 0 CA-C-O 121.064 0.459 . . . . 0.0 111.364 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -73.34 48.76 0.25 Allowed 'General case' 0 CA--C 1.554 1.13 0 C-N-CA 126.371 1.868 . . . . 0.0 113.54 177.627 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 85.4 m -61.99 156.79 55.65 Favored Pre-proline 0 CA--C 1.548 0.897 0 C-N-CA 125.718 1.607 . . . . 0.0 113.724 179.853 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_endo -68.62 151.82 74.88 Favored 'Trans proline' 0 C--N 1.351 0.7 0 C-N-CA 123.275 2.65 . . . . 0.0 112.137 177.17 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 10.4 ptpp? -74.28 -30.71 62.22 Favored 'General case' 0 N--CA 1.478 0.964 0 C-N-CA 125.058 1.343 . . . . 0.0 114.198 176.399 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 40.8 mm -58.05 126.95 16.47 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.741 0 C-N-CA 126.893 2.077 . . . . 0.0 111.457 -176.571 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 2.0 pt? -61.6 126.67 28.17 Favored 'General case' 0 CA--C 1.542 0.662 0 C-N-CA 125.128 1.371 . . . . 0.0 112.851 -179.777 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 74.9 mmtt -136.33 71.91 59.6 Favored Pre-proline 0 N--CA 1.479 1.004 0 C-N-CA 125.314 1.446 . . . . 0.0 111.604 173.25 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 75.1 Cg_endo -72.85 84.59 1.25 Allowed 'Trans proline' 0 CA--C 1.54 0.817 0 C-N-CA 123.84 3.027 . . . . 0.0 112.818 -178.058 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 15.1 m -76.99 162.13 4.35 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.589 0 C-N-CA 126.739 2.016 . . . . 0.0 113.296 178.824 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 10.6 t -80.19 -5.54 56.26 Favored 'General case' 0 CA--C 1.553 1.068 0 C-N-CA 125.492 1.517 . . . . 0.0 114.166 174.321 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 64.71 -164.67 34.45 Favored Glycine 0 CA--C 1.538 1.504 0 C-N-CA 125.072 1.32 . . . . 0.0 113.974 -178.371 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 25.1 t -111.27 -38.9 4.87 Favored 'General case' 0 N--CA 1.477 0.901 0 C-N-CA 124.775 1.23 . . . . 0.0 112.591 172.57 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 29.5 t70 -72.29 -13.42 61.5 Favored 'General case' 0 N--CA 1.478 0.955 0 N-CA-C 114.249 1.203 . . . . 0.0 114.249 177.718 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 98.15 39.27 3.81 Favored Glycine 0 CA--C 1.533 1.202 0 C-N-CA 125.92 1.724 . . . . 0.0 112.827 -178.745 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 16.2 mmm180 -135.33 150.88 50.07 Favored 'General case' 0 N--CA 1.475 0.776 0 C-N-CA 127.366 2.266 . . . . 0.0 110.822 -168.716 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 27.9 m -95.82 134.45 38.76 Favored 'General case' 0 N--CA 1.476 0.866 0 C-N-CA 124.209 1.004 . . . . 0.0 110.569 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 73.5 m-85 -128.67 160.92 30.94 Favored 'General case' 0 N--CA 1.471 0.613 0 C-N-CA 125.541 1.537 . . . . 0.0 111.215 178.666 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.9 -60.95 2.49 Favored 'General case' 0 CA--C 1.542 0.658 0 N-CA-C 111.784 0.29 . . . . 0.0 111.784 -172.247 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 30.1 m-20 -129.04 162.49 27.53 Favored 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 125.962 1.705 . . . . 0.0 110.322 170.896 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 26.7 p -63.24 -40.98 98.98 Favored 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 124.637 1.175 . . . . 0.0 113.684 177.299 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 49.5 t -57.89 -48.2 80.56 Favored 'General case' 0 N--CA 1.468 0.441 0 C-N-CA 125.303 1.441 . . . . 0.0 112.372 177.049 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 1.4 mp -52.31 -45.91 44.95 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.727 0 C-N-CA 124.815 1.246 . . . . 0.0 111.669 174.224 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -59.67 -46.63 88.46 Favored 'General case' 0 CA--C 1.545 0.753 0 CA-C-N 119.631 1.105 . . . . 0.0 112.14 177.281 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -57.69 -47.65 81.74 Favored 'General case' 0 N--CA 1.478 0.937 0 C-N-CA 124.877 1.271 . . . . 0.0 111.615 175.639 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 50.7 t -56.31 -48.21 77.13 Favored 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 125.38 1.472 . . . . 0.0 112.297 174.099 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -67.8 -30.06 69.39 Favored 'General case' 0 CA--C 1.548 0.882 0 C-N-CA 124.718 1.207 . . . . 0.0 112.792 -177.516 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 123.32 22.25 2.36 Favored Glycine 0 CA--C 1.537 1.409 0 C-N-CA 124.911 1.243 . . . . 0.0 115.954 175.401 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 5.0 t -124.27 143.59 37.09 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.568 0 C-N-CA 125.906 1.682 . . . . 0.0 109.315 -179.216 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 16.0 t -97.54 169.97 9.36 Favored 'General case' 0 N--CA 1.473 0.721 0 C-N-CA 125.362 1.465 . . . . 0.0 112.134 178.121 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 2.4 mt . . . . . 0 CA--C 1.552 1.054 0 C-N-CA 126.999 2.12 . . . . 0.0 110.494 -179.225 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 58.5 m . . . . . 0 CA--C 1.544 0.722 0 CA-C-O 120.651 0.262 . . . . 0.0 110.963 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -74.6 53.5 0.56 Allowed 'General case' 0 CA--C 1.553 1.059 0 C-N-CA 126.101 1.76 . . . . 0.0 113.629 -178.503 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 80.0 m -67.14 153.99 93.54 Favored Pre-proline 0 CA--C 1.551 0.982 0 C-N-CA 125.373 1.469 . . . . 0.0 113.306 -178.071 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -72.59 157.37 52.65 Favored 'Trans proline' 0 CA--C 1.541 0.847 0 C-N-CA 123.05 2.5 . . . . 0.0 112.514 179.459 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -88.72 -9.54 51.59 Favored 'General case' 0 N--CA 1.48 1.045 0 C-N-CA 124.927 1.291 . . . . 0.0 113.678 176.649 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 79.9 mt -62.02 139.82 20.2 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.756 0 C-N-CA 125.106 1.362 . . . . 0.0 109.692 174.176 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 10.4 mp -82.53 97.8 8.62 Favored 'General case' 0 CA--C 1.538 0.507 0 C-N-CA 124.744 1.218 . . . . 0.0 110.354 172.806 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 2.4 mmmp? -126.47 65.99 61.36 Favored Pre-proline 0 CA--C 1.546 0.815 0 C-N-CA 125.331 1.452 . . . . 0.0 110.632 170.147 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 66.5 Cg_endo -66.32 154.29 74.78 Favored 'Trans proline' 0 C--N 1.352 0.747 0 C-N-CA 122.813 2.342 . . . . 0.0 112.169 -179.263 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -142.18 160.2 20.1 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.757 0 C-N-CA 125.088 1.355 . . . . 0.0 110.476 -178.746 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 47.3 t -73.41 105.04 4.61 Favored 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 124.735 1.214 . . . . 0.0 110.283 169.97 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -65.99 148.02 50.65 Favored Glycine 0 CA--C 1.531 1.041 0 C-N-CA 124.1 0.857 . . . . 0.0 112.416 174.136 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 69.5 m -65.56 -17.58 64.68 Favored 'General case' 0 N--CA 1.475 0.819 0 N-CA-C 114.941 1.46 . . . . 0.0 114.941 -174.8 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 32.1 t70 -79.81 -8.12 59.08 Favored 'General case' 0 CA--C 1.552 1.032 0 C-N-CA 124.698 1.199 . . . . 0.0 113.569 169.148 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 97.34 27.38 9.29 Favored Glycine 0 CA--C 1.536 1.39 0 C-N-CA 126.548 2.023 . . . . 0.0 114.084 -179.593 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 64.3 mtt-85 -127.31 170.57 12.33 Favored 'General case' 0 N--CA 1.481 1.075 0 C-N-CA 125.241 1.416 . . . . 0.0 113.826 -166.385 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 33.1 m -103.45 125.36 49.99 Favored 'General case' 0 N--CA 1.475 0.78 0 C-N-CA 125.761 1.625 . . . . 0.0 110.674 -177.293 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 77.6 m-85 -131.57 157.43 43.62 Favored 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 125.097 1.359 . . . . 0.0 111.631 174.789 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.21 -48.82 74.39 Favored 'General case' 0 CA--C 1.542 0.645 0 N-CA-C 113.211 0.819 . . . . 0.0 113.211 -166.993 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 71.8 m-80 -144.32 174.23 11.09 Favored 'General case' 0 CA--C 1.549 0.936 0 C-N-CA 126.754 2.021 . . . . 0.0 111.08 174.865 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 69.5 m -65.58 -27.92 68.77 Favored 'General case' 0 N--CA 1.483 1.194 0 O-C-N 120.485 -1.385 . . . . 0.0 112.992 171.61 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 46.0 t -58.57 -58.36 8.9 Favored 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 125.414 1.486 . . . . 0.0 112.218 175.652 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 10.5 tp -60.7 -33.95 56.94 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 N-CA-C 112.219 0.452 . . . . 0.0 112.219 -179.619 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -59.24 -53.89 53.13 Favored 'General case' 0 CA--C 1.542 0.663 0 CA-C-N 118.684 0.675 . . . . 0.0 111.852 173.152 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 18.4 mmm180 -62.9 -33.56 75.56 Favored 'General case' 0 N--CA 1.48 1.031 0 C-N-CA 123.812 0.845 . . . . 0.0 113.217 176.088 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 19.3 t -62.83 -46.69 86.74 Favored 'General case' 0 CA--C 1.545 0.762 0 C-N-CA 124.513 1.125 . . . . 0.0 111.741 172.554 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 88.1 m-20 -69.34 -49.66 53.64 Favored 'General case' 0 CA--C 1.542 0.654 0 C-N-CA 125.552 1.541 . . . . 0.0 113.015 -179.691 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 142.63 24.5 0.19 Allowed Glycine 0 CA--C 1.538 1.518 0 N-CA-C 116.484 1.353 . . . . 0.0 116.484 -177.867 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 6.6 t -128.4 147.02 32.97 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.706 0 C-N-CA 126.211 1.804 . . . . 0.0 108.878 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 68.8 m -117.43 133.33 56.09 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 125.337 1.455 . . . . 0.0 112.231 -175.369 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 9.9 mm . . . . . 0 N--CA 1.48 1.04 0 C-N-CA 126.375 1.87 . . . . 0.0 111.582 -166.631 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 34.2 m . . . . . 0 CA--C 1.547 0.834 0 N-CA-C 112.981 0.734 . . . . 0.0 112.981 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . 46.46 34.33 2.31 Favored 'General case' 0 CA--C 1.549 0.931 0 C-N-CA 127.366 2.266 . . . . 0.0 114.612 -174.462 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 53.2 m -63.22 152.78 83.77 Favored Pre-proline 0 CA--C 1.548 0.891 0 C-N-CA 124.264 1.026 . . . . 0.0 113.285 -176.658 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -67.75 157.54 61.32 Favored 'Trans proline' 0 CA--C 1.54 0.78 0 C-N-CA 123.595 2.863 . . . . 0.0 112.942 179.873 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 32.1 mmmt -74.24 -8.91 57.85 Favored 'General case' 0 N--CA 1.481 1.085 0 C-N-CA 126.353 1.861 . . . . 0.0 114.116 -179.05 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -54.89 138.52 14.93 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.691 0 C-N-CA 127.43 2.292 . . . . 0.0 112.838 179.396 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 42.5 tp -114.0 101.05 8.88 Favored 'General case' 0 CA--C 1.539 0.52 0 C-N-CA 127.269 2.228 . . . . 0.0 109.127 -176.588 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 59.0 tttm -148.74 78.17 9.15 Favored Pre-proline 0 N--CA 1.473 0.7 0 C-N-CA 124.635 1.174 . . . . 0.0 110.662 175.646 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 67.0 Cg_endo -72.26 108.24 2.45 Favored 'Trans proline' 0 N--CA 1.458 -0.612 0 C-N-CA 123.035 2.49 . . . . 0.0 111.913 -177.871 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 14.9 m -107.09 172.65 1.82 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.463 0 C-N-CA 126.867 2.067 . . . . 0.0 111.793 -179.836 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 24.2 t -75.75 154.07 36.59 Favored 'General case' 0 CA--C 1.541 0.599 0 C-N-CA 123.981 0.912 . . . . 0.0 111.184 -179.851 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -121.48 152.82 16.76 Favored Glycine 0 CA--C 1.531 1.061 0 C-N-CA 125.012 1.292 . . . . 0.0 113.239 177.002 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 9.2 t -55.98 -36.05 67.43 Favored 'General case' 0 N--CA 1.476 0.841 0 C-N-CA 125.86 1.664 . . . . 0.0 114.064 -173.783 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 32.8 t70 -80.04 -9.31 59.69 Favored 'General case' 0 CA--C 1.551 1.0 0 C-N-CA 125.027 1.331 . . . . 0.0 114.368 179.119 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 89.88 53.4 2.4 Favored Glycine 0 CA--C 1.532 1.136 0 C-N-CA 125.311 1.434 . . . . 0.0 112.068 -175.203 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 4.0 mmp_? -137.81 174.89 10.1 Favored 'General case' 0 N--CA 1.477 0.91 0 C-N-CA 127.658 2.383 . . . . 0.0 110.916 -172.462 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 9.4 m -137.71 140.49 40.76 Favored 'General case' 0 N--CA 1.48 1.025 0 C-N-CA 125.301 1.44 . . . . 0.0 110.512 179.7 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 49.1 m-85 -139.25 161.33 37.68 Favored 'General case' 0 N--CA 1.473 0.699 0 C-N-CA 125.533 1.533 . . . . 0.0 111.32 -176.894 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.39 -45.42 87.77 Favored 'General case' 0 CA--C 1.545 0.772 0 N-CA-C 113.525 0.935 . . . . 0.0 113.525 -167.553 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 28.0 p30 -146.08 -178.42 6.12 Favored 'General case' 0 CA--C 1.548 0.886 0 C-N-CA 125.226 1.411 . . . . 0.0 111.864 166.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 29.0 p -66.28 -30.16 70.53 Favored 'General case' 0 N--CA 1.472 0.629 0 N-CA-C 114.226 1.195 . . . . 0.0 114.226 179.094 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 49.1 t -64.98 -56.58 12.32 Favored 'General case' 0 N--CA 1.47 0.526 0 C-N-CA 124.058 0.943 . . . . 0.0 111.524 177.401 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 11.2 tp -57.6 -38.88 66.59 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.618 0 CA-C-O 119.354 -0.355 . . . . 0.0 111.757 179.853 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -61.11 -45.09 96.12 Favored 'General case' 0 CA--C 1.543 0.683 0 C-N-CA 123.949 0.9 . . . . 0.0 112.797 175.809 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 5.1 tpt180 -64.8 -42.06 95.31 Favored 'General case' 0 N--CA 1.474 0.734 0 C-N-CA 123.448 0.699 . . . . 0.0 112.524 176.203 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 2.9 t -65.35 -36.08 82.94 Favored 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 123.117 0.567 . . . . 0.0 112.164 174.858 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 24.7 t-20 -66.68 -53.71 30.82 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 125.594 1.558 . . . . 0.0 112.486 176.674 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 151.49 19.4 0.06 OUTLIER Glycine 0 CA--C 1.538 1.526 0 N-CA-C 117.602 1.801 . . . . 0.0 117.602 179.284 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 3.7 t -127.78 138.69 53.99 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.814 0 CA-C-N 120.25 2.025 . . . . 0.0 110.309 -177.659 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 8.6 t -91.87 94.65 9.42 Favored 'General case' 0 N--CA 1.472 0.658 0 C-N-CA 125.245 1.418 . . . . 0.0 112.324 -173.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 19.6 mm . . . . . 0 N--CA 1.479 1.006 0 C-N-CA 124.368 1.067 . . . . 0.0 112.972 -176.861 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 3.7 m . . . . . 0 CA--C 1.544 0.737 0 N-CA-C 110.002 -0.37 . . . . 0.0 110.002 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -74.66 60.22 0.9 Allowed 'General case' 0 CA--C 1.553 1.085 0 C-N-CA 124.607 1.163 . . . . 0.0 112.827 179.351 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 84.3 m -64.12 156.11 76.15 Favored Pre-proline 0 CA--C 1.55 0.947 0 C-N-CA 125.78 1.632 . . . . 0.0 112.96 179.497 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 93.0 Cg_endo -71.35 168.42 23.5 Favored 'Trans proline' 0 CA--C 1.54 0.819 0 C-N-CA 123.056 2.504 . . . . 0.0 112.334 176.589 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 38.0 tttp -64.09 -20.33 65.88 Favored 'General case' 0 N--CA 1.479 0.977 0 C-N-CA 124.761 1.224 . . . . 0.0 113.188 174.721 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 61.7 mt -57.89 120.05 3.62 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.589 0 C-N-CA 126.715 2.006 . . . . 0.0 111.066 179.908 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 15.9 tp -99.44 117.41 33.79 Favored 'General case' 0 CA--C 1.538 0.508 0 C-N-CA 129.048 2.939 . . . . 0.0 108.363 174.533 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -132.18 78.27 69.14 Favored Pre-proline 0 N--CA 1.473 0.704 0 C-N-CA 125.786 1.634 . . . . 0.0 108.882 -178.695 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 66.2 Cg_endo -71.38 102.66 1.3 Allowed 'Trans proline' 0 CA--C 1.537 0.67 0 C-N-CA 123.831 3.021 . . . . 0.0 112.181 -168.527 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -100.2 158.13 3.91 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.003 0 C-N-CA 124.332 1.053 . . . . 0.0 112.245 -176.162 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 18.0 t -72.94 -18.2 61.41 Favored 'General case' 0 CA--C 1.547 0.843 0 N-CA-C 114.209 1.189 . . . . 0.0 114.209 -178.896 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 63.51 -178.63 6.68 Favored Glycine 0 CA--C 1.537 1.457 0 C-N-CA 126.416 1.96 . . . . 0.0 115.514 176.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 14.1 m -84.53 -38.46 20.0 Favored 'General case' 0 N--CA 1.476 0.857 0 C-N-CA 124.066 0.947 . . . . 0.0 113.083 173.484 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 20.4 m-20 -77.03 -14.97 59.76 Favored 'General case' 0 N--CA 1.479 0.98 0 N-CA-C 113.581 0.956 . . . . 0.0 113.581 179.695 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 98.07 -11.77 63.91 Favored Glycine 0 CA--C 1.536 1.353 0 C-N-CA 126.391 1.948 . . . . 0.0 114.392 179.842 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -78.41 156.53 29.4 Favored 'General case' 0 N--CA 1.474 0.761 0 C-N-CA 125.262 1.425 . . . . 0.0 112.084 171.239 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -84.26 113.14 20.9 Favored 'General case' 0 N--CA 1.472 0.638 0 C-N-CA 124.88 1.272 . . . . 0.0 112.857 178.069 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 79.0 m-85 -91.45 149.53 21.66 Favored 'General case' 0 N--CA 1.475 0.785 0 C-N-CA 124.792 1.237 . . . . 0.0 111.599 173.489 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.69 -46.75 77.84 Favored 'General case' 0 CA--C 1.542 0.665 0 N-CA-C 113.355 0.872 . . . . 0.0 113.355 -168.936 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 26.0 p30 -157.06 -179.35 8.12 Favored 'General case' 0 CA--C 1.545 0.773 0 C-N-CA 125.441 1.496 . . . . 0.0 111.88 174.348 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 36.7 p -61.69 -32.57 72.78 Favored 'General case' 0 N--CA 1.473 0.708 0 O-C-N 120.977 -1.077 . . . . 0.0 113.342 173.956 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 49.5 t -58.82 -60.51 3.73 Favored 'General case' 0 CA--C 1.533 0.299 0 C-N-CA 124.85 1.26 . . . . 0.0 111.765 176.75 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 9.8 tp -56.98 -40.45 72.64 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.881 0 N-CA-C 112.431 0.53 . . . . 0.0 112.431 178.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -57.32 -59.34 5.27 Favored 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 123.886 0.874 . . . . 0.0 111.461 176.498 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 46.3 mmm-85 -59.27 -41.85 89.84 Favored 'General case' 0 N--CA 1.475 0.799 0 C-N-CA 124.773 1.229 . . . . 0.0 113.028 178.775 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 2.9 t -66.6 -41.33 88.62 Favored 'General case' 0 CA--C 1.545 0.757 0 C-N-CA 123.609 0.763 . . . . 0.0 112.536 179.579 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 53.1 t30 -71.52 -42.0 68.51 Favored 'General case' 0 CA--C 1.543 0.7 0 C-N-CA 124.655 1.182 . . . . 0.0 113.181 178.833 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 129.71 30.1 0.66 Allowed Glycine 0 CA--C 1.538 1.475 0 C-N-CA 124.611 1.1 . . . . 0.0 115.206 -179.333 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -123.08 169.7 14.16 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 C-N-CA 127.37 2.268 . . . . 0.0 109.192 -177.866 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 29.8 t -145.77 161.52 39.74 Favored 'General case' 0 N--CA 1.471 0.614 0 C-N-CA 125.259 1.423 . . . . 0.0 112.42 -179.005 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 18.7 mm . . . . . 0 N--CA 1.476 0.86 0 C-N-CA 125.956 1.703 . . . . 0.0 111.69 178.019 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 29.2 m . . . . . 0 CA--C 1.54 0.585 0 CA-C-O 120.548 0.213 . . . . 0.0 110.532 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -71.64 55.78 0.26 Allowed 'General case' 0 CA--C 1.552 1.045 0 C-N-CA 126.516 1.926 . . . . 0.0 113.101 -179.961 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 93.0 m -63.59 157.59 64.79 Favored Pre-proline 0 CA--C 1.549 0.937 0 C-N-CA 126.083 1.753 . . . . 0.0 112.739 178.496 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -64.89 155.02 70.14 Favored 'Trans proline' 0 CA--C 1.537 0.671 0 C-N-CA 123.281 2.654 . . . . 0.0 112.803 -179.871 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 19.5 ptpt -59.75 -25.59 64.99 Favored 'General case' 0 N--CA 1.48 1.074 0 C-N-CA 125.707 1.603 . . . . 0.0 114.497 178.029 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 8.9 tp -57.11 144.47 9.34 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.473 0 C-N-CA 127.089 2.155 . . . . 0.0 113.212 -178.68 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 23.8 tp -119.66 108.24 14.21 Favored 'General case' 0 CA--C 1.535 0.402 0 C-N-CA 126.708 2.003 . . . . 0.0 108.292 -178.283 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 39.5 ttpt -128.95 79.03 75.34 Favored Pre-proline 0 CA--C 1.54 0.576 0 C-N-CA 126.38 1.872 . . . . 0.0 108.511 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -73.68 90.34 0.94 Allowed 'Trans proline' 0 CA--C 1.539 0.742 0 C-N-CA 123.72 2.947 . . . . 0.0 111.909 -171.442 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 1.1 t -83.56 161.26 3.38 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 C-N-CA 124.421 1.089 . . . . 0.0 111.03 -177.56 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 46.3 t -72.44 111.59 7.76 Favored 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 124.342 1.057 . . . . 0.0 109.839 170.448 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -65.51 146.01 49.25 Favored Glycine 0 CA--C 1.532 1.118 0 C-N-CA 123.778 0.704 . . . . 0.0 112.422 177.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 82.7 p -61.39 -29.86 70.19 Favored 'General case' 0 N--CA 1.476 0.865 0 N-CA-C 113.935 1.087 . . . . 0.0 113.935 -174.072 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 31.8 t70 -84.98 -8.19 58.84 Favored 'General case' 0 CA--C 1.551 0.993 0 C-N-CA 125.964 1.706 . . . . 0.0 113.894 176.92 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 107.51 1.04 34.96 Favored Glycine 0 CA--C 1.536 1.386 0 C-N-CA 126.504 2.002 . . . . 0.0 114.674 -178.623 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 22.1 mtm180 -90.32 -172.21 3.37 Favored 'General case' 0 N--CA 1.479 0.988 0 C-N-CA 126.355 1.862 . . . . 0.0 112.387 -177.269 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 23.0 m -128.8 135.26 48.91 Favored 'General case' 0 N--CA 1.479 1.01 0 C-N-CA 125.487 1.515 . . . . 0.0 110.492 -178.274 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 81.8 m-85 -135.94 150.39 49.27 Favored 'General case' 0 N--CA 1.474 0.74 0 C-N-CA 125.055 1.342 . . . . 0.0 111.488 -177.573 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.31 -45.08 89.52 Favored 'General case' 0 CA--C 1.543 0.683 0 N-CA-C 113.929 1.085 . . . . 0.0 113.929 -165.242 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 27.0 p30 -157.74 178.62 10.05 Favored 'General case' 0 CA--C 1.549 0.932 0 C-N-CA 125.927 1.691 . . . . 0.0 111.124 170.298 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 89.0 p -60.54 -29.69 69.29 Favored 'General case' 0 N--CA 1.478 0.973 0 N-CA-C 114.015 1.117 . . . . 0.0 114.015 179.052 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 45.4 t -61.66 -57.93 10.05 Favored 'General case' 0 N--CA 1.465 0.312 0 C-N-CA 124.24 1.016 . . . . 0.0 111.704 176.888 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 7.6 tp -59.75 -37.89 73.38 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.819 0 N-CA-C 112.062 0.393 . . . . 0.0 112.062 -179.878 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -57.3 -55.96 28.02 Favored 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 124.199 1.0 . . . . 0.0 111.583 173.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 70.4 mtp85 -61.23 -40.63 94.73 Favored 'General case' 0 N--CA 1.475 0.809 0 N-CA-C 113.297 0.851 . . . . 0.0 113.297 178.341 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -65.41 -36.35 83.68 Favored 'General case' 0 CA--C 1.546 0.819 0 N-CA-C 112.57 0.582 . . . . 0.0 112.57 177.132 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 25.9 t-20 -72.37 -47.53 48.68 Favored 'General case' 0 CA--C 1.546 0.815 0 C-N-CA 124.798 1.239 . . . . 0.0 113.003 175.926 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 135.8 29.5 0.36 Allowed Glycine 0 CA--C 1.538 1.53 0 C-N-CA 124.911 1.243 . . . . 0.0 115.469 -178.437 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 34.6 t -127.87 152.32 35.8 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.464 0 C-N-CA 127.416 2.286 . . . . 0.0 108.645 -176.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 58.2 m -141.72 160.06 40.95 Favored 'General case' 0 N--CA 1.476 0.838 0 C-N-CA 125.878 1.671 . . . . 0.0 112.302 -179.343 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 16.3 mt . . . . . 0 N--CA 1.481 1.108 0 C-N-CA 125.102 1.361 . . . . 0.0 111.828 -175.067 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 4.7 t . . . . . 0 CA--C 1.548 0.87 0 N-CA-C 114.111 1.152 . . . . 0.0 114.111 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . 49.34 30.73 3.39 Favored 'General case' 0 CA--C 1.549 0.921 0 C-N-CA 127.018 2.127 . . . . 0.0 115.603 178.421 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 58.0 m -61.8 151.29 79.76 Favored Pre-proline 0 CA--C 1.547 0.828 0 C-N-CA 124.368 1.067 . . . . 0.0 112.379 177.141 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -75.1 -4.13 14.93 Favored 'Trans proline' 0 CA--C 1.543 0.955 0 C-N-CA 124.135 3.223 . . . . 0.0 115.735 -168.769 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 37.8 mmtm 58.86 6.93 0.7 Allowed 'General case' 0 N--CA 1.481 1.093 0 C-N-CA 128.247 2.619 . . . . 0.0 116.299 179.839 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 11.2 tp -51.76 142.47 4.27 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.631 0 C-N-CA 126.698 1.999 . . . . 0.0 112.329 178.436 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 4.5 tt -78.46 89.99 4.45 Favored 'General case' 0 CA--C 1.545 0.772 0 C-N-CA 127.209 2.204 . . . . 0.0 110.907 -177.706 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 3.8 ttmp? -143.83 74.83 16.34 Favored Pre-proline 0 N--CA 1.477 0.897 0 C-N-CA 124.992 1.317 . . . . 0.0 111.843 178.33 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -67.8 91.1 0.36 Allowed 'Trans proline' 0 CA--C 1.54 0.809 0 C-N-CA 124.347 3.364 . . . . 0.0 112.754 -175.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 5.7 m -87.27 143.08 12.05 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 C-N-CA 126.32 1.848 . . . . 0.0 112.101 179.652 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 47.3 t -63.7 119.82 10.65 Favored 'General case' 0 CA--C 1.542 0.653 0 C-N-CA 124.125 0.97 . . . . 0.0 110.988 172.475 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -92.23 154.79 22.53 Favored Glycine 0 CA--C 1.533 1.17 0 C-N-CA 124.597 1.094 . . . . 0.0 112.861 177.911 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 7.5 t -61.74 -27.26 68.6 Favored 'General case' 0 N--CA 1.475 0.781 0 N-CA-C 114.463 1.283 . . . . 0.0 114.463 -173.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 10.5 t0 -76.52 -10.25 59.25 Favored 'General case' 0 CA--C 1.547 0.841 0 N-CA-C 113.69 0.996 . . . . 0.0 113.69 176.216 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 105.09 -10.11 47.3 Favored Glycine 0 CA--C 1.536 1.354 0 C-N-CA 126.586 2.041 . . . . 0.0 114.048 178.21 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 5.9 ptp85 -82.31 -171.13 3.27 Favored 'General case' 0 N--CA 1.473 0.706 0 C-N-CA 126.067 1.747 . . . . 0.0 112.723 173.365 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 11.5 t -123.34 157.62 32.86 Favored 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 125.595 1.558 . . . . 0.0 111.688 174.307 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -137.51 148.53 46.08 Favored 'General case' 0 N--CA 1.471 0.6 0 C-N-CA 126.263 1.825 . . . . 0.0 110.917 -179.9 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -60.28 -36.86 78.8 Favored 'General case' 0 CA--C 1.543 0.673 0 N-CA-C 114.049 1.129 . . . . 0.0 114.049 -164.277 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 12.4 p30 -156.89 177.54 11.39 Favored 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 126.443 1.897 . . . . 0.0 111.848 168.889 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 27.6 t -58.73 -38.95 79.49 Favored 'General case' 0 N--CA 1.472 0.637 0 O-C-N 121.345 -0.847 . . . . 0.0 113.099 176.486 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 20.0 t -60.14 -55.94 27.66 Favored 'General case' 0 N--CA 1.468 0.47 0 O-C-N 121.493 -0.755 . . . . 0.0 111.806 -179.886 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 7.4 tt -59.4 -38.71 76.42 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.698 0 CA-C-O 118.996 -0.526 . . . . 0.0 112.292 178.437 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -59.61 -53.6 56.12 Favored 'General case' 0 CA--C 1.543 0.684 0 CA-C-N 119.132 0.878 . . . . 0.0 111.904 174.814 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 5.7 mtp-105 -57.41 -44.07 84.27 Favored 'General case' 0 N--CA 1.477 0.884 0 C-N-CA 124.824 1.25 . . . . 0.0 112.3 178.034 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -71.51 -34.0 69.71 Favored 'General case' 0 CA--C 1.544 0.737 0 N-CA-C 113.448 0.907 . . . . 0.0 113.448 178.748 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 28.8 t-20 -66.85 -40.39 87.91 Favored 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 124.277 1.031 . . . . 0.0 112.541 174.056 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 135.29 22.59 0.63 Allowed Glycine 0 CA--C 1.538 1.471 0 C-N-CA 125.051 1.31 . . . . 0.0 115.896 176.366 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 40.4 t -128.26 149.54 33.2 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.525 0 C-N-CA 126.26 1.824 . . . . 0.0 109.866 -174.556 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 58.8 m -121.92 171.81 8.66 Favored 'General case' 0 N--CA 1.475 0.78 0 C-N-CA 126.857 2.063 . . . . 0.0 112.063 -176.702 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.468 0.447 0 C-N-CA 125.513 1.525 . . . . 0.0 108.92 -176.37 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 10.9 t . . . . . 0 CA--C 1.544 0.746 0 N-CA-C 111.83 0.307 . . . . 0.0 111.83 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -74.04 32.36 0.08 Allowed 'General case' 0 CA--C 1.554 1.128 0 C-N-CA 126.588 1.955 . . . . 0.0 115.668 -172.654 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 62.8 m -64.25 152.65 87.9 Favored Pre-proline 0 CA--C 1.549 0.926 0 C-N-CA 124.907 1.283 . . . . 0.0 113.67 179.275 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 89.1 Cg_endo -72.6 153.86 54.71 Favored 'Trans proline' 0 C--N 1.352 0.742 0 C-N-CA 123.359 2.706 . . . . 0.0 112.326 176.581 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 57.3 mtmt -76.38 -1.93 29.33 Favored 'General case' 0 N--CA 1.48 1.053 0 C-N-CA 125.708 1.603 . . . . 0.0 114.685 -179.361 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 46.9 mm -51.18 120.59 1.34 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.715 0 C-N-CA 126.145 1.778 . . . . 0.0 111.181 174.716 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 54.9 tp -84.71 102.27 12.85 Favored 'General case' 0 CA--C 1.539 0.546 0 C-N-CA 127.401 2.28 . . . . 0.0 109.614 177.935 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 20.8 tptp -147.07 91.94 5.04 Favored Pre-proline 0 N--CA 1.471 0.582 0 C-N-CA 124.098 0.959 . . . . 0.0 110.753 166.432 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -64.47 137.89 57.35 Favored 'Trans proline' 0 N--CA 1.456 -0.689 0 C-N-CA 121.191 1.261 . . . . 0.0 111.024 172.266 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 8.7 m -140.79 159.09 23.98 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.361 0 C-N-CA 127.373 2.269 . . . . 0.0 110.845 -179.346 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 37.6 t -72.78 149.52 43.58 Favored 'General case' 0 CA--C 1.545 0.763 0 C-N-CA 123.822 0.849 . . . . 0.0 111.785 171.973 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -123.76 156.21 17.93 Favored Glycine 0 CA--C 1.535 1.325 0 C-N-CA 125.859 1.695 . . . . 0.0 112.544 169.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 14.6 t -51.53 -40.64 60.05 Favored 'General case' 0 N--CA 1.478 0.966 0 C-N-CA 126.059 1.744 . . . . 0.0 115.431 -166.119 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 13.9 m-20 -71.1 -5.86 34.79 Favored 'General case' 0 CA--C 1.548 0.879 0 N-CA-C 114.863 1.431 . . . . 0.0 114.863 -179.193 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 86.83 61.32 1.61 Allowed Glycine 0 CA--C 1.527 0.805 0 C-N-CA 125.107 1.337 . . . . 0.0 110.592 -173.387 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 89.5 mmt-85 -142.18 168.29 20.09 Favored 'General case' 0 N--CA 1.472 0.671 0 C-N-CA 127.36 2.264 . . . . 0.0 111.103 -172.806 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 6.6 p -132.14 145.23 51.24 Favored 'General case' 0 C--O 1.235 0.322 0 C-N-CA 126.301 1.84 . . . . 0.0 111.089 172.455 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 92.8 m-85 -141.63 157.04 45.59 Favored 'General case' 0 N--CA 1.471 0.62 0 C-N-CA 125.604 1.561 . . . . 0.0 111.454 -179.461 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.69 -32.89 74.77 Favored 'General case' 0 CA--C 1.545 0.788 0 N-CA-C 114.451 1.278 . . . . 0.0 114.451 -165.222 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 60.5 t30 -149.37 168.13 24.24 Favored 'General case' 0 CA--C 1.544 0.747 0 C-N-CA 125.558 1.543 . . . . 0.0 111.17 171.26 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 34.6 p -57.19 -42.63 81.56 Favored 'General case' 0 N--CA 1.472 0.653 0 C-N-CA 124.769 1.228 . . . . 0.0 113.106 175.216 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 38.1 t -56.51 -55.76 29.68 Favored 'General case' 0 CA--C 1.533 0.292 0 C-N-CA 124.376 1.07 . . . . 0.0 112.11 177.507 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.8 tt -62.21 -35.25 68.08 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.672 0 CA-C-O 118.684 -0.674 . . . . 0.0 112.407 -177.679 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -57.82 -53.43 58.27 Favored 'General case' 0 CA--C 1.54 0.563 0 CA-C-N 119.288 0.949 . . . . 0.0 111.443 173.516 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -56.38 -49.78 73.47 Favored 'General case' 0 N--CA 1.474 0.768 0 C-N-CA 125.042 1.337 . . . . 0.0 111.282 176.124 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -63.7 -39.84 95.29 Favored 'General case' 0 CA--C 1.541 0.622 0 C-N-CA 123.786 0.834 . . . . 0.0 113.089 -177.68 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 88.8 m-20 -66.27 -33.44 75.74 Favored 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 124.86 1.264 . . . . 0.0 112.79 174.458 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 130.17 17.21 1.64 Allowed Glycine 0 CA--C 1.536 1.369 0 N-CA-C 116.389 1.316 . . . . 0.0 116.389 171.618 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 7.4 t -118.63 132.97 66.96 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.666 0 CA-C-N 119.629 1.714 . . . . 0.0 110.608 -178.229 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 38.5 m -78.54 164.69 24.48 Favored 'General case' 0 C--N 1.322 -0.597 0 C-N-CA 126.826 2.05 . . . . 0.0 112.714 -179.583 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.469 0.525 0 C-N-CA 125.873 1.669 . . . . 0.0 109.1 -178.959 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 3.2 m . . . . . 0 CA--C 1.548 0.884 0 N-CA-C 110.377 -0.231 . . . . 0.0 110.377 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -75.89 58.45 1.15 Allowed 'General case' 0 CA--C 1.554 1.1 0 C-N-CA 124.798 1.239 . . . . 0.0 113.24 -179.519 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 76.3 m -69.75 159.32 84.39 Favored Pre-proline 0 CA--C 1.553 1.082 0 C-N-CA 126.048 1.739 . . . . 0.0 113.746 -177.413 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -71.06 165.44 32.39 Favored 'Trans proline' 0 CA--C 1.542 0.877 0 C-N-CA 123.497 2.798 . . . . 0.0 113.407 179.141 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 7.9 ptpp? -68.35 -27.56 66.36 Favored 'General case' 0 N--CA 1.482 1.161 0 C-N-CA 125.072 1.349 . . . . 0.0 114.613 175.501 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 34.9 mm -60.08 161.88 1.24 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.83 0 C-N-CA 128.162 2.585 . . . . 0.0 111.294 176.295 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 20.1 tp -141.98 101.89 4.03 Favored 'General case' 0 CA--C 1.537 0.472 0 C-N-CA 126.257 1.823 . . . . 0.0 109.879 -170.646 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -115.52 84.92 12.77 Favored Pre-proline 0 N--CA 1.474 0.726 0 C-N-CA 126.096 1.759 . . . . 0.0 109.42 175.399 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 93.7 Cg_endo -74.52 81.14 2.14 Favored 'Trans proline' 0 CA--C 1.541 0.848 0 C-N-CA 124.043 3.162 . . . . 0.0 111.717 -176.616 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 9.0 m -85.84 164.24 2.48 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 C-N-CA 127.195 2.198 . . . . 0.0 113.003 -175.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 30.1 p -68.29 173.97 4.37 Favored 'General case' 0 CA--C 1.549 0.933 0 C-N-CA 124.231 1.012 . . . . 0.0 112.294 159.289 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -148.48 155.98 26.66 Favored Glycine 0 CA--C 1.532 1.132 0 C-N-CA 125.691 1.615 . . . . 0.0 111.392 173.712 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 19.0 t -57.09 -35.55 69.54 Favored 'General case' 0 N--CA 1.476 0.872 0 N-CA-C 115.144 1.535 . . . . 0.0 115.144 -163.138 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 31.5 t70 -71.86 -9.1 57.84 Favored 'General case' 0 CA--C 1.551 1.008 0 N-CA-C 114.415 1.265 . . . . 0.0 114.415 179.305 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 106.84 12.58 23.94 Favored Glycine 0 CA--C 1.535 1.286 0 C-N-CA 126.063 1.792 . . . . 0.0 114.073 179.35 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 31.2 mtm180 -120.99 134.46 55.3 Favored 'General case' 0 N--CA 1.476 0.844 0 C-N-CA 126.225 1.81 . . . . 0.0 111.181 -171.542 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 18.0 p -75.23 151.55 38.41 Favored 'General case' 0 N--CA 1.471 0.597 0 C-N-CA 124.622 1.169 . . . . 0.0 112.614 177.927 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 76.5 m-85 -139.69 149.03 43.19 Favored 'General case' 0 N--CA 1.471 0.592 0 C-N-CA 125.434 1.494 . . . . 0.0 112.93 -179.87 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -69.74 -33.72 72.84 Favored 'General case' 0 CA--C 1.545 0.76 0 N-CA-C 113.902 1.075 . . . . 0.0 113.902 -165.895 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 14.7 m-20 -145.87 170.85 15.76 Favored 'General case' 0 CA--C 1.543 0.703 0 C-N-CA 125.813 1.645 . . . . 0.0 110.946 166.116 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 40.7 p -59.46 -35.55 74.27 Favored 'General case' 0 N--CA 1.473 0.722 0 O-C-N 121.368 -0.832 . . . . 0.0 112.45 165.824 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 43.5 t -52.87 -63.33 1.18 Allowed 'General case' 0 CA--C 1.533 0.316 0 C-N-CA 126.01 1.724 . . . . 0.0 112.369 174.064 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 9.1 tp -58.38 -37.3 62.85 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.788 0 N-CA-C 112.592 0.59 . . . . 0.0 112.592 -178.583 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -59.94 -54.59 44.32 Favored 'General case' 0 CA--C 1.544 0.716 0 CA-C-N 118.697 0.68 . . . . 0.0 111.836 173.961 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 25.4 mmm180 -61.57 -39.98 93.09 Favored 'General case' 0 N--CA 1.478 0.975 0 C-N-CA 124.707 1.203 . . . . 0.0 113.207 177.933 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 9.2 t -62.15 -43.92 97.76 Favored 'General case' 0 CA--C 1.544 0.729 0 C-N-CA 124.832 1.253 . . . . 0.0 111.644 175.128 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 28.7 t-20 -68.79 -46.62 68.21 Favored 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 124.837 1.255 . . . . 0.0 113.179 178.263 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 136.11 26.42 0.45 Allowed Glycine 0 CA--C 1.539 1.534 0 C-N-CA 124.787 1.184 . . . . 0.0 115.964 -179.528 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 40.1 t -124.29 156.12 31.9 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.512 0 C-N-CA 127.11 2.164 . . . . 0.0 108.607 -179.658 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 6.2 t -134.21 177.8 7.47 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 126.25 1.82 . . . . 0.0 112.216 179.143 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 CA--C 1.533 0.299 0 C-N-CA 126.438 1.895 . . . . 0.0 108.869 -170.52 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 31.2 m . . . . . 0 CA--C 1.542 0.665 0 N-CA-C 110.968 -0.012 . . . . 0.0 110.968 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -73.27 31.78 0.07 Allowed 'General case' 0 CA--C 1.555 1.163 0 C-N-CA 125.629 1.572 . . . . 0.0 114.37 177.777 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 60.1 m -63.32 160.76 38.6 Favored Pre-proline 0 CA--C 1.549 0.924 0 C-N-CA 126.335 1.854 . . . . 0.0 113.237 177.439 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -67.61 169.77 15.18 Favored 'Trans proline' 0 CA--C 1.541 0.872 0 C-N-CA 123.254 2.636 . . . . 0.0 112.156 170.899 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 10.1 tppt? -107.89 1.98 23.1 Favored 'General case' 0 N--CA 1.482 1.145 0 C-N-CA 125.968 1.707 . . . . 0.0 112.946 172.186 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 83.2 mt -52.24 131.76 13.88 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.762 0 C-N-CA 126.632 1.973 . . . . 0.0 110.821 179.426 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 5.2 tt -69.74 97.85 1.13 Allowed 'General case' 0 CA--C 1.542 0.652 0 C-N-CA 127.399 2.28 . . . . 0.0 111.497 -174.823 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 86.8 tttt -140.6 74.45 27.86 Favored Pre-proline 0 N--CA 1.476 0.828 0 C-N-CA 125.719 1.608 . . . . 0.0 111.101 -177.882 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -66.14 101.33 0.49 Allowed 'Trans proline' 0 CA--C 1.54 0.818 0 C-N-CA 123.956 3.104 . . . . 0.0 112.343 -178.605 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 15.9 m -127.21 159.52 37.33 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.479 0 C-N-CA 126.001 1.72 . . . . 0.0 112.859 -176.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 24.4 p -88.4 123.29 32.81 Favored 'General case' 0 CA--C 1.539 0.529 0 C-N-CA 124.358 1.063 . . . . 0.0 111.889 176.572 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -79.17 55.68 4.34 Favored Glycine 0 CA--C 1.53 0.977 0 C-N-CA 124.665 1.126 . . . . 0.0 112.117 172.673 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 3.9 t 54.81 -11.68 0.01 OUTLIER 'General case' 0 CA--C 1.55 0.979 0 C-N-CA 129.385 3.074 . . . . 0.0 117.268 -175.009 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 63.5 m-20 -95.11 -17.8 21.52 Favored 'General case' 0 N--CA 1.475 0.775 0 C-N-CA 126.041 1.736 . . . . 0.0 114.545 -179.148 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 105.66 2.99 40.36 Favored Glycine 0 CA--C 1.538 1.505 0 C-N-CA 125.498 1.523 . . . . 0.0 114.84 177.713 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 2.1 mmp_? -67.37 -177.98 0.79 Allowed 'General case' 0 N--CA 1.476 0.841 0 C-N-CA 128.541 2.736 . . . . 0.0 112.195 172.501 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 24.1 m -128.58 85.72 2.37 Favored 'General case' 0 N--CA 1.476 0.841 0 C-N-CA 124.92 1.288 . . . . 0.0 110.157 176.318 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 26.8 m-85 -76.12 154.17 35.71 Favored 'General case' 0 N--CA 1.47 0.541 0 C-N-CA 123.94 0.896 . . . . 0.0 112.252 173.389 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.15 -37.63 88.15 Favored 'General case' 0 CA--C 1.542 0.643 0 N-CA-C 113.288 0.847 . . . . 0.0 113.288 -170.447 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 14.3 p30 -152.56 179.42 8.61 Favored 'General case' 0 CA--C 1.545 0.765 0 C-N-CA 126.172 1.789 . . . . 0.0 111.968 172.283 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 9.1 p -70.67 -32.03 69.15 Favored 'General case' 0 N--CA 1.473 0.7 0 O-C-N 121.018 -1.051 . . . . 0.0 113.788 176.369 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 34.8 t -62.42 -49.99 73.27 Favored 'General case' 0 N--CA 1.469 0.484 0 C-N-CA 124.31 1.044 . . . . 0.0 112.269 178.627 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 8.5 tt -58.82 -39.77 78.1 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 N-CA-C 112.194 0.442 . . . . 0.0 112.194 179.338 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -64.88 -44.62 89.05 Favored 'General case' 0 CA--C 1.543 0.712 0 C-N-CA 124.285 1.034 . . . . 0.0 112.599 175.051 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 25.1 mmt180 -55.67 -52.5 63.64 Favored 'General case' 0 N--CA 1.478 0.941 0 C-N-CA 124.378 1.071 . . . . 0.0 111.734 170.814 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 4.9 t -63.08 -37.36 86.89 Favored 'General case' 0 CA--C 1.544 0.714 0 C-N-CA 124.13 0.972 . . . . 0.0 113.023 -178.59 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 28.4 t30 -62.66 -30.55 71.46 Favored 'General case' 0 CA--C 1.545 0.762 0 C-N-CA 124.43 1.092 . . . . 0.0 113.351 176.888 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 135.21 9.97 1.57 Allowed Glycine 0 CA--C 1.536 1.373 0 N-CA-C 116.13 1.212 . . . . 0.0 116.13 175.471 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.46 HG12 ' H ' ' A' ' 33' ' ' SER . 0.5 OUTLIER -107.51 -170.16 0.34 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.653 0 CA-C-N 119.351 1.576 . . . . 0.0 110.689 -177.242 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' SER . . . . . 0.46 ' H ' HG12 ' A' ' 32' ' ' VAL . 27.7 m -147.91 166.96 26.07 Favored 'General case' 0 N--CA 1.471 0.599 0 C-N-CA 128.258 2.623 . . . . 0.0 110.529 174.863 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 1.1 mt . . . . . 0 N--CA 1.471 0.622 0 C-N-CA 125.069 1.347 . . . . 0.0 108.765 172.43 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 80.9 m . . . . . 0 CA--C 1.544 0.749 0 N-CA-C 111.809 0.3 . . . . 0.0 111.809 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -73.49 37.52 0.09 Allowed 'General case' 0 CA--C 1.556 1.175 0 C-N-CA 126.462 1.905 . . . . 0.0 114.841 -177.161 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 98.8 m -63.92 156.67 72.49 Favored Pre-proline 0 CA--C 1.55 0.956 0 C-N-CA 125.726 1.61 . . . . 0.0 113.742 -179.555 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -71.78 159.42 50.75 Favored 'Trans proline' 0 CA--C 1.54 0.811 0 C-N-CA 123.411 2.741 . . . . 0.0 113.2 -178.677 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 34.5 ttmt -86.37 -11.11 52.95 Favored 'General case' 0 N--CA 1.48 1.066 0 C-N-CA 125.786 1.634 . . . . 0.0 113.751 177.501 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 80.3 mt -55.85 146.3 5.27 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.883 0 C-N-CA 126.662 1.985 . . . . 0.0 110.444 178.862 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 11.1 mp -89.68 113.27 24.74 Favored 'General case' 0 CA--C 1.539 0.548 0 C-N-CA 124.229 1.012 . . . . 0.0 110.809 175.161 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 33.2 ttmt -135.02 75.3 61.12 Favored Pre-proline 0 CA--C 1.545 0.77 0 C-N-CA 124.874 1.27 . . . . 0.0 110.277 167.734 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 62.5 Cg_endo -68.88 86.15 0.47 Allowed 'Trans proline' 0 CA--C 1.541 0.85 0 C-N-CA 123.978 3.119 . . . . 0.0 112.535 -177.68 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 10.5 m -85.63 154.94 3.46 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.534 0 C-N-CA 126.527 1.931 . . . . 0.0 112.785 -178.391 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 46.0 t -78.2 108.49 11.55 Favored 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 124.861 1.264 . . . . 0.0 110.74 168.429 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -76.57 153.53 42.66 Favored Glycine 0 CA--C 1.531 1.079 0 C-N-CA 124.603 1.097 . . . . 0.0 113.357 174.697 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 13.5 t -58.72 -33.96 70.79 Favored 'General case' 0 N--CA 1.476 0.833 0 C-N-CA 124.595 1.158 . . . . 0.0 114.123 -172.096 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 10.4 m-20 -73.73 -3.56 29.16 Favored 'General case' 0 CA--C 1.549 0.923 0 N-CA-C 114.667 1.358 . . . . 0.0 114.667 176.359 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 95.79 18.01 33.71 Favored Glycine 0 CA--C 1.533 1.21 0 C-N-CA 125.318 1.437 . . . . 0.0 114.11 178.205 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 29.5 mtp85 -121.52 154.49 36.58 Favored 'General case' 0 N--CA 1.476 0.857 0 C-N-CA 126.164 1.786 . . . . 0.0 111.308 -173.79 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 13.5 p -87.91 146.48 25.54 Favored 'General case' 0 N--CA 1.469 0.513 0 C-N-CA 124.173 0.989 . . . . 0.0 112.185 177.162 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 97.9 m-85 -138.74 147.7 43.0 Favored 'General case' 0 N--CA 1.472 0.668 0 C-N-CA 125.327 1.451 . . . . 0.0 111.381 177.562 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.54 -32.76 74.55 Favored 'General case' 0 CA--C 1.544 0.734 0 N-CA-C 114.118 1.155 . . . . 0.0 114.118 -165.954 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 67.2 m-80 -146.2 172.84 12.85 Favored 'General case' 0 CA--C 1.543 0.688 0 C-N-CA 127.399 2.28 . . . . 0.0 110.467 168.184 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 27.7 p -63.87 -33.27 75.31 Favored 'General case' 0 N--CA 1.472 0.629 0 O-C-N 121.136 -0.977 . . . . 0.0 112.968 165.098 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 33.6 t -57.46 -55.23 37.51 Favored 'General case' 0 N--CA 1.467 0.411 0 C-N-CA 124.404 1.082 . . . . 0.0 112.623 176.029 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 6.5 tp -62.84 -31.68 53.2 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.742 0 N-CA-C 112.325 0.491 . . . . 0.0 112.325 -179.112 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -59.39 -48.8 80.27 Favored 'General case' 0 CA--C 1.542 0.658 0 O-C-N 121.482 -0.761 . . . . 0.0 111.35 170.907 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 24.0 mtp-105 -62.3 -33.61 75.0 Favored 'General case' 0 N--CA 1.479 0.992 0 C-N-CA 123.619 0.768 . . . . 0.0 113.031 175.492 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 46.9 t -62.88 -48.47 78.83 Favored 'General case' 0 CA--C 1.542 0.635 0 C-N-CA 124.302 1.041 . . . . 0.0 111.52 171.373 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 19.5 m120 -66.79 -31.6 72.35 Favored 'General case' 0 CA--C 1.546 0.822 0 C-N-CA 124.583 1.153 . . . . 0.0 113.526 178.515 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 116.86 28.81 2.36 Favored Glycine 0 CA--C 1.539 1.537 0 C-N-CA 125.602 1.572 . . . . 0.0 115.01 178.782 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 18.1 t -129.32 153.99 39.48 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.5 0 C-N-CA 127.528 2.331 . . . . 0.0 108.809 -176.335 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 68.6 m -119.73 156.07 31.25 Favored 'General case' 0 N--CA 1.474 0.761 0 C-N-CA 125.858 1.663 . . . . 0.0 112.445 179.285 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 22.0 mm . . . . . 0 N--CA 1.481 1.114 0 C-N-CA 126.111 1.765 . . . . 0.0 112.373 -171.864 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 32.9 m . . . . . 0 CA--C 1.542 0.647 0 CA-C-O 121.041 0.448 . . . . 0.0 110.81 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -75.06 54.34 0.67 Allowed 'General case' 0 CA--C 1.554 1.119 0 C-N-CA 125.525 1.53 . . . . 0.0 113.021 178.938 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 64.7 m -65.22 152.19 92.23 Favored Pre-proline 0 CA--C 1.552 1.023 0 C-N-CA 125.437 1.495 . . . . 0.0 112.893 -177.901 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -72.03 151.99 56.56 Favored 'Trans proline' 0 CA--C 1.539 0.763 0 C-N-CA 122.957 2.438 . . . . 0.0 112.57 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 32.3 mmtp -72.49 -21.67 61.17 Favored 'General case' 0 N--CA 1.479 1.014 0 C-N-CA 125.232 1.413 . . . . 0.0 113.605 174.664 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 4.9 mp -67.8 127.26 29.17 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.548 0 C-N-CA 125.508 1.523 . . . . 0.0 110.198 178.879 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 2.0 pt? -68.55 131.41 45.19 Favored 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 124.912 1.285 . . . . 0.0 111.6 173.72 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 37.0 ttmt -152.08 64.86 5.91 Favored Pre-proline 0 N--CA 1.474 0.745 0 C-N-CA 124.323 1.049 . . . . 0.0 111.114 175.181 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -66.85 153.04 79.29 Favored 'Trans proline' 0 CA--C 1.536 0.619 0 C-N-CA 122.552 2.168 . . . . 0.0 112.199 -176.049 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 18.4 t -134.84 -68.91 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.059 0 C-N-CA 123.695 0.798 . . . . 0.0 112.071 -173.818 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 31.1 p -143.18 -173.9 4.05 Favored 'General case' 0 CA--C 1.544 0.72 0 C-N-CA 126.355 1.862 . . . . 0.0 112.156 -173.812 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -163.75 87.57 0.1 Allowed Glycine 0 CA--C 1.528 0.882 0 C-N-CA 124.098 0.856 . . . . 0.0 114.126 -175.543 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 11.4 t -55.7 -38.17 69.35 Favored 'General case' 0 N--CA 1.478 0.969 0 C-N-CA 124.132 0.973 . . . . 0.0 113.261 176.781 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 54.6 m-20 -78.39 -5.69 53.04 Favored 'General case' 0 N--CA 1.478 0.942 0 C-N-CA 125.141 1.376 . . . . 0.0 113.953 174.541 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 93.86 9.93 59.29 Favored Glycine 0 CA--C 1.537 1.467 0 C-N-CA 125.532 1.539 . . . . 0.0 114.321 -174.018 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 13.5 ptp180 -122.19 135.86 54.83 Favored 'General case' 0 N--CA 1.477 0.898 0 C-N-CA 126.738 2.015 . . . . 0.0 112.21 -177.03 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.1 p -66.64 110.84 3.36 Favored 'General case' 0 N--CA 1.474 0.728 0 C-N-CA 125.347 1.459 . . . . 0.0 111.783 175.657 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 44.6 m-85 -76.86 154.37 33.87 Favored 'General case' 0 N--CA 1.472 0.636 0 O-C-N 121.628 -0.67 . . . . 0.0 111.829 174.794 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.96 -43.83 82.1 Favored 'General case' 0 CA--C 1.542 0.662 0 N-CA-C 113.238 0.829 . . . . 0.0 113.238 -169.416 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 21.2 p30 -160.98 178.68 9.13 Favored 'General case' 0 CA--C 1.548 0.866 0 C-N-CA 126.755 2.022 . . . . 0.0 111.569 173.487 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 16.2 m -63.36 -27.62 69.44 Favored 'General case' 0 N--CA 1.475 0.815 0 O-C-N 120.625 -1.297 . . . . 0.0 113.913 179.833 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 38.6 t -63.1 -56.41 17.07 Favored 'General case' 0 CA--C 1.532 0.257 0 C-N-CA 124.708 1.203 . . . . 0.0 111.555 177.166 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 8.3 tp -59.17 -35.24 56.54 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.87 0 N-CA-C 112.54 0.571 . . . . 0.0 112.54 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -59.3 -57.83 11.31 Favored 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 123.937 0.895 . . . . 0.0 111.993 175.332 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 73.6 mtp180 -60.56 -38.92 86.13 Favored 'General case' 0 N--CA 1.479 1.001 0 N-CA-C 113.058 0.762 . . . . 0.0 113.058 176.561 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 47.7 t -59.83 -50.38 74.04 Favored 'General case' 0 CA--C 1.542 0.646 0 C-N-CA 124.422 1.089 . . . . 0.0 112.179 176.048 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 63.3 t30 -69.95 -40.26 75.56 Favored 'General case' 0 CA--C 1.545 0.767 0 C-N-CA 125.01 1.324 . . . . 0.0 112.925 -176.911 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 129.26 30.2 0.68 Allowed Glycine 0 CA--C 1.536 1.375 0 C-N-CA 124.676 1.131 . . . . 0.0 115.161 178.369 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -120.14 178.49 2.49 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.545 0 C-N-CA 126.943 2.097 . . . . 0.0 110.037 -176.411 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 83.8 p -138.04 159.69 41.34 Favored 'General case' 0 N--CA 1.476 0.854 0 C-N-CA 124.843 1.257 . . . . 0.0 113.466 -178.135 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 16.0 mm . . . . . 0 N--CA 1.478 0.965 0 C-N-CA 124.545 1.138 . . . . 0.0 112.509 -175.003 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 8.5 t . . . . . 0 CA--C 1.543 0.676 0 N-CA-C 112.805 0.668 . . . . 0.0 112.805 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -75.24 32.4 0.1 Allowed 'General case' 0 CA--C 1.553 1.077 0 C-N-CA 126.873 2.069 . . . . 0.0 115.214 -174.132 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 58.4 m -62.96 157.48 60.75 Favored Pre-proline 0 CA--C 1.549 0.912 0 C-N-CA 124.851 1.26 . . . . 0.0 113.15 176.062 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 97.1 Cg_endo -70.58 172.13 14.03 Favored 'Trans proline' 0 CA--C 1.54 0.799 0 C-N-CA 123.419 2.746 . . . . 0.0 112.176 173.141 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 29.9 mtpp -121.05 3.09 10.47 Favored 'General case' 0 N--CA 1.481 1.112 0 C-N-CA 126.2 1.8 . . . . 0.0 114.011 179.765 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -53.0 138.63 12.0 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.785 0 C-N-CA 126.366 1.867 . . . . 0.0 112.347 179.649 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 3.2 tt -70.69 77.61 0.6 Allowed 'General case' 0 CA--C 1.547 0.849 0 C-N-CA 126.72 2.008 . . . . 0.0 111.382 -178.773 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 25.7 tptp -140.15 68.86 34.42 Favored Pre-proline 0 N--CA 1.473 0.722 0 C-N-CA 125.875 1.67 . . . . 0.0 110.893 179.6 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -64.86 148.55 89.98 Favored 'Trans proline' 0 CA--C 1.534 0.524 0 C-N-CA 122.326 2.017 . . . . 0.0 111.868 -178.676 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 1.7 t -137.75 161.0 33.8 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.804 0 C-N-CA 125.542 1.537 . . . . 0.0 109.99 -177.501 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 21.6 p -73.35 130.64 40.61 Favored 'General case' 0 CA--C 1.543 0.683 0 C-N-CA 124.582 1.153 . . . . 0.0 111.669 176.1 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -110.59 159.96 13.57 Favored Glycine 0 CA--C 1.535 1.325 0 C-N-CA 125.135 1.35 . . . . 0.0 112.026 170.729 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 56.6 p -63.53 -30.68 71.76 Favored 'General case' 0 N--CA 1.475 0.781 0 N-CA-C 114.28 1.215 . . . . 0.0 114.28 -172.822 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 17.0 t70 -77.17 -20.37 55.55 Favored 'General case' 0 N--CA 1.477 0.906 0 C-N-CA 124.437 1.095 . . . . 0.0 113.69 177.078 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 106.34 1.27 38.05 Favored Glycine 0 CA--C 1.537 1.411 0 C-N-CA 126.876 2.179 . . . . 0.0 114.789 176.325 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 56.2 mtt180 -85.78 156.21 20.69 Favored 'General case' 0 N--CA 1.476 0.866 0 C-N-CA 125.221 1.408 . . . . 0.0 112.974 -173.688 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 9.6 p -81.58 126.67 32.0 Favored 'General case' 0 N--CA 1.467 0.418 0 C-N-CA 125.959 1.703 . . . . 0.0 111.319 169.799 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 86.1 m-85 -126.13 159.28 33.3 Favored 'General case' 0 N--CA 1.47 0.566 0 C-N-CA 125.71 1.604 . . . . 0.0 110.789 171.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -62.57 -42.39 99.52 Favored 'General case' 0 CA--C 1.543 0.701 0 N-CA-C 113.078 0.77 . . . . 0.0 113.078 -168.381 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 14.2 p30 -155.47 178.36 10.32 Favored 'General case' 0 CA--C 1.545 0.78 0 C-N-CA 126.179 1.792 . . . . 0.0 112.258 173.56 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 33.1 t -62.48 -38.25 89.11 Favored 'General case' 0 N--CA 1.473 0.696 0 O-C-N 121.148 -0.97 . . . . 0.0 113.088 178.904 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 24.6 t -59.18 -57.64 12.15 Favored 'General case' 0 N--CA 1.467 0.377 0 C-N-CA 123.974 0.91 . . . . 0.0 111.25 179.749 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 8.4 tt -57.68 -39.45 70.26 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.618 0 N-CA-C 111.783 0.29 . . . . 0.0 111.783 -179.074 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -65.65 -45.73 81.87 Favored 'General case' 0 CA--C 1.542 0.663 0 C-N-CA 123.561 0.745 . . . . 0.0 112.42 179.411 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 16.7 ttp180 -62.87 -44.93 94.8 Favored 'General case' 0 N--CA 1.474 0.728 0 O-C-N 121.372 -0.83 . . . . 0.0 112.198 174.318 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -65.59 -32.54 74.18 Favored 'General case' 0 CA--C 1.545 0.756 0 N-CA-C 113.173 0.805 . . . . 0.0 113.173 177.67 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 51.9 t30 -65.7 -44.06 87.28 Favored 'General case' 0 CA--C 1.544 0.719 0 C-N-CA 124.698 1.199 . . . . 0.0 112.591 173.574 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 159.35 1.29 0.07 OUTLIER Glycine 0 CA--C 1.537 1.409 0 N-CA-C 117.519 1.767 . . . . 0.0 117.519 175.098 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -90.65 178.18 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.453 0 CA-C-N 119.823 1.812 . . . . 0.0 112.036 -176.288 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 66.1 m -133.03 108.36 8.82 Favored 'General case' 0 N--CA 1.477 0.881 0 C-N-CA 125.918 1.687 . . . . 0.0 111.986 177.995 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 16.4 mt . . . . . 0 N--CA 1.485 1.3 0 C-N-CA 125.065 1.346 . . . . 0.0 112.377 178.899 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 64.3 m . . . . . 0 CA--C 1.542 0.637 0 N-CA-C 111.517 0.191 . . . . 0.0 111.517 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -73.8 42.88 0.14 Allowed 'General case' 0 CA--C 1.554 1.115 0 C-N-CA 125.928 1.691 . . . . 0.0 113.96 179.093 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 56.4 m -60.52 153.56 60.26 Favored Pre-proline 0 CA--C 1.55 0.955 0 C-N-CA 125.254 1.422 . . . . 0.0 113.125 177.908 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 88.3 Cg_endo -71.74 158.15 53.88 Favored 'Trans proline' 0 CA--C 1.539 0.735 0 C-N-CA 123.146 2.564 . . . . 0.0 112.309 179.568 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 1.4 mptm? -73.31 -8.56 56.36 Favored 'General case' 0 N--CA 1.48 1.039 0 C-N-CA 125.469 1.508 . . . . 0.0 113.88 179.631 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 51.1 mm -52.95 125.46 7.01 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.668 0 C-N-CA 126.442 1.897 . . . . 0.0 111.498 177.233 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 50.3 tp -95.35 100.44 12.21 Favored 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 127.339 2.256 . . . . 0.0 109.033 176.382 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 29.4 ttmt -146.76 82.34 8.69 Favored Pre-proline 0 N--CA 1.472 0.655 0 C-N-CA 124.565 1.146 . . . . 0.0 110.66 171.22 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 70.2 Cg_endo -68.69 148.32 71.56 Favored 'Trans proline' 0 N--CA 1.459 -0.549 0 C-N-CA 121.805 1.67 . . . . 0.0 110.926 177.543 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 1.4 t -138.41 160.52 31.59 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.752 0 C-N-CA 124.879 1.271 . . . . 0.0 109.966 -179.12 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 49.8 t -75.88 96.34 3.69 Favored 'General case' 0 CA--C 1.54 0.585 0 C-N-CA 124.334 1.054 . . . . 0.0 110.097 173.0 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -62.78 153.3 44.64 Favored Glycine 0 CA--C 1.534 1.265 0 C-N-CA 123.427 0.537 . . . . 0.0 112.113 174.084 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 21.1 t -53.93 -36.09 62.4 Favored 'General case' 0 N--CA 1.477 0.887 0 C-N-CA 125.256 1.422 . . . . 0.0 114.315 -171.51 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 17.8 m-20 -78.67 -2.77 40.77 Favored 'General case' 0 CA--C 1.55 0.945 0 C-N-CA 125.276 1.43 . . . . 0.0 114.589 178.781 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 92.96 37.27 5.76 Favored Glycine 0 CA--C 1.535 1.295 0 C-N-CA 125.503 1.525 . . . . 0.0 113.321 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 13.3 mmm180 -129.52 125.46 36.37 Favored 'General case' 0 N--CA 1.477 0.911 0 C-N-CA 126.604 1.962 . . . . 0.0 111.025 -166.125 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 2.8 p -83.74 90.35 7.3 Favored 'General case' 0 N--CA 1.474 0.746 0 C-N-CA 125.6 1.56 . . . . 0.0 112.074 177.292 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -77.34 154.9 32.36 Favored 'General case' 0 N--CA 1.473 0.691 0 C-N-CA 124.385 1.074 . . . . 0.0 111.851 172.348 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -67.69 -40.82 84.35 Favored 'General case' 0 CA--C 1.545 0.779 0 N-CA-C 113.458 0.91 . . . . 0.0 113.458 -168.705 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 62.1 t30 -144.77 172.27 13.24 Favored 'General case' 0 CA--C 1.548 0.885 0 C-N-CA 125.171 1.388 . . . . 0.0 110.898 169.955 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 88.3 p -62.07 -34.52 76.43 Favored 'General case' 0 N--CA 1.472 0.66 0 O-C-N 120.574 -1.329 . . . . 0.0 113.317 176.365 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 35.4 t -59.72 -57.41 13.03 Favored 'General case' 0 N--CA 1.467 0.414 0 C-N-CA 124.604 1.162 . . . . 0.0 112.669 177.341 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 7.6 tp -58.21 -34.1 48.82 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 CA-C-O 119.06 -0.495 . . . . 0.0 112.286 179.591 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -58.29 -53.6 56.49 Favored 'General case' 0 CA--C 1.544 0.734 0 CA-C-N 118.929 0.786 . . . . 0.0 111.934 172.986 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -58.98 -46.05 89.06 Favored 'General case' 0 N--CA 1.48 1.032 0 N-CA-C 112.666 0.617 . . . . 0.0 112.666 175.338 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -65.3 -32.58 74.31 Favored 'General case' 0 CA--C 1.545 0.776 0 N-CA-C 113.301 0.852 . . . . 0.0 113.301 -179.948 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 25.6 t-20 -71.61 -49.03 44.07 Favored 'General case' 0 CA--C 1.543 0.701 0 C-N-CA 124.758 1.223 . . . . 0.0 112.62 173.86 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 145.47 21.18 0.14 Allowed Glycine 0 CA--C 1.537 1.46 0 N-CA-C 116.813 1.485 . . . . 0.0 116.813 178.965 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 21.7 t -127.48 150.05 33.0 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.607 0 C-N-CA 126.067 1.747 . . . . 0.0 109.548 -176.966 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 80.0 p -124.42 138.69 54.33 Favored 'General case' 0 N--CA 1.47 0.542 0 C-N-CA 126.157 1.783 . . . . 0.0 112.129 -179.499 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 23.5 mm . . . . . 0 N--CA 1.477 0.917 0 C-N-CA 124.961 1.304 . . . . 0.0 111.854 -179.03 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 60.1 m . . . . . 0 CA--C 1.545 0.762 0 CA-C-O 121.069 0.461 . . . . 0.0 111.69 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -75.3 67.6 1.92 Allowed 'General case' 0 CA--C 1.551 1.006 0 C-N-CA 125.56 1.544 . . . . 0.0 113.091 179.802 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 72.8 m -68.92 155.57 93.16 Favored Pre-proline 0 CA--C 1.552 1.027 0 C-N-CA 124.882 1.273 . . . . 0.0 113.586 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 90.4 Cg_endo -74.11 168.01 25.81 Favored 'Trans proline' 0 CA--C 1.541 0.849 0 C-N-CA 123.591 2.861 . . . . 0.0 113.173 179.38 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -76.59 -3.23 36.56 Favored 'General case' 0 N--CA 1.482 1.155 0 C-N-CA 125.619 1.567 . . . . 0.0 114.447 177.927 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 85.6 mt -55.69 151.42 2.22 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.899 0 C-N-CA 126.868 2.067 . . . . 0.0 110.744 174.555 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 50.8 tp -136.9 93.49 2.85 Favored 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 125.914 1.686 . . . . 0.0 109.401 -175.538 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 16.7 mmtm -135.21 82.1 42.44 Favored Pre-proline 0 N--CA 1.475 0.779 0 C-N-CA 125.828 1.651 . . . . 0.0 110.129 174.307 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 65.0 Cg_endo -69.83 91.17 0.52 Allowed 'Trans proline' 0 CA--C 1.54 0.805 0 C-N-CA 123.809 3.006 . . . . 0.0 112.061 -177.238 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 5.0 m -87.11 157.87 3.19 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.522 0 C-N-CA 126.723 2.009 . . . . 0.0 112.882 -177.356 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 45.0 t -68.23 143.29 55.36 Favored 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 124.05 0.94 . . . . 0.0 111.064 171.366 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -111.72 148.97 18.1 Favored Glycine 0 CA--C 1.532 1.108 0 C-N-CA 125.472 1.51 . . . . 0.0 112.786 177.803 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 68.9 m -59.58 -22.81 62.29 Favored 'General case' 0 N--CA 1.477 0.878 0 N-CA-C 115.564 1.69 . . . . 0.0 115.564 -170.498 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 33.4 t70 -77.89 -10.74 59.73 Favored 'General case' 0 CA--C 1.549 0.929 0 C-N-CA 124.904 1.282 . . . . 0.0 114.15 175.238 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 98.39 31.85 6.3 Favored Glycine 0 CA--C 1.536 1.391 0 C-N-CA 125.422 1.487 . . . . 0.0 113.111 -172.097 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 15.3 mmp_? -121.91 -175.0 3.01 Favored 'General case' 0 N--CA 1.478 0.969 0 C-N-CA 127.743 2.417 . . . . 0.0 111.281 -169.734 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 9.3 t -136.84 143.95 43.36 Favored 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 125.191 1.396 . . . . 0.0 111.427 173.007 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 85.4 m-85 -142.39 147.94 37.04 Favored 'General case' 0 N--CA 1.473 0.705 0 C-N-CA 125.22 1.408 . . . . 0.0 112.217 -175.713 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -61.14 -44.81 96.74 Favored 'General case' 0 CA--C 1.542 0.667 0 N-CA-C 114.003 1.112 . . . . 0.0 114.003 -164.608 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 65.6 m-80 -146.85 175.06 10.93 Favored 'General case' 0 CA--C 1.548 0.886 0 C-N-CA 126.461 1.904 . . . . 0.0 110.633 167.576 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 20.0 m -57.76 -30.09 65.33 Favored 'General case' 0 N--CA 1.477 0.903 0 O-C-N 120.945 -1.097 . . . . 0.0 113.599 171.666 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 46.7 t -58.56 -61.1 2.85 Favored 'General case' 0 N--CA 1.466 0.368 0 C-N-CA 124.964 1.306 . . . . 0.0 112.312 175.557 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 8.5 tp -62.56 -33.3 58.85 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.744 0 N-CA-C 112.039 0.385 . . . . 0.0 112.039 179.995 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -57.41 -54.51 46.0 Favored 'General case' 0 CA--C 1.542 0.661 0 C-N-CA 123.348 0.659 . . . . 0.0 111.556 171.56 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 5.5 mtp85 -58.95 -40.22 84.03 Favored 'General case' 0 N--CA 1.48 1.031 0 N-CA-C 113.243 0.831 . . . . 0.0 113.243 174.907 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 33.0 t -59.95 -46.64 88.77 Favored 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 124.517 1.127 . . . . 0.0 111.628 177.17 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 95.4 m-20 -69.15 -48.07 63.31 Favored 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 125.546 1.538 . . . . 0.0 112.786 179.116 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 129.6 39.84 0.28 Allowed Glycine 0 CA--C 1.536 1.36 0 C-N-CA 125.212 1.387 . . . . 0.0 114.652 -176.867 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 44.7 t -133.25 158.18 42.94 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.597 0 C-N-CA 126.938 2.095 . . . . 0.0 108.494 174.528 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 42.7 t -123.57 143.29 50.3 Favored 'General case' 0 N--CA 1.47 0.572 0 C-N-CA 125.545 1.538 . . . . 0.0 111.937 175.492 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 17.1 mm . . . . . 0 N--CA 1.475 0.79 0 C-N-CA 126.034 1.734 . . . . 0.0 111.331 175.889 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 57.2 m . . . . . 0 N--CA 1.476 0.839 0 N-CA-C 113.6 0.963 . . . . 0.0 113.6 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . 50.07 26.32 2.04 Favored 'General case' 0 CA--C 1.552 1.023 0 C-N-CA 127.254 2.222 . . . . 0.0 115.285 -171.032 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 61.9 m -70.22 160.72 79.8 Favored Pre-proline 0 CA--C 1.548 0.869 0 C-N-CA 125.363 1.465 . . . . 0.0 112.922 177.157 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -67.58 167.59 20.48 Favored 'Trans proline' 0 CA--C 1.54 0.798 0 C-N-CA 123.295 2.663 . . . . 0.0 112.231 169.736 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 10.2 mtpm? -112.53 1.38 15.83 Favored 'General case' 0 N--CA 1.48 1.059 0 C-N-CA 126.282 1.833 . . . . 0.0 113.28 173.672 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 48.9 mm -55.93 133.03 19.99 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.593 0 C-N-CA 126.386 1.874 . . . . 0.0 111.082 178.587 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 5.4 tt -69.87 96.0 0.97 Allowed 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 127.771 2.428 . . . . 0.0 111.08 -176.723 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 34.7 ttpt -144.45 73.97 15.53 Favored Pre-proline 0 CA--C 1.546 0.801 0 C-N-CA 124.467 1.107 . . . . 0.0 111.901 -179.427 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -68.21 89.43 0.39 Allowed 'Trans proline' 0 CA--C 1.538 0.708 0 C-N-CA 124.188 3.259 . . . . 0.0 112.922 -175.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 16.3 m -73.73 160.24 5.36 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.412 0 C-N-CA 126.084 1.754 . . . . 0.0 112.244 175.273 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 16.5 t -69.36 165.95 19.65 Favored 'General case' 0 CA--C 1.549 0.908 0 C-N-CA 123.625 0.77 . . . . 0.0 111.141 166.998 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -143.6 134.55 5.9 Favored Glycine 0 CA--C 1.53 0.973 0 C-N-CA 124.778 1.18 . . . . 0.0 112.151 177.783 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 63.7 m -57.22 -24.48 54.9 Favored 'General case' 0 N--CA 1.477 0.886 0 C-N-CA 125.847 1.659 . . . . 0.0 114.906 -176.993 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -83.29 -4.58 58.58 Favored 'General case' 0 CA--C 1.548 0.887 0 C-N-CA 125.775 1.63 . . . . 0.0 113.955 176.985 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 94.65 20.21 29.8 Favored Glycine 0 CA--C 1.535 1.311 0 C-N-CA 125.38 1.467 . . . . 0.0 114.284 179.111 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 43.7 mtt180 -121.01 178.18 4.83 Favored 'General case' 0 N--CA 1.477 0.908 0 C-N-CA 126.169 1.788 . . . . 0.0 112.536 -173.88 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 31.8 m -128.35 142.64 51.06 Favored 'General case' 0 N--CA 1.477 0.9 0 C-N-CA 126.107 1.763 . . . . 0.0 110.049 -179.584 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 86.8 m-85 -135.57 155.64 50.15 Favored 'General case' 0 N--CA 1.471 0.588 0 C-N-CA 125.171 1.388 . . . . 0.0 111.651 -175.438 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -61.66 -38.63 88.46 Favored 'General case' 0 CA--C 1.544 0.742 0 N-CA-C 113.212 0.819 . . . . 0.0 113.212 -167.956 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 14.8 p30 -150.33 179.33 8.21 Favored 'General case' 0 CA--C 1.548 0.876 0 C-N-CA 126.213 1.805 . . . . 0.0 111.901 166.441 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 25.0 p -65.63 -34.83 79.12 Favored 'General case' 0 N--CA 1.474 0.745 0 O-C-N 121.007 -1.058 . . . . 0.0 113.755 177.298 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 34.4 t -62.93 -54.04 44.77 Favored 'General case' 0 N--CA 1.466 0.361 0 C-N-CA 124.083 0.953 . . . . 0.0 111.481 179.057 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 9.3 tp -59.0 -37.18 66.14 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.553 0 N-CA-C 112.143 0.423 . . . . 0.0 112.143 -179.277 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -63.32 -42.62 99.02 Favored 'General case' 0 CA--C 1.544 0.717 0 CA-C-N 118.851 0.75 . . . . 0.0 112.927 176.216 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 8.7 tpm_? -62.98 -41.96 99.7 Favored 'General case' 0 N--CA 1.475 0.816 0 C-N-CA 123.828 0.851 . . . . 0.0 112.278 173.82 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 7.3 t -65.06 -39.72 93.67 Favored 'General case' 0 CA--C 1.547 0.839 0 C-N-CA 123.025 0.53 . . . . 0.0 112.245 174.286 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 23.0 t-20 -63.93 -52.03 61.66 Favored 'General case' 0 CA--C 1.544 0.716 0 C-N-CA 125.82 1.648 . . . . 0.0 112.464 178.739 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 149.81 18.12 0.08 OUTLIER Glycine 0 CA--C 1.537 1.436 0 N-CA-C 117.344 1.698 . . . . 0.0 117.344 179.095 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 14.5 t -124.43 144.38 34.51 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.672 0 CA-C-N 119.98 1.89 . . . . 0.0 109.882 -176.828 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 72.3 m -89.47 128.53 35.98 Favored 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 125.805 1.642 . . . . 0.0 111.322 -179.024 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 14.3 mm . . . . . 0 N--CA 1.484 1.23 0 C-N-CA 124.687 1.195 . . . . 0.0 112.486 -175.778 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 22.4 m . . . . . 0 CA--C 1.545 0.776 0 N-CA-C 110.447 -0.205 . . . . 0.0 110.447 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -72.84 35.88 0.07 Allowed 'General case' 0 CA--C 1.556 1.195 0 C-N-CA 125.702 1.601 . . . . 0.0 114.321 178.257 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 63.8 m -64.85 159.03 66.45 Favored Pre-proline 0 CA--C 1.549 0.932 0 C-N-CA 126.499 1.92 . . . . 0.0 113.934 -178.232 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -70.81 158.96 54.15 Favored 'Trans proline' 0 C--N 1.352 0.736 0 C-N-CA 123.293 2.662 . . . . 0.0 112.785 -179.64 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 48.3 tttm -71.54 -21.17 61.94 Favored 'General case' 0 N--CA 1.478 0.953 0 C-N-CA 125.272 1.429 . . . . 0.0 113.397 176.401 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 43.7 mm -57.32 130.61 20.45 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.652 0 C-N-CA 126.257 1.823 . . . . 0.0 110.994 -179.651 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 2.0 pt? -93.05 133.95 35.68 Favored 'General case' 0 CA--C 1.539 0.548 0 C-N-CA 125.312 1.445 . . . . 0.0 111.981 176.426 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 54.2 mttm -144.17 81.39 11.56 Favored Pre-proline 0 N--CA 1.471 0.611 0 C-N-CA 126.87 2.068 . . . . 0.0 109.236 166.748 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -71.53 85.03 0.93 Allowed 'Trans proline' 0 CA--C 1.539 0.729 0 C-N-CA 123.522 2.815 . . . . 0.0 111.915 178.836 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 35.2 m -110.96 166.72 5.37 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.344 0 C-N-CA 126.987 2.115 . . . . 0.0 112.609 -176.877 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 24.4 p -76.38 130.82 38.61 Favored 'General case' 0 CA--C 1.544 0.717 0 C-N-CA 124.124 0.97 . . . . 0.0 111.961 176.338 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -89.29 160.14 29.15 Favored Glycine 0 CA--C 1.534 1.255 0 C-N-CA 124.925 1.25 . . . . 0.0 111.974 168.239 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 91.2 p -59.39 -26.19 64.91 Favored 'General case' 0 N--CA 1.476 0.873 0 N-CA-C 115.252 1.575 . . . . 0.0 115.252 -171.928 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 32.2 m-20 -81.56 -2.77 51.18 Favored 'General case' 0 CA--C 1.547 0.858 0 C-N-CA 125.321 1.448 . . . . 0.0 114.451 176.585 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 89.59 31.4 11.48 Favored Glycine 0 CA--C 1.536 1.387 0 C-N-CA 124.772 1.177 . . . . 0.0 113.089 -176.285 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 42.9 mmm-85 -114.68 172.24 7.16 Favored 'General case' 0 N--CA 1.477 0.877 0 C-N-CA 127.808 2.443 . . . . 0.0 111.022 -170.873 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 31.7 m -128.68 133.53 48.23 Favored 'General case' 0 N--CA 1.481 1.086 0 C-N-CA 124.717 1.207 . . . . 0.0 110.748 178.921 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 87.3 m-85 -135.73 156.15 49.28 Favored 'General case' 0 N--CA 1.473 0.682 0 C-N-CA 125.186 1.394 . . . . 0.0 112.155 -178.106 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.99 -40.76 95.44 Favored 'General case' 0 CA--C 1.543 0.689 0 N-CA-C 113.499 0.926 . . . . 0.0 113.499 -166.965 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 28.7 p30 -148.4 179.7 7.59 Favored 'General case' 0 CA--C 1.547 0.847 0 C-N-CA 125.326 1.45 . . . . 0.0 112.194 164.813 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 44.6 p -62.64 -34.12 76.42 Favored 'General case' 0 N--CA 1.474 0.76 0 C-N-CA 124.228 1.011 . . . . 0.0 113.531 176.772 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 47.3 t -62.39 -55.1 31.08 Favored 'General case' 0 N--CA 1.465 0.276 0 C-N-CA 124.321 1.049 . . . . 0.0 111.917 178.093 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 9.3 tp -61.26 -35.71 67.87 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.611 0 N-CA-C 112.25 0.463 . . . . 0.0 112.25 179.576 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -58.99 -51.37 70.38 Favored 'General case' 0 CA--C 1.544 0.73 0 C-N-CA 123.698 0.799 . . . . 0.0 111.885 172.499 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 77.5 mtp85 -57.92 -45.55 86.36 Favored 'General case' 0 N--CA 1.477 0.925 0 C-N-CA 124.644 1.177 . . . . 0.0 112.772 174.85 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 6.7 t -62.48 -40.83 97.95 Favored 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 123.766 0.826 . . . . 0.0 112.275 177.139 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 43.9 t30 -67.67 -42.04 82.79 Favored 'General case' 0 CA--C 1.543 0.681 0 C-N-CA 125.026 1.33 . . . . 0.0 113.245 178.32 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 134.43 23.79 0.64 Allowed Glycine 0 CA--C 1.538 1.476 0 N-CA-C 116.046 1.178 . . . . 0.0 116.046 178.013 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 38.0 t -125.01 154.47 33.06 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.448 0 C-N-CA 126.835 2.054 . . . . 0.0 108.379 -178.147 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 91.3 p -135.79 166.97 22.05 Favored 'General case' 0 N--CA 1.472 0.646 0 C-N-CA 124.618 1.167 . . . . 0.0 112.875 175.918 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 2.0 mt . . . . . 0 N--CA 1.48 1.04 0 C-N-CA 124.862 1.265 . . . . 0.0 112.006 -172.193 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 81.0 m . . . . . 0 CA--C 1.544 0.736 0 CA-C-O 120.693 0.282 . . . . 0.0 110.782 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -74.95 68.62 1.82 Allowed 'General case' 0 CA--C 1.549 0.935 0 C-N-CA 125.686 1.595 . . . . 0.0 113.17 -177.672 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 62.6 m -69.05 154.89 94.57 Favored Pre-proline 0 CA--C 1.549 0.909 0 C-N-CA 124.536 1.134 . . . . 0.0 113.431 -179.404 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -68.5 152.77 74.82 Favored 'Trans proline' 0 CA--C 1.54 0.811 0 C-N-CA 123.201 2.601 . . . . 0.0 111.854 172.637 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 15.2 ptmt -63.86 -26.03 68.43 Favored 'General case' 0 N--CA 1.479 1.023 0 C-N-CA 125.685 1.594 . . . . 0.0 114.678 177.571 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 9.5 tt -57.78 158.32 1.35 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.614 0 C-N-CA 126.673 1.989 . . . . 0.0 112.301 176.079 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 16.8 tp -126.96 114.78 18.29 Favored 'General case' 0 CA--C 1.538 0.487 0 C-N-CA 126.433 1.893 . . . . 0.0 108.518 -178.07 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 31.1 mmmt -127.61 80.18 72.29 Favored Pre-proline 0 N--CA 1.473 0.716 0 C-N-CA 126.125 1.77 . . . . 0.0 109.792 -176.362 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -72.78 84.28 1.27 Allowed 'Trans proline' 0 CA--C 1.541 0.83 0 C-N-CA 124.274 3.316 . . . . 0.0 112.402 -175.427 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 14.4 m -73.78 164.76 3.41 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.598 0 C-N-CA 126.883 2.073 . . . . 0.0 112.832 177.556 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 10.0 t -79.79 -5.21 54.92 Favored 'General case' 0 CA--C 1.551 0.995 0 C-N-CA 124.539 1.135 . . . . 0.0 113.983 174.406 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 57.29 -155.19 18.24 Favored Glycine 0 CA--C 1.539 1.548 0 C-N-CA 125.338 1.447 . . . . 0.0 113.984 179.211 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 38.0 m -121.22 -20.54 6.7 Favored 'General case' 0 N--CA 1.475 0.776 0 C-N-CA 124.94 1.296 . . . . 0.0 114.223 174.454 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -80.81 -13.88 58.56 Favored 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 124.252 1.021 . . . . 0.0 113.102 171.703 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 98.51 -14.91 61.71 Favored Glycine 0 CA--C 1.537 1.456 0 C-N-CA 126.782 2.134 . . . . 0.0 114.008 -177.945 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 9.8 ptm180 -77.96 168.83 19.28 Favored 'General case' 0 N--CA 1.474 0.747 0 C-N-CA 125.378 1.471 . . . . 0.0 112.279 168.269 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 54.7 m -95.22 149.36 21.4 Favored 'General case' 0 N--CA 1.475 0.779 0 C-N-CA 124.452 1.101 . . . . 0.0 111.708 174.823 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 56.1 m-85 -131.63 151.99 51.18 Favored 'General case' 0 N--CA 1.47 0.562 0 C-N-CA 126.249 1.819 . . . . 0.0 110.676 173.797 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.89 -40.54 87.79 Favored 'General case' 0 CA--C 1.544 0.713 0 N-CA-C 113.273 0.842 . . . . 0.0 113.273 -169.855 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 16.5 m120 -144.61 170.96 15.07 Favored 'General case' 0 CA--C 1.545 0.786 0 C-N-CA 126.29 1.836 . . . . 0.0 110.954 174.894 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 28.4 p -61.41 -32.06 72.0 Favored 'General case' 0 N--CA 1.475 0.797 0 C-N-CA 124.152 0.981 . . . . 0.0 112.618 162.073 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 42.3 t -54.84 -64.25 0.89 Allowed 'General case' 0 CA--C 1.535 0.374 0 C-N-CA 125.699 1.599 . . . . 0.0 112.366 173.264 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 13.6 tt -58.54 -35.62 55.6 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.812 0 N-CA-C 112.211 0.449 . . . . 0.0 112.211 -178.021 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -59.07 -56.63 19.72 Favored 'General case' 0 CA--C 1.541 0.617 0 C-N-CA 123.5 0.72 . . . . 0.0 111.505 174.671 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 69.6 mtm180 -64.55 -37.5 87.77 Favored 'General case' 0 N--CA 1.479 0.977 0 N-CA-C 113.209 0.818 . . . . 0.0 113.209 179.009 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 35.9 t -58.35 -45.25 88.54 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 125.233 1.413 . . . . 0.0 111.833 172.695 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 23.0 t-20 -71.57 -48.84 45.73 Favored 'General case' 0 CA--C 1.546 0.816 0 C-N-CA 125.03 1.332 . . . . 0.0 112.79 179.911 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 144.7 23.43 0.14 Allowed Glycine 0 CA--C 1.54 1.629 0 N-CA-C 116.523 1.369 . . . . 0.0 116.523 179.765 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 18.4 t -130.88 151.56 36.12 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.603 0 C-N-CA 126.637 1.975 . . . . 0.0 109.179 -174.789 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 95.0 p -144.91 124.81 13.45 Favored 'General case' 0 N--CA 1.47 0.562 0 C-N-CA 125.106 1.362 . . . . 0.0 112.108 -179.724 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 6.3 mt . . . . . 0 N--CA 1.482 1.149 0 C-N-CA 124.306 1.042 . . . . 0.0 112.132 -178.805 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 61.2 m . . . . . 0 CA--C 1.541 0.605 0 CA-C-O 120.868 0.366 . . . . 0.0 110.832 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -73.99 52.89 0.45 Allowed 'General case' 0 CA--C 1.554 1.123 0 C-N-CA 125.612 1.565 . . . . 0.0 113.131 177.36 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 92.8 m -62.86 157.03 62.98 Favored Pre-proline 0 CA--C 1.551 1.001 0 C-N-CA 125.791 1.636 . . . . 0.0 113.232 178.977 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -71.82 167.7 25.87 Favored 'Trans proline' 0 CA--C 1.542 0.881 0 C-N-CA 123.29 2.66 . . . . 0.0 113.283 -177.24 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 61.7 mtpt -66.46 -16.8 64.39 Favored 'General case' 0 N--CA 1.481 1.088 0 C-N-CA 126.033 1.733 . . . . 0.0 114.097 176.171 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 79.8 mt -58.47 136.36 21.96 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.722 0 C-N-CA 126.489 1.916 . . . . 0.0 110.24 178.064 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.9 pt? -130.98 26.42 4.93 Favored 'General case' 0 CA--C 1.546 0.816 0 C-N-CA 125.416 1.487 . . . . 0.0 113.951 -178.48 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 26.4 mmtp -52.59 107.22 0.79 Allowed Pre-proline 0 N--CA 1.477 0.893 0 C-N-CA 126.516 1.926 . . . . 0.0 111.553 175.182 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 91.6 Cg_endo -73.61 87.76 1.08 Allowed 'Trans proline' 0 CA--C 1.539 0.729 0 C-N-CA 123.526 2.818 . . . . 0.0 112.01 -173.816 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 13.6 m -73.8 157.85 6.17 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.459 0 C-N-CA 125.636 1.574 . . . . 0.0 112.297 179.246 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 30.3 p -63.44 165.2 8.1 Favored 'General case' 0 CA--C 1.544 0.741 0 C-N-CA 123.412 0.685 . . . . 0.0 111.835 165.637 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -133.97 143.29 14.93 Favored Glycine 0 CA--C 1.527 0.798 0 C-N-CA 125.058 1.313 . . . . 0.0 111.972 179.999 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 55.6 m -65.08 -15.82 62.79 Favored 'General case' 0 N--CA 1.473 0.706 0 C-N-CA 125.362 1.465 . . . . 0.0 114.913 -174.598 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 42.0 m-20 -95.32 5.78 50.78 Favored 'General case' 0 CA--C 1.553 1.082 0 C-N-CA 125.972 1.709 . . . . 0.0 113.514 171.955 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 88.91 24.81 31.27 Favored Glycine 0 N--CA 1.473 1.108 0 C-N-CA 125.05 1.309 . . . . 0.0 114.157 179.921 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 24.0 mtp85 -120.47 -170.53 2.0 Favored 'General case' 0 N--CA 1.481 1.098 0 C-N-CA 126.297 1.839 . . . . 0.0 112.348 -171.409 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 41.2 m -134.42 139.04 45.27 Favored 'General case' 0 N--CA 1.478 0.964 0 C-N-CA 125.952 1.701 . . . . 0.0 110.37 -179.34 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 65.6 m-85 -134.3 159.4 41.09 Favored 'General case' 0 N--CA 1.473 0.694 0 C-N-CA 124.921 1.288 . . . . 0.0 111.603 179.036 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -63.97 -40.53 96.6 Favored 'General case' 0 CA--C 1.543 0.682 0 N-CA-C 112.92 0.711 . . . . 0.0 112.92 -168.075 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 28.5 p30 -154.77 -178.39 7.17 Favored 'General case' 0 CA--C 1.551 0.991 0 C-N-CA 125.314 1.445 . . . . 0.0 111.635 168.877 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 83.4 p -73.12 -16.79 61.45 Favored 'General case' 0 N--CA 1.48 1.046 0 N-CA-C 114.753 1.39 . . . . 0.0 114.753 177.843 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 38.8 t -76.6 -56.06 4.95 Favored 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 124.77 1.228 . . . . 0.0 111.136 173.861 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 7.7 tp -57.85 -34.63 48.77 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.859 0 C-N-CA 123.528 0.731 . . . . 0.0 112.406 179.115 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -55.24 -53.35 57.17 Favored 'General case' 0 CA--C 1.541 0.627 0 C-N-CA 123.885 0.874 . . . . 0.0 111.484 172.967 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 81.3 mtm180 -67.02 -37.42 84.13 Favored 'General case' 0 N--CA 1.475 0.786 0 C-N-CA 125.031 1.332 . . . . 0.0 113.49 178.317 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 42.5 t -57.22 -47.0 82.43 Favored 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 124.325 1.05 . . . . 0.0 111.599 170.844 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 63.6 t30 -70.96 -49.84 41.09 Favored 'General case' 0 CA--C 1.546 0.797 0 C-N-CA 125.502 1.521 . . . . 0.0 112.961 -178.172 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 145.42 23.22 0.12 Allowed Glycine 0 CA--C 1.539 1.561 0 N-CA-C 116.792 1.477 . . . . 0.0 116.792 178.663 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 19.3 t -125.55 150.84 31.06 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.613 0 C-N-CA 126.714 2.006 . . . . 0.0 108.839 -178.069 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 32.5 t -144.61 118.54 9.35 Favored 'General case' 0 N--CA 1.472 0.666 0 C-N-CA 124.907 1.283 . . . . 0.0 112.698 179.197 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.427 HD12 ' H ' ' A' ' 34' ' ' ILE . 0.7 OUTLIER . . . . . 0 CA--C 1.555 1.16 0 C-N-CA 126.789 2.035 . . . . 0.0 111.469 -178.638 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 4.9 m . . . . . 0 CA--C 1.547 0.843 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -74.44 51.19 0.44 Allowed 'General case' 0 CA--C 1.554 1.101 0 C-N-CA 125.571 1.549 . . . . 0.0 113.58 -177.588 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 81.2 m -71.5 156.07 91.88 Favored Pre-proline 0 CA--C 1.548 0.885 0 C-N-CA 125.624 1.569 . . . . 0.0 114.039 -172.704 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -68.93 158.83 56.34 Favored 'Trans proline' 0 CA--C 1.54 0.814 0 C-N-CA 123.63 2.887 . . . . 0.0 113.213 177.979 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 64.8 mttm -69.98 -14.02 62.5 Favored 'General case' 0 N--CA 1.481 1.093 0 C-N-CA 126.399 1.88 . . . . 0.0 114.142 177.813 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 10.3 tp -62.41 146.49 12.42 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 C-N-CA 126.438 1.895 . . . . 0.0 113.446 -177.114 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 62.7 tp -116.8 88.36 2.88 Favored 'General case' 0 CA--C 1.539 0.544 0 C-N-CA 127.138 2.175 . . . . 0.0 108.881 -175.677 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 13.1 mmmm -134.38 74.12 67.28 Favored Pre-proline 0 N--CA 1.474 0.739 0 C-N-CA 126.519 1.928 . . . . 0.0 109.179 175.536 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -67.21 120.02 7.07 Favored 'Trans proline' 0 CA--C 1.536 0.611 0 C-N-CA 122.929 2.419 . . . . 0.0 111.12 -175.732 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -107.51 155.75 8.17 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.747 0 C-N-CA 124.929 1.291 . . . . 0.0 110.961 -175.8 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 8.8 p -81.98 106.33 13.81 Favored 'General case' 0 CA--C 1.545 0.754 0 C-N-CA 125.792 1.637 . . . . 0.0 110.813 171.582 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -69.11 154.07 53.11 Favored Glycine 0 CA--C 1.534 1.272 0 O-C-N 121.45 -0.781 . . . . 0.0 112.085 172.063 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 73.2 m -61.69 -18.71 60.73 Favored 'General case' 0 N--CA 1.479 0.982 0 N-CA-C 116.084 1.883 . . . . 0.0 116.084 -168.854 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 31.8 t70 -82.14 -11.29 58.82 Favored 'General case' 0 CA--C 1.548 0.902 0 N-CA-C 114.105 1.15 . . . . 0.0 114.105 175.252 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 107.42 6.13 33.73 Favored Glycine 0 CA--C 1.536 1.377 0 C-N-CA 126.3 1.905 . . . . 0.0 114.418 -179.452 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 40.2 mtp180 -104.39 138.55 40.63 Favored 'General case' 0 N--CA 1.475 0.798 0 C-N-CA 126.073 1.749 . . . . 0.0 111.211 -175.139 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 8.1 p -77.91 141.9 38.75 Favored 'General case' 0 N--CA 1.47 0.55 0 C-N-CA 123.901 0.88 . . . . 0.0 112.39 175.961 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 92.8 m-85 -135.49 144.05 46.16 Favored 'General case' 0 N--CA 1.472 0.666 0 C-N-CA 125.437 1.495 . . . . 0.0 111.742 175.786 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -60.33 -40.98 92.56 Favored 'General case' 0 CA--C 1.543 0.688 0 N-CA-C 114.145 1.165 . . . . 0.0 114.145 -163.402 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 14.1 p30 -155.3 174.28 15.44 Favored 'General case' 0 CA--C 1.55 0.971 0 C-N-CA 126.282 1.833 . . . . 0.0 110.175 163.818 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 73.8 p -60.82 -25.98 66.99 Favored 'General case' 0 N--CA 1.48 1.037 0 N-CA-C 114.391 1.256 . . . . 0.0 114.391 -175.883 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 48.7 t -57.91 -62.25 1.94 Allowed 'General case' 0 CA--C 1.532 0.277 0 C-N-CA 124.923 1.289 . . . . 0.0 111.742 172.344 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 6.4 tt -59.91 -36.09 64.61 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.773 0 N-CA-C 112.289 0.477 . . . . 0.0 112.289 -177.336 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -58.26 -58.18 9.61 Favored 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 124.179 0.992 . . . . 0.0 111.518 174.589 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 65.2 mtm180 -64.17 -36.06 82.82 Favored 'General case' 0 N--CA 1.477 0.881 0 N-CA-C 113.271 0.841 . . . . 0.0 113.271 179.417 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 6.6 t -61.93 -42.97 99.71 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 124.009 0.924 . . . . 0.0 111.631 174.197 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 26.9 t-20 -69.37 -49.08 58.82 Favored 'General case' 0 CA--C 1.546 0.792 0 C-N-CA 124.851 1.26 . . . . 0.0 112.68 176.679 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 139.52 24.38 0.3 Allowed Glycine 0 CA--C 1.539 1.568 0 N-CA-C 116.16 1.224 . . . . 0.0 116.16 179.595 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 32.5 t -129.74 153.23 38.52 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.636 0 C-N-CA 126.373 1.869 . . . . 0.0 109.385 -177.927 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 68.9 m -134.41 170.48 15.67 Favored 'General case' 0 N--CA 1.47 0.575 0 C-N-CA 126.312 1.845 . . . . 0.0 112.099 -179.582 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 1.9 mp . . . . . 0 CA--C 1.554 1.1 0 C-N-CA 126.414 1.886 . . . . 0.0 111.443 -178.924 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 61.8 m . . . . . 0 CA--C 1.551 0.999 0 N-CA-C 113.248 0.833 . . . . 0.0 113.248 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . 54.41 30.85 13.46 Favored 'General case' 0 CA--C 1.551 1.002 0 C-N-CA 127.795 2.438 . . . . 0.0 114.408 -170.016 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 64.1 m -64.42 156.83 75.15 Favored Pre-proline 0 CA--C 1.55 0.958 0 C-N-CA 125.388 1.475 . . . . 0.0 113.387 177.321 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 95.3 Cg_endo -74.18 165.18 32.55 Favored 'Trans proline' 0 CA--C 1.542 0.894 0 C-N-CA 123.419 2.746 . . . . 0.0 113.522 -174.682 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 73.9 mmtt -78.87 -0.26 29.98 Favored 'General case' 0 N--CA 1.482 1.146 0 C-N-CA 126.28 1.832 . . . . 0.0 114.746 178.632 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 50.8 mm -56.86 157.97 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.766 0 C-N-CA 126.696 1.998 . . . . 0.0 111.146 170.536 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 51.5 tp -135.7 92.71 2.85 Favored 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 126.515 1.926 . . . . 0.0 108.583 -178.857 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 53.5 tptt -139.2 80.77 22.43 Favored Pre-proline 0 N--CA 1.471 0.595 0 C-N-CA 125.327 1.451 . . . . 0.0 110.124 174.186 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 62.1 Cg_endo -68.92 146.92 66.99 Favored 'Trans proline' 0 CA--C 1.537 0.67 0 C-N-CA 121.919 1.746 . . . . 0.0 111.102 177.68 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 1.4 t -137.08 159.81 36.41 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.977 0 C-N-CA 124.933 1.293 . . . . 0.0 110.518 -176.589 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 29.9 p -85.83 -7.47 58.71 Favored 'General case' 0 CA--C 1.547 0.828 0 C-N-CA 125.85 1.66 . . . . 0.0 114.764 -174.487 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 56.86 -178.38 0.78 Allowed Glycine 0 CA--C 1.537 1.442 0 C-N-CA 127.136 2.303 . . . . 0.0 116.447 177.274 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 11.2 t -79.46 -36.36 38.93 Favored 'General case' 0 CA--C 1.543 0.692 0 C-N-CA 123.653 0.781 . . . . 0.0 112.166 170.732 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -75.63 -12.22 60.17 Favored 'General case' 0 CA--C 1.548 0.877 0 C-N-CA 125.441 1.497 . . . . 0.0 114.596 -177.857 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 92.26 7.44 63.79 Favored Glycine 0 CA--C 1.536 1.373 0 C-N-CA 125.745 1.641 . . . . 0.0 114.723 176.13 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 38.3 mtt180 -95.84 -178.08 4.25 Favored 'General case' 0 N--CA 1.477 0.902 0 C-N-CA 126.353 1.861 . . . . 0.0 112.172 -177.046 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 47.3 m -122.24 128.19 50.84 Favored 'General case' 0 N--CA 1.476 0.85 0 C-N-CA 124.573 1.149 . . . . 0.0 110.505 179.32 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 56.4 m-85 -131.85 156.34 46.24 Favored 'General case' 0 N--CA 1.47 0.566 0 C-N-CA 125.491 1.517 . . . . 0.0 111.483 179.243 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.19 -43.83 85.7 Favored 'General case' 0 CA--C 1.544 0.748 0 N-CA-C 113.307 0.854 . . . . 0.0 113.307 -169.197 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 70.6 m-80 -139.66 175.9 9.18 Favored 'General case' 0 CA--C 1.544 0.729 0 C-N-CA 125.739 1.616 . . . . 0.0 111.557 171.184 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 42.4 t -61.34 -40.44 94.25 Favored 'General case' 0 N--CA 1.473 0.723 0 O-C-N 121.339 -0.851 . . . . 0.0 112.199 167.018 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 46.0 t -53.49 -57.42 10.76 Favored 'General case' 0 N--CA 1.467 0.398 0 C-N-CA 125.095 1.358 . . . . 0.0 112.795 -179.782 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 10.8 tp -59.97 -39.37 80.01 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.694 0 C-N-CA 122.791 0.436 . . . . 0.0 112.108 -179.099 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -68.76 -40.15 79.88 Favored 'General case' 0 CA--C 1.542 0.635 0 O-C-N 121.525 -0.735 . . . . 0.0 112.386 178.2 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 20.8 tpt180 -68.85 -35.66 77.2 Favored 'General case' 0 N--CA 1.472 0.654 0 C-N-CA 124.57 1.148 . . . . 0.0 112.691 176.107 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 47.8 t -59.45 -49.29 78.37 Favored 'General case' 0 CA--C 1.542 0.648 0 C-N-CA 125.059 1.344 . . . . 0.0 111.083 167.479 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 25.9 t-20 -62.97 -45.35 92.83 Favored 'General case' 0 CA--C 1.546 0.796 0 C-N-CA 124.814 1.246 . . . . 0.0 113.324 -179.535 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 143.66 17.22 0.24 Allowed Glycine 0 CA--C 1.54 1.614 0 N-CA-C 117.191 1.636 . . . . 0.0 117.191 175.386 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 21.7 t -115.7 144.15 23.98 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.704 0 CA-C-N 119.882 1.841 . . . . 0.0 110.232 -176.27 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 23.0 t -91.11 126.84 36.32 Favored 'General case' 0 N--CA 1.472 0.65 0 C-N-CA 126.48 1.912 . . . . 0.0 111.525 176.041 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 22.8 mm . . . . . 0 N--CA 1.479 0.991 0 C-N-CA 125.08 1.352 . . . . 0.0 112.686 -174.655 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 21.0 pttp . . . . . 0 N--CA 1.495 1.797 0 N-CA-C 115.539 1.681 . . . . 0.0 115.539 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 23.4 pttp -61.8 160.57 11.69 Favored 'General case' 0 N--CA 1.482 1.175 0 CA-C-N 120.605 1.548 . . . . 0.0 113.569 -176.733 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 13.2 p -141.66 144.57 25.62 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.844 0 C-N-CA 125.556 1.542 . . . . 0.0 111.307 179.837 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 67.9 m -77.24 98.27 5.08 Favored 'General case' 0 CA--C 1.541 0.612 0 C-N-CA 125.1 1.36 . . . . 0.0 111.364 179.108 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -73.34 48.76 0.25 Allowed 'General case' 0 CA--C 1.554 1.13 0 C-N-CA 126.371 1.868 . . . . 0.0 113.54 177.627 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 85.4 m -61.99 156.79 55.65 Favored Pre-proline 0 CA--C 1.548 0.897 0 C-N-CA 125.718 1.607 . . . . 0.0 113.724 179.853 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_endo -68.62 151.82 74.88 Favored 'Trans proline' 0 C--N 1.351 0.7 0 C-N-CA 123.275 2.65 . . . . 0.0 112.137 177.17 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 10.4 ptpp? -74.28 -30.71 62.22 Favored 'General case' 0 N--CA 1.478 0.964 0 C-N-CA 125.058 1.343 . . . . 0.0 114.198 176.399 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 40.8 mm -58.05 126.95 16.47 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.741 0 C-N-CA 126.893 2.077 . . . . 0.0 111.457 -176.571 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 2.0 pt? -61.6 126.67 28.17 Favored 'General case' 0 CA--C 1.542 0.662 0 C-N-CA 125.128 1.371 . . . . 0.0 112.851 -179.777 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 74.9 mmtt -136.33 71.91 59.6 Favored Pre-proline 0 N--CA 1.479 1.004 0 C-N-CA 125.314 1.446 . . . . 0.0 111.604 173.25 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 75.1 Cg_endo -72.85 84.59 1.25 Allowed 'Trans proline' 0 CA--C 1.54 0.817 0 C-N-CA 123.84 3.027 . . . . 0.0 112.818 -178.058 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 15.1 m -76.99 162.13 4.35 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.589 0 C-N-CA 126.739 2.016 . . . . 0.0 113.296 178.824 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 10.6 t -80.19 -5.54 56.26 Favored 'General case' 0 CA--C 1.553 1.068 0 C-N-CA 125.492 1.517 . . . . 0.0 114.166 174.321 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 64.71 -164.67 34.45 Favored Glycine 0 CA--C 1.538 1.504 0 C-N-CA 125.072 1.32 . . . . 0.0 113.974 -178.371 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 25.1 t -111.27 -38.9 4.87 Favored 'General case' 0 N--CA 1.477 0.901 0 C-N-CA 124.775 1.23 . . . . 0.0 112.591 172.57 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 29.5 t70 -72.29 -13.42 61.5 Favored 'General case' 0 N--CA 1.478 0.955 0 N-CA-C 114.249 1.203 . . . . 0.0 114.249 177.718 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 98.15 39.27 3.81 Favored Glycine 0 CA--C 1.533 1.202 0 C-N-CA 125.92 1.724 . . . . 0.0 112.827 -178.745 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 16.2 mmm180 -135.33 150.88 50.07 Favored 'General case' 0 N--CA 1.475 0.776 0 C-N-CA 127.366 2.266 . . . . 0.0 110.822 -168.716 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 27.9 m -95.82 134.45 38.76 Favored 'General case' 0 N--CA 1.476 0.866 0 C-N-CA 124.209 1.004 . . . . 0.0 110.569 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 73.5 m-85 -128.67 160.92 30.94 Favored 'General case' 0 N--CA 1.471 0.613 0 C-N-CA 125.541 1.537 . . . . 0.0 111.215 178.666 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.9 -60.95 2.49 Favored 'General case' 0 CA--C 1.542 0.658 0 N-CA-C 111.784 0.29 . . . . 0.0 111.784 -172.247 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 30.1 m-20 -129.04 162.49 27.53 Favored 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 125.962 1.705 . . . . 0.0 110.322 170.896 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 26.7 p -63.24 -40.98 98.98 Favored 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 124.637 1.175 . . . . 0.0 113.684 177.299 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 49.5 t -57.89 -48.2 80.56 Favored 'General case' 0 N--CA 1.468 0.441 0 C-N-CA 125.303 1.441 . . . . 0.0 112.372 177.049 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 1.4 mp -52.31 -45.91 44.95 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.727 0 C-N-CA 124.815 1.246 . . . . 0.0 111.669 174.224 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -59.67 -46.63 88.46 Favored 'General case' 0 CA--C 1.545 0.753 0 CA-C-N 119.631 1.105 . . . . 0.0 112.14 177.281 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -57.69 -47.65 81.74 Favored 'General case' 0 N--CA 1.478 0.937 0 C-N-CA 124.877 1.271 . . . . 0.0 111.615 175.639 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 50.7 t -56.31 -48.21 77.13 Favored 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 125.38 1.472 . . . . 0.0 112.297 174.099 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -67.8 -30.06 69.39 Favored 'General case' 0 CA--C 1.548 0.882 0 C-N-CA 124.718 1.207 . . . . 0.0 112.792 -177.516 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 123.32 22.25 2.36 Favored Glycine 0 CA--C 1.537 1.409 0 C-N-CA 124.911 1.243 . . . . 0.0 115.954 175.401 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 5.0 t -124.27 143.59 37.09 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.568 0 C-N-CA 125.906 1.682 . . . . 0.0 109.315 -179.216 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 16.0 t -97.54 169.97 9.36 Favored 'General case' 0 N--CA 1.473 0.721 0 C-N-CA 125.362 1.465 . . . . 0.0 112.134 178.121 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 2.4 mt -141.17 12.74 0.49 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.054 0 C-N-CA 126.999 2.12 . . . . 0.0 110.494 -179.225 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 58.22 18.95 5.76 Favored 'General case' 0 N--CA 1.485 1.295 0 C-N-CA 126.916 2.086 . . . . 0.0 114.495 -174.285 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 1.4 t -116.7 22.18 12.88 Favored 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 126.924 2.09 . . . . 0.0 113.717 -174.521 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 52.9 mt-10 -54.35 -22.77 13.06 Favored 'General case' 0 CA--C 1.546 0.804 0 C-N-CA 126.082 1.753 . . . . 0.0 114.622 177.507 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -76.99 -10.07 86.43 Favored Glycine 0 CA--C 1.54 1.605 0 C-N-CA 124.857 1.218 . . . . 0.0 115.446 176.04 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 12.6 t -146.07 89.91 1.92 Allowed 'General case' 0 N--CA 1.472 0.667 0 CA-C-N 118.975 1.388 . . . . 0.0 111.369 178.83 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 29.5 p -139.6 160.58 60.79 Favored Pre-proline 0 CA--C 1.549 0.94 0 C-N-CA 125.581 1.552 . . . . 0.0 111.994 -177.049 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -74.13 -14.6 23.34 Favored 'Trans proline' 0 CA--C 1.542 0.897 0 C-N-CA 123.15 2.567 . . . . 0.0 113.953 179.179 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 13.7 m -60.7 112.65 2.1 Favored 'General case' 0 N--CA 1.473 0.717 0 C-N-CA 126.454 1.902 . . . . 0.0 111.685 178.338 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -156.58 68.75 0.29 Allowed Glycine 0 CA--C 1.531 1.084 0 C-N-CA 124.4 1.0 . . . . 0.0 113.432 -175.421 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.255 1.353 0 C-N-CA 125.656 1.582 . . . . 0.0 111.529 174.383 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 4.1 mppt? . . . . . 0 N--CA 1.491 1.612 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 11.5 ptmm? -157.34 175.17 14.36 Favored 'General case' 0 N--CA 1.484 1.238 0 C-N-CA 127.068 2.147 . . . . 0.0 111.488 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 12.6 p -141.52 149.98 19.93 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.009 0 C-N-CA 125.317 1.447 . . . . 0.0 111.532 175.84 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 58.5 m -71.47 105.95 3.77 Favored 'General case' 0 CA--C 1.544 0.722 0 C-N-CA 125.486 1.514 . . . . 0.0 110.963 175.301 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -74.6 53.5 0.56 Allowed 'General case' 0 CA--C 1.553 1.059 0 C-N-CA 126.101 1.76 . . . . 0.0 113.629 -178.503 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 80.0 m -67.14 153.99 93.54 Favored Pre-proline 0 CA--C 1.551 0.982 0 C-N-CA 125.373 1.469 . . . . 0.0 113.306 -178.071 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -72.59 157.37 52.65 Favored 'Trans proline' 0 CA--C 1.541 0.847 0 C-N-CA 123.05 2.5 . . . . 0.0 112.514 179.459 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -88.72 -9.54 51.59 Favored 'General case' 0 N--CA 1.48 1.045 0 C-N-CA 124.927 1.291 . . . . 0.0 113.678 176.649 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 79.9 mt -62.02 139.82 20.2 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.756 0 C-N-CA 125.106 1.362 . . . . 0.0 109.692 174.176 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 10.4 mp -82.53 97.8 8.62 Favored 'General case' 0 CA--C 1.538 0.507 0 C-N-CA 124.744 1.218 . . . . 0.0 110.354 172.806 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 2.4 mmmp? -126.47 65.99 61.36 Favored Pre-proline 0 CA--C 1.546 0.815 0 C-N-CA 125.331 1.452 . . . . 0.0 110.632 170.147 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 66.5 Cg_endo -66.32 154.29 74.78 Favored 'Trans proline' 0 C--N 1.352 0.747 0 C-N-CA 122.813 2.342 . . . . 0.0 112.169 -179.263 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -142.18 160.2 20.1 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.757 0 C-N-CA 125.088 1.355 . . . . 0.0 110.476 -178.746 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 47.3 t -73.41 105.04 4.61 Favored 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 124.735 1.214 . . . . 0.0 110.283 169.97 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -65.99 148.02 50.65 Favored Glycine 0 CA--C 1.531 1.041 0 C-N-CA 124.1 0.857 . . . . 0.0 112.416 174.136 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 69.5 m -65.56 -17.58 64.68 Favored 'General case' 0 N--CA 1.475 0.819 0 N-CA-C 114.941 1.46 . . . . 0.0 114.941 -174.8 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 32.1 t70 -79.81 -8.12 59.08 Favored 'General case' 0 CA--C 1.552 1.032 0 C-N-CA 124.698 1.199 . . . . 0.0 113.569 169.148 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 97.34 27.38 9.29 Favored Glycine 0 CA--C 1.536 1.39 0 C-N-CA 126.548 2.023 . . . . 0.0 114.084 -179.593 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 64.3 mtt-85 -127.31 170.57 12.33 Favored 'General case' 0 N--CA 1.481 1.075 0 C-N-CA 125.241 1.416 . . . . 0.0 113.826 -166.385 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 33.1 m -103.45 125.36 49.99 Favored 'General case' 0 N--CA 1.475 0.78 0 C-N-CA 125.761 1.625 . . . . 0.0 110.674 -177.293 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 77.6 m-85 -131.57 157.43 43.62 Favored 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 125.097 1.359 . . . . 0.0 111.631 174.789 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.21 -48.82 74.39 Favored 'General case' 0 CA--C 1.542 0.645 0 N-CA-C 113.211 0.819 . . . . 0.0 113.211 -166.993 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 71.8 m-80 -144.32 174.23 11.09 Favored 'General case' 0 CA--C 1.549 0.936 0 C-N-CA 126.754 2.021 . . . . 0.0 111.08 174.865 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 69.5 m -65.58 -27.92 68.77 Favored 'General case' 0 N--CA 1.483 1.194 0 O-C-N 120.485 -1.385 . . . . 0.0 112.992 171.61 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 46.0 t -58.57 -58.36 8.9 Favored 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 125.414 1.486 . . . . 0.0 112.218 175.652 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 10.5 tp -60.7 -33.95 56.94 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 N-CA-C 112.219 0.452 . . . . 0.0 112.219 -179.619 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -59.24 -53.89 53.13 Favored 'General case' 0 CA--C 1.542 0.663 0 CA-C-N 118.684 0.675 . . . . 0.0 111.852 173.152 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 18.4 mmm180 -62.9 -33.56 75.56 Favored 'General case' 0 N--CA 1.48 1.031 0 C-N-CA 123.812 0.845 . . . . 0.0 113.217 176.088 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 19.3 t -62.83 -46.69 86.74 Favored 'General case' 0 CA--C 1.545 0.762 0 C-N-CA 124.513 1.125 . . . . 0.0 111.741 172.554 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 88.1 m-20 -69.34 -49.66 53.64 Favored 'General case' 0 CA--C 1.542 0.654 0 C-N-CA 125.552 1.541 . . . . 0.0 113.015 -179.691 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 142.63 24.5 0.19 Allowed Glycine 0 CA--C 1.538 1.518 0 N-CA-C 116.484 1.353 . . . . 0.0 116.484 -177.867 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 6.6 t -128.4 147.02 32.97 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.706 0 C-N-CA 126.211 1.804 . . . . 0.0 108.878 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 68.8 m -117.43 133.33 56.09 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 125.337 1.455 . . . . 0.0 112.231 -175.369 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 9.9 mm -121.62 8.14 5.9 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.04 0 C-N-CA 126.375 1.87 . . . . 0.0 111.582 -166.631 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 26.0 mmmt 60.3 14.22 4.5 Favored 'General case' 0 N--CA 1.488 1.46 0 C-N-CA 127.208 2.203 . . . . 0.0 115.162 -170.38 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 75.7 m -118.97 41.24 3.1 Favored 'General case' 0 N--CA 1.473 0.698 0 C-N-CA 127.083 2.153 . . . . 0.0 112.05 -179.577 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 39.4 mt-10 -58.99 160.01 6.47 Favored 'General case' 0 CA--C 1.547 0.856 0 C-N-CA 125.196 1.398 . . . . 0.0 113.104 171.437 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -179.54 -65.76 0.07 OUTLIER Glycine 0 CA--C 1.532 1.109 0 C-N-CA 124.653 1.12 . . . . 0.0 112.313 177.876 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 46.6 m -63.27 106.5 0.9 Allowed 'General case' 0 N--CA 1.472 0.653 0 C-N-CA 125.408 1.483 . . . . 0.0 111.36 172.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 46.6 t -60.41 118.96 38.8 Favored Pre-proline 0 CA--C 1.552 1.026 0 C-N-CA 124.473 1.109 . . . . 0.0 112.083 -177.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 85.6 Cg_endo -75.84 -15.74 18.79 Favored 'Trans proline' 0 CA--C 1.54 0.824 0 C-N-CA 122.948 2.432 . . . . 0.0 113.978 -177.224 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 5.1 m 55.86 36.66 27.71 Favored 'General case' 0 N--CA 1.483 1.217 0 C-N-CA 125.949 1.699 . . . . 0.0 112.478 -176.87 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -102.25 -97.05 2.34 Favored Glycine 0 CA--C 1.536 1.373 0 C-N-CA 125.646 1.593 . . . . 0.0 112.578 179.599 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 67.6 mt . . . . . 0 C--O 1.254 1.31 0 C-N-CA 126.178 1.791 . . . . 0.0 110.863 178.319 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 70.3 mmtt . . . . . 0 N--CA 1.491 1.617 0 N-CA-C 110.681 -0.118 . . . . 0.0 110.681 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 6.3 ttpm? -69.24 141.63 54.38 Favored 'General case' 0 N--CA 1.481 1.097 0 C-N-CA 124.307 1.043 . . . . 0.0 110.678 174.226 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 13.8 p -144.28 143.47 23.33 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.796 0 C-N-CA 125.022 1.329 . . . . 0.0 111.371 -179.669 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 34.2 m -111.87 -18.33 12.71 Favored 'General case' 0 CA--C 1.547 0.834 0 C-N-CA 125.426 1.49 . . . . 0.0 112.981 178.346 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . 46.46 34.33 2.31 Favored 'General case' 0 CA--C 1.549 0.931 0 C-N-CA 127.366 2.266 . . . . 0.0 114.612 -174.462 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 53.2 m -63.22 152.78 83.77 Favored Pre-proline 0 CA--C 1.548 0.891 0 C-N-CA 124.264 1.026 . . . . 0.0 113.285 -176.658 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -67.75 157.54 61.32 Favored 'Trans proline' 0 CA--C 1.54 0.78 0 C-N-CA 123.595 2.863 . . . . 0.0 112.942 179.873 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 32.1 mmmt -74.24 -8.91 57.85 Favored 'General case' 0 N--CA 1.481 1.085 0 C-N-CA 126.353 1.861 . . . . 0.0 114.116 -179.05 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -54.89 138.52 14.93 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.691 0 C-N-CA 127.43 2.292 . . . . 0.0 112.838 179.396 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 42.5 tp -114.0 101.05 8.88 Favored 'General case' 0 CA--C 1.539 0.52 0 C-N-CA 127.269 2.228 . . . . 0.0 109.127 -176.588 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 59.0 tttm -148.74 78.17 9.15 Favored Pre-proline 0 N--CA 1.473 0.7 0 C-N-CA 124.635 1.174 . . . . 0.0 110.662 175.646 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 67.0 Cg_endo -72.26 108.24 2.45 Favored 'Trans proline' 0 N--CA 1.458 -0.612 0 C-N-CA 123.035 2.49 . . . . 0.0 111.913 -177.871 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 14.9 m -107.09 172.65 1.82 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.463 0 C-N-CA 126.867 2.067 . . . . 0.0 111.793 -179.836 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 24.2 t -75.75 154.07 36.59 Favored 'General case' 0 CA--C 1.541 0.599 0 C-N-CA 123.981 0.912 . . . . 0.0 111.184 -179.851 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -121.48 152.82 16.76 Favored Glycine 0 CA--C 1.531 1.061 0 C-N-CA 125.012 1.292 . . . . 0.0 113.239 177.002 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 9.2 t -55.98 -36.05 67.43 Favored 'General case' 0 N--CA 1.476 0.841 0 C-N-CA 125.86 1.664 . . . . 0.0 114.064 -173.783 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 32.8 t70 -80.04 -9.31 59.69 Favored 'General case' 0 CA--C 1.551 1.0 0 C-N-CA 125.027 1.331 . . . . 0.0 114.368 179.119 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 89.88 53.4 2.4 Favored Glycine 0 CA--C 1.532 1.136 0 C-N-CA 125.311 1.434 . . . . 0.0 112.068 -175.203 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 4.0 mmp_? -137.81 174.89 10.1 Favored 'General case' 0 N--CA 1.477 0.91 0 C-N-CA 127.658 2.383 . . . . 0.0 110.916 -172.462 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 9.4 m -137.71 140.49 40.76 Favored 'General case' 0 N--CA 1.48 1.025 0 C-N-CA 125.301 1.44 . . . . 0.0 110.512 179.7 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 49.1 m-85 -139.25 161.33 37.68 Favored 'General case' 0 N--CA 1.473 0.699 0 C-N-CA 125.533 1.533 . . . . 0.0 111.32 -176.894 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.39 -45.42 87.77 Favored 'General case' 0 CA--C 1.545 0.772 0 N-CA-C 113.525 0.935 . . . . 0.0 113.525 -167.553 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 28.0 p30 -146.08 -178.42 6.12 Favored 'General case' 0 CA--C 1.548 0.886 0 C-N-CA 125.226 1.411 . . . . 0.0 111.864 166.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 29.0 p -66.28 -30.16 70.53 Favored 'General case' 0 N--CA 1.472 0.629 0 N-CA-C 114.226 1.195 . . . . 0.0 114.226 179.094 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 49.1 t -64.98 -56.58 12.32 Favored 'General case' 0 N--CA 1.47 0.526 0 C-N-CA 124.058 0.943 . . . . 0.0 111.524 177.401 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 11.2 tp -57.6 -38.88 66.59 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.618 0 CA-C-O 119.354 -0.355 . . . . 0.0 111.757 179.853 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -61.11 -45.09 96.12 Favored 'General case' 0 CA--C 1.543 0.683 0 C-N-CA 123.949 0.9 . . . . 0.0 112.797 175.809 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 5.1 tpt180 -64.8 -42.06 95.31 Favored 'General case' 0 N--CA 1.474 0.734 0 C-N-CA 123.448 0.699 . . . . 0.0 112.524 176.203 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 2.9 t -65.35 -36.08 82.94 Favored 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 123.117 0.567 . . . . 0.0 112.164 174.858 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 24.7 t-20 -66.68 -53.71 30.82 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 125.594 1.558 . . . . 0.0 112.486 176.674 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 151.49 19.4 0.06 OUTLIER Glycine 0 CA--C 1.538 1.526 0 N-CA-C 117.602 1.801 . . . . 0.0 117.602 179.284 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 3.7 t -127.78 138.69 53.99 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.814 0 CA-C-N 120.25 2.025 . . . . 0.0 110.309 -177.659 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 8.6 t -91.87 94.65 9.42 Favored 'General case' 0 N--CA 1.472 0.658 0 C-N-CA 125.245 1.418 . . . . 0.0 112.324 -173.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 19.6 mm -98.28 -25.55 4.03 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.006 0 C-N-CA 124.368 1.067 . . . . 0.0 112.972 -176.861 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -78.94 -25.02 43.6 Favored 'General case' 0 N--CA 1.48 1.048 0 C-N-CA 125.065 1.346 . . . . 0.0 113.848 178.501 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER 53.83 36.23 23.57 Favored 'General case' 0 N--CA 1.48 1.025 0 C-N-CA 125.15 1.38 . . . . 0.0 113.231 -169.92 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -60.1 164.36 4.13 Favored 'General case' 0 CA--C 1.548 0.903 0 C-N-CA 127.045 2.138 . . . . 0.0 113.726 178.93 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 109.43 -11.03 33.3 Favored Glycine 0 CA--C 1.539 1.572 0 C-N-CA 126.805 2.145 . . . . 0.0 114.919 -177.85 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 62.4 m -110.55 -40.48 4.6 Favored 'General case' 0 N--CA 1.478 0.962 0 C-N-CA 125.281 1.432 . . . . 0.0 113.773 -178.182 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 84.9 m -132.9 155.63 80.95 Favored Pre-proline 0 CA--C 1.545 0.773 0 C-N-CA 126.393 1.877 . . . . 0.0 110.599 179.179 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -72.19 -13.14 28.32 Favored 'Trans proline' 0 CA--C 1.544 1.023 0 C-N-CA 123.18 2.587 . . . . 0.0 114.222 -176.562 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.8 m -66.13 133.27 50.35 Favored 'General case' 0 N--CA 1.473 0.709 0 C-N-CA 125.769 1.628 . . . . 0.0 111.254 176.618 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -160.07 -83.07 0.05 OUTLIER Glycine 0 CA--C 1.533 1.161 0 O-C-N 121.756 -0.59 . . . . 0.0 113.6 179.943 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 44.1 mt . . . . . 0 C--O 1.254 1.326 0 C-N-CA 125.213 1.405 . . . . 0.0 110.74 175.821 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 13.6 tmtt? . . . . . 0 N--CA 1.49 1.575 0 N-CA-C 110.436 -0.209 . . . . 0.0 110.436 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 46.7 tttp 48.99 57.53 6.35 Favored 'General case' 0 N--CA 1.483 1.223 0 C-N-CA 126.826 2.05 . . . . 0.0 113.885 -177.392 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 47.9 t -129.44 127.16 64.65 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.072 0 C-N-CA 125.871 1.668 . . . . 0.0 110.497 176.386 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 3.7 m -77.58 103.13 7.34 Favored 'General case' 0 CA--C 1.544 0.737 0 C-N-CA 125.699 1.6 . . . . 0.0 110.002 175.022 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -74.66 60.22 0.9 Allowed 'General case' 0 CA--C 1.553 1.085 0 C-N-CA 124.607 1.163 . . . . 0.0 112.827 179.351 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 84.3 m -64.12 156.11 76.15 Favored Pre-proline 0 CA--C 1.55 0.947 0 C-N-CA 125.78 1.632 . . . . 0.0 112.96 179.497 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 93.0 Cg_endo -71.35 168.42 23.5 Favored 'Trans proline' 0 CA--C 1.54 0.819 0 C-N-CA 123.056 2.504 . . . . 0.0 112.334 176.589 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 38.0 tttp -64.09 -20.33 65.88 Favored 'General case' 0 N--CA 1.479 0.977 0 C-N-CA 124.761 1.224 . . . . 0.0 113.188 174.721 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 61.7 mt -57.89 120.05 3.62 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.589 0 C-N-CA 126.715 2.006 . . . . 0.0 111.066 179.908 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 15.9 tp -99.44 117.41 33.79 Favored 'General case' 0 CA--C 1.538 0.508 0 C-N-CA 129.048 2.939 . . . . 0.0 108.363 174.533 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -132.18 78.27 69.14 Favored Pre-proline 0 N--CA 1.473 0.704 0 C-N-CA 125.786 1.634 . . . . 0.0 108.882 -178.695 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 66.2 Cg_endo -71.38 102.66 1.3 Allowed 'Trans proline' 0 CA--C 1.537 0.67 0 C-N-CA 123.831 3.021 . . . . 0.0 112.181 -168.527 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -100.2 158.13 3.91 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.003 0 C-N-CA 124.332 1.053 . . . . 0.0 112.245 -176.162 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 18.0 t -72.94 -18.2 61.41 Favored 'General case' 0 CA--C 1.547 0.843 0 N-CA-C 114.209 1.189 . . . . 0.0 114.209 -178.896 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 63.51 -178.63 6.68 Favored Glycine 0 CA--C 1.537 1.457 0 C-N-CA 126.416 1.96 . . . . 0.0 115.514 176.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 14.1 m -84.53 -38.46 20.0 Favored 'General case' 0 N--CA 1.476 0.857 0 C-N-CA 124.066 0.947 . . . . 0.0 113.083 173.484 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 20.4 m-20 -77.03 -14.97 59.76 Favored 'General case' 0 N--CA 1.479 0.98 0 N-CA-C 113.581 0.956 . . . . 0.0 113.581 179.695 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 98.07 -11.77 63.91 Favored Glycine 0 CA--C 1.536 1.353 0 C-N-CA 126.391 1.948 . . . . 0.0 114.392 179.842 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -78.41 156.53 29.4 Favored 'General case' 0 N--CA 1.474 0.761 0 C-N-CA 125.262 1.425 . . . . 0.0 112.084 171.239 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -84.26 113.14 20.9 Favored 'General case' 0 N--CA 1.472 0.638 0 C-N-CA 124.88 1.272 . . . . 0.0 112.857 178.069 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 79.0 m-85 -91.45 149.53 21.66 Favored 'General case' 0 N--CA 1.475 0.785 0 C-N-CA 124.792 1.237 . . . . 0.0 111.599 173.489 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.69 -46.75 77.84 Favored 'General case' 0 CA--C 1.542 0.665 0 N-CA-C 113.355 0.872 . . . . 0.0 113.355 -168.936 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 26.0 p30 -157.06 -179.35 8.12 Favored 'General case' 0 CA--C 1.545 0.773 0 C-N-CA 125.441 1.496 . . . . 0.0 111.88 174.348 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 36.7 p -61.69 -32.57 72.78 Favored 'General case' 0 N--CA 1.473 0.708 0 O-C-N 120.977 -1.077 . . . . 0.0 113.342 173.956 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 49.5 t -58.82 -60.51 3.73 Favored 'General case' 0 CA--C 1.533 0.299 0 C-N-CA 124.85 1.26 . . . . 0.0 111.765 176.75 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 9.8 tp -56.98 -40.45 72.64 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.881 0 N-CA-C 112.431 0.53 . . . . 0.0 112.431 178.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -57.32 -59.34 5.27 Favored 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 123.886 0.874 . . . . 0.0 111.461 176.498 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 46.3 mmm-85 -59.27 -41.85 89.84 Favored 'General case' 0 N--CA 1.475 0.799 0 C-N-CA 124.773 1.229 . . . . 0.0 113.028 178.775 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 2.9 t -66.6 -41.33 88.62 Favored 'General case' 0 CA--C 1.545 0.757 0 C-N-CA 123.609 0.763 . . . . 0.0 112.536 179.579 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 53.1 t30 -71.52 -42.0 68.51 Favored 'General case' 0 CA--C 1.543 0.7 0 C-N-CA 124.655 1.182 . . . . 0.0 113.181 178.833 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 129.71 30.1 0.66 Allowed Glycine 0 CA--C 1.538 1.475 0 C-N-CA 124.611 1.1 . . . . 0.0 115.206 -179.333 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -123.08 169.7 14.16 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 C-N-CA 127.37 2.268 . . . . 0.0 109.192 -177.866 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 29.8 t -145.77 161.52 39.74 Favored 'General case' 0 N--CA 1.471 0.614 0 C-N-CA 125.259 1.423 . . . . 0.0 112.42 -179.005 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 18.7 mm -100.91 -7.36 9.08 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.86 0 C-N-CA 125.956 1.703 . . . . 0.0 111.69 178.019 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 8.4 mmpt? -62.37 -28.73 69.97 Favored 'General case' 0 N--CA 1.481 1.078 0 C-N-CA 125.22 1.408 . . . . 0.0 113.323 -178.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 21.8 t -62.78 -54.54 37.5 Favored 'General case' 0 N--CA 1.471 0.576 0 C-N-CA 124.84 1.256 . . . . 0.0 111.609 172.522 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 4.3 mt-10 -165.07 151.07 9.94 Favored 'General case' 0 N--CA 1.473 0.718 0 C-N-CA 126.239 1.816 . . . . 0.0 111.41 -179.231 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 133.85 93.1 0.48 Allowed Glycine 0 CA--C 1.531 1.06 0 C-N-CA 125.272 1.415 . . . . 0.0 112.276 179.531 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 34.1 m -55.95 145.86 23.91 Favored 'General case' 0 N--CA 1.474 0.754 0 C-N-CA 124.676 1.191 . . . . 0.0 112.649 178.747 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 28.9 p -146.42 158.7 46.73 Favored Pre-proline 0 CA--C 1.547 0.855 0 C-N-CA 125.084 1.354 . . . . 0.0 112.289 -176.938 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -69.98 124.13 10.69 Favored 'Trans proline' 0 CA--C 1.541 0.846 0 C-N-CA 123.141 2.561 . . . . 0.0 111.134 174.675 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 22.5 p -65.54 129.12 38.62 Favored 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 124.0 0.92 . . . . 0.0 111.389 174.998 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -112.32 -68.38 0.53 Allowed Glycine 0 CA--C 1.532 1.114 0 C-N-CA 125.284 1.421 . . . . 0.0 113.27 -175.237 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 10.7 tp . . . . . 0 C--O 1.253 1.263 0 C-N-CA 126.989 2.115 . . . . 0.0 112.202 -178.207 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 14.8 ptpt . . . . . 0 N--CA 1.497 1.901 0 N-CA-C 114.63 1.344 . . . . 0.0 114.63 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 12.4 mmmm 52.05 37.51 21.58 Favored 'General case' 0 N--CA 1.491 1.579 0 C-N-CA 126.284 1.834 . . . . 0.0 114.538 179.491 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.9 p -119.43 -4.17 10.17 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.315 0 C-N-CA 125.885 1.674 . . . . 0.0 113.954 -177.293 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 29.2 m -63.15 103.81 0.52 Allowed 'General case' 0 CA--C 1.54 0.585 0 C-N-CA 126.446 1.899 . . . . 0.0 110.532 177.752 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -71.64 55.78 0.26 Allowed 'General case' 0 CA--C 1.552 1.045 0 C-N-CA 126.516 1.926 . . . . 0.0 113.101 -179.961 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 93.0 m -63.59 157.59 64.79 Favored Pre-proline 0 CA--C 1.549 0.937 0 C-N-CA 126.083 1.753 . . . . 0.0 112.739 178.496 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -64.89 155.02 70.14 Favored 'Trans proline' 0 CA--C 1.537 0.671 0 C-N-CA 123.281 2.654 . . . . 0.0 112.803 -179.871 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 19.5 ptpt -59.75 -25.59 64.99 Favored 'General case' 0 N--CA 1.48 1.074 0 C-N-CA 125.707 1.603 . . . . 0.0 114.497 178.029 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 8.9 tp -57.11 144.47 9.34 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.473 0 C-N-CA 127.089 2.155 . . . . 0.0 113.212 -178.68 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 23.8 tp -119.66 108.24 14.21 Favored 'General case' 0 CA--C 1.535 0.402 0 C-N-CA 126.708 2.003 . . . . 0.0 108.292 -178.283 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 39.5 ttpt -128.95 79.03 75.34 Favored Pre-proline 0 CA--C 1.54 0.576 0 C-N-CA 126.38 1.872 . . . . 0.0 108.511 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -73.68 90.34 0.94 Allowed 'Trans proline' 0 CA--C 1.539 0.742 0 C-N-CA 123.72 2.947 . . . . 0.0 111.909 -171.442 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 1.1 t -83.56 161.26 3.38 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 C-N-CA 124.421 1.089 . . . . 0.0 111.03 -177.56 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 46.3 t -72.44 111.59 7.76 Favored 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 124.342 1.057 . . . . 0.0 109.839 170.448 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -65.51 146.01 49.25 Favored Glycine 0 CA--C 1.532 1.118 0 C-N-CA 123.778 0.704 . . . . 0.0 112.422 177.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 82.7 p -61.39 -29.86 70.19 Favored 'General case' 0 N--CA 1.476 0.865 0 N-CA-C 113.935 1.087 . . . . 0.0 113.935 -174.072 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 31.8 t70 -84.98 -8.19 58.84 Favored 'General case' 0 CA--C 1.551 0.993 0 C-N-CA 125.964 1.706 . . . . 0.0 113.894 176.92 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 107.51 1.04 34.96 Favored Glycine 0 CA--C 1.536 1.386 0 C-N-CA 126.504 2.002 . . . . 0.0 114.674 -178.623 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 22.1 mtm180 -90.32 -172.21 3.37 Favored 'General case' 0 N--CA 1.479 0.988 0 C-N-CA 126.355 1.862 . . . . 0.0 112.387 -177.269 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 23.0 m -128.8 135.26 48.91 Favored 'General case' 0 N--CA 1.479 1.01 0 C-N-CA 125.487 1.515 . . . . 0.0 110.492 -178.274 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 81.8 m-85 -135.94 150.39 49.27 Favored 'General case' 0 N--CA 1.474 0.74 0 C-N-CA 125.055 1.342 . . . . 0.0 111.488 -177.573 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.31 -45.08 89.52 Favored 'General case' 0 CA--C 1.543 0.683 0 N-CA-C 113.929 1.085 . . . . 0.0 113.929 -165.242 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 27.0 p30 -157.74 178.62 10.05 Favored 'General case' 0 CA--C 1.549 0.932 0 C-N-CA 125.927 1.691 . . . . 0.0 111.124 170.298 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 89.0 p -60.54 -29.69 69.29 Favored 'General case' 0 N--CA 1.478 0.973 0 N-CA-C 114.015 1.117 . . . . 0.0 114.015 179.052 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 45.4 t -61.66 -57.93 10.05 Favored 'General case' 0 N--CA 1.465 0.312 0 C-N-CA 124.24 1.016 . . . . 0.0 111.704 176.888 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 7.6 tp -59.75 -37.89 73.38 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.819 0 N-CA-C 112.062 0.393 . . . . 0.0 112.062 -179.878 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -57.3 -55.96 28.02 Favored 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 124.199 1.0 . . . . 0.0 111.583 173.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 70.4 mtp85 -61.23 -40.63 94.73 Favored 'General case' 0 N--CA 1.475 0.809 0 N-CA-C 113.297 0.851 . . . . 0.0 113.297 178.341 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -65.41 -36.35 83.68 Favored 'General case' 0 CA--C 1.546 0.819 0 N-CA-C 112.57 0.582 . . . . 0.0 112.57 177.132 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 25.9 t-20 -72.37 -47.53 48.68 Favored 'General case' 0 CA--C 1.546 0.815 0 C-N-CA 124.798 1.239 . . . . 0.0 113.003 175.926 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 135.8 29.5 0.36 Allowed Glycine 0 CA--C 1.538 1.53 0 C-N-CA 124.911 1.243 . . . . 0.0 115.469 -178.437 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 34.6 t -127.87 152.32 35.8 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.464 0 C-N-CA 127.416 2.286 . . . . 0.0 108.645 -176.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 58.2 m -141.72 160.06 40.95 Favored 'General case' 0 N--CA 1.476 0.838 0 C-N-CA 125.878 1.671 . . . . 0.0 112.302 -179.343 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 16.3 mt -113.17 -12.84 11.64 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.108 0 C-N-CA 125.102 1.361 . . . . 0.0 111.828 -175.067 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -58.21 -26.06 62.38 Favored 'General case' 0 N--CA 1.482 1.157 0 C-N-CA 125.699 1.6 . . . . 0.0 114.255 176.25 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 20.8 m -63.59 -49.74 72.15 Favored 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 125.654 1.582 . . . . 0.0 112.349 179.114 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -156.93 133.68 10.14 Favored 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 125.912 1.685 . . . . 0.0 111.511 175.086 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.82 -64.24 0.48 Allowed Glycine 0 CA--C 1.531 1.081 0 C-N-CA 124.985 1.279 . . . . 0.0 112.504 -178.41 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 95.6 p -150.43 165.71 32.33 Favored 'General case' 0 N--CA 1.473 0.694 0 C-N-CA 125.089 1.356 . . . . 0.0 113.018 178.312 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 13.2 p -149.38 66.17 8.29 Favored Pre-proline 0 CA--C 1.553 1.085 0 C-N-CA 125.495 1.518 . . . . 0.0 112.045 175.626 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -70.83 103.86 1.4 Allowed 'Trans proline' 0 CA--C 1.542 0.911 0 C-N-CA 123.875 3.05 . . . . 0.0 112.387 -177.179 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 16.1 m -61.21 139.16 58.19 Favored 'General case' 0 N--CA 1.477 0.887 0 C-N-CA 125.252 1.421 . . . . 0.0 111.976 178.207 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -166.1 165.21 38.02 Favored Glycine 0 CA--C 1.535 1.321 0 C-N-CA 125.059 1.314 . . . . 0.0 112.75 172.819 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 19.9 tt . . . . . 0 C--O 1.252 1.228 0 C-N-CA 126.571 1.948 . . . . 0.0 112.184 -179.596 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 18.8 ptpt . . . . . 0 N--CA 1.492 1.638 0 N-CA-C 111.6 0.222 . . . . 0.0 111.6 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 4.0 mppt? -114.35 130.71 56.69 Favored 'General case' 0 N--CA 1.478 0.968 0 C-N-CA 125.711 1.604 . . . . 0.0 110.248 172.9 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 33.2 t -136.36 128.21 44.16 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.942 0 C-N-CA 125.922 1.689 . . . . 0.0 109.481 179.153 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 4.7 t -124.99 -4.92 7.45 Favored 'General case' 0 CA--C 1.548 0.87 0 C-N-CA 124.726 1.211 . . . . 0.0 114.111 -178.118 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . 49.34 30.73 3.39 Favored 'General case' 0 CA--C 1.549 0.921 0 C-N-CA 127.018 2.127 . . . . 0.0 115.603 178.421 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 58.0 m -61.8 151.29 79.76 Favored Pre-proline 0 CA--C 1.547 0.828 0 C-N-CA 124.368 1.067 . . . . 0.0 112.379 177.141 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -75.1 -4.13 14.93 Favored 'Trans proline' 0 CA--C 1.543 0.955 0 C-N-CA 124.135 3.223 . . . . 0.0 115.735 -168.769 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 37.8 mmtm 58.86 6.93 0.7 Allowed 'General case' 0 N--CA 1.481 1.093 0 C-N-CA 128.247 2.619 . . . . 0.0 116.299 179.839 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 11.2 tp -51.76 142.47 4.27 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.631 0 C-N-CA 126.698 1.999 . . . . 0.0 112.329 178.436 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 4.5 tt -78.46 89.99 4.45 Favored 'General case' 0 CA--C 1.545 0.772 0 C-N-CA 127.209 2.204 . . . . 0.0 110.907 -177.706 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 3.8 ttmp? -143.83 74.83 16.34 Favored Pre-proline 0 N--CA 1.477 0.897 0 C-N-CA 124.992 1.317 . . . . 0.0 111.843 178.33 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -67.8 91.1 0.36 Allowed 'Trans proline' 0 CA--C 1.54 0.809 0 C-N-CA 124.347 3.364 . . . . 0.0 112.754 -175.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 5.7 m -87.27 143.08 12.05 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 C-N-CA 126.32 1.848 . . . . 0.0 112.101 179.652 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 47.3 t -63.7 119.82 10.65 Favored 'General case' 0 CA--C 1.542 0.653 0 C-N-CA 124.125 0.97 . . . . 0.0 110.988 172.475 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -92.23 154.79 22.53 Favored Glycine 0 CA--C 1.533 1.17 0 C-N-CA 124.597 1.094 . . . . 0.0 112.861 177.911 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 7.5 t -61.74 -27.26 68.6 Favored 'General case' 0 N--CA 1.475 0.781 0 N-CA-C 114.463 1.283 . . . . 0.0 114.463 -173.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 10.5 t0 -76.52 -10.25 59.25 Favored 'General case' 0 CA--C 1.547 0.841 0 N-CA-C 113.69 0.996 . . . . 0.0 113.69 176.216 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 105.09 -10.11 47.3 Favored Glycine 0 CA--C 1.536 1.354 0 C-N-CA 126.586 2.041 . . . . 0.0 114.048 178.21 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 5.9 ptp85 -82.31 -171.13 3.27 Favored 'General case' 0 N--CA 1.473 0.706 0 C-N-CA 126.067 1.747 . . . . 0.0 112.723 173.365 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 11.5 t -123.34 157.62 32.86 Favored 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 125.595 1.558 . . . . 0.0 111.688 174.307 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -137.51 148.53 46.08 Favored 'General case' 0 N--CA 1.471 0.6 0 C-N-CA 126.263 1.825 . . . . 0.0 110.917 -179.9 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -60.28 -36.86 78.8 Favored 'General case' 0 CA--C 1.543 0.673 0 N-CA-C 114.049 1.129 . . . . 0.0 114.049 -164.277 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 12.4 p30 -156.89 177.54 11.39 Favored 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 126.443 1.897 . . . . 0.0 111.848 168.889 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 27.6 t -58.73 -38.95 79.49 Favored 'General case' 0 N--CA 1.472 0.637 0 O-C-N 121.345 -0.847 . . . . 0.0 113.099 176.486 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 20.0 t -60.14 -55.94 27.66 Favored 'General case' 0 N--CA 1.468 0.47 0 O-C-N 121.493 -0.755 . . . . 0.0 111.806 -179.886 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 7.4 tt -59.4 -38.71 76.42 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.698 0 CA-C-O 118.996 -0.526 . . . . 0.0 112.292 178.437 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -59.61 -53.6 56.12 Favored 'General case' 0 CA--C 1.543 0.684 0 CA-C-N 119.132 0.878 . . . . 0.0 111.904 174.814 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 5.7 mtp-105 -57.41 -44.07 84.27 Favored 'General case' 0 N--CA 1.477 0.884 0 C-N-CA 124.824 1.25 . . . . 0.0 112.3 178.034 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -71.51 -34.0 69.71 Favored 'General case' 0 CA--C 1.544 0.737 0 N-CA-C 113.448 0.907 . . . . 0.0 113.448 178.748 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 28.8 t-20 -66.85 -40.39 87.91 Favored 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 124.277 1.031 . . . . 0.0 112.541 174.056 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 135.29 22.59 0.63 Allowed Glycine 0 CA--C 1.538 1.471 0 C-N-CA 125.051 1.31 . . . . 0.0 115.896 176.366 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 40.4 t -128.26 149.54 33.2 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.525 0 C-N-CA 126.26 1.824 . . . . 0.0 109.866 -174.556 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 58.8 m -121.92 171.81 8.66 Favored 'General case' 0 N--CA 1.475 0.78 0 C-N-CA 126.857 2.063 . . . . 0.0 112.063 -176.702 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -138.82 108.37 4.07 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.447 0 C-N-CA 125.513 1.525 . . . . 0.0 108.92 -176.37 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 47.6 mmtm -58.32 -39.08 78.45 Favored 'General case' 0 N--CA 1.478 0.957 0 C-N-CA 125.808 1.643 . . . . 0.0 112.729 177.719 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER 55.43 24.02 6.33 Favored 'General case' 0 N--CA 1.478 0.951 0 C-N-CA 126.746 2.018 . . . . 0.0 114.928 176.024 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 33.8 tt0 -59.79 -33.81 72.21 Favored 'General case' 0 N--CA 1.474 0.765 0 C-N-CA 125.858 1.663 . . . . 0.0 113.8 -171.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -89.37 -2.53 76.66 Favored Glycine 0 CA--C 1.537 1.448 0 C-N-CA 124.975 1.274 . . . . 0.0 115.218 179.233 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 44.4 m -89.05 173.59 8.37 Favored 'General case' 0 N--CA 1.472 0.657 0 C-N-CA 125.161 1.384 . . . . 0.0 113.404 -173.933 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 73.7 m -125.15 70.92 62.45 Favored Pre-proline 0 CA--C 1.549 0.904 0 C-N-CA 126.103 1.761 . . . . 0.0 111.225 174.676 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 76.6 Cg_endo -70.83 157.79 57.34 Favored 'Trans proline' 0 CA--C 1.541 0.851 0 C-N-CA 123.077 2.518 . . . . 0.0 112.465 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 6.3 t -108.2 -12.58 15.07 Favored 'General case' 0 N--CA 1.481 1.114 0 C-N-CA 125.051 1.34 . . . . 0.0 113.724 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -110.58 -59.84 0.49 Allowed Glycine 0 CA--C 1.535 1.286 0 C-N-CA 125.585 1.564 . . . . 0.0 114.349 -176.557 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 19.5 tt . . . . . 0 C--O 1.253 1.264 0 C-N-CA 126.608 1.963 . . . . 0.0 112.619 -173.433 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.723 0 N-CA-C 111.781 0.289 . . . . 0.0 111.781 . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 57.0 mtpt -126.52 171.73 10.82 Favored 'General case' 0 N--CA 1.482 1.17 0 C-N-CA 126.47 1.908 . . . . 0.0 111.12 173.683 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 49.2 t -142.85 141.49 27.05 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.17 0 C-N-CA 126.725 2.01 . . . . 0.0 109.258 176.121 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 10.9 t -67.61 123.89 21.72 Favored 'General case' 0 CA--C 1.544 0.746 0 C-N-CA 123.324 0.65 . . . . 0.0 111.83 176.212 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -74.04 32.36 0.08 Allowed 'General case' 0 CA--C 1.554 1.128 0 C-N-CA 126.588 1.955 . . . . 0.0 115.668 -172.654 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 62.8 m -64.25 152.65 87.9 Favored Pre-proline 0 CA--C 1.549 0.926 0 C-N-CA 124.907 1.283 . . . . 0.0 113.67 179.275 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 89.1 Cg_endo -72.6 153.86 54.71 Favored 'Trans proline' 0 C--N 1.352 0.742 0 C-N-CA 123.359 2.706 . . . . 0.0 112.326 176.581 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 57.3 mtmt -76.38 -1.93 29.33 Favored 'General case' 0 N--CA 1.48 1.053 0 C-N-CA 125.708 1.603 . . . . 0.0 114.685 -179.361 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 46.9 mm -51.18 120.59 1.34 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.715 0 C-N-CA 126.145 1.778 . . . . 0.0 111.181 174.716 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 54.9 tp -84.71 102.27 12.85 Favored 'General case' 0 CA--C 1.539 0.546 0 C-N-CA 127.401 2.28 . . . . 0.0 109.614 177.935 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 20.8 tptp -147.07 91.94 5.04 Favored Pre-proline 0 N--CA 1.471 0.582 0 C-N-CA 124.098 0.959 . . . . 0.0 110.753 166.432 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -64.47 137.89 57.35 Favored 'Trans proline' 0 N--CA 1.456 -0.689 0 C-N-CA 121.191 1.261 . . . . 0.0 111.024 172.266 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 8.7 m -140.79 159.09 23.98 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.361 0 C-N-CA 127.373 2.269 . . . . 0.0 110.845 -179.346 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 37.6 t -72.78 149.52 43.58 Favored 'General case' 0 CA--C 1.545 0.763 0 C-N-CA 123.822 0.849 . . . . 0.0 111.785 171.973 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -123.76 156.21 17.93 Favored Glycine 0 CA--C 1.535 1.325 0 C-N-CA 125.859 1.695 . . . . 0.0 112.544 169.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 14.6 t -51.53 -40.64 60.05 Favored 'General case' 0 N--CA 1.478 0.966 0 C-N-CA 126.059 1.744 . . . . 0.0 115.431 -166.119 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 13.9 m-20 -71.1 -5.86 34.79 Favored 'General case' 0 CA--C 1.548 0.879 0 N-CA-C 114.863 1.431 . . . . 0.0 114.863 -179.193 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 86.83 61.32 1.61 Allowed Glycine 0 CA--C 1.527 0.805 0 C-N-CA 125.107 1.337 . . . . 0.0 110.592 -173.387 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 89.5 mmt-85 -142.18 168.29 20.09 Favored 'General case' 0 N--CA 1.472 0.671 0 C-N-CA 127.36 2.264 . . . . 0.0 111.103 -172.806 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 6.6 p -132.14 145.23 51.24 Favored 'General case' 0 C--O 1.235 0.322 0 C-N-CA 126.301 1.84 . . . . 0.0 111.089 172.455 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 92.8 m-85 -141.63 157.04 45.59 Favored 'General case' 0 N--CA 1.471 0.62 0 C-N-CA 125.604 1.561 . . . . 0.0 111.454 -179.461 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.69 -32.89 74.77 Favored 'General case' 0 CA--C 1.545 0.788 0 N-CA-C 114.451 1.278 . . . . 0.0 114.451 -165.222 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 60.5 t30 -149.37 168.13 24.24 Favored 'General case' 0 CA--C 1.544 0.747 0 C-N-CA 125.558 1.543 . . . . 0.0 111.17 171.26 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 34.6 p -57.19 -42.63 81.56 Favored 'General case' 0 N--CA 1.472 0.653 0 C-N-CA 124.769 1.228 . . . . 0.0 113.106 175.216 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 38.1 t -56.51 -55.76 29.68 Favored 'General case' 0 CA--C 1.533 0.292 0 C-N-CA 124.376 1.07 . . . . 0.0 112.11 177.507 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.8 tt -62.21 -35.25 68.08 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.672 0 CA-C-O 118.684 -0.674 . . . . 0.0 112.407 -177.679 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -57.82 -53.43 58.27 Favored 'General case' 0 CA--C 1.54 0.563 0 CA-C-N 119.288 0.949 . . . . 0.0 111.443 173.516 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -56.38 -49.78 73.47 Favored 'General case' 0 N--CA 1.474 0.768 0 C-N-CA 125.042 1.337 . . . . 0.0 111.282 176.124 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -63.7 -39.84 95.29 Favored 'General case' 0 CA--C 1.541 0.622 0 C-N-CA 123.786 0.834 . . . . 0.0 113.089 -177.68 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 88.8 m-20 -66.27 -33.44 75.74 Favored 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 124.86 1.264 . . . . 0.0 112.79 174.458 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 130.17 17.21 1.64 Allowed Glycine 0 CA--C 1.536 1.369 0 N-CA-C 116.389 1.316 . . . . 0.0 116.389 171.618 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 7.4 t -118.63 132.97 66.96 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.666 0 CA-C-N 119.629 1.714 . . . . 0.0 110.608 -178.229 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 38.5 m -78.54 164.69 24.48 Favored 'General case' 0 C--N 1.322 -0.597 0 C-N-CA 126.826 2.05 . . . . 0.0 112.714 -179.583 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -134.36 98.8 2.51 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.525 0 C-N-CA 125.873 1.669 . . . . 0.0 109.1 -178.959 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -87.93 -13.74 41.06 Favored 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 125.849 1.66 . . . . 0.0 113.405 -179.723 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 22.7 t -84.88 119.59 25.51 Favored 'General case' 0 CA--C 1.532 0.273 0 C-N-CA 125.954 1.701 . . . . 0.0 110.935 173.608 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 8.2 tp10 -63.43 -15.08 56.6 Favored 'General case' 0 CA--C 1.551 1.015 0 C-N-CA 125.478 1.511 . . . . 0.0 113.169 169.844 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -78.22 58.43 4.01 Favored Glycine 0 CA--C 1.536 1.366 0 C-N-CA 126.135 1.826 . . . . 0.0 113.79 178.434 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 71.6 p -140.2 168.46 19.75 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 126.299 1.84 . . . . 0.0 112.491 179.681 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 1.9 m -65.1 159.16 67.28 Favored Pre-proline 0 CA--C 1.549 0.909 0 C-N-CA 123.575 0.75 . . . . 0.0 112.792 174.036 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -68.8 164.88 31.68 Favored 'Trans proline' 0 CA--C 1.541 0.836 0 C-N-CA 123.182 2.588 . . . . 0.0 112.462 175.945 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 20.7 m -137.49 143.82 41.9 Favored 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 125.521 1.528 . . . . 0.0 110.651 -175.691 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -81.75 -171.4 45.71 Favored Glycine 0 CA--C 1.538 1.496 0 C-N-CA 125.138 1.351 . . . . 0.0 114.044 178.179 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 4.6 mp . . . . . 0 C--O 1.252 1.227 0 C-N-CA 126.728 2.011 . . . . 0.0 110.191 179.068 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 68.4 mttm . . . . . 0 N--CA 1.492 1.654 0 N-CA-C 110.537 -0.171 . . . . 0.0 110.537 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 37.7 ttpt -72.38 94.74 1.66 Allowed 'General case' 0 N--CA 1.48 1.037 0 C-N-CA 125.224 1.41 . . . . 0.0 111.31 175.776 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 13.8 p -143.41 147.1 20.59 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.028 0 C-N-CA 125.043 1.337 . . . . 0.0 112.304 179.737 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 3.2 m -66.8 113.25 4.74 Favored 'General case' 0 CA--C 1.548 0.884 0 C-N-CA 125.515 1.526 . . . . 0.0 110.377 173.77 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -75.89 58.45 1.15 Allowed 'General case' 0 CA--C 1.554 1.1 0 C-N-CA 124.798 1.239 . . . . 0.0 113.24 -179.519 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 76.3 m -69.75 159.32 84.39 Favored Pre-proline 0 CA--C 1.553 1.082 0 C-N-CA 126.048 1.739 . . . . 0.0 113.746 -177.413 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -71.06 165.44 32.39 Favored 'Trans proline' 0 CA--C 1.542 0.877 0 C-N-CA 123.497 2.798 . . . . 0.0 113.407 179.141 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 7.9 ptpp? -68.35 -27.56 66.36 Favored 'General case' 0 N--CA 1.482 1.161 0 C-N-CA 125.072 1.349 . . . . 0.0 114.613 175.501 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 34.9 mm -60.08 161.88 1.24 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.83 0 C-N-CA 128.162 2.585 . . . . 0.0 111.294 176.295 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 20.1 tp -141.98 101.89 4.03 Favored 'General case' 0 CA--C 1.537 0.472 0 C-N-CA 126.257 1.823 . . . . 0.0 109.879 -170.646 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -115.52 84.92 12.77 Favored Pre-proline 0 N--CA 1.474 0.726 0 C-N-CA 126.096 1.759 . . . . 0.0 109.42 175.399 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 93.7 Cg_endo -74.52 81.14 2.14 Favored 'Trans proline' 0 CA--C 1.541 0.848 0 C-N-CA 124.043 3.162 . . . . 0.0 111.717 -176.616 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 9.0 m -85.84 164.24 2.48 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 C-N-CA 127.195 2.198 . . . . 0.0 113.003 -175.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 30.1 p -68.29 173.97 4.37 Favored 'General case' 0 CA--C 1.549 0.933 0 C-N-CA 124.231 1.012 . . . . 0.0 112.294 159.289 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -148.48 155.98 26.66 Favored Glycine 0 CA--C 1.532 1.132 0 C-N-CA 125.691 1.615 . . . . 0.0 111.392 173.712 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 19.0 t -57.09 -35.55 69.54 Favored 'General case' 0 N--CA 1.476 0.872 0 N-CA-C 115.144 1.535 . . . . 0.0 115.144 -163.138 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 31.5 t70 -71.86 -9.1 57.84 Favored 'General case' 0 CA--C 1.551 1.008 0 N-CA-C 114.415 1.265 . . . . 0.0 114.415 179.305 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 106.84 12.58 23.94 Favored Glycine 0 CA--C 1.535 1.286 0 C-N-CA 126.063 1.792 . . . . 0.0 114.073 179.35 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 31.2 mtm180 -120.99 134.46 55.3 Favored 'General case' 0 N--CA 1.476 0.844 0 C-N-CA 126.225 1.81 . . . . 0.0 111.181 -171.542 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 18.0 p -75.23 151.55 38.41 Favored 'General case' 0 N--CA 1.471 0.597 0 C-N-CA 124.622 1.169 . . . . 0.0 112.614 177.927 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 76.5 m-85 -139.69 149.03 43.19 Favored 'General case' 0 N--CA 1.471 0.592 0 C-N-CA 125.434 1.494 . . . . 0.0 112.93 -179.87 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -69.74 -33.72 72.84 Favored 'General case' 0 CA--C 1.545 0.76 0 N-CA-C 113.902 1.075 . . . . 0.0 113.902 -165.895 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 14.7 m-20 -145.87 170.85 15.76 Favored 'General case' 0 CA--C 1.543 0.703 0 C-N-CA 125.813 1.645 . . . . 0.0 110.946 166.116 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 40.7 p -59.46 -35.55 74.27 Favored 'General case' 0 N--CA 1.473 0.722 0 O-C-N 121.368 -0.832 . . . . 0.0 112.45 165.824 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 43.5 t -52.87 -63.33 1.18 Allowed 'General case' 0 CA--C 1.533 0.316 0 C-N-CA 126.01 1.724 . . . . 0.0 112.369 174.064 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 9.1 tp -58.38 -37.3 62.85 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.788 0 N-CA-C 112.592 0.59 . . . . 0.0 112.592 -178.583 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -59.94 -54.59 44.32 Favored 'General case' 0 CA--C 1.544 0.716 0 CA-C-N 118.697 0.68 . . . . 0.0 111.836 173.961 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 25.4 mmm180 -61.57 -39.98 93.09 Favored 'General case' 0 N--CA 1.478 0.975 0 C-N-CA 124.707 1.203 . . . . 0.0 113.207 177.933 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 9.2 t -62.15 -43.92 97.76 Favored 'General case' 0 CA--C 1.544 0.729 0 C-N-CA 124.832 1.253 . . . . 0.0 111.644 175.128 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 28.7 t-20 -68.79 -46.62 68.21 Favored 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 124.837 1.255 . . . . 0.0 113.179 178.263 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 136.11 26.42 0.45 Allowed Glycine 0 CA--C 1.539 1.534 0 C-N-CA 124.787 1.184 . . . . 0.0 115.964 -179.528 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 40.1 t -124.29 156.12 31.9 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.512 0 C-N-CA 127.11 2.164 . . . . 0.0 108.607 -179.658 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 6.2 t -134.21 177.8 7.47 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 126.25 1.82 . . . . 0.0 112.216 179.143 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -141.61 107.13 1.74 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.299 0 C-N-CA 126.438 1.895 . . . . 0.0 108.869 -170.52 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 2.5 tppp? -61.67 -27.69 68.86 Favored 'General case' 0 N--CA 1.475 0.821 0 C-N-CA 124.617 1.167 . . . . 0.0 112.868 175.033 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 8.2 t -62.33 -47.12 85.66 Favored 'General case' 0 N--CA 1.472 0.644 0 C-N-CA 125.77 1.628 . . . . 0.0 113.28 179.217 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -153.48 131.15 11.52 Favored 'General case' 0 CA--C 1.542 0.661 0 C-N-CA 124.94 1.296 . . . . 0.0 112.196 179.059 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 164.57 57.44 0.02 OUTLIER Glycine 0 CA--C 1.533 1.157 0 C-N-CA 123.787 0.708 . . . . 0.0 113.647 -177.139 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 51.6 p -67.48 160.54 27.35 Favored 'General case' 0 N--CA 1.473 0.685 0 C-N-CA 124.722 1.209 . . . . 0.0 113.362 176.787 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 74.6 m -71.45 156.13 91.87 Favored Pre-proline 0 CA--C 1.549 0.94 0 C-N-CA 124.273 1.029 . . . . 0.0 112.483 176.716 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 96.2 Cg_endo -71.8 164.3 36.12 Favored 'Trans proline' 0 CA--C 1.54 0.78 0 C-N-CA 123.147 2.564 . . . . 0.0 112.357 174.011 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 38.7 p -77.22 -15.7 59.37 Favored 'General case' 0 N--CA 1.48 1.057 0 C-N-CA 124.991 1.316 . . . . 0.0 113.772 174.755 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -113.37 -157.72 12.7 Favored Glycine 0 CA--C 1.537 1.427 0 C-N-CA 127.092 2.282 . . . . 0.0 113.485 -178.76 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 4.1 mp . . . . . 0 C--O 1.253 1.265 0 C-N-CA 126.589 1.956 . . . . 0.0 110.318 178.622 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 26.1 mmmt . . . . . 0 N--CA 1.492 1.643 0 CA-C-O 120.462 0.173 . . . . 0.0 111.118 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 60.4 mttm -62.29 141.81 58.07 Favored 'General case' 0 N--CA 1.48 1.031 0 C-N-CA 125.522 1.529 . . . . 0.0 111.452 172.792 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 40.1 t -140.77 129.84 25.41 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.062 0 C-N-CA 125.789 1.635 . . . . 0.0 109.775 175.972 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 31.2 m -68.25 126.54 29.87 Favored 'General case' 0 CA--C 1.542 0.665 0 C-N-CA 124.632 1.173 . . . . 0.0 110.968 175.384 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -73.27 31.78 0.07 Allowed 'General case' 0 CA--C 1.555 1.163 0 C-N-CA 125.629 1.572 . . . . 0.0 114.37 177.777 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 60.1 m -63.32 160.76 38.6 Favored Pre-proline 0 CA--C 1.549 0.924 0 C-N-CA 126.335 1.854 . . . . 0.0 113.237 177.439 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -67.61 169.77 15.18 Favored 'Trans proline' 0 CA--C 1.541 0.872 0 C-N-CA 123.254 2.636 . . . . 0.0 112.156 170.899 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 10.1 tppt? -107.89 1.98 23.1 Favored 'General case' 0 N--CA 1.482 1.145 0 C-N-CA 125.968 1.707 . . . . 0.0 112.946 172.186 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 83.2 mt -52.24 131.76 13.88 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.762 0 C-N-CA 126.632 1.973 . . . . 0.0 110.821 179.426 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 5.2 tt -69.74 97.85 1.13 Allowed 'General case' 0 CA--C 1.542 0.652 0 C-N-CA 127.399 2.28 . . . . 0.0 111.497 -174.823 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 86.8 tttt -140.6 74.45 27.86 Favored Pre-proline 0 N--CA 1.476 0.828 0 C-N-CA 125.719 1.608 . . . . 0.0 111.101 -177.882 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -66.14 101.33 0.49 Allowed 'Trans proline' 0 CA--C 1.54 0.818 0 C-N-CA 123.956 3.104 . . . . 0.0 112.343 -178.605 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 15.9 m -127.21 159.52 37.33 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.479 0 C-N-CA 126.001 1.72 . . . . 0.0 112.859 -176.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 24.4 p -88.4 123.29 32.81 Favored 'General case' 0 CA--C 1.539 0.529 0 C-N-CA 124.358 1.063 . . . . 0.0 111.889 176.572 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -79.17 55.68 4.34 Favored Glycine 0 CA--C 1.53 0.977 0 C-N-CA 124.665 1.126 . . . . 0.0 112.117 172.673 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 3.9 t 54.81 -11.68 0.01 OUTLIER 'General case' 0 CA--C 1.55 0.979 0 C-N-CA 129.385 3.074 . . . . 0.0 117.268 -175.009 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 63.5 m-20 -95.11 -17.8 21.52 Favored 'General case' 0 N--CA 1.475 0.775 0 C-N-CA 126.041 1.736 . . . . 0.0 114.545 -179.148 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 105.66 2.99 40.36 Favored Glycine 0 CA--C 1.538 1.505 0 C-N-CA 125.498 1.523 . . . . 0.0 114.84 177.713 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 2.1 mmp_? -67.37 -177.98 0.79 Allowed 'General case' 0 N--CA 1.476 0.841 0 C-N-CA 128.541 2.736 . . . . 0.0 112.195 172.501 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 24.1 m -128.58 85.72 2.37 Favored 'General case' 0 N--CA 1.476 0.841 0 C-N-CA 124.92 1.288 . . . . 0.0 110.157 176.318 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 26.8 m-85 -76.12 154.17 35.71 Favored 'General case' 0 N--CA 1.47 0.541 0 C-N-CA 123.94 0.896 . . . . 0.0 112.252 173.389 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.15 -37.63 88.15 Favored 'General case' 0 CA--C 1.542 0.643 0 N-CA-C 113.288 0.847 . . . . 0.0 113.288 -170.447 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 14.3 p30 -152.56 179.42 8.61 Favored 'General case' 0 CA--C 1.545 0.765 0 C-N-CA 126.172 1.789 . . . . 0.0 111.968 172.283 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 9.1 p -70.67 -32.03 69.15 Favored 'General case' 0 N--CA 1.473 0.7 0 O-C-N 121.018 -1.051 . . . . 0.0 113.788 176.369 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 34.8 t -62.42 -49.99 73.27 Favored 'General case' 0 N--CA 1.469 0.484 0 C-N-CA 124.31 1.044 . . . . 0.0 112.269 178.627 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 8.5 tt -58.82 -39.77 78.1 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 N-CA-C 112.194 0.442 . . . . 0.0 112.194 179.338 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -64.88 -44.62 89.05 Favored 'General case' 0 CA--C 1.543 0.712 0 C-N-CA 124.285 1.034 . . . . 0.0 112.599 175.051 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 25.1 mmt180 -55.67 -52.5 63.64 Favored 'General case' 0 N--CA 1.478 0.941 0 C-N-CA 124.378 1.071 . . . . 0.0 111.734 170.814 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 4.9 t -63.08 -37.36 86.89 Favored 'General case' 0 CA--C 1.544 0.714 0 C-N-CA 124.13 0.972 . . . . 0.0 113.023 -178.59 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 28.4 t30 -62.66 -30.55 71.46 Favored 'General case' 0 CA--C 1.545 0.762 0 C-N-CA 124.43 1.092 . . . . 0.0 113.351 176.888 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 135.21 9.97 1.57 Allowed Glycine 0 CA--C 1.536 1.373 0 N-CA-C 116.13 1.212 . . . . 0.0 116.13 175.471 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.46 HG12 ' H ' ' A' ' 33' ' ' SER . 0.5 OUTLIER -107.51 -170.16 0.34 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.653 0 CA-C-N 119.351 1.576 . . . . 0.0 110.689 -177.242 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' SER . . . . . 0.46 ' H ' HG12 ' A' ' 32' ' ' VAL . 27.7 m -147.91 166.96 26.07 Favored 'General case' 0 N--CA 1.471 0.599 0 C-N-CA 128.258 2.623 . . . . 0.0 110.529 174.863 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 1.1 mt -141.31 105.36 1.54 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.622 0 C-N-CA 125.069 1.347 . . . . 0.0 108.765 172.43 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -95.92 -14.66 22.93 Favored 'General case' 0 N--CA 1.481 1.081 0 C-N-CA 125.552 1.541 . . . . 0.0 113.35 176.794 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 1.5 t -78.49 31.28 0.19 Allowed 'General case' 0 N--CA 1.478 0.971 0 C-N-CA 127.382 2.273 . . . . 0.0 114.215 -176.854 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 3.3 mm-40 -61.05 159.99 10.76 Favored 'General case' 0 CA--C 1.543 0.704 0 C-N-CA 125.171 1.388 . . . . 0.0 113.635 176.863 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -75.83 -15.78 81.1 Favored Glycine 0 CA--C 1.538 1.472 0 C-N-CA 124.446 1.022 . . . . 0.0 115.077 -175.824 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 88.4 p -154.98 -178.6 7.35 Favored 'General case' 0 N--CA 1.473 0.7 0 C-N-CA 126.893 2.077 . . . . 0.0 111.061 174.79 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 73.5 m 48.37 69.66 2.56 Favored Pre-proline 0 CA--C 1.553 1.09 0 C-N-CA 126.335 1.854 . . . . 0.0 114.197 178.359 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -67.96 164.32 32.25 Favored 'Trans proline' 0 CA--C 1.54 0.811 0 C-N-CA 123.351 2.701 . . . . 0.0 112.977 -179.113 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 6.4 t -129.51 2.38 5.04 Favored 'General case' 0 N--CA 1.481 1.111 0 C-N-CA 125.189 1.396 . . . . 0.0 114.064 -172.567 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 133.62 -77.86 0.37 Allowed Glycine 0 CA--C 1.532 1.152 0 C-N-CA 125.923 1.725 . . . . 0.0 112.351 175.282 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 43.5 pt . . . . . 0 C--O 1.251 1.134 0 C-N-CA 127.102 2.161 . . . . 0.0 112.675 178.61 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 12.2 tmtt? . . . . . 0 N--CA 1.49 1.539 0 N-CA-C 110.151 -0.314 . . . . 0.0 110.151 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -141.62 162.6 35.09 Favored 'General case' 0 N--CA 1.483 1.21 0 C-N-CA 126.847 2.059 . . . . 0.0 111.138 176.978 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 41.1 t -140.27 146.73 24.2 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.099 0 C-N-CA 125.962 1.705 . . . . 0.0 110.473 -179.607 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 80.9 m -60.67 117.54 5.48 Favored 'General case' 0 CA--C 1.544 0.749 0 C-N-CA 125.559 1.544 . . . . 0.0 111.809 172.974 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -73.49 37.52 0.09 Allowed 'General case' 0 CA--C 1.556 1.175 0 C-N-CA 126.462 1.905 . . . . 0.0 114.841 -177.161 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 98.8 m -63.92 156.67 72.49 Favored Pre-proline 0 CA--C 1.55 0.956 0 C-N-CA 125.726 1.61 . . . . 0.0 113.742 -179.555 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -71.78 159.42 50.75 Favored 'Trans proline' 0 CA--C 1.54 0.811 0 C-N-CA 123.411 2.741 . . . . 0.0 113.2 -178.677 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 34.5 ttmt -86.37 -11.11 52.95 Favored 'General case' 0 N--CA 1.48 1.066 0 C-N-CA 125.786 1.634 . . . . 0.0 113.751 177.501 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 80.3 mt -55.85 146.3 5.27 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.883 0 C-N-CA 126.662 1.985 . . . . 0.0 110.444 178.862 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 11.1 mp -89.68 113.27 24.74 Favored 'General case' 0 CA--C 1.539 0.548 0 C-N-CA 124.229 1.012 . . . . 0.0 110.809 175.161 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 33.2 ttmt -135.02 75.3 61.12 Favored Pre-proline 0 CA--C 1.545 0.77 0 C-N-CA 124.874 1.27 . . . . 0.0 110.277 167.734 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 62.5 Cg_endo -68.88 86.15 0.47 Allowed 'Trans proline' 0 CA--C 1.541 0.85 0 C-N-CA 123.978 3.119 . . . . 0.0 112.535 -177.68 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 10.5 m -85.63 154.94 3.46 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.534 0 C-N-CA 126.527 1.931 . . . . 0.0 112.785 -178.391 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 46.0 t -78.2 108.49 11.55 Favored 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 124.861 1.264 . . . . 0.0 110.74 168.429 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -76.57 153.53 42.66 Favored Glycine 0 CA--C 1.531 1.079 0 C-N-CA 124.603 1.097 . . . . 0.0 113.357 174.697 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 13.5 t -58.72 -33.96 70.79 Favored 'General case' 0 N--CA 1.476 0.833 0 C-N-CA 124.595 1.158 . . . . 0.0 114.123 -172.096 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 10.4 m-20 -73.73 -3.56 29.16 Favored 'General case' 0 CA--C 1.549 0.923 0 N-CA-C 114.667 1.358 . . . . 0.0 114.667 176.359 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 95.79 18.01 33.71 Favored Glycine 0 CA--C 1.533 1.21 0 C-N-CA 125.318 1.437 . . . . 0.0 114.11 178.205 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 29.5 mtp85 -121.52 154.49 36.58 Favored 'General case' 0 N--CA 1.476 0.857 0 C-N-CA 126.164 1.786 . . . . 0.0 111.308 -173.79 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 13.5 p -87.91 146.48 25.54 Favored 'General case' 0 N--CA 1.469 0.513 0 C-N-CA 124.173 0.989 . . . . 0.0 112.185 177.162 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 97.9 m-85 -138.74 147.7 43.0 Favored 'General case' 0 N--CA 1.472 0.668 0 C-N-CA 125.327 1.451 . . . . 0.0 111.381 177.562 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.54 -32.76 74.55 Favored 'General case' 0 CA--C 1.544 0.734 0 N-CA-C 114.118 1.155 . . . . 0.0 114.118 -165.954 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 67.2 m-80 -146.2 172.84 12.85 Favored 'General case' 0 CA--C 1.543 0.688 0 C-N-CA 127.399 2.28 . . . . 0.0 110.467 168.184 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 27.7 p -63.87 -33.27 75.31 Favored 'General case' 0 N--CA 1.472 0.629 0 O-C-N 121.136 -0.977 . . . . 0.0 112.968 165.098 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 33.6 t -57.46 -55.23 37.51 Favored 'General case' 0 N--CA 1.467 0.411 0 C-N-CA 124.404 1.082 . . . . 0.0 112.623 176.029 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 6.5 tp -62.84 -31.68 53.2 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.742 0 N-CA-C 112.325 0.491 . . . . 0.0 112.325 -179.112 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -59.39 -48.8 80.27 Favored 'General case' 0 CA--C 1.542 0.658 0 O-C-N 121.482 -0.761 . . . . 0.0 111.35 170.907 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 24.0 mtp-105 -62.3 -33.61 75.0 Favored 'General case' 0 N--CA 1.479 0.992 0 C-N-CA 123.619 0.768 . . . . 0.0 113.031 175.492 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 46.9 t -62.88 -48.47 78.83 Favored 'General case' 0 CA--C 1.542 0.635 0 C-N-CA 124.302 1.041 . . . . 0.0 111.52 171.373 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 19.5 m120 -66.79 -31.6 72.35 Favored 'General case' 0 CA--C 1.546 0.822 0 C-N-CA 124.583 1.153 . . . . 0.0 113.526 178.515 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 116.86 28.81 2.36 Favored Glycine 0 CA--C 1.539 1.537 0 C-N-CA 125.602 1.572 . . . . 0.0 115.01 178.782 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 18.1 t -129.32 153.99 39.48 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.5 0 C-N-CA 127.528 2.331 . . . . 0.0 108.809 -176.335 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 68.6 m -119.73 156.07 31.25 Favored 'General case' 0 N--CA 1.474 0.761 0 C-N-CA 125.858 1.663 . . . . 0.0 112.445 179.285 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 22.0 mm -126.21 -14.02 4.16 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.114 0 C-N-CA 126.111 1.765 . . . . 0.0 112.373 -171.864 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 63.4 pttt 46.66 21.48 0.14 Allowed 'General case' 0 N--CA 1.487 1.406 0 C-N-CA 129.872 3.269 . . . . 0.0 117.96 175.78 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 19.6 t -57.53 -41.0 80.02 Favored 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 127.437 2.295 . . . . 0.0 113.683 -174.454 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 27.3 tt0 -146.18 159.91 42.67 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 124.898 1.279 . . . . 0.0 111.592 175.61 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -84.5 60.59 4.81 Favored Glycine 0 CA--C 1.532 1.15 0 C-N-CA 125.721 1.629 . . . . 0.0 113.298 -178.781 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 8.6 t -63.84 158.47 21.92 Favored 'General case' 0 N--CA 1.474 0.74 0 C-N-CA 124.325 1.05 . . . . 0.0 112.835 177.878 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 13.8 p -141.84 69.82 24.45 Favored Pre-proline 0 CA--C 1.551 1.004 0 C-N-CA 125.588 1.555 . . . . 0.0 112.235 -178.324 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_endo -70.16 162.38 42.48 Favored 'Trans proline' 0 CA--C 1.541 0.863 0 C-N-CA 123.163 2.575 . . . . 0.0 112.5 177.495 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 26.8 p -79.45 171.14 15.57 Favored 'General case' 0 N--CA 1.477 0.915 0 C-N-CA 125.215 1.406 . . . . 0.0 112.359 172.159 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 77.9 18.59 76.76 Favored Glycine 0 CA--C 1.539 1.58 0 N-CA-C 115.313 0.885 . . . . 0.0 115.313 174.573 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 20.6 tt . . . . . 0 C--O 1.255 1.345 0 C-N-CA 127.356 2.262 . . . . 0.0 112.696 -176.929 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 9.8 mtpm? . . . . . 0 N--CA 1.491 1.619 0 N-CA-C 110.307 -0.257 . . . . 0.0 110.307 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -76.65 91.17 3.41 Favored 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 125.612 1.565 . . . . 0.0 111.052 179.443 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 11.7 p -140.73 146.79 23.62 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.027 0 C-N-CA 124.959 1.304 . . . . 0.0 112.399 -177.685 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 32.9 m -94.64 91.68 6.67 Favored 'General case' 0 CA--C 1.542 0.647 0 C-N-CA 125.737 1.615 . . . . 0.0 110.81 179.712 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -75.06 54.34 0.67 Allowed 'General case' 0 CA--C 1.554 1.119 0 C-N-CA 125.525 1.53 . . . . 0.0 113.021 178.938 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 64.7 m -65.22 152.19 92.23 Favored Pre-proline 0 CA--C 1.552 1.023 0 C-N-CA 125.437 1.495 . . . . 0.0 112.893 -177.901 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -72.03 151.99 56.56 Favored 'Trans proline' 0 CA--C 1.539 0.763 0 C-N-CA 122.957 2.438 . . . . 0.0 112.57 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 32.3 mmtp -72.49 -21.67 61.17 Favored 'General case' 0 N--CA 1.479 1.014 0 C-N-CA 125.232 1.413 . . . . 0.0 113.605 174.664 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 4.9 mp -67.8 127.26 29.17 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.548 0 C-N-CA 125.508 1.523 . . . . 0.0 110.198 178.879 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 2.0 pt? -68.55 131.41 45.19 Favored 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 124.912 1.285 . . . . 0.0 111.6 173.72 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 37.0 ttmt -152.08 64.86 5.91 Favored Pre-proline 0 N--CA 1.474 0.745 0 C-N-CA 124.323 1.049 . . . . 0.0 111.114 175.181 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -66.85 153.04 79.29 Favored 'Trans proline' 0 CA--C 1.536 0.619 0 C-N-CA 122.552 2.168 . . . . 0.0 112.199 -176.049 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 18.4 t -134.84 -68.91 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.059 0 C-N-CA 123.695 0.798 . . . . 0.0 112.071 -173.818 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 31.1 p -143.18 -173.9 4.05 Favored 'General case' 0 CA--C 1.544 0.72 0 C-N-CA 126.355 1.862 . . . . 0.0 112.156 -173.812 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -163.75 87.57 0.1 Allowed Glycine 0 CA--C 1.528 0.882 0 C-N-CA 124.098 0.856 . . . . 0.0 114.126 -175.543 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 11.4 t -55.7 -38.17 69.35 Favored 'General case' 0 N--CA 1.478 0.969 0 C-N-CA 124.132 0.973 . . . . 0.0 113.261 176.781 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 54.6 m-20 -78.39 -5.69 53.04 Favored 'General case' 0 N--CA 1.478 0.942 0 C-N-CA 125.141 1.376 . . . . 0.0 113.953 174.541 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 93.86 9.93 59.29 Favored Glycine 0 CA--C 1.537 1.467 0 C-N-CA 125.532 1.539 . . . . 0.0 114.321 -174.018 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 13.5 ptp180 -122.19 135.86 54.83 Favored 'General case' 0 N--CA 1.477 0.898 0 C-N-CA 126.738 2.015 . . . . 0.0 112.21 -177.03 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.1 p -66.64 110.84 3.36 Favored 'General case' 0 N--CA 1.474 0.728 0 C-N-CA 125.347 1.459 . . . . 0.0 111.783 175.657 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 44.6 m-85 -76.86 154.37 33.87 Favored 'General case' 0 N--CA 1.472 0.636 0 O-C-N 121.628 -0.67 . . . . 0.0 111.829 174.794 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.96 -43.83 82.1 Favored 'General case' 0 CA--C 1.542 0.662 0 N-CA-C 113.238 0.829 . . . . 0.0 113.238 -169.416 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 21.2 p30 -160.98 178.68 9.13 Favored 'General case' 0 CA--C 1.548 0.866 0 C-N-CA 126.755 2.022 . . . . 0.0 111.569 173.487 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 16.2 m -63.36 -27.62 69.44 Favored 'General case' 0 N--CA 1.475 0.815 0 O-C-N 120.625 -1.297 . . . . 0.0 113.913 179.833 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 38.6 t -63.1 -56.41 17.07 Favored 'General case' 0 CA--C 1.532 0.257 0 C-N-CA 124.708 1.203 . . . . 0.0 111.555 177.166 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 8.3 tp -59.17 -35.24 56.54 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.87 0 N-CA-C 112.54 0.571 . . . . 0.0 112.54 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -59.3 -57.83 11.31 Favored 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 123.937 0.895 . . . . 0.0 111.993 175.332 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 73.6 mtp180 -60.56 -38.92 86.13 Favored 'General case' 0 N--CA 1.479 1.001 0 N-CA-C 113.058 0.762 . . . . 0.0 113.058 176.561 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 47.7 t -59.83 -50.38 74.04 Favored 'General case' 0 CA--C 1.542 0.646 0 C-N-CA 124.422 1.089 . . . . 0.0 112.179 176.048 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 63.3 t30 -69.95 -40.26 75.56 Favored 'General case' 0 CA--C 1.545 0.767 0 C-N-CA 125.01 1.324 . . . . 0.0 112.925 -176.911 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 129.26 30.2 0.68 Allowed Glycine 0 CA--C 1.536 1.375 0 C-N-CA 124.676 1.131 . . . . 0.0 115.161 178.369 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -120.14 178.49 2.49 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.545 0 C-N-CA 126.943 2.097 . . . . 0.0 110.037 -176.411 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 83.8 p -138.04 159.69 41.34 Favored 'General case' 0 N--CA 1.476 0.854 0 C-N-CA 124.843 1.257 . . . . 0.0 113.466 -178.135 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 16.0 mm -87.53 -23.5 6.56 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.965 0 C-N-CA 124.545 1.138 . . . . 0.0 112.509 -175.003 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 8.3 tptm -68.69 -3.04 10.61 Favored 'General case' 0 N--CA 1.477 0.913 0 C-N-CA 127.102 2.161 . . . . 0.0 114.292 178.921 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 18.6 t -51.27 -41.84 60.69 Favored 'General case' 0 N--CA 1.473 0.686 0 C-N-CA 127.014 2.126 . . . . 0.0 113.591 179.998 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 7.4 tp10 -153.02 -52.71 0.11 Allowed 'General case' 0 N--CA 1.474 0.74 0 C-N-CA 124.365 1.066 . . . . 0.0 111.476 173.099 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -76.82 65.81 2.85 Favored Glycine 0 CA--C 1.533 1.196 0 C-N-CA 125.615 1.578 . . . . 0.0 113.474 -179.661 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 25.7 t -57.76 119.1 6.06 Favored 'General case' 0 N--CA 1.47 0.552 0 C-N-CA 125.462 1.505 . . . . 0.0 111.83 175.493 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 93.7 m -119.07 159.22 45.81 Favored Pre-proline 0 CA--C 1.549 0.906 0 C-N-CA 125.928 1.691 . . . . 0.0 111.787 -179.239 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -72.8 95.56 0.82 Allowed 'Trans proline' 0 CA--C 1.542 0.91 0 C-N-CA 123.672 2.914 . . . . 0.0 112.057 178.244 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 27.9 m -57.94 130.66 47.56 Favored 'General case' 0 N--CA 1.476 0.869 0 C-N-CA 125.695 1.598 . . . . 0.0 111.773 177.112 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -78.42 -69.95 1.35 Allowed Glycine 0 CA--C 1.536 1.365 0 C-N-CA 124.634 1.111 . . . . 0.0 113.696 -177.068 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 21.3 tt . . . . . 0 C--O 1.252 1.198 0 C-N-CA 126.863 2.065 . . . . 0.0 112.251 -178.301 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 65.8 mttm . . . . . 0 N--CA 1.493 1.719 0 CA-C-O 120.834 0.349 . . . . 0.0 110.593 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 9.5 mtmp? -97.05 104.09 16.08 Favored 'General case' 0 N--CA 1.482 1.161 0 C-N-CA 125.109 1.363 . . . . 0.0 110.818 -178.833 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 40.9 t -129.62 140.28 49.49 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.065 0 C-N-CA 125.841 1.656 . . . . 0.0 110.029 -178.867 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 8.5 t -66.37 118.07 9.51 Favored 'General case' 0 CA--C 1.543 0.676 0 C-N-CA 124.401 1.08 . . . . 0.0 112.805 -174.787 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -75.24 32.4 0.1 Allowed 'General case' 0 CA--C 1.553 1.077 0 C-N-CA 126.873 2.069 . . . . 0.0 115.214 -174.132 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 58.4 m -62.96 157.48 60.75 Favored Pre-proline 0 CA--C 1.549 0.912 0 C-N-CA 124.851 1.26 . . . . 0.0 113.15 176.062 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 97.1 Cg_endo -70.58 172.13 14.03 Favored 'Trans proline' 0 CA--C 1.54 0.799 0 C-N-CA 123.419 2.746 . . . . 0.0 112.176 173.141 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 29.9 mtpp -121.05 3.09 10.47 Favored 'General case' 0 N--CA 1.481 1.112 0 C-N-CA 126.2 1.8 . . . . 0.0 114.011 179.765 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -53.0 138.63 12.0 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.785 0 C-N-CA 126.366 1.867 . . . . 0.0 112.347 179.649 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 3.2 tt -70.69 77.61 0.6 Allowed 'General case' 0 CA--C 1.547 0.849 0 C-N-CA 126.72 2.008 . . . . 0.0 111.382 -178.773 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 25.7 tptp -140.15 68.86 34.42 Favored Pre-proline 0 N--CA 1.473 0.722 0 C-N-CA 125.875 1.67 . . . . 0.0 110.893 179.6 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -64.86 148.55 89.98 Favored 'Trans proline' 0 CA--C 1.534 0.524 0 C-N-CA 122.326 2.017 . . . . 0.0 111.868 -178.676 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 1.7 t -137.75 161.0 33.8 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.804 0 C-N-CA 125.542 1.537 . . . . 0.0 109.99 -177.501 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 21.6 p -73.35 130.64 40.61 Favored 'General case' 0 CA--C 1.543 0.683 0 C-N-CA 124.582 1.153 . . . . 0.0 111.669 176.1 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -110.59 159.96 13.57 Favored Glycine 0 CA--C 1.535 1.325 0 C-N-CA 125.135 1.35 . . . . 0.0 112.026 170.729 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 56.6 p -63.53 -30.68 71.76 Favored 'General case' 0 N--CA 1.475 0.781 0 N-CA-C 114.28 1.215 . . . . 0.0 114.28 -172.822 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 17.0 t70 -77.17 -20.37 55.55 Favored 'General case' 0 N--CA 1.477 0.906 0 C-N-CA 124.437 1.095 . . . . 0.0 113.69 177.078 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 106.34 1.27 38.05 Favored Glycine 0 CA--C 1.537 1.411 0 C-N-CA 126.876 2.179 . . . . 0.0 114.789 176.325 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 56.2 mtt180 -85.78 156.21 20.69 Favored 'General case' 0 N--CA 1.476 0.866 0 C-N-CA 125.221 1.408 . . . . 0.0 112.974 -173.688 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 9.6 p -81.58 126.67 32.0 Favored 'General case' 0 N--CA 1.467 0.418 0 C-N-CA 125.959 1.703 . . . . 0.0 111.319 169.799 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 86.1 m-85 -126.13 159.28 33.3 Favored 'General case' 0 N--CA 1.47 0.566 0 C-N-CA 125.71 1.604 . . . . 0.0 110.789 171.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -62.57 -42.39 99.52 Favored 'General case' 0 CA--C 1.543 0.701 0 N-CA-C 113.078 0.77 . . . . 0.0 113.078 -168.381 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 14.2 p30 -155.47 178.36 10.32 Favored 'General case' 0 CA--C 1.545 0.78 0 C-N-CA 126.179 1.792 . . . . 0.0 112.258 173.56 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 33.1 t -62.48 -38.25 89.11 Favored 'General case' 0 N--CA 1.473 0.696 0 O-C-N 121.148 -0.97 . . . . 0.0 113.088 178.904 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 24.6 t -59.18 -57.64 12.15 Favored 'General case' 0 N--CA 1.467 0.377 0 C-N-CA 123.974 0.91 . . . . 0.0 111.25 179.749 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 8.4 tt -57.68 -39.45 70.26 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.618 0 N-CA-C 111.783 0.29 . . . . 0.0 111.783 -179.074 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -65.65 -45.73 81.87 Favored 'General case' 0 CA--C 1.542 0.663 0 C-N-CA 123.561 0.745 . . . . 0.0 112.42 179.411 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 16.7 ttp180 -62.87 -44.93 94.8 Favored 'General case' 0 N--CA 1.474 0.728 0 O-C-N 121.372 -0.83 . . . . 0.0 112.198 174.318 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -65.59 -32.54 74.18 Favored 'General case' 0 CA--C 1.545 0.756 0 N-CA-C 113.173 0.805 . . . . 0.0 113.173 177.67 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 51.9 t30 -65.7 -44.06 87.28 Favored 'General case' 0 CA--C 1.544 0.719 0 C-N-CA 124.698 1.199 . . . . 0.0 112.591 173.574 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 159.35 1.29 0.07 OUTLIER Glycine 0 CA--C 1.537 1.409 0 N-CA-C 117.519 1.767 . . . . 0.0 117.519 175.098 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -90.65 178.18 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.453 0 CA-C-N 119.823 1.812 . . . . 0.0 112.036 -176.288 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 66.1 m -133.03 108.36 8.82 Favored 'General case' 0 N--CA 1.477 0.881 0 C-N-CA 125.918 1.687 . . . . 0.0 111.986 177.995 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 16.4 mt -117.43 -34.05 1.77 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.3 0 C-N-CA 125.065 1.346 . . . . 0.0 112.377 178.899 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 9.2 tptm -69.49 -16.74 63.52 Favored 'General case' 0 N--CA 1.479 0.988 0 C-N-CA 125.568 1.547 . . . . 0.0 113.702 179.643 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 13.1 p -66.79 97.44 0.47 Allowed 'General case' 0 CA--C 1.538 0.501 0 C-N-CA 126.727 2.011 . . . . 0.0 111.704 167.877 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 26.8 tt0 -62.39 168.99 3.15 Favored 'General case' 0 CA--C 1.551 0.993 0 C-N-CA 125.077 1.351 . . . . 0.0 112.175 172.457 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -69.1 -9.73 60.77 Favored Glycine 0 CA--C 1.54 1.638 0 C-N-CA 124.74 1.162 . . . . 0.0 115.797 -177.863 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 63.2 p -70.4 162.47 28.59 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 125.009 1.324 . . . . 0.0 112.743 170.341 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 71.7 m -133.38 71.24 76.47 Favored Pre-proline 0 CA--C 1.547 0.856 0 C-N-CA 124.913 1.285 . . . . 0.0 111.301 179.078 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 93.3 Cg_endo -72.65 163.06 39.58 Favored 'Trans proline' 0 CA--C 1.54 0.815 0 C-N-CA 123.168 2.579 . . . . 0.0 112.542 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 6.5 t -75.77 -14.84 60.32 Favored 'General case' 0 N--CA 1.48 1.065 0 N-CA-C 113.903 1.075 . . . . 0.0 113.903 178.764 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -171.56 -82.97 0.05 OUTLIER Glycine 0 CA--C 1.534 1.254 0 C-N-CA 124.468 1.032 . . . . 0.0 113.301 176.13 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 21.4 tt . . . . . 0 C--O 1.254 1.314 0 C-N-CA 126.127 1.771 . . . . 0.0 113.668 179.894 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 64.2 mttm . . . . . 0 N--CA 1.496 1.863 0 N-CA-C 113.67 0.989 . . . . 0.0 113.67 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -119.8 90.38 3.32 Favored 'General case' 0 N--CA 1.483 1.192 0 O-C-N 120.12 -1.613 . . . . 0.0 110.673 179.126 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 46.3 t -137.35 132.89 46.27 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.953 0 C-N-CA 126.255 1.822 . . . . 0.0 109.746 179.179 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 64.3 m -67.78 126.03 28.12 Favored 'General case' 0 CA--C 1.542 0.637 0 C-N-CA 123.846 0.858 . . . . 0.0 111.517 175.423 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -73.8 42.88 0.14 Allowed 'General case' 0 CA--C 1.554 1.115 0 C-N-CA 125.928 1.691 . . . . 0.0 113.96 179.093 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 56.4 m -60.52 153.56 60.26 Favored Pre-proline 0 CA--C 1.55 0.955 0 C-N-CA 125.254 1.422 . . . . 0.0 113.125 177.908 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 88.3 Cg_endo -71.74 158.15 53.88 Favored 'Trans proline' 0 CA--C 1.539 0.735 0 C-N-CA 123.146 2.564 . . . . 0.0 112.309 179.568 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 1.4 mptm? -73.31 -8.56 56.36 Favored 'General case' 0 N--CA 1.48 1.039 0 C-N-CA 125.469 1.508 . . . . 0.0 113.88 179.631 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 51.1 mm -52.95 125.46 7.01 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.668 0 C-N-CA 126.442 1.897 . . . . 0.0 111.498 177.233 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 50.3 tp -95.35 100.44 12.21 Favored 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 127.339 2.256 . . . . 0.0 109.033 176.382 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 29.4 ttmt -146.76 82.34 8.69 Favored Pre-proline 0 N--CA 1.472 0.655 0 C-N-CA 124.565 1.146 . . . . 0.0 110.66 171.22 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 70.2 Cg_endo -68.69 148.32 71.56 Favored 'Trans proline' 0 N--CA 1.459 -0.549 0 C-N-CA 121.805 1.67 . . . . 0.0 110.926 177.543 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 1.4 t -138.41 160.52 31.59 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.752 0 C-N-CA 124.879 1.271 . . . . 0.0 109.966 -179.12 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 49.8 t -75.88 96.34 3.69 Favored 'General case' 0 CA--C 1.54 0.585 0 C-N-CA 124.334 1.054 . . . . 0.0 110.097 173.0 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -62.78 153.3 44.64 Favored Glycine 0 CA--C 1.534 1.265 0 C-N-CA 123.427 0.537 . . . . 0.0 112.113 174.084 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 21.1 t -53.93 -36.09 62.4 Favored 'General case' 0 N--CA 1.477 0.887 0 C-N-CA 125.256 1.422 . . . . 0.0 114.315 -171.51 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 17.8 m-20 -78.67 -2.77 40.77 Favored 'General case' 0 CA--C 1.55 0.945 0 C-N-CA 125.276 1.43 . . . . 0.0 114.589 178.781 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 92.96 37.27 5.76 Favored Glycine 0 CA--C 1.535 1.295 0 C-N-CA 125.503 1.525 . . . . 0.0 113.321 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 13.3 mmm180 -129.52 125.46 36.37 Favored 'General case' 0 N--CA 1.477 0.911 0 C-N-CA 126.604 1.962 . . . . 0.0 111.025 -166.125 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 2.8 p -83.74 90.35 7.3 Favored 'General case' 0 N--CA 1.474 0.746 0 C-N-CA 125.6 1.56 . . . . 0.0 112.074 177.292 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -77.34 154.9 32.36 Favored 'General case' 0 N--CA 1.473 0.691 0 C-N-CA 124.385 1.074 . . . . 0.0 111.851 172.348 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -67.69 -40.82 84.35 Favored 'General case' 0 CA--C 1.545 0.779 0 N-CA-C 113.458 0.91 . . . . 0.0 113.458 -168.705 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 62.1 t30 -144.77 172.27 13.24 Favored 'General case' 0 CA--C 1.548 0.885 0 C-N-CA 125.171 1.388 . . . . 0.0 110.898 169.955 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 88.3 p -62.07 -34.52 76.43 Favored 'General case' 0 N--CA 1.472 0.66 0 O-C-N 120.574 -1.329 . . . . 0.0 113.317 176.365 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 35.4 t -59.72 -57.41 13.03 Favored 'General case' 0 N--CA 1.467 0.414 0 C-N-CA 124.604 1.162 . . . . 0.0 112.669 177.341 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 7.6 tp -58.21 -34.1 48.82 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 CA-C-O 119.06 -0.495 . . . . 0.0 112.286 179.591 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -58.29 -53.6 56.49 Favored 'General case' 0 CA--C 1.544 0.734 0 CA-C-N 118.929 0.786 . . . . 0.0 111.934 172.986 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -58.98 -46.05 89.06 Favored 'General case' 0 N--CA 1.48 1.032 0 N-CA-C 112.666 0.617 . . . . 0.0 112.666 175.338 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -65.3 -32.58 74.31 Favored 'General case' 0 CA--C 1.545 0.776 0 N-CA-C 113.301 0.852 . . . . 0.0 113.301 -179.948 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 25.6 t-20 -71.61 -49.03 44.07 Favored 'General case' 0 CA--C 1.543 0.701 0 C-N-CA 124.758 1.223 . . . . 0.0 112.62 173.86 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 145.47 21.18 0.14 Allowed Glycine 0 CA--C 1.537 1.46 0 N-CA-C 116.813 1.485 . . . . 0.0 116.813 178.965 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 21.7 t -127.48 150.05 33.0 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.607 0 C-N-CA 126.067 1.747 . . . . 0.0 109.548 -176.966 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 80.0 p -124.42 138.69 54.33 Favored 'General case' 0 N--CA 1.47 0.542 0 C-N-CA 126.157 1.783 . . . . 0.0 112.129 -179.499 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 23.5 mm -91.66 -18.93 7.18 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.917 0 C-N-CA 124.961 1.304 . . . . 0.0 111.854 -179.03 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 10.0 mtpm? -83.38 15.21 3.11 Favored 'General case' 0 N--CA 1.482 1.132 0 C-N-CA 128.276 2.631 . . . . 0.0 113.543 173.135 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 8.2 p -68.77 61.56 0.1 Allowed 'General case' 0 N--CA 1.476 0.851 0 C-N-CA 128.464 2.706 . . . . 0.0 114.314 179.919 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 57.6 mm-40 -80.17 165.76 22.11 Favored 'General case' 0 CA--C 1.547 0.828 0 C-N-CA 126.784 2.034 . . . . 0.0 112.766 176.163 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -154.9 41.04 0.61 Allowed Glycine 0 CA--C 1.534 1.271 0 C-N-CA 125.185 1.374 . . . . 0.0 113.615 -177.206 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 13.4 t -129.73 168.95 15.74 Favored 'General case' 0 N--CA 1.473 0.722 0 C-N-CA 126.084 1.754 . . . . 0.0 111.822 -179.725 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 81.8 m 37.13 68.68 1.5 Allowed Pre-proline 0 CA--C 1.552 1.024 0 C-N-CA 127.818 2.447 . . . . 0.0 114.036 -177.448 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -63.48 140.0 73.62 Favored 'Trans proline' 0 CA--C 1.538 0.692 0 C-N-CA 123.056 2.504 . . . . 0.0 111.696 -176.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 78.0 p -67.64 162.04 24.47 Favored 'General case' 0 N--CA 1.477 0.9 0 C-N-CA 123.849 0.86 . . . . 0.0 112.676 -178.398 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -170.94 175.39 44.66 Favored Glycine 0 CA--C 1.534 1.237 0 C-N-CA 124.435 1.017 . . . . 0.0 113.553 -178.331 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 17.5 tt . . . . . 0 C--O 1.254 1.341 0 C-N-CA 126.317 1.847 . . . . 0.0 113.416 178.466 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 56.0 mttp . . . . . 0 N--CA 1.49 1.565 0 N-CA-C 109.692 -0.485 . . . . 0.0 109.692 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -142.84 168.41 19.79 Favored 'General case' 0 N--CA 1.484 1.23 0 C-N-CA 125.713 1.605 . . . . 0.0 112.8 -177.298 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 11.7 p -148.63 151.83 12.85 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.093 0 C-N-CA 125.301 1.44 . . . . 0.0 112.184 -178.159 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 60.1 m -77.93 97.51 5.34 Favored 'General case' 0 CA--C 1.545 0.762 0 C-N-CA 126.017 1.727 . . . . 0.0 111.69 177.408 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -75.3 67.6 1.92 Allowed 'General case' 0 CA--C 1.551 1.006 0 C-N-CA 125.56 1.544 . . . . 0.0 113.091 179.802 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 72.8 m -68.92 155.57 93.16 Favored Pre-proline 0 CA--C 1.552 1.027 0 C-N-CA 124.882 1.273 . . . . 0.0 113.586 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 90.4 Cg_endo -74.11 168.01 25.81 Favored 'Trans proline' 0 CA--C 1.541 0.849 0 C-N-CA 123.591 2.861 . . . . 0.0 113.173 179.38 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -76.59 -3.23 36.56 Favored 'General case' 0 N--CA 1.482 1.155 0 C-N-CA 125.619 1.567 . . . . 0.0 114.447 177.927 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 85.6 mt -55.69 151.42 2.22 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.899 0 C-N-CA 126.868 2.067 . . . . 0.0 110.744 174.555 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 50.8 tp -136.9 93.49 2.85 Favored 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 125.914 1.686 . . . . 0.0 109.401 -175.538 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 16.7 mmtm -135.21 82.1 42.44 Favored Pre-proline 0 N--CA 1.475 0.779 0 C-N-CA 125.828 1.651 . . . . 0.0 110.129 174.307 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 65.0 Cg_endo -69.83 91.17 0.52 Allowed 'Trans proline' 0 CA--C 1.54 0.805 0 C-N-CA 123.809 3.006 . . . . 0.0 112.061 -177.238 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 5.0 m -87.11 157.87 3.19 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.522 0 C-N-CA 126.723 2.009 . . . . 0.0 112.882 -177.356 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 45.0 t -68.23 143.29 55.36 Favored 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 124.05 0.94 . . . . 0.0 111.064 171.366 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -111.72 148.97 18.1 Favored Glycine 0 CA--C 1.532 1.108 0 C-N-CA 125.472 1.51 . . . . 0.0 112.786 177.803 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 68.9 m -59.58 -22.81 62.29 Favored 'General case' 0 N--CA 1.477 0.878 0 N-CA-C 115.564 1.69 . . . . 0.0 115.564 -170.498 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 33.4 t70 -77.89 -10.74 59.73 Favored 'General case' 0 CA--C 1.549 0.929 0 C-N-CA 124.904 1.282 . . . . 0.0 114.15 175.238 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 98.39 31.85 6.3 Favored Glycine 0 CA--C 1.536 1.391 0 C-N-CA 125.422 1.487 . . . . 0.0 113.111 -172.097 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 15.3 mmp_? -121.91 -175.0 3.01 Favored 'General case' 0 N--CA 1.478 0.969 0 C-N-CA 127.743 2.417 . . . . 0.0 111.281 -169.734 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 9.3 t -136.84 143.95 43.36 Favored 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 125.191 1.396 . . . . 0.0 111.427 173.007 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 85.4 m-85 -142.39 147.94 37.04 Favored 'General case' 0 N--CA 1.473 0.705 0 C-N-CA 125.22 1.408 . . . . 0.0 112.217 -175.713 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -61.14 -44.81 96.74 Favored 'General case' 0 CA--C 1.542 0.667 0 N-CA-C 114.003 1.112 . . . . 0.0 114.003 -164.608 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 65.6 m-80 -146.85 175.06 10.93 Favored 'General case' 0 CA--C 1.548 0.886 0 C-N-CA 126.461 1.904 . . . . 0.0 110.633 167.576 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 20.0 m -57.76 -30.09 65.33 Favored 'General case' 0 N--CA 1.477 0.903 0 O-C-N 120.945 -1.097 . . . . 0.0 113.599 171.666 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 46.7 t -58.56 -61.1 2.85 Favored 'General case' 0 N--CA 1.466 0.368 0 C-N-CA 124.964 1.306 . . . . 0.0 112.312 175.557 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 8.5 tp -62.56 -33.3 58.85 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.744 0 N-CA-C 112.039 0.385 . . . . 0.0 112.039 179.995 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -57.41 -54.51 46.0 Favored 'General case' 0 CA--C 1.542 0.661 0 C-N-CA 123.348 0.659 . . . . 0.0 111.556 171.56 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 5.5 mtp85 -58.95 -40.22 84.03 Favored 'General case' 0 N--CA 1.48 1.031 0 N-CA-C 113.243 0.831 . . . . 0.0 113.243 174.907 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 33.0 t -59.95 -46.64 88.77 Favored 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 124.517 1.127 . . . . 0.0 111.628 177.17 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 95.4 m-20 -69.15 -48.07 63.31 Favored 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 125.546 1.538 . . . . 0.0 112.786 179.116 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 129.6 39.84 0.28 Allowed Glycine 0 CA--C 1.536 1.36 0 C-N-CA 125.212 1.387 . . . . 0.0 114.652 -176.867 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 44.7 t -133.25 158.18 42.94 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.597 0 C-N-CA 126.938 2.095 . . . . 0.0 108.494 174.528 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 42.7 t -123.57 143.29 50.3 Favored 'General case' 0 N--CA 1.47 0.572 0 C-N-CA 125.545 1.538 . . . . 0.0 111.937 175.492 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 17.1 mm -100.76 -15.58 7.52 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.79 0 C-N-CA 126.034 1.734 . . . . 0.0 111.331 175.889 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 10.7 mmmm -101.7 -24.13 14.13 Favored 'General case' 0 N--CA 1.479 0.984 0 C-N-CA 126.642 1.977 . . . . 0.0 113.877 -177.359 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 1.4 t 55.26 32.53 18.78 Favored 'General case' 0 N--CA 1.478 0.953 0 C-N-CA 126.024 1.73 . . . . 0.0 114.647 178.396 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 14.3 mm-40 -65.52 -13.3 58.61 Favored 'General case' 0 N--CA 1.477 0.911 0 C-N-CA 125.852 1.661 . . . . 0.0 114.735 178.828 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 149.23 2.85 0.31 Allowed Glycine 0 CA--C 1.538 1.496 0 C-N-CA 124.875 1.226 . . . . 0.0 116.032 178.121 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 12.1 m -59.11 -33.51 70.94 Favored 'General case' 0 N--CA 1.475 0.799 0 C-N-CA 125.457 1.503 . . . . 0.0 114.927 -172.302 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 83.9 m 30.64 66.56 0.85 Allowed Pre-proline 0 CA--C 1.555 1.157 0 C-N-CA 128.345 2.658 . . . . 0.0 114.956 177.723 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo -68.56 116.33 4.35 Favored 'Trans proline' 0 CA--C 1.539 0.733 0 C-N-CA 123.666 2.911 . . . . 0.0 112.979 -171.444 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 24.1 p -76.08 -45.96 31.41 Favored 'General case' 0 N--CA 1.476 0.845 0 C-N-CA 125.629 1.571 . . . . 0.0 113.614 -178.437 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 151.57 -126.59 2.11 Favored Glycine 0 CA--C 1.535 1.324 0 C-N-CA 125.366 1.46 . . . . 0.0 112.744 -176.648 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 34.6 pt . . . . . 0 C--O 1.254 1.308 0 C-N-CA 126.091 1.757 . . . . 0.0 114.082 177.978 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 83.4 tttt . . . . . 0 N--CA 1.491 1.575 0 N-CA-C 110.416 -0.216 . . . . 0.0 110.416 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 1.9 mptp? -71.9 142.56 49.51 Favored 'General case' 0 N--CA 1.481 1.09 0 C-N-CA 124.111 0.964 . . . . 0.0 110.733 173.717 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 13.7 p -149.86 145.26 17.48 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.917 0 C-N-CA 124.939 1.296 . . . . 0.0 111.564 179.285 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 57.2 m -107.88 -18.86 13.7 Favored 'General case' 0 N--CA 1.476 0.839 0 C-N-CA 125.095 1.358 . . . . 0.0 113.6 179.481 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . 50.07 26.32 2.04 Favored 'General case' 0 CA--C 1.552 1.023 0 C-N-CA 127.254 2.222 . . . . 0.0 115.285 -171.032 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 61.9 m -70.22 160.72 79.8 Favored Pre-proline 0 CA--C 1.548 0.869 0 C-N-CA 125.363 1.465 . . . . 0.0 112.922 177.157 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -67.58 167.59 20.48 Favored 'Trans proline' 0 CA--C 1.54 0.798 0 C-N-CA 123.295 2.663 . . . . 0.0 112.231 169.736 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 10.2 mtpm? -112.53 1.38 15.83 Favored 'General case' 0 N--CA 1.48 1.059 0 C-N-CA 126.282 1.833 . . . . 0.0 113.28 173.672 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 48.9 mm -55.93 133.03 19.99 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.593 0 C-N-CA 126.386 1.874 . . . . 0.0 111.082 178.587 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 5.4 tt -69.87 96.0 0.97 Allowed 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 127.771 2.428 . . . . 0.0 111.08 -176.723 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 34.7 ttpt -144.45 73.97 15.53 Favored Pre-proline 0 CA--C 1.546 0.801 0 C-N-CA 124.467 1.107 . . . . 0.0 111.901 -179.427 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -68.21 89.43 0.39 Allowed 'Trans proline' 0 CA--C 1.538 0.708 0 C-N-CA 124.188 3.259 . . . . 0.0 112.922 -175.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 16.3 m -73.73 160.24 5.36 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.412 0 C-N-CA 126.084 1.754 . . . . 0.0 112.244 175.273 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 16.5 t -69.36 165.95 19.65 Favored 'General case' 0 CA--C 1.549 0.908 0 C-N-CA 123.625 0.77 . . . . 0.0 111.141 166.998 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -143.6 134.55 5.9 Favored Glycine 0 CA--C 1.53 0.973 0 C-N-CA 124.778 1.18 . . . . 0.0 112.151 177.783 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 63.7 m -57.22 -24.48 54.9 Favored 'General case' 0 N--CA 1.477 0.886 0 C-N-CA 125.847 1.659 . . . . 0.0 114.906 -176.993 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -83.29 -4.58 58.58 Favored 'General case' 0 CA--C 1.548 0.887 0 C-N-CA 125.775 1.63 . . . . 0.0 113.955 176.985 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 94.65 20.21 29.8 Favored Glycine 0 CA--C 1.535 1.311 0 C-N-CA 125.38 1.467 . . . . 0.0 114.284 179.111 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 43.7 mtt180 -121.01 178.18 4.83 Favored 'General case' 0 N--CA 1.477 0.908 0 C-N-CA 126.169 1.788 . . . . 0.0 112.536 -173.88 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 31.8 m -128.35 142.64 51.06 Favored 'General case' 0 N--CA 1.477 0.9 0 C-N-CA 126.107 1.763 . . . . 0.0 110.049 -179.584 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 86.8 m-85 -135.57 155.64 50.15 Favored 'General case' 0 N--CA 1.471 0.588 0 C-N-CA 125.171 1.388 . . . . 0.0 111.651 -175.438 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -61.66 -38.63 88.46 Favored 'General case' 0 CA--C 1.544 0.742 0 N-CA-C 113.212 0.819 . . . . 0.0 113.212 -167.956 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 14.8 p30 -150.33 179.33 8.21 Favored 'General case' 0 CA--C 1.548 0.876 0 C-N-CA 126.213 1.805 . . . . 0.0 111.901 166.441 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 25.0 p -65.63 -34.83 79.12 Favored 'General case' 0 N--CA 1.474 0.745 0 O-C-N 121.007 -1.058 . . . . 0.0 113.755 177.298 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 34.4 t -62.93 -54.04 44.77 Favored 'General case' 0 N--CA 1.466 0.361 0 C-N-CA 124.083 0.953 . . . . 0.0 111.481 179.057 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 9.3 tp -59.0 -37.18 66.14 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.553 0 N-CA-C 112.143 0.423 . . . . 0.0 112.143 -179.277 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -63.32 -42.62 99.02 Favored 'General case' 0 CA--C 1.544 0.717 0 CA-C-N 118.851 0.75 . . . . 0.0 112.927 176.216 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 8.7 tpm_? -62.98 -41.96 99.7 Favored 'General case' 0 N--CA 1.475 0.816 0 C-N-CA 123.828 0.851 . . . . 0.0 112.278 173.82 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 7.3 t -65.06 -39.72 93.67 Favored 'General case' 0 CA--C 1.547 0.839 0 C-N-CA 123.025 0.53 . . . . 0.0 112.245 174.286 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 23.0 t-20 -63.93 -52.03 61.66 Favored 'General case' 0 CA--C 1.544 0.716 0 C-N-CA 125.82 1.648 . . . . 0.0 112.464 178.739 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 149.81 18.12 0.08 OUTLIER Glycine 0 CA--C 1.537 1.436 0 N-CA-C 117.344 1.698 . . . . 0.0 117.344 179.095 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 14.5 t -124.43 144.38 34.51 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.672 0 CA-C-N 119.98 1.89 . . . . 0.0 109.882 -176.828 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 72.3 m -89.47 128.53 35.98 Favored 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 125.805 1.642 . . . . 0.0 111.322 -179.024 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 14.3 mm -117.48 -9.33 11.99 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.23 0 C-N-CA 124.687 1.195 . . . . 0.0 112.486 -175.778 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 84.3 tttt -59.6 -33.05 70.98 Favored 'General case' 0 N--CA 1.477 0.9 0 C-N-CA 126.018 1.727 . . . . 0.0 113.409 173.707 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 18.5 t -131.48 113.4 13.64 Favored 'General case' 0 N--CA 1.468 0.446 0 C-N-CA 125.852 1.661 . . . . 0.0 110.495 -179.512 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 78.2 mm-40 -61.75 136.71 58.1 Favored 'General case' 0 N--CA 1.474 0.743 0 C-N-CA 124.698 1.199 . . . . 0.0 112.796 179.91 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -86.37 -31.85 18.15 Favored Glycine 0 CA--C 1.537 1.418 0 C-N-CA 123.912 0.768 . . . . 0.0 114.683 -179.06 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 66.2 m -76.69 93.72 3.69 Favored 'General case' 0 N--CA 1.473 0.688 0 C-N-CA 124.97 1.308 . . . . 0.0 112.045 -179.485 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 48.8 t -60.53 132.25 90.96 Favored Pre-proline 0 CA--C 1.551 1.001 0 C-N-CA 124.33 1.052 . . . . 0.0 111.607 174.979 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -71.64 161.61 44.72 Favored 'Trans proline' 0 CA--C 1.542 0.913 0 C-N-CA 123.125 2.55 . . . . 0.0 112.652 178.656 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 34.5 m -127.29 -37.42 2.04 Favored 'General case' 0 N--CA 1.483 1.202 0 C-N-CA 124.965 1.306 . . . . 0.0 112.912 -175.559 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 172.94 -168.08 41.05 Favored Glycine 0 CA--C 1.534 1.219 0 C-N-CA 125.03 1.3 . . . . 0.0 112.72 -173.177 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 11.2 tp . . . . . 0 C--O 1.254 1.301 0 C-N-CA 126.41 1.884 . . . . 0.0 112.98 -179.877 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.489 1.512 0 CA-C-O 120.491 0.186 . . . . 0.0 111.172 . . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -79.76 74.86 6.45 Favored 'General case' 0 N--CA 1.482 1.127 0 C-N-CA 125.204 1.402 . . . . 0.0 111.738 179.087 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 24.7 t -137.34 123.82 28.31 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.999 0 C-N-CA 125.486 1.515 . . . . 0.0 110.588 179.91 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 22.4 m -71.14 114.37 9.13 Favored 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 125.285 1.434 . . . . 0.0 110.447 173.426 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -72.84 35.88 0.07 Allowed 'General case' 0 CA--C 1.556 1.195 0 C-N-CA 125.702 1.601 . . . . 0.0 114.321 178.257 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 63.8 m -64.85 159.03 66.45 Favored Pre-proline 0 CA--C 1.549 0.932 0 C-N-CA 126.499 1.92 . . . . 0.0 113.934 -178.232 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -70.81 158.96 54.15 Favored 'Trans proline' 0 C--N 1.352 0.736 0 C-N-CA 123.293 2.662 . . . . 0.0 112.785 -179.64 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 48.3 tttm -71.54 -21.17 61.94 Favored 'General case' 0 N--CA 1.478 0.953 0 C-N-CA 125.272 1.429 . . . . 0.0 113.397 176.401 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 43.7 mm -57.32 130.61 20.45 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.652 0 C-N-CA 126.257 1.823 . . . . 0.0 110.994 -179.651 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 2.0 pt? -93.05 133.95 35.68 Favored 'General case' 0 CA--C 1.539 0.548 0 C-N-CA 125.312 1.445 . . . . 0.0 111.981 176.426 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 54.2 mttm -144.17 81.39 11.56 Favored Pre-proline 0 N--CA 1.471 0.611 0 C-N-CA 126.87 2.068 . . . . 0.0 109.236 166.748 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -71.53 85.03 0.93 Allowed 'Trans proline' 0 CA--C 1.539 0.729 0 C-N-CA 123.522 2.815 . . . . 0.0 111.915 178.836 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 35.2 m -110.96 166.72 5.37 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.344 0 C-N-CA 126.987 2.115 . . . . 0.0 112.609 -176.877 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 24.4 p -76.38 130.82 38.61 Favored 'General case' 0 CA--C 1.544 0.717 0 C-N-CA 124.124 0.97 . . . . 0.0 111.961 176.338 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -89.29 160.14 29.15 Favored Glycine 0 CA--C 1.534 1.255 0 C-N-CA 124.925 1.25 . . . . 0.0 111.974 168.239 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 91.2 p -59.39 -26.19 64.91 Favored 'General case' 0 N--CA 1.476 0.873 0 N-CA-C 115.252 1.575 . . . . 0.0 115.252 -171.928 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 32.2 m-20 -81.56 -2.77 51.18 Favored 'General case' 0 CA--C 1.547 0.858 0 C-N-CA 125.321 1.448 . . . . 0.0 114.451 176.585 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 89.59 31.4 11.48 Favored Glycine 0 CA--C 1.536 1.387 0 C-N-CA 124.772 1.177 . . . . 0.0 113.089 -176.285 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 42.9 mmm-85 -114.68 172.24 7.16 Favored 'General case' 0 N--CA 1.477 0.877 0 C-N-CA 127.808 2.443 . . . . 0.0 111.022 -170.873 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 31.7 m -128.68 133.53 48.23 Favored 'General case' 0 N--CA 1.481 1.086 0 C-N-CA 124.717 1.207 . . . . 0.0 110.748 178.921 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 87.3 m-85 -135.73 156.15 49.28 Favored 'General case' 0 N--CA 1.473 0.682 0 C-N-CA 125.186 1.394 . . . . 0.0 112.155 -178.106 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.99 -40.76 95.44 Favored 'General case' 0 CA--C 1.543 0.689 0 N-CA-C 113.499 0.926 . . . . 0.0 113.499 -166.965 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 28.7 p30 -148.4 179.7 7.59 Favored 'General case' 0 CA--C 1.547 0.847 0 C-N-CA 125.326 1.45 . . . . 0.0 112.194 164.813 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 44.6 p -62.64 -34.12 76.42 Favored 'General case' 0 N--CA 1.474 0.76 0 C-N-CA 124.228 1.011 . . . . 0.0 113.531 176.772 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 47.3 t -62.39 -55.1 31.08 Favored 'General case' 0 N--CA 1.465 0.276 0 C-N-CA 124.321 1.049 . . . . 0.0 111.917 178.093 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 9.3 tp -61.26 -35.71 67.87 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.611 0 N-CA-C 112.25 0.463 . . . . 0.0 112.25 179.576 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -58.99 -51.37 70.38 Favored 'General case' 0 CA--C 1.544 0.73 0 C-N-CA 123.698 0.799 . . . . 0.0 111.885 172.499 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 77.5 mtp85 -57.92 -45.55 86.36 Favored 'General case' 0 N--CA 1.477 0.925 0 C-N-CA 124.644 1.177 . . . . 0.0 112.772 174.85 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 6.7 t -62.48 -40.83 97.95 Favored 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 123.766 0.826 . . . . 0.0 112.275 177.139 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 43.9 t30 -67.67 -42.04 82.79 Favored 'General case' 0 CA--C 1.543 0.681 0 C-N-CA 125.026 1.33 . . . . 0.0 113.245 178.32 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 134.43 23.79 0.64 Allowed Glycine 0 CA--C 1.538 1.476 0 N-CA-C 116.046 1.178 . . . . 0.0 116.046 178.013 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 38.0 t -125.01 154.47 33.06 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.448 0 C-N-CA 126.835 2.054 . . . . 0.0 108.379 -178.147 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 91.3 p -135.79 166.97 22.05 Favored 'General case' 0 N--CA 1.472 0.646 0 C-N-CA 124.618 1.167 . . . . 0.0 112.875 175.918 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 2.0 mt -125.98 -8.71 5.38 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.04 0 C-N-CA 124.862 1.265 . . . . 0.0 112.006 -172.193 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 25.7 pttm -60.46 -30.78 69.88 Favored 'General case' 0 N--CA 1.479 0.981 0 C-N-CA 126.366 1.866 . . . . 0.0 113.584 174.291 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 33.8 m -83.62 83.19 7.99 Favored 'General case' 0 N--CA 1.468 0.467 0 C-N-CA 126.263 1.825 . . . . 0.0 110.551 -179.559 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 16.9 pt-20 -130.01 163.45 26.45 Favored 'General case' 0 CA--C 1.543 0.709 0 C-N-CA 125.949 1.7 . . . . 0.0 112.657 -177.049 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -91.67 -27.89 15.87 Favored Glycine 0 CA--C 1.537 1.418 0 C-N-CA 123.953 0.787 . . . . 0.0 115.037 -173.848 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 25.6 p -85.05 166.37 16.75 Favored 'General case' 0 N--CA 1.473 0.676 0 C-N-CA 125.209 1.403 . . . . 0.0 113.127 177.365 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 48.6 t -65.6 127.98 93.45 Favored Pre-proline 0 CA--C 1.55 0.96 0 C-N-CA 123.91 0.884 . . . . 0.0 111.593 176.917 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -71.34 94.08 0.67 Allowed 'Trans proline' 0 CA--C 1.543 0.945 0 C-N-CA 123.886 3.057 . . . . 0.0 112.211 -178.089 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 8.6 m -138.6 147.26 42.75 Favored 'General case' 0 N--CA 1.48 1.032 0 C-N-CA 126.029 1.732 . . . . 0.0 110.86 -177.441 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 143.7 -62.28 0.5 Allowed Glycine 0 CA--C 1.532 1.154 0 C-N-CA 124.891 1.234 . . . . 0.0 113.63 171.452 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 21.1 tt . . . . . 0 C--O 1.252 1.204 0 C-N-CA 126.954 2.102 . . . . 0.0 112.273 -178.011 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.636 0 N-CA-C 111.622 0.231 . . . . 0.0 111.622 . . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 48.5 tttm 51.05 47.46 24.82 Favored 'General case' 0 N--CA 1.484 1.241 0 C-N-CA 127.084 2.154 . . . . 0.0 113.586 178.912 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 12.8 p -142.41 144.93 24.18 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.966 0 C-N-CA 126.047 1.739 . . . . 0.0 111.69 -179.414 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 81.0 m -80.92 110.27 16.29 Favored 'General case' 0 CA--C 1.544 0.736 0 C-N-CA 125.584 1.554 . . . . 0.0 110.782 175.736 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -74.95 68.62 1.82 Allowed 'General case' 0 CA--C 1.549 0.935 0 C-N-CA 125.686 1.595 . . . . 0.0 113.17 -177.672 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 62.6 m -69.05 154.89 94.57 Favored Pre-proline 0 CA--C 1.549 0.909 0 C-N-CA 124.536 1.134 . . . . 0.0 113.431 -179.404 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -68.5 152.77 74.82 Favored 'Trans proline' 0 CA--C 1.54 0.811 0 C-N-CA 123.201 2.601 . . . . 0.0 111.854 172.637 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 15.2 ptmt -63.86 -26.03 68.43 Favored 'General case' 0 N--CA 1.479 1.023 0 C-N-CA 125.685 1.594 . . . . 0.0 114.678 177.571 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 9.5 tt -57.78 158.32 1.35 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.614 0 C-N-CA 126.673 1.989 . . . . 0.0 112.301 176.079 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 16.8 tp -126.96 114.78 18.29 Favored 'General case' 0 CA--C 1.538 0.487 0 C-N-CA 126.433 1.893 . . . . 0.0 108.518 -178.07 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 31.1 mmmt -127.61 80.18 72.29 Favored Pre-proline 0 N--CA 1.473 0.716 0 C-N-CA 126.125 1.77 . . . . 0.0 109.792 -176.362 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -72.78 84.28 1.27 Allowed 'Trans proline' 0 CA--C 1.541 0.83 0 C-N-CA 124.274 3.316 . . . . 0.0 112.402 -175.427 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 14.4 m -73.78 164.76 3.41 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.598 0 C-N-CA 126.883 2.073 . . . . 0.0 112.832 177.556 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 10.0 t -79.79 -5.21 54.92 Favored 'General case' 0 CA--C 1.551 0.995 0 C-N-CA 124.539 1.135 . . . . 0.0 113.983 174.406 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 57.29 -155.19 18.24 Favored Glycine 0 CA--C 1.539 1.548 0 C-N-CA 125.338 1.447 . . . . 0.0 113.984 179.211 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 38.0 m -121.22 -20.54 6.7 Favored 'General case' 0 N--CA 1.475 0.776 0 C-N-CA 124.94 1.296 . . . . 0.0 114.223 174.454 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -80.81 -13.88 58.56 Favored 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 124.252 1.021 . . . . 0.0 113.102 171.703 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 98.51 -14.91 61.71 Favored Glycine 0 CA--C 1.537 1.456 0 C-N-CA 126.782 2.134 . . . . 0.0 114.008 -177.945 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 9.8 ptm180 -77.96 168.83 19.28 Favored 'General case' 0 N--CA 1.474 0.747 0 C-N-CA 125.378 1.471 . . . . 0.0 112.279 168.269 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 54.7 m -95.22 149.36 21.4 Favored 'General case' 0 N--CA 1.475 0.779 0 C-N-CA 124.452 1.101 . . . . 0.0 111.708 174.823 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 56.1 m-85 -131.63 151.99 51.18 Favored 'General case' 0 N--CA 1.47 0.562 0 C-N-CA 126.249 1.819 . . . . 0.0 110.676 173.797 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.89 -40.54 87.79 Favored 'General case' 0 CA--C 1.544 0.713 0 N-CA-C 113.273 0.842 . . . . 0.0 113.273 -169.855 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 16.5 m120 -144.61 170.96 15.07 Favored 'General case' 0 CA--C 1.545 0.786 0 C-N-CA 126.29 1.836 . . . . 0.0 110.954 174.894 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 28.4 p -61.41 -32.06 72.0 Favored 'General case' 0 N--CA 1.475 0.797 0 C-N-CA 124.152 0.981 . . . . 0.0 112.618 162.073 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 42.3 t -54.84 -64.25 0.89 Allowed 'General case' 0 CA--C 1.535 0.374 0 C-N-CA 125.699 1.599 . . . . 0.0 112.366 173.264 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 13.6 tt -58.54 -35.62 55.6 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.812 0 N-CA-C 112.211 0.449 . . . . 0.0 112.211 -178.021 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -59.07 -56.63 19.72 Favored 'General case' 0 CA--C 1.541 0.617 0 C-N-CA 123.5 0.72 . . . . 0.0 111.505 174.671 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 69.6 mtm180 -64.55 -37.5 87.77 Favored 'General case' 0 N--CA 1.479 0.977 0 N-CA-C 113.209 0.818 . . . . 0.0 113.209 179.009 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 35.9 t -58.35 -45.25 88.54 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 125.233 1.413 . . . . 0.0 111.833 172.695 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 23.0 t-20 -71.57 -48.84 45.73 Favored 'General case' 0 CA--C 1.546 0.816 0 C-N-CA 125.03 1.332 . . . . 0.0 112.79 179.911 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 144.7 23.43 0.14 Allowed Glycine 0 CA--C 1.54 1.629 0 N-CA-C 116.523 1.369 . . . . 0.0 116.523 179.765 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 18.4 t -130.88 151.56 36.12 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.603 0 C-N-CA 126.637 1.975 . . . . 0.0 109.179 -174.789 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 95.0 p -144.91 124.81 13.45 Favored 'General case' 0 N--CA 1.47 0.562 0 C-N-CA 125.106 1.362 . . . . 0.0 112.108 -179.724 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 6.3 mt -63.57 -20.88 27.23 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.149 0 C-N-CA 124.306 1.042 . . . . 0.0 112.132 -178.805 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -67.29 -16.1 64.08 Favored 'General case' 0 N--CA 1.475 0.813 0 C-N-CA 126.808 2.043 . . . . 0.0 113.254 173.014 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 1.1 t 61.93 20.21 11.33 Favored 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 126.402 1.881 . . . . 0.0 114.768 -179.372 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -147.59 166.41 27.45 Favored 'General case' 0 CA--C 1.541 0.622 0 C-N-CA 124.913 1.285 . . . . 0.0 113.298 -178.391 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -80.0 52.5 4.25 Favored Glycine 0 CA--C 1.534 1.252 0 C-N-CA 125.581 1.562 . . . . 0.0 113.794 -179.581 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 10.8 t -72.44 88.68 1.22 Allowed 'General case' 0 CA--C 1.54 0.594 0 C-N-CA 124.851 1.261 . . . . 0.0 111.128 176.802 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 17.7 t 40.87 75.02 0.64 Allowed Pre-proline 0 CA--C 1.556 1.177 0 C-N-CA 127.884 2.474 . . . . 0.0 114.358 -175.398 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 74.9 Cg_endo -72.35 89.16 0.82 Allowed 'Trans proline' 0 CA--C 1.543 0.962 0 C-N-CA 124.174 3.249 . . . . 0.0 112.605 -177.318 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 22.1 p -71.75 102.12 2.74 Favored 'General case' 0 N--CA 1.475 0.791 0 C-N-CA 126.074 1.75 . . . . 0.0 112.307 176.911 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 97.39 114.1 3.18 Favored Glycine 0 CA--C 1.535 1.313 0 C-N-CA 124.848 1.213 . . . . 0.0 113.1 176.673 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 27.6 mm . . . . . 0 C--O 1.254 1.309 0 C-N-CA 126.025 1.73 . . . . 0.0 111.391 177.304 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 62.8 pttt . . . . . 0 N--CA 1.491 1.611 0 N-CA-C 111.606 0.224 . . . . 0.0 111.606 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 8.8 mtmp? 48.21 46.74 19.82 Favored 'General case' 0 N--CA 1.487 1.401 0 C-N-CA 126.983 2.113 . . . . 0.0 113.975 -179.027 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 11.1 p -138.8 142.53 34.16 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.003 0 C-N-CA 125.002 1.321 . . . . 0.0 112.046 -179.036 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 61.2 m -82.05 100.41 9.72 Favored 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 125.494 1.518 . . . . 0.0 110.832 177.266 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -73.99 52.89 0.45 Allowed 'General case' 0 CA--C 1.554 1.123 0 C-N-CA 125.612 1.565 . . . . 0.0 113.131 177.36 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 92.8 m -62.86 157.03 62.98 Favored Pre-proline 0 CA--C 1.551 1.001 0 C-N-CA 125.791 1.636 . . . . 0.0 113.232 178.977 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -71.82 167.7 25.87 Favored 'Trans proline' 0 CA--C 1.542 0.881 0 C-N-CA 123.29 2.66 . . . . 0.0 113.283 -177.24 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 61.7 mtpt -66.46 -16.8 64.39 Favored 'General case' 0 N--CA 1.481 1.088 0 C-N-CA 126.033 1.733 . . . . 0.0 114.097 176.171 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 79.8 mt -58.47 136.36 21.96 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.722 0 C-N-CA 126.489 1.916 . . . . 0.0 110.24 178.064 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.9 pt? -130.98 26.42 4.93 Favored 'General case' 0 CA--C 1.546 0.816 0 C-N-CA 125.416 1.487 . . . . 0.0 113.951 -178.48 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 26.4 mmtp -52.59 107.22 0.79 Allowed Pre-proline 0 N--CA 1.477 0.893 0 C-N-CA 126.516 1.926 . . . . 0.0 111.553 175.182 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 91.6 Cg_endo -73.61 87.76 1.08 Allowed 'Trans proline' 0 CA--C 1.539 0.729 0 C-N-CA 123.526 2.818 . . . . 0.0 112.01 -173.816 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 13.6 m -73.8 157.85 6.17 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.459 0 C-N-CA 125.636 1.574 . . . . 0.0 112.297 179.246 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 30.3 p -63.44 165.2 8.1 Favored 'General case' 0 CA--C 1.544 0.741 0 C-N-CA 123.412 0.685 . . . . 0.0 111.835 165.637 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -133.97 143.29 14.93 Favored Glycine 0 CA--C 1.527 0.798 0 C-N-CA 125.058 1.313 . . . . 0.0 111.972 179.999 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 55.6 m -65.08 -15.82 62.79 Favored 'General case' 0 N--CA 1.473 0.706 0 C-N-CA 125.362 1.465 . . . . 0.0 114.913 -174.598 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 42.0 m-20 -95.32 5.78 50.78 Favored 'General case' 0 CA--C 1.553 1.082 0 C-N-CA 125.972 1.709 . . . . 0.0 113.514 171.955 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 88.91 24.81 31.27 Favored Glycine 0 N--CA 1.473 1.108 0 C-N-CA 125.05 1.309 . . . . 0.0 114.157 179.921 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 24.0 mtp85 -120.47 -170.53 2.0 Favored 'General case' 0 N--CA 1.481 1.098 0 C-N-CA 126.297 1.839 . . . . 0.0 112.348 -171.409 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 41.2 m -134.42 139.04 45.27 Favored 'General case' 0 N--CA 1.478 0.964 0 C-N-CA 125.952 1.701 . . . . 0.0 110.37 -179.34 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 65.6 m-85 -134.3 159.4 41.09 Favored 'General case' 0 N--CA 1.473 0.694 0 C-N-CA 124.921 1.288 . . . . 0.0 111.603 179.036 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -63.97 -40.53 96.6 Favored 'General case' 0 CA--C 1.543 0.682 0 N-CA-C 112.92 0.711 . . . . 0.0 112.92 -168.075 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 28.5 p30 -154.77 -178.39 7.17 Favored 'General case' 0 CA--C 1.551 0.991 0 C-N-CA 125.314 1.445 . . . . 0.0 111.635 168.877 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 83.4 p -73.12 -16.79 61.45 Favored 'General case' 0 N--CA 1.48 1.046 0 N-CA-C 114.753 1.39 . . . . 0.0 114.753 177.843 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 38.8 t -76.6 -56.06 4.95 Favored 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 124.77 1.228 . . . . 0.0 111.136 173.861 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 7.7 tp -57.85 -34.63 48.77 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.859 0 C-N-CA 123.528 0.731 . . . . 0.0 112.406 179.115 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -55.24 -53.35 57.17 Favored 'General case' 0 CA--C 1.541 0.627 0 C-N-CA 123.885 0.874 . . . . 0.0 111.484 172.967 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 81.3 mtm180 -67.02 -37.42 84.13 Favored 'General case' 0 N--CA 1.475 0.786 0 C-N-CA 125.031 1.332 . . . . 0.0 113.49 178.317 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 42.5 t -57.22 -47.0 82.43 Favored 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 124.325 1.05 . . . . 0.0 111.599 170.844 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 63.6 t30 -70.96 -49.84 41.09 Favored 'General case' 0 CA--C 1.546 0.797 0 C-N-CA 125.502 1.521 . . . . 0.0 112.961 -178.172 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 145.42 23.22 0.12 Allowed Glycine 0 CA--C 1.539 1.561 0 N-CA-C 116.792 1.477 . . . . 0.0 116.792 178.663 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 19.3 t -125.55 150.84 31.06 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.613 0 C-N-CA 126.714 2.006 . . . . 0.0 108.839 -178.069 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 32.5 t -144.61 118.54 9.35 Favored 'General case' 0 N--CA 1.472 0.666 0 C-N-CA 124.907 1.283 . . . . 0.0 112.698 179.197 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.427 HD12 ' H ' ' A' ' 34' ' ' ILE . 0.7 OUTLIER -86.51 13.12 0.96 Allowed 'Isoleucine or valine' 0 CA--C 1.555 1.16 0 C-N-CA 126.789 2.035 . . . . 0.0 111.469 -178.638 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 1.1 mptm? 60.99 5.13 0.92 Allowed 'General case' 0 N--CA 1.487 1.392 0 C-N-CA 128.728 2.811 . . . . 0.0 115.433 -174.978 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 7.5 t -67.98 -21.23 65.07 Favored 'General case' 0 N--CA 1.474 0.727 0 C-N-CA 125.181 1.393 . . . . 0.0 114.58 -178.45 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 14.1 tt0 -144.62 162.12 37.45 Favored 'General case' 0 CA--C 1.548 0.87 0 C-N-CA 124.659 1.184 . . . . 0.0 111.546 177.021 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -79.54 47.92 3.34 Favored Glycine 0 CA--C 1.536 1.392 0 C-N-CA 125.711 1.624 . . . . 0.0 116.044 -166.077 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 21.3 t -78.18 -59.74 2.66 Favored 'General case' 0 N--CA 1.475 0.784 0 C-N-CA 124.617 1.167 . . . . 0.0 112.661 -179.361 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 13.2 p -143.14 70.39 18.26 Favored Pre-proline 0 CA--C 1.551 1.005 0 C-N-CA 125.234 1.414 . . . . 0.0 111.869 -178.363 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 79.3 Cg_endo -70.11 162.34 42.62 Favored 'Trans proline' 0 CA--C 1.543 0.95 0 C-N-CA 123.173 2.582 . . . . 0.0 112.544 178.475 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 21.3 m -130.0 77.67 1.8 Allowed 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 125.287 1.435 . . . . 0.0 109.959 -178.922 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -84.28 71.68 2.94 Favored Glycine 0 CA--C 1.533 1.187 0 C-N-CA 125.154 1.359 . . . . 0.0 113.476 -175.296 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 54.2 mt . . . . . 0 C--O 1.254 1.311 0 C-N-CA 126.171 1.789 . . . . 0.0 111.085 176.172 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 74.6 tttt . . . . . 0 N--CA 1.492 1.648 0 N-CA-C 111.503 0.186 . . . . 0.0 111.503 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 10.4 ptpp? -166.15 167.31 16.37 Favored 'General case' 0 N--CA 1.487 1.388 0 C-N-CA 127.17 2.188 . . . . 0.0 111.122 167.923 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 45.8 t -139.77 133.08 36.34 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.042 0 C-N-CA 125.675 1.59 . . . . 0.0 110.172 177.51 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 4.9 m -68.99 104.05 2.0 Allowed 'General case' 0 CA--C 1.547 0.843 0 C-N-CA 124.686 1.194 . . . . 0.0 109.888 171.139 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -74.44 51.19 0.44 Allowed 'General case' 0 CA--C 1.554 1.101 0 C-N-CA 125.571 1.549 . . . . 0.0 113.58 -177.588 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 81.2 m -71.5 156.07 91.88 Favored Pre-proline 0 CA--C 1.548 0.885 0 C-N-CA 125.624 1.569 . . . . 0.0 114.039 -172.704 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -68.93 158.83 56.34 Favored 'Trans proline' 0 CA--C 1.54 0.814 0 C-N-CA 123.63 2.887 . . . . 0.0 113.213 177.979 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 64.8 mttm -69.98 -14.02 62.5 Favored 'General case' 0 N--CA 1.481 1.093 0 C-N-CA 126.399 1.88 . . . . 0.0 114.142 177.813 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 10.3 tp -62.41 146.49 12.42 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 C-N-CA 126.438 1.895 . . . . 0.0 113.446 -177.114 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 62.7 tp -116.8 88.36 2.88 Favored 'General case' 0 CA--C 1.539 0.544 0 C-N-CA 127.138 2.175 . . . . 0.0 108.881 -175.677 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 13.1 mmmm -134.38 74.12 67.28 Favored Pre-proline 0 N--CA 1.474 0.739 0 C-N-CA 126.519 1.928 . . . . 0.0 109.179 175.536 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -67.21 120.02 7.07 Favored 'Trans proline' 0 CA--C 1.536 0.611 0 C-N-CA 122.929 2.419 . . . . 0.0 111.12 -175.732 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -107.51 155.75 8.17 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.747 0 C-N-CA 124.929 1.291 . . . . 0.0 110.961 -175.8 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 8.8 p -81.98 106.33 13.81 Favored 'General case' 0 CA--C 1.545 0.754 0 C-N-CA 125.792 1.637 . . . . 0.0 110.813 171.582 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -69.11 154.07 53.11 Favored Glycine 0 CA--C 1.534 1.272 0 O-C-N 121.45 -0.781 . . . . 0.0 112.085 172.063 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 73.2 m -61.69 -18.71 60.73 Favored 'General case' 0 N--CA 1.479 0.982 0 N-CA-C 116.084 1.883 . . . . 0.0 116.084 -168.854 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 31.8 t70 -82.14 -11.29 58.82 Favored 'General case' 0 CA--C 1.548 0.902 0 N-CA-C 114.105 1.15 . . . . 0.0 114.105 175.252 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 107.42 6.13 33.73 Favored Glycine 0 CA--C 1.536 1.377 0 C-N-CA 126.3 1.905 . . . . 0.0 114.418 -179.452 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 40.2 mtp180 -104.39 138.55 40.63 Favored 'General case' 0 N--CA 1.475 0.798 0 C-N-CA 126.073 1.749 . . . . 0.0 111.211 -175.139 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 8.1 p -77.91 141.9 38.75 Favored 'General case' 0 N--CA 1.47 0.55 0 C-N-CA 123.901 0.88 . . . . 0.0 112.39 175.961 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 92.8 m-85 -135.49 144.05 46.16 Favored 'General case' 0 N--CA 1.472 0.666 0 C-N-CA 125.437 1.495 . . . . 0.0 111.742 175.786 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -60.33 -40.98 92.56 Favored 'General case' 0 CA--C 1.543 0.688 0 N-CA-C 114.145 1.165 . . . . 0.0 114.145 -163.402 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 14.1 p30 -155.3 174.28 15.44 Favored 'General case' 0 CA--C 1.55 0.971 0 C-N-CA 126.282 1.833 . . . . 0.0 110.175 163.818 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 73.8 p -60.82 -25.98 66.99 Favored 'General case' 0 N--CA 1.48 1.037 0 N-CA-C 114.391 1.256 . . . . 0.0 114.391 -175.883 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 48.7 t -57.91 -62.25 1.94 Allowed 'General case' 0 CA--C 1.532 0.277 0 C-N-CA 124.923 1.289 . . . . 0.0 111.742 172.344 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 6.4 tt -59.91 -36.09 64.61 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.773 0 N-CA-C 112.289 0.477 . . . . 0.0 112.289 -177.336 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -58.26 -58.18 9.61 Favored 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 124.179 0.992 . . . . 0.0 111.518 174.589 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 65.2 mtm180 -64.17 -36.06 82.82 Favored 'General case' 0 N--CA 1.477 0.881 0 N-CA-C 113.271 0.841 . . . . 0.0 113.271 179.417 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 6.6 t -61.93 -42.97 99.71 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 124.009 0.924 . . . . 0.0 111.631 174.197 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 26.9 t-20 -69.37 -49.08 58.82 Favored 'General case' 0 CA--C 1.546 0.792 0 C-N-CA 124.851 1.26 . . . . 0.0 112.68 176.679 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 139.52 24.38 0.3 Allowed Glycine 0 CA--C 1.539 1.568 0 N-CA-C 116.16 1.224 . . . . 0.0 116.16 179.595 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 32.5 t -129.74 153.23 38.52 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.636 0 C-N-CA 126.373 1.869 . . . . 0.0 109.385 -177.927 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 68.9 m -134.41 170.48 15.67 Favored 'General case' 0 N--CA 1.47 0.575 0 C-N-CA 126.312 1.845 . . . . 0.0 112.099 -179.582 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 1.9 mp -118.01 3.34 7.28 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.1 0 C-N-CA 126.414 1.886 . . . . 0.0 111.443 -178.924 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 28.0 tptp -49.72 -61.88 1.87 Allowed 'General case' 0 N--CA 1.479 1.017 0 C-N-CA 127.044 2.137 . . . . 0.0 112.96 -178.904 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 13.4 t -156.29 129.75 8.22 Favored 'General case' 0 N--CA 1.466 0.328 0 C-N-CA 125.737 1.615 . . . . 0.0 110.054 -179.533 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 44.4 mt-10 -68.04 168.74 11.35 Favored 'General case' 0 CA--C 1.547 0.834 0 C-N-CA 124.857 1.263 . . . . 0.0 113.175 -179.444 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -69.12 -12.24 65.17 Favored Glycine 0 CA--C 1.54 1.642 0 N-CA-C 115.63 1.012 . . . . 0.0 115.63 -178.771 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 89.1 p -147.97 165.27 31.22 Favored 'General case' 0 N--CA 1.473 0.715 0 C-N-CA 126.069 1.748 . . . . 0.0 112.064 174.197 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 10.8 p -147.9 72.67 11.37 Favored Pre-proline 0 CA--C 1.551 1.017 0 C-N-CA 125.044 1.338 . . . . 0.0 112.052 178.589 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_endo -76.1 84.48 1.81 Allowed 'Trans proline' 0 CA--C 1.545 1.039 0 C-N-CA 123.811 3.007 . . . . 0.0 112.177 -179.551 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 2.0 m -74.27 43.12 0.17 Allowed 'General case' 0 N--CA 1.485 1.281 0 C-N-CA 126.701 2.0 . . . . 0.0 112.651 176.899 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 82.92 142.98 4.75 Favored Glycine 0 CA--C 1.537 1.422 0 C-N-CA 126.545 2.021 . . . . 0.0 113.034 -171.172 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 37.9 pt . . . . . 0 C--O 1.252 1.203 0 C-N-CA 127.447 2.299 . . . . 0.0 112.593 179.67 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 60.2 mtpt . . . . . 0 N--CA 1.494 1.738 0 CA-C-O 119.731 -0.176 . . . . 0.0 110.82 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 59.5 pttt 48.29 26.2 1.04 Allowed 'General case' 0 N--CA 1.49 1.568 0 C-N-CA 128.682 2.793 . . . . 0.0 117.27 179.236 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 25.0 t -77.63 124.13 35.5 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.853 0 C-N-CA 124.531 1.132 . . . . 0.0 111.049 -179.185 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 61.8 m -115.3 4.11 14.37 Favored 'General case' 0 CA--C 1.551 0.999 0 C-N-CA 126.351 1.861 . . . . 0.0 113.248 174.897 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . 54.41 30.85 13.46 Favored 'General case' 0 CA--C 1.551 1.002 0 C-N-CA 127.795 2.438 . . . . 0.0 114.408 -170.016 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 64.1 m -64.42 156.83 75.15 Favored Pre-proline 0 CA--C 1.55 0.958 0 C-N-CA 125.388 1.475 . . . . 0.0 113.387 177.321 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 95.3 Cg_endo -74.18 165.18 32.55 Favored 'Trans proline' 0 CA--C 1.542 0.894 0 C-N-CA 123.419 2.746 . . . . 0.0 113.522 -174.682 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 73.9 mmtt -78.87 -0.26 29.98 Favored 'General case' 0 N--CA 1.482 1.146 0 C-N-CA 126.28 1.832 . . . . 0.0 114.746 178.632 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 50.8 mm -56.86 157.97 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.766 0 C-N-CA 126.696 1.998 . . . . 0.0 111.146 170.536 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 51.5 tp -135.7 92.71 2.85 Favored 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 126.515 1.926 . . . . 0.0 108.583 -178.857 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 53.5 tptt -139.2 80.77 22.43 Favored Pre-proline 0 N--CA 1.471 0.595 0 C-N-CA 125.327 1.451 . . . . 0.0 110.124 174.186 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 62.1 Cg_endo -68.92 146.92 66.99 Favored 'Trans proline' 0 CA--C 1.537 0.67 0 C-N-CA 121.919 1.746 . . . . 0.0 111.102 177.68 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 1.4 t -137.08 159.81 36.41 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.977 0 C-N-CA 124.933 1.293 . . . . 0.0 110.518 -176.589 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 29.9 p -85.83 -7.47 58.71 Favored 'General case' 0 CA--C 1.547 0.828 0 C-N-CA 125.85 1.66 . . . . 0.0 114.764 -174.487 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 56.86 -178.38 0.78 Allowed Glycine 0 CA--C 1.537 1.442 0 C-N-CA 127.136 2.303 . . . . 0.0 116.447 177.274 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 11.2 t -79.46 -36.36 38.93 Favored 'General case' 0 CA--C 1.543 0.692 0 C-N-CA 123.653 0.781 . . . . 0.0 112.166 170.732 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -75.63 -12.22 60.17 Favored 'General case' 0 CA--C 1.548 0.877 0 C-N-CA 125.441 1.497 . . . . 0.0 114.596 -177.857 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 92.26 7.44 63.79 Favored Glycine 0 CA--C 1.536 1.373 0 C-N-CA 125.745 1.641 . . . . 0.0 114.723 176.13 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 38.3 mtt180 -95.84 -178.08 4.25 Favored 'General case' 0 N--CA 1.477 0.902 0 C-N-CA 126.353 1.861 . . . . 0.0 112.172 -177.046 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 47.3 m -122.24 128.19 50.84 Favored 'General case' 0 N--CA 1.476 0.85 0 C-N-CA 124.573 1.149 . . . . 0.0 110.505 179.32 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 56.4 m-85 -131.85 156.34 46.24 Favored 'General case' 0 N--CA 1.47 0.566 0 C-N-CA 125.491 1.517 . . . . 0.0 111.483 179.243 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.19 -43.83 85.7 Favored 'General case' 0 CA--C 1.544 0.748 0 N-CA-C 113.307 0.854 . . . . 0.0 113.307 -169.197 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 70.6 m-80 -139.66 175.9 9.18 Favored 'General case' 0 CA--C 1.544 0.729 0 C-N-CA 125.739 1.616 . . . . 0.0 111.557 171.184 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 42.4 t -61.34 -40.44 94.25 Favored 'General case' 0 N--CA 1.473 0.723 0 O-C-N 121.339 -0.851 . . . . 0.0 112.199 167.018 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 46.0 t -53.49 -57.42 10.76 Favored 'General case' 0 N--CA 1.467 0.398 0 C-N-CA 125.095 1.358 . . . . 0.0 112.795 -179.782 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 10.8 tp -59.97 -39.37 80.01 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.694 0 C-N-CA 122.791 0.436 . . . . 0.0 112.108 -179.099 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -68.76 -40.15 79.88 Favored 'General case' 0 CA--C 1.542 0.635 0 O-C-N 121.525 -0.735 . . . . 0.0 112.386 178.2 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 20.8 tpt180 -68.85 -35.66 77.2 Favored 'General case' 0 N--CA 1.472 0.654 0 C-N-CA 124.57 1.148 . . . . 0.0 112.691 176.107 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 47.8 t -59.45 -49.29 78.37 Favored 'General case' 0 CA--C 1.542 0.648 0 C-N-CA 125.059 1.344 . . . . 0.0 111.083 167.479 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 25.9 t-20 -62.97 -45.35 92.83 Favored 'General case' 0 CA--C 1.546 0.796 0 C-N-CA 124.814 1.246 . . . . 0.0 113.324 -179.535 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 143.66 17.22 0.24 Allowed Glycine 0 CA--C 1.54 1.614 0 N-CA-C 117.191 1.636 . . . . 0.0 117.191 175.386 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 21.7 t -115.7 144.15 23.98 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.704 0 CA-C-N 119.882 1.841 . . . . 0.0 110.232 -176.27 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 23.0 t -91.11 126.84 36.32 Favored 'General case' 0 N--CA 1.472 0.65 0 C-N-CA 126.48 1.912 . . . . 0.0 111.525 176.041 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 22.8 mm -116.65 -23.02 4.15 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.991 0 C-N-CA 125.08 1.352 . . . . 0.0 112.686 -174.655 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 26.5 mmmt -65.46 -21.08 66.61 Favored 'General case' 0 N--CA 1.48 1.027 0 C-N-CA 126.183 1.793 . . . . 0.0 113.72 173.548 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 1.7 t -76.11 9.55 2.44 Favored 'General case' 0 N--CA 1.476 0.868 0 C-N-CA 126.336 1.854 . . . . 0.0 114.982 -177.669 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 37.5 tp10 -48.85 -40.77 30.77 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 126.942 2.097 . . . . 0.0 115.179 -176.568 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -156.23 55.54 0.4 Allowed Glycine 0 CA--C 1.53 0.975 0 C-N-CA 124.098 0.856 . . . . 0.0 113.616 -174.77 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 43.0 m -64.05 -30.28 71.37 Favored 'General case' 0 N--CA 1.475 0.819 0 C-N-CA 124.618 1.167 . . . . 0.0 114.021 179.902 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 38.2 t -149.29 83.07 6.69 Favored Pre-proline 0 CA--C 1.551 0.997 0 C-N-CA 125.448 1.499 . . . . 0.0 111.07 175.661 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 95.1 Cg_endo -75.9 170.4 20.22 Favored 'Trans proline' 0 CA--C 1.542 0.909 0 C-N-CA 123.423 2.748 . . . . 0.0 112.37 178.9 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 6.2 t -70.6 171.86 9.58 Favored 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 123.94 0.896 . . . . 0.0 112.456 170.716 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -92.66 -110.63 1.91 Allowed Glycine 0 CA--C 1.535 1.296 0 C-N-CA 125.486 1.517 . . . . 0.0 112.919 -179.135 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 33.9 pt . . . . . 0 C--O 1.252 1.217 0 C-N-CA 125.874 1.67 . . . . 0.0 113.748 177.705 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 67.9 m . . . . . 0 CA--C 1.541 0.612 0 CA-C-O 121.064 0.459 . . . . 0.0 111.364 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -73.34 48.76 0.25 Allowed 'General case' 0 CA--C 1.554 1.13 0 C-N-CA 126.371 1.868 . . . . 0.0 113.54 177.627 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 85.4 m -61.99 156.79 55.65 Favored Pre-proline 0 CA--C 1.548 0.897 0 C-N-CA 125.718 1.607 . . . . 0.0 113.724 179.853 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_endo -68.62 151.82 74.88 Favored 'Trans proline' 0 C--N 1.351 0.7 0 C-N-CA 123.275 2.65 . . . . 0.0 112.137 177.17 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 10.4 ptpp? -74.28 -30.71 62.22 Favored 'General case' 0 N--CA 1.478 0.964 0 C-N-CA 125.058 1.343 . . . . 0.0 114.198 176.399 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 40.8 mm -58.05 126.95 16.47 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.741 0 C-N-CA 126.893 2.077 . . . . 0.0 111.457 -176.571 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 2.0 pt? -61.6 126.67 28.17 Favored 'General case' 0 CA--C 1.542 0.662 0 C-N-CA 125.128 1.371 . . . . 0.0 112.851 -179.777 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 74.9 mmtt -136.33 71.91 59.6 Favored Pre-proline 0 N--CA 1.479 1.004 0 C-N-CA 125.314 1.446 . . . . 0.0 111.604 173.25 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 75.1 Cg_endo -72.85 84.59 1.25 Allowed 'Trans proline' 0 CA--C 1.54 0.817 0 C-N-CA 123.84 3.027 . . . . 0.0 112.818 -178.058 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 15.1 m -76.99 162.13 4.35 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.589 0 C-N-CA 126.739 2.016 . . . . 0.0 113.296 178.824 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 10.6 t -80.19 -5.54 56.26 Favored 'General case' 0 CA--C 1.553 1.068 0 C-N-CA 125.492 1.517 . . . . 0.0 114.166 174.321 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 64.71 -164.67 34.45 Favored Glycine 0 CA--C 1.538 1.504 0 C-N-CA 125.072 1.32 . . . . 0.0 113.974 -178.371 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 25.1 t -111.27 -38.9 4.87 Favored 'General case' 0 N--CA 1.477 0.901 0 C-N-CA 124.775 1.23 . . . . 0.0 112.591 172.57 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 29.5 t70 -72.29 -13.42 61.5 Favored 'General case' 0 N--CA 1.478 0.955 0 N-CA-C 114.249 1.203 . . . . 0.0 114.249 177.718 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 98.15 39.27 3.81 Favored Glycine 0 CA--C 1.533 1.202 0 C-N-CA 125.92 1.724 . . . . 0.0 112.827 -178.745 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 16.2 mmm180 -135.33 150.88 50.07 Favored 'General case' 0 N--CA 1.475 0.776 0 C-N-CA 127.366 2.266 . . . . 0.0 110.822 -168.716 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 27.9 m -95.82 134.45 38.76 Favored 'General case' 0 N--CA 1.476 0.866 0 C-N-CA 124.209 1.004 . . . . 0.0 110.569 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 73.5 m-85 -128.67 160.92 30.94 Favored 'General case' 0 N--CA 1.471 0.613 0 C-N-CA 125.541 1.537 . . . . 0.0 111.215 178.666 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.9 -60.95 2.49 Favored 'General case' 0 CA--C 1.542 0.658 0 N-CA-C 111.784 0.29 . . . . 0.0 111.784 -172.247 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 30.1 m-20 -129.04 162.49 27.53 Favored 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 125.962 1.705 . . . . 0.0 110.322 170.896 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 26.7 p -63.24 -40.98 98.98 Favored 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 124.637 1.175 . . . . 0.0 113.684 177.299 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 49.5 t -57.89 -48.2 80.56 Favored 'General case' 0 N--CA 1.468 0.441 0 C-N-CA 125.303 1.441 . . . . 0.0 112.372 177.049 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 1.4 mp -52.31 -45.91 44.95 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.727 0 C-N-CA 124.815 1.246 . . . . 0.0 111.669 174.224 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -59.67 -46.63 88.46 Favored 'General case' 0 CA--C 1.545 0.753 0 CA-C-N 119.631 1.105 . . . . 0.0 112.14 177.281 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -57.69 -47.65 81.74 Favored 'General case' 0 N--CA 1.478 0.937 0 C-N-CA 124.877 1.271 . . . . 0.0 111.615 175.639 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 50.7 t -56.31 -48.21 77.13 Favored 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 125.38 1.472 . . . . 0.0 112.297 174.099 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -67.8 -30.06 69.39 Favored 'General case' 0 CA--C 1.548 0.882 0 C-N-CA 124.718 1.207 . . . . 0.0 112.792 -177.516 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 123.32 22.25 2.36 Favored Glycine 0 CA--C 1.537 1.409 0 C-N-CA 124.911 1.243 . . . . 0.0 115.954 175.401 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 5.0 t -124.27 143.59 37.09 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.568 0 C-N-CA 125.906 1.682 . . . . 0.0 109.315 -179.216 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 16.0 t -97.54 169.97 9.36 Favored 'General case' 0 N--CA 1.473 0.721 0 C-N-CA 125.362 1.465 . . . . 0.0 112.134 178.121 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 2.4 mt . . . . . 0 CA--C 1.552 1.054 0 C-N-CA 126.999 2.12 . . . . 0.0 110.494 -179.225 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 58.5 m . . . . . 0 CA--C 1.544 0.722 0 CA-C-O 120.651 0.262 . . . . 0.0 110.963 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -74.6 53.5 0.56 Allowed 'General case' 0 CA--C 1.553 1.059 0 C-N-CA 126.101 1.76 . . . . 0.0 113.629 -178.503 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 80.0 m -67.14 153.99 93.54 Favored Pre-proline 0 CA--C 1.551 0.982 0 C-N-CA 125.373 1.469 . . . . 0.0 113.306 -178.071 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -72.59 157.37 52.65 Favored 'Trans proline' 0 CA--C 1.541 0.847 0 C-N-CA 123.05 2.5 . . . . 0.0 112.514 179.459 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -88.72 -9.54 51.59 Favored 'General case' 0 N--CA 1.48 1.045 0 C-N-CA 124.927 1.291 . . . . 0.0 113.678 176.649 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 79.9 mt -62.02 139.82 20.2 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.756 0 C-N-CA 125.106 1.362 . . . . 0.0 109.692 174.176 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 10.4 mp -82.53 97.8 8.62 Favored 'General case' 0 CA--C 1.538 0.507 0 C-N-CA 124.744 1.218 . . . . 0.0 110.354 172.806 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 2.4 mmmp? -126.47 65.99 61.36 Favored Pre-proline 0 CA--C 1.546 0.815 0 C-N-CA 125.331 1.452 . . . . 0.0 110.632 170.147 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 66.5 Cg_endo -66.32 154.29 74.78 Favored 'Trans proline' 0 C--N 1.352 0.747 0 C-N-CA 122.813 2.342 . . . . 0.0 112.169 -179.263 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -142.18 160.2 20.1 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.757 0 C-N-CA 125.088 1.355 . . . . 0.0 110.476 -178.746 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 47.3 t -73.41 105.04 4.61 Favored 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 124.735 1.214 . . . . 0.0 110.283 169.97 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -65.99 148.02 50.65 Favored Glycine 0 CA--C 1.531 1.041 0 C-N-CA 124.1 0.857 . . . . 0.0 112.416 174.136 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 69.5 m -65.56 -17.58 64.68 Favored 'General case' 0 N--CA 1.475 0.819 0 N-CA-C 114.941 1.46 . . . . 0.0 114.941 -174.8 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 32.1 t70 -79.81 -8.12 59.08 Favored 'General case' 0 CA--C 1.552 1.032 0 C-N-CA 124.698 1.199 . . . . 0.0 113.569 169.148 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 97.34 27.38 9.29 Favored Glycine 0 CA--C 1.536 1.39 0 C-N-CA 126.548 2.023 . . . . 0.0 114.084 -179.593 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 64.3 mtt-85 -127.31 170.57 12.33 Favored 'General case' 0 N--CA 1.481 1.075 0 C-N-CA 125.241 1.416 . . . . 0.0 113.826 -166.385 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 33.1 m -103.45 125.36 49.99 Favored 'General case' 0 N--CA 1.475 0.78 0 C-N-CA 125.761 1.625 . . . . 0.0 110.674 -177.293 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 77.6 m-85 -131.57 157.43 43.62 Favored 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 125.097 1.359 . . . . 0.0 111.631 174.789 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.21 -48.82 74.39 Favored 'General case' 0 CA--C 1.542 0.645 0 N-CA-C 113.211 0.819 . . . . 0.0 113.211 -166.993 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' ASN . . . . . 0.407 ' H ' HG22 ' A' ' 26' ' ' ILE . 71.8 m-80 -144.32 174.23 11.09 Favored 'General case' 0 CA--C 1.549 0.936 0 C-N-CA 126.754 2.021 . . . . 0.0 111.08 174.865 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 69.5 m -65.58 -27.92 68.77 Favored 'General case' 0 N--CA 1.483 1.194 0 O-C-N 120.485 -1.385 . . . . 0.0 112.992 171.61 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 46.0 t -58.57 -58.36 8.9 Favored 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 125.414 1.486 . . . . 0.0 112.218 175.652 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.407 HG22 ' H ' ' A' ' 23' ' ' ASN . 10.5 tp -60.7 -33.95 56.94 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 N-CA-C 112.219 0.452 . . . . 0.0 112.219 -179.619 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -59.24 -53.89 53.13 Favored 'General case' 0 CA--C 1.542 0.663 0 CA-C-N 118.684 0.675 . . . . 0.0 111.852 173.152 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 18.4 mmm180 -62.9 -33.56 75.56 Favored 'General case' 0 N--CA 1.48 1.031 0 C-N-CA 123.812 0.845 . . . . 0.0 113.217 176.088 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 19.3 t -62.83 -46.69 86.74 Favored 'General case' 0 CA--C 1.545 0.762 0 C-N-CA 124.513 1.125 . . . . 0.0 111.741 172.554 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 88.1 m-20 -69.34 -49.66 53.64 Favored 'General case' 0 CA--C 1.542 0.654 0 C-N-CA 125.552 1.541 . . . . 0.0 113.015 -179.691 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 142.63 24.5 0.19 Allowed Glycine 0 CA--C 1.538 1.518 0 N-CA-C 116.484 1.353 . . . . 0.0 116.484 -177.867 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 6.6 t -128.4 147.02 32.97 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.706 0 C-N-CA 126.211 1.804 . . . . 0.0 108.878 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 68.8 m -117.43 133.33 56.09 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 125.337 1.455 . . . . 0.0 112.231 -175.369 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 9.9 mm . . . . . 0 N--CA 1.48 1.04 0 C-N-CA 126.375 1.87 . . . . 0.0 111.582 -166.631 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 34.2 m . . . . . 0 CA--C 1.547 0.834 0 N-CA-C 112.981 0.734 . . . . 0.0 112.981 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . 46.46 34.33 2.31 Favored 'General case' 0 CA--C 1.549 0.931 0 C-N-CA 127.366 2.266 . . . . 0.0 114.612 -174.462 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 53.2 m -63.22 152.78 83.77 Favored Pre-proline 0 CA--C 1.548 0.891 0 C-N-CA 124.264 1.026 . . . . 0.0 113.285 -176.658 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -67.75 157.54 61.32 Favored 'Trans proline' 0 CA--C 1.54 0.78 0 C-N-CA 123.595 2.863 . . . . 0.0 112.942 179.873 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 32.1 mmmt -74.24 -8.91 57.85 Favored 'General case' 0 N--CA 1.481 1.085 0 C-N-CA 126.353 1.861 . . . . 0.0 114.116 -179.05 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -54.89 138.52 14.93 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.691 0 C-N-CA 127.43 2.292 . . . . 0.0 112.838 179.396 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 42.5 tp -114.0 101.05 8.88 Favored 'General case' 0 CA--C 1.539 0.52 0 C-N-CA 127.269 2.228 . . . . 0.0 109.127 -176.588 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 59.0 tttm -148.74 78.17 9.15 Favored Pre-proline 0 N--CA 1.473 0.7 0 C-N-CA 124.635 1.174 . . . . 0.0 110.662 175.646 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 67.0 Cg_endo -72.26 108.24 2.45 Favored 'Trans proline' 0 N--CA 1.458 -0.612 0 C-N-CA 123.035 2.49 . . . . 0.0 111.913 -177.871 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 14.9 m -107.09 172.65 1.82 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.463 0 C-N-CA 126.867 2.067 . . . . 0.0 111.793 -179.836 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 24.2 t -75.75 154.07 36.59 Favored 'General case' 0 CA--C 1.541 0.599 0 C-N-CA 123.981 0.912 . . . . 0.0 111.184 -179.851 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -121.48 152.82 16.76 Favored Glycine 0 CA--C 1.531 1.061 0 C-N-CA 125.012 1.292 . . . . 0.0 113.239 177.002 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 9.2 t -55.98 -36.05 67.43 Favored 'General case' 0 N--CA 1.476 0.841 0 C-N-CA 125.86 1.664 . . . . 0.0 114.064 -173.783 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 32.8 t70 -80.04 -9.31 59.69 Favored 'General case' 0 CA--C 1.551 1.0 0 C-N-CA 125.027 1.331 . . . . 0.0 114.368 179.119 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 89.88 53.4 2.4 Favored Glycine 0 CA--C 1.532 1.136 0 C-N-CA 125.311 1.434 . . . . 0.0 112.068 -175.203 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 4.0 mmp_? -137.81 174.89 10.1 Favored 'General case' 0 N--CA 1.477 0.91 0 C-N-CA 127.658 2.383 . . . . 0.0 110.916 -172.462 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 9.4 m -137.71 140.49 40.76 Favored 'General case' 0 N--CA 1.48 1.025 0 C-N-CA 125.301 1.44 . . . . 0.0 110.512 179.7 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 49.1 m-85 -139.25 161.33 37.68 Favored 'General case' 0 N--CA 1.473 0.699 0 C-N-CA 125.533 1.533 . . . . 0.0 111.32 -176.894 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.39 -45.42 87.77 Favored 'General case' 0 CA--C 1.545 0.772 0 N-CA-C 113.525 0.935 . . . . 0.0 113.525 -167.553 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' ASN . . . . . 0.433 ' H ' HG22 ' A' ' 26' ' ' ILE . 28.0 p30 -146.08 -178.42 6.12 Favored 'General case' 0 CA--C 1.548 0.886 0 C-N-CA 125.226 1.411 . . . . 0.0 111.864 166.984 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 29.0 p -66.28 -30.16 70.53 Favored 'General case' 0 N--CA 1.472 0.629 0 N-CA-C 114.226 1.195 . . . . 0.0 114.226 179.094 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 49.1 t -64.98 -56.58 12.32 Favored 'General case' 0 N--CA 1.47 0.526 0 C-N-CA 124.058 0.943 . . . . 0.0 111.524 177.401 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.433 HG22 ' H ' ' A' ' 23' ' ' ASN . 11.2 tp -57.6 -38.88 66.59 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.618 0 CA-C-O 119.354 -0.355 . . . . 0.0 111.757 179.853 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -61.11 -45.09 96.12 Favored 'General case' 0 CA--C 1.543 0.683 0 C-N-CA 123.949 0.9 . . . . 0.0 112.797 175.809 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 5.1 tpt180 -64.8 -42.06 95.31 Favored 'General case' 0 N--CA 1.474 0.734 0 C-N-CA 123.448 0.699 . . . . 0.0 112.524 176.203 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 2.9 t -65.35 -36.08 82.94 Favored 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 123.117 0.567 . . . . 0.0 112.164 174.858 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 24.7 t-20 -66.68 -53.71 30.82 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 125.594 1.558 . . . . 0.0 112.486 176.674 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 151.49 19.4 0.06 OUTLIER Glycine 0 CA--C 1.538 1.526 0 N-CA-C 117.602 1.801 . . . . 0.0 117.602 179.284 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 3.7 t -127.78 138.69 53.99 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.814 0 CA-C-N 120.25 2.025 . . . . 0.0 110.309 -177.659 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 8.6 t -91.87 94.65 9.42 Favored 'General case' 0 N--CA 1.472 0.658 0 C-N-CA 125.245 1.418 . . . . 0.0 112.324 -173.987 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 19.6 mm . . . . . 0 N--CA 1.479 1.006 0 C-N-CA 124.368 1.067 . . . . 0.0 112.972 -176.861 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 3.7 m . . . . . 0 CA--C 1.544 0.737 0 N-CA-C 110.002 -0.37 . . . . 0.0 110.002 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -74.66 60.22 0.9 Allowed 'General case' 0 CA--C 1.553 1.085 0 C-N-CA 124.607 1.163 . . . . 0.0 112.827 179.351 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 84.3 m -64.12 156.11 76.15 Favored Pre-proline 0 CA--C 1.55 0.947 0 C-N-CA 125.78 1.632 . . . . 0.0 112.96 179.497 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 93.0 Cg_endo -71.35 168.42 23.5 Favored 'Trans proline' 0 CA--C 1.54 0.819 0 C-N-CA 123.056 2.504 . . . . 0.0 112.334 176.589 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 38.0 tttp -64.09 -20.33 65.88 Favored 'General case' 0 N--CA 1.479 0.977 0 C-N-CA 124.761 1.224 . . . . 0.0 113.188 174.721 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 61.7 mt -57.89 120.05 3.62 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.589 0 C-N-CA 126.715 2.006 . . . . 0.0 111.066 179.908 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 15.9 tp -99.44 117.41 33.79 Favored 'General case' 0 CA--C 1.538 0.508 0 C-N-CA 129.048 2.939 . . . . 0.0 108.363 174.533 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -132.18 78.27 69.14 Favored Pre-proline 0 N--CA 1.473 0.704 0 C-N-CA 125.786 1.634 . . . . 0.0 108.882 -178.695 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 66.2 Cg_endo -71.38 102.66 1.3 Allowed 'Trans proline' 0 CA--C 1.537 0.67 0 C-N-CA 123.831 3.021 . . . . 0.0 112.181 -168.527 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -100.2 158.13 3.91 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.003 0 C-N-CA 124.332 1.053 . . . . 0.0 112.245 -176.162 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 18.0 t -72.94 -18.2 61.41 Favored 'General case' 0 CA--C 1.547 0.843 0 N-CA-C 114.209 1.189 . . . . 0.0 114.209 -178.896 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 63.51 -178.63 6.68 Favored Glycine 0 CA--C 1.537 1.457 0 C-N-CA 126.416 1.96 . . . . 0.0 115.514 176.971 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 14.1 m -84.53 -38.46 20.0 Favored 'General case' 0 N--CA 1.476 0.857 0 C-N-CA 124.066 0.947 . . . . 0.0 113.083 173.484 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 20.4 m-20 -77.03 -14.97 59.76 Favored 'General case' 0 N--CA 1.479 0.98 0 N-CA-C 113.581 0.956 . . . . 0.0 113.581 179.695 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 98.07 -11.77 63.91 Favored Glycine 0 CA--C 1.536 1.353 0 C-N-CA 126.391 1.948 . . . . 0.0 114.392 179.842 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -78.41 156.53 29.4 Favored 'General case' 0 N--CA 1.474 0.761 0 C-N-CA 125.262 1.425 . . . . 0.0 112.084 171.239 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -84.26 113.14 20.9 Favored 'General case' 0 N--CA 1.472 0.638 0 C-N-CA 124.88 1.272 . . . . 0.0 112.857 178.069 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 79.0 m-85 -91.45 149.53 21.66 Favored 'General case' 0 N--CA 1.475 0.785 0 C-N-CA 124.792 1.237 . . . . 0.0 111.599 173.489 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.69 -46.75 77.84 Favored 'General case' 0 CA--C 1.542 0.665 0 N-CA-C 113.355 0.872 . . . . 0.0 113.355 -168.936 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 26.0 p30 -157.06 -179.35 8.12 Favored 'General case' 0 CA--C 1.545 0.773 0 C-N-CA 125.441 1.496 . . . . 0.0 111.88 174.348 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 36.7 p -61.69 -32.57 72.78 Favored 'General case' 0 N--CA 1.473 0.708 0 O-C-N 120.977 -1.077 . . . . 0.0 113.342 173.956 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 49.5 t -58.82 -60.51 3.73 Favored 'General case' 0 CA--C 1.533 0.299 0 C-N-CA 124.85 1.26 . . . . 0.0 111.765 176.75 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 9.8 tp -56.98 -40.45 72.64 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.881 0 N-CA-C 112.431 0.53 . . . . 0.0 112.431 178.943 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -57.32 -59.34 5.27 Favored 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 123.886 0.874 . . . . 0.0 111.461 176.498 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 46.3 mmm-85 -59.27 -41.85 89.84 Favored 'General case' 0 N--CA 1.475 0.799 0 C-N-CA 124.773 1.229 . . . . 0.0 113.028 178.775 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 2.9 t -66.6 -41.33 88.62 Favored 'General case' 0 CA--C 1.545 0.757 0 C-N-CA 123.609 0.763 . . . . 0.0 112.536 179.579 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 53.1 t30 -71.52 -42.0 68.51 Favored 'General case' 0 CA--C 1.543 0.7 0 C-N-CA 124.655 1.182 . . . . 0.0 113.181 178.833 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 129.71 30.1 0.66 Allowed Glycine 0 CA--C 1.538 1.475 0 C-N-CA 124.611 1.1 . . . . 0.0 115.206 -179.333 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -123.08 169.7 14.16 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 C-N-CA 127.37 2.268 . . . . 0.0 109.192 -177.866 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 29.8 t -145.77 161.52 39.74 Favored 'General case' 0 N--CA 1.471 0.614 0 C-N-CA 125.259 1.423 . . . . 0.0 112.42 -179.005 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 18.7 mm . . . . . 0 N--CA 1.476 0.86 0 C-N-CA 125.956 1.703 . . . . 0.0 111.69 178.019 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 29.2 m . . . . . 0 CA--C 1.54 0.585 0 CA-C-O 120.548 0.213 . . . . 0.0 110.532 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -71.64 55.78 0.26 Allowed 'General case' 0 CA--C 1.552 1.045 0 C-N-CA 126.516 1.926 . . . . 0.0 113.101 -179.961 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 93.0 m -63.59 157.59 64.79 Favored Pre-proline 0 CA--C 1.549 0.937 0 C-N-CA 126.083 1.753 . . . . 0.0 112.739 178.496 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -64.89 155.02 70.14 Favored 'Trans proline' 0 CA--C 1.537 0.671 0 C-N-CA 123.281 2.654 . . . . 0.0 112.803 -179.871 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 19.5 ptpt -59.75 -25.59 64.99 Favored 'General case' 0 N--CA 1.48 1.074 0 C-N-CA 125.707 1.603 . . . . 0.0 114.497 178.029 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 8.9 tp -57.11 144.47 9.34 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.473 0 C-N-CA 127.089 2.155 . . . . 0.0 113.212 -178.68 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 23.8 tp -119.66 108.24 14.21 Favored 'General case' 0 CA--C 1.535 0.402 0 C-N-CA 126.708 2.003 . . . . 0.0 108.292 -178.283 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 39.5 ttpt -128.95 79.03 75.34 Favored Pre-proline 0 CA--C 1.54 0.576 0 C-N-CA 126.38 1.872 . . . . 0.0 108.511 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -73.68 90.34 0.94 Allowed 'Trans proline' 0 CA--C 1.539 0.742 0 C-N-CA 123.72 2.947 . . . . 0.0 111.909 -171.442 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 1.1 t -83.56 161.26 3.38 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 C-N-CA 124.421 1.089 . . . . 0.0 111.03 -177.56 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 46.3 t -72.44 111.59 7.76 Favored 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 124.342 1.057 . . . . 0.0 109.839 170.448 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -65.51 146.01 49.25 Favored Glycine 0 CA--C 1.532 1.118 0 C-N-CA 123.778 0.704 . . . . 0.0 112.422 177.988 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 82.7 p -61.39 -29.86 70.19 Favored 'General case' 0 N--CA 1.476 0.865 0 N-CA-C 113.935 1.087 . . . . 0.0 113.935 -174.072 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 31.8 t70 -84.98 -8.19 58.84 Favored 'General case' 0 CA--C 1.551 0.993 0 C-N-CA 125.964 1.706 . . . . 0.0 113.894 176.92 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 107.51 1.04 34.96 Favored Glycine 0 CA--C 1.536 1.386 0 C-N-CA 126.504 2.002 . . . . 0.0 114.674 -178.623 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 22.1 mtm180 -90.32 -172.21 3.37 Favored 'General case' 0 N--CA 1.479 0.988 0 C-N-CA 126.355 1.862 . . . . 0.0 112.387 -177.269 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 23.0 m -128.8 135.26 48.91 Favored 'General case' 0 N--CA 1.479 1.01 0 C-N-CA 125.487 1.515 . . . . 0.0 110.492 -178.274 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 81.8 m-85 -135.94 150.39 49.27 Favored 'General case' 0 N--CA 1.474 0.74 0 C-N-CA 125.055 1.342 . . . . 0.0 111.488 -177.573 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.31 -45.08 89.52 Favored 'General case' 0 CA--C 1.543 0.683 0 N-CA-C 113.929 1.085 . . . . 0.0 113.929 -165.242 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 27.0 p30 -157.74 178.62 10.05 Favored 'General case' 0 CA--C 1.549 0.932 0 C-N-CA 125.927 1.691 . . . . 0.0 111.124 170.298 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 89.0 p -60.54 -29.69 69.29 Favored 'General case' 0 N--CA 1.478 0.973 0 N-CA-C 114.015 1.117 . . . . 0.0 114.015 179.052 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 45.4 t -61.66 -57.93 10.05 Favored 'General case' 0 N--CA 1.465 0.312 0 C-N-CA 124.24 1.016 . . . . 0.0 111.704 176.888 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 7.6 tp -59.75 -37.89 73.38 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.819 0 N-CA-C 112.062 0.393 . . . . 0.0 112.062 -179.878 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -57.3 -55.96 28.02 Favored 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 124.199 1.0 . . . . 0.0 111.583 173.967 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 70.4 mtp85 -61.23 -40.63 94.73 Favored 'General case' 0 N--CA 1.475 0.809 0 N-CA-C 113.297 0.851 . . . . 0.0 113.297 178.341 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -65.41 -36.35 83.68 Favored 'General case' 0 CA--C 1.546 0.819 0 N-CA-C 112.57 0.582 . . . . 0.0 112.57 177.132 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 25.9 t-20 -72.37 -47.53 48.68 Favored 'General case' 0 CA--C 1.546 0.815 0 C-N-CA 124.798 1.239 . . . . 0.0 113.003 175.926 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 135.8 29.5 0.36 Allowed Glycine 0 CA--C 1.538 1.53 0 C-N-CA 124.911 1.243 . . . . 0.0 115.469 -178.437 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 34.6 t -127.87 152.32 35.8 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.464 0 C-N-CA 127.416 2.286 . . . . 0.0 108.645 -176.992 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 58.2 m -141.72 160.06 40.95 Favored 'General case' 0 N--CA 1.476 0.838 0 C-N-CA 125.878 1.671 . . . . 0.0 112.302 -179.343 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 16.3 mt . . . . . 0 N--CA 1.481 1.108 0 C-N-CA 125.102 1.361 . . . . 0.0 111.828 -175.067 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 4.7 t . . . . . 0 CA--C 1.548 0.87 0 N-CA-C 114.111 1.152 . . . . 0.0 114.111 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . 49.34 30.73 3.39 Favored 'General case' 0 CA--C 1.549 0.921 0 C-N-CA 127.018 2.127 . . . . 0.0 115.603 178.421 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 58.0 m -61.8 151.29 79.76 Favored Pre-proline 0 CA--C 1.547 0.828 0 C-N-CA 124.368 1.067 . . . . 0.0 112.379 177.141 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -75.1 -4.13 14.93 Favored 'Trans proline' 0 CA--C 1.543 0.955 0 C-N-CA 124.135 3.223 . . . . 0.0 115.735 -168.769 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 37.8 mmtm 58.86 6.93 0.7 Allowed 'General case' 0 N--CA 1.481 1.093 0 C-N-CA 128.247 2.619 . . . . 0.0 116.299 179.839 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 11.2 tp -51.76 142.47 4.27 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.631 0 C-N-CA 126.698 1.999 . . . . 0.0 112.329 178.436 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 4.5 tt -78.46 89.99 4.45 Favored 'General case' 0 CA--C 1.545 0.772 0 C-N-CA 127.209 2.204 . . . . 0.0 110.907 -177.706 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 3.8 ttmp? -143.83 74.83 16.34 Favored Pre-proline 0 N--CA 1.477 0.897 0 C-N-CA 124.992 1.317 . . . . 0.0 111.843 178.33 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -67.8 91.1 0.36 Allowed 'Trans proline' 0 CA--C 1.54 0.809 0 C-N-CA 124.347 3.364 . . . . 0.0 112.754 -175.995 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 5.7 m -87.27 143.08 12.05 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 C-N-CA 126.32 1.848 . . . . 0.0 112.101 179.652 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 47.3 t -63.7 119.82 10.65 Favored 'General case' 0 CA--C 1.542 0.653 0 C-N-CA 124.125 0.97 . . . . 0.0 110.988 172.475 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -92.23 154.79 22.53 Favored Glycine 0 CA--C 1.533 1.17 0 C-N-CA 124.597 1.094 . . . . 0.0 112.861 177.911 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 7.5 t -61.74 -27.26 68.6 Favored 'General case' 0 N--CA 1.475 0.781 0 N-CA-C 114.463 1.283 . . . . 0.0 114.463 -173.943 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 10.5 t0 -76.52 -10.25 59.25 Favored 'General case' 0 CA--C 1.547 0.841 0 N-CA-C 113.69 0.996 . . . . 0.0 113.69 176.216 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 105.09 -10.11 47.3 Favored Glycine 0 CA--C 1.536 1.354 0 C-N-CA 126.586 2.041 . . . . 0.0 114.048 178.21 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 5.9 ptp85 -82.31 -171.13 3.27 Favored 'General case' 0 N--CA 1.473 0.706 0 C-N-CA 126.067 1.747 . . . . 0.0 112.723 173.365 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 11.5 t -123.34 157.62 32.86 Favored 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 125.595 1.558 . . . . 0.0 111.688 174.307 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -137.51 148.53 46.08 Favored 'General case' 0 N--CA 1.471 0.6 0 C-N-CA 126.263 1.825 . . . . 0.0 110.917 -179.9 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -60.28 -36.86 78.8 Favored 'General case' 0 CA--C 1.543 0.673 0 N-CA-C 114.049 1.129 . . . . 0.0 114.049 -164.277 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 12.4 p30 -156.89 177.54 11.39 Favored 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 126.443 1.897 . . . . 0.0 111.848 168.889 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 27.6 t -58.73 -38.95 79.49 Favored 'General case' 0 N--CA 1.472 0.637 0 O-C-N 121.345 -0.847 . . . . 0.0 113.099 176.486 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 20.0 t -60.14 -55.94 27.66 Favored 'General case' 0 N--CA 1.468 0.47 0 O-C-N 121.493 -0.755 . . . . 0.0 111.806 -179.886 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 7.4 tt -59.4 -38.71 76.42 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.698 0 CA-C-O 118.996 -0.526 . . . . 0.0 112.292 178.437 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -59.61 -53.6 56.12 Favored 'General case' 0 CA--C 1.543 0.684 0 CA-C-N 119.132 0.878 . . . . 0.0 111.904 174.814 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 5.7 mtp-105 -57.41 -44.07 84.27 Favored 'General case' 0 N--CA 1.477 0.884 0 C-N-CA 124.824 1.25 . . . . 0.0 112.3 178.034 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -71.51 -34.0 69.71 Favored 'General case' 0 CA--C 1.544 0.737 0 N-CA-C 113.448 0.907 . . . . 0.0 113.448 178.748 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 28.8 t-20 -66.85 -40.39 87.91 Favored 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 124.277 1.031 . . . . 0.0 112.541 174.056 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 135.29 22.59 0.63 Allowed Glycine 0 CA--C 1.538 1.471 0 C-N-CA 125.051 1.31 . . . . 0.0 115.896 176.366 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 40.4 t -128.26 149.54 33.2 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.525 0 C-N-CA 126.26 1.824 . . . . 0.0 109.866 -174.556 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 58.8 m -121.92 171.81 8.66 Favored 'General case' 0 N--CA 1.475 0.78 0 C-N-CA 126.857 2.063 . . . . 0.0 112.063 -176.702 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.468 0.447 0 C-N-CA 125.513 1.525 . . . . 0.0 108.92 -176.37 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 10.9 t . . . . . 0 CA--C 1.544 0.746 0 N-CA-C 111.83 0.307 . . . . 0.0 111.83 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -74.04 32.36 0.08 Allowed 'General case' 0 CA--C 1.554 1.128 0 C-N-CA 126.588 1.955 . . . . 0.0 115.668 -172.654 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 62.8 m -64.25 152.65 87.9 Favored Pre-proline 0 CA--C 1.549 0.926 0 C-N-CA 124.907 1.283 . . . . 0.0 113.67 179.275 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 89.1 Cg_endo -72.6 153.86 54.71 Favored 'Trans proline' 0 C--N 1.352 0.742 0 C-N-CA 123.359 2.706 . . . . 0.0 112.326 176.581 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 57.3 mtmt -76.38 -1.93 29.33 Favored 'General case' 0 N--CA 1.48 1.053 0 C-N-CA 125.708 1.603 . . . . 0.0 114.685 -179.361 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 46.9 mm -51.18 120.59 1.34 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.715 0 C-N-CA 126.145 1.778 . . . . 0.0 111.181 174.716 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 54.9 tp -84.71 102.27 12.85 Favored 'General case' 0 CA--C 1.539 0.546 0 C-N-CA 127.401 2.28 . . . . 0.0 109.614 177.935 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 20.8 tptp -147.07 91.94 5.04 Favored Pre-proline 0 N--CA 1.471 0.582 0 C-N-CA 124.098 0.959 . . . . 0.0 110.753 166.432 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -64.47 137.89 57.35 Favored 'Trans proline' 0 N--CA 1.456 -0.689 0 C-N-CA 121.191 1.261 . . . . 0.0 111.024 172.266 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 8.7 m -140.79 159.09 23.98 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.361 0 C-N-CA 127.373 2.269 . . . . 0.0 110.845 -179.346 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 37.6 t -72.78 149.52 43.58 Favored 'General case' 0 CA--C 1.545 0.763 0 C-N-CA 123.822 0.849 . . . . 0.0 111.785 171.973 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -123.76 156.21 17.93 Favored Glycine 0 CA--C 1.535 1.325 0 C-N-CA 125.859 1.695 . . . . 0.0 112.544 169.974 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 14.6 t -51.53 -40.64 60.05 Favored 'General case' 0 N--CA 1.478 0.966 0 C-N-CA 126.059 1.744 . . . . 0.0 115.431 -166.119 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 13.9 m-20 -71.1 -5.86 34.79 Favored 'General case' 0 CA--C 1.548 0.879 0 N-CA-C 114.863 1.431 . . . . 0.0 114.863 -179.193 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 86.83 61.32 1.61 Allowed Glycine 0 CA--C 1.527 0.805 0 C-N-CA 125.107 1.337 . . . . 0.0 110.592 -173.387 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 89.5 mmt-85 -142.18 168.29 20.09 Favored 'General case' 0 N--CA 1.472 0.671 0 C-N-CA 127.36 2.264 . . . . 0.0 111.103 -172.806 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 6.6 p -132.14 145.23 51.24 Favored 'General case' 0 C--O 1.235 0.322 0 C-N-CA 126.301 1.84 . . . . 0.0 111.089 172.455 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 92.8 m-85 -141.63 157.04 45.59 Favored 'General case' 0 N--CA 1.471 0.62 0 C-N-CA 125.604 1.561 . . . . 0.0 111.454 -179.461 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.69 -32.89 74.77 Favored 'General case' 0 CA--C 1.545 0.788 0 N-CA-C 114.451 1.278 . . . . 0.0 114.451 -165.222 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 60.5 t30 -149.37 168.13 24.24 Favored 'General case' 0 CA--C 1.544 0.747 0 C-N-CA 125.558 1.543 . . . . 0.0 111.17 171.26 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 34.6 p -57.19 -42.63 81.56 Favored 'General case' 0 N--CA 1.472 0.653 0 C-N-CA 124.769 1.228 . . . . 0.0 113.106 175.216 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 38.1 t -56.51 -55.76 29.68 Favored 'General case' 0 CA--C 1.533 0.292 0 C-N-CA 124.376 1.07 . . . . 0.0 112.11 177.507 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.8 tt -62.21 -35.25 68.08 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.672 0 CA-C-O 118.684 -0.674 . . . . 0.0 112.407 -177.679 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -57.82 -53.43 58.27 Favored 'General case' 0 CA--C 1.54 0.563 0 CA-C-N 119.288 0.949 . . . . 0.0 111.443 173.516 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -56.38 -49.78 73.47 Favored 'General case' 0 N--CA 1.474 0.768 0 C-N-CA 125.042 1.337 . . . . 0.0 111.282 176.124 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -63.7 -39.84 95.29 Favored 'General case' 0 CA--C 1.541 0.622 0 C-N-CA 123.786 0.834 . . . . 0.0 113.089 -177.68 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 88.8 m-20 -66.27 -33.44 75.74 Favored 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 124.86 1.264 . . . . 0.0 112.79 174.458 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 130.17 17.21 1.64 Allowed Glycine 0 CA--C 1.536 1.369 0 N-CA-C 116.389 1.316 . . . . 0.0 116.389 171.618 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 7.4 t -118.63 132.97 66.96 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.666 0 CA-C-N 119.629 1.714 . . . . 0.0 110.608 -178.229 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 38.5 m -78.54 164.69 24.48 Favored 'General case' 0 C--N 1.322 -0.597 0 C-N-CA 126.826 2.05 . . . . 0.0 112.714 -179.583 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.469 0.525 0 C-N-CA 125.873 1.669 . . . . 0.0 109.1 -178.959 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 3.2 m . . . . . 0 CA--C 1.548 0.884 0 N-CA-C 110.377 -0.231 . . . . 0.0 110.377 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -75.89 58.45 1.15 Allowed 'General case' 0 CA--C 1.554 1.1 0 C-N-CA 124.798 1.239 . . . . 0.0 113.24 -179.519 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 76.3 m -69.75 159.32 84.39 Favored Pre-proline 0 CA--C 1.553 1.082 0 C-N-CA 126.048 1.739 . . . . 0.0 113.746 -177.413 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -71.06 165.44 32.39 Favored 'Trans proline' 0 CA--C 1.542 0.877 0 C-N-CA 123.497 2.798 . . . . 0.0 113.407 179.141 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 7.9 ptpp? -68.35 -27.56 66.36 Favored 'General case' 0 N--CA 1.482 1.161 0 C-N-CA 125.072 1.349 . . . . 0.0 114.613 175.501 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 34.9 mm -60.08 161.88 1.24 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.83 0 C-N-CA 128.162 2.585 . . . . 0.0 111.294 176.295 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 20.1 tp -141.98 101.89 4.03 Favored 'General case' 0 CA--C 1.537 0.472 0 C-N-CA 126.257 1.823 . . . . 0.0 109.879 -170.646 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -115.52 84.92 12.77 Favored Pre-proline 0 N--CA 1.474 0.726 0 C-N-CA 126.096 1.759 . . . . 0.0 109.42 175.399 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 93.7 Cg_endo -74.52 81.14 2.14 Favored 'Trans proline' 0 CA--C 1.541 0.848 0 C-N-CA 124.043 3.162 . . . . 0.0 111.717 -176.616 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 9.0 m -85.84 164.24 2.48 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 C-N-CA 127.195 2.198 . . . . 0.0 113.003 -175.938 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 30.1 p -68.29 173.97 4.37 Favored 'General case' 0 CA--C 1.549 0.933 0 C-N-CA 124.231 1.012 . . . . 0.0 112.294 159.289 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -148.48 155.98 26.66 Favored Glycine 0 CA--C 1.532 1.132 0 C-N-CA 125.691 1.615 . . . . 0.0 111.392 173.712 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 19.0 t -57.09 -35.55 69.54 Favored 'General case' 0 N--CA 1.476 0.872 0 N-CA-C 115.144 1.535 . . . . 0.0 115.144 -163.138 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 31.5 t70 -71.86 -9.1 57.84 Favored 'General case' 0 CA--C 1.551 1.008 0 N-CA-C 114.415 1.265 . . . . 0.0 114.415 179.305 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 106.84 12.58 23.94 Favored Glycine 0 CA--C 1.535 1.286 0 C-N-CA 126.063 1.792 . . . . 0.0 114.073 179.35 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 31.2 mtm180 -120.99 134.46 55.3 Favored 'General case' 0 N--CA 1.476 0.844 0 C-N-CA 126.225 1.81 . . . . 0.0 111.181 -171.542 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 18.0 p -75.23 151.55 38.41 Favored 'General case' 0 N--CA 1.471 0.597 0 C-N-CA 124.622 1.169 . . . . 0.0 112.614 177.927 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 76.5 m-85 -139.69 149.03 43.19 Favored 'General case' 0 N--CA 1.471 0.592 0 C-N-CA 125.434 1.494 . . . . 0.0 112.93 -179.87 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -69.74 -33.72 72.84 Favored 'General case' 0 CA--C 1.545 0.76 0 N-CA-C 113.902 1.075 . . . . 0.0 113.902 -165.895 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' ASN . . . . . 0.463 ' H ' HG22 ' A' ' 26' ' ' ILE . 14.7 m-20 -145.87 170.85 15.76 Favored 'General case' 0 CA--C 1.543 0.703 0 C-N-CA 125.813 1.645 . . . . 0.0 110.946 166.116 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 40.7 p -59.46 -35.55 74.27 Favored 'General case' 0 N--CA 1.473 0.722 0 O-C-N 121.368 -0.832 . . . . 0.0 112.45 165.824 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 43.5 t -52.87 -63.33 1.18 Allowed 'General case' 0 CA--C 1.533 0.316 0 C-N-CA 126.01 1.724 . . . . 0.0 112.369 174.064 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.463 HG22 ' H ' ' A' ' 23' ' ' ASN . 9.1 tp -58.38 -37.3 62.85 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.788 0 N-CA-C 112.592 0.59 . . . . 0.0 112.592 -178.583 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -59.94 -54.59 44.32 Favored 'General case' 0 CA--C 1.544 0.716 0 CA-C-N 118.697 0.68 . . . . 0.0 111.836 173.961 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 25.4 mmm180 -61.57 -39.98 93.09 Favored 'General case' 0 N--CA 1.478 0.975 0 C-N-CA 124.707 1.203 . . . . 0.0 113.207 177.933 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 9.2 t -62.15 -43.92 97.76 Favored 'General case' 0 CA--C 1.544 0.729 0 C-N-CA 124.832 1.253 . . . . 0.0 111.644 175.128 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 28.7 t-20 -68.79 -46.62 68.21 Favored 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 124.837 1.255 . . . . 0.0 113.179 178.263 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 136.11 26.42 0.45 Allowed Glycine 0 CA--C 1.539 1.534 0 C-N-CA 124.787 1.184 . . . . 0.0 115.964 -179.528 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 40.1 t -124.29 156.12 31.9 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.512 0 C-N-CA 127.11 2.164 . . . . 0.0 108.607 -179.658 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 6.2 t -134.21 177.8 7.47 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 126.25 1.82 . . . . 0.0 112.216 179.143 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 CA--C 1.533 0.299 0 C-N-CA 126.438 1.895 . . . . 0.0 108.869 -170.52 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 31.2 m . . . . . 0 CA--C 1.542 0.665 0 N-CA-C 110.968 -0.012 . . . . 0.0 110.968 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -73.27 31.78 0.07 Allowed 'General case' 0 CA--C 1.555 1.163 0 C-N-CA 125.629 1.572 . . . . 0.0 114.37 177.777 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 60.1 m -63.32 160.76 38.6 Favored Pre-proline 0 CA--C 1.549 0.924 0 C-N-CA 126.335 1.854 . . . . 0.0 113.237 177.439 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -67.61 169.77 15.18 Favored 'Trans proline' 0 CA--C 1.541 0.872 0 C-N-CA 123.254 2.636 . . . . 0.0 112.156 170.899 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 10.1 tppt? -107.89 1.98 23.1 Favored 'General case' 0 N--CA 1.482 1.145 0 C-N-CA 125.968 1.707 . . . . 0.0 112.946 172.186 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 83.2 mt -52.24 131.76 13.88 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.762 0 C-N-CA 126.632 1.973 . . . . 0.0 110.821 179.426 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 5.2 tt -69.74 97.85 1.13 Allowed 'General case' 0 CA--C 1.542 0.652 0 C-N-CA 127.399 2.28 . . . . 0.0 111.497 -174.823 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 86.8 tttt -140.6 74.45 27.86 Favored Pre-proline 0 N--CA 1.476 0.828 0 C-N-CA 125.719 1.608 . . . . 0.0 111.101 -177.882 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -66.14 101.33 0.49 Allowed 'Trans proline' 0 CA--C 1.54 0.818 0 C-N-CA 123.956 3.104 . . . . 0.0 112.343 -178.605 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 15.9 m -127.21 159.52 37.33 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.479 0 C-N-CA 126.001 1.72 . . . . 0.0 112.859 -176.98 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 24.4 p -88.4 123.29 32.81 Favored 'General case' 0 CA--C 1.539 0.529 0 C-N-CA 124.358 1.063 . . . . 0.0 111.889 176.572 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -79.17 55.68 4.34 Favored Glycine 0 CA--C 1.53 0.977 0 C-N-CA 124.665 1.126 . . . . 0.0 112.117 172.673 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 3.9 t 54.81 -11.68 0.01 OUTLIER 'General case' 0 CA--C 1.55 0.979 0 C-N-CA 129.385 3.074 . . . . 0.0 117.268 -175.009 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 63.5 m-20 -95.11 -17.8 21.52 Favored 'General case' 0 N--CA 1.475 0.775 0 C-N-CA 126.041 1.736 . . . . 0.0 114.545 -179.148 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 105.66 2.99 40.36 Favored Glycine 0 CA--C 1.538 1.505 0 C-N-CA 125.498 1.523 . . . . 0.0 114.84 177.713 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 2.1 mmp_? -67.37 -177.98 0.79 Allowed 'General case' 0 N--CA 1.476 0.841 0 C-N-CA 128.541 2.736 . . . . 0.0 112.195 172.501 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 24.1 m -128.58 85.72 2.37 Favored 'General case' 0 N--CA 1.476 0.841 0 C-N-CA 124.92 1.288 . . . . 0.0 110.157 176.318 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 26.8 m-85 -76.12 154.17 35.71 Favored 'General case' 0 N--CA 1.47 0.541 0 C-N-CA 123.94 0.896 . . . . 0.0 112.252 173.389 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.15 -37.63 88.15 Favored 'General case' 0 CA--C 1.542 0.643 0 N-CA-C 113.288 0.847 . . . . 0.0 113.288 -170.447 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 14.3 p30 -152.56 179.42 8.61 Favored 'General case' 0 CA--C 1.545 0.765 0 C-N-CA 126.172 1.789 . . . . 0.0 111.968 172.283 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 9.1 p -70.67 -32.03 69.15 Favored 'General case' 0 N--CA 1.473 0.7 0 O-C-N 121.018 -1.051 . . . . 0.0 113.788 176.369 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 34.8 t -62.42 -49.99 73.27 Favored 'General case' 0 N--CA 1.469 0.484 0 C-N-CA 124.31 1.044 . . . . 0.0 112.269 178.627 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 8.5 tt -58.82 -39.77 78.1 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 N-CA-C 112.194 0.442 . . . . 0.0 112.194 179.338 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -64.88 -44.62 89.05 Favored 'General case' 0 CA--C 1.543 0.712 0 C-N-CA 124.285 1.034 . . . . 0.0 112.599 175.051 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 25.1 mmt180 -55.67 -52.5 63.64 Favored 'General case' 0 N--CA 1.478 0.941 0 C-N-CA 124.378 1.071 . . . . 0.0 111.734 170.814 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 4.9 t -63.08 -37.36 86.89 Favored 'General case' 0 CA--C 1.544 0.714 0 C-N-CA 124.13 0.972 . . . . 0.0 113.023 -178.59 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 28.4 t30 -62.66 -30.55 71.46 Favored 'General case' 0 CA--C 1.545 0.762 0 C-N-CA 124.43 1.092 . . . . 0.0 113.351 176.888 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 135.21 9.97 1.57 Allowed Glycine 0 CA--C 1.536 1.373 0 N-CA-C 116.13 1.212 . . . . 0.0 116.13 175.471 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.612 HG12 ' H ' ' A' ' 33' ' ' SER . 0.5 OUTLIER -107.51 -170.16 0.34 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.653 0 CA-C-N 119.351 1.576 . . . . 0.0 110.689 -177.242 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 33' ' ' SER . . . . . 0.612 ' H ' HG12 ' A' ' 32' ' ' VAL . 27.7 m -147.91 166.96 26.07 Favored 'General case' 0 N--CA 1.471 0.599 0 C-N-CA 128.258 2.623 . . . . 0.0 110.529 174.863 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 1.1 mt . . . . . 0 N--CA 1.471 0.622 0 C-N-CA 125.069 1.347 . . . . 0.0 108.765 172.43 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 80.9 m . . . . . 0 CA--C 1.544 0.749 0 N-CA-C 111.809 0.3 . . . . 0.0 111.809 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -73.49 37.52 0.09 Allowed 'General case' 0 CA--C 1.556 1.175 0 C-N-CA 126.462 1.905 . . . . 0.0 114.841 -177.161 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 98.8 m -63.92 156.67 72.49 Favored Pre-proline 0 CA--C 1.55 0.956 0 C-N-CA 125.726 1.61 . . . . 0.0 113.742 -179.555 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -71.78 159.42 50.75 Favored 'Trans proline' 0 CA--C 1.54 0.811 0 C-N-CA 123.411 2.741 . . . . 0.0 113.2 -178.677 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 34.5 ttmt -86.37 -11.11 52.95 Favored 'General case' 0 N--CA 1.48 1.066 0 C-N-CA 125.786 1.634 . . . . 0.0 113.751 177.501 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 80.3 mt -55.85 146.3 5.27 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.883 0 C-N-CA 126.662 1.985 . . . . 0.0 110.444 178.862 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 11.1 mp -89.68 113.27 24.74 Favored 'General case' 0 CA--C 1.539 0.548 0 C-N-CA 124.229 1.012 . . . . 0.0 110.809 175.161 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 33.2 ttmt -135.02 75.3 61.12 Favored Pre-proline 0 CA--C 1.545 0.77 0 C-N-CA 124.874 1.27 . . . . 0.0 110.277 167.734 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 62.5 Cg_endo -68.88 86.15 0.47 Allowed 'Trans proline' 0 CA--C 1.541 0.85 0 C-N-CA 123.978 3.119 . . . . 0.0 112.535 -177.68 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 10.5 m -85.63 154.94 3.46 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.534 0 C-N-CA 126.527 1.931 . . . . 0.0 112.785 -178.391 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 46.0 t -78.2 108.49 11.55 Favored 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 124.861 1.264 . . . . 0.0 110.74 168.429 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -76.57 153.53 42.66 Favored Glycine 0 CA--C 1.531 1.079 0 C-N-CA 124.603 1.097 . . . . 0.0 113.357 174.697 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 13.5 t -58.72 -33.96 70.79 Favored 'General case' 0 N--CA 1.476 0.833 0 C-N-CA 124.595 1.158 . . . . 0.0 114.123 -172.096 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 10.4 m-20 -73.73 -3.56 29.16 Favored 'General case' 0 CA--C 1.549 0.923 0 N-CA-C 114.667 1.358 . . . . 0.0 114.667 176.359 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 95.79 18.01 33.71 Favored Glycine 0 CA--C 1.533 1.21 0 C-N-CA 125.318 1.437 . . . . 0.0 114.11 178.205 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 29.5 mtp85 -121.52 154.49 36.58 Favored 'General case' 0 N--CA 1.476 0.857 0 C-N-CA 126.164 1.786 . . . . 0.0 111.308 -173.79 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 13.5 p -87.91 146.48 25.54 Favored 'General case' 0 N--CA 1.469 0.513 0 C-N-CA 124.173 0.989 . . . . 0.0 112.185 177.162 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 97.9 m-85 -138.74 147.7 43.0 Favored 'General case' 0 N--CA 1.472 0.668 0 C-N-CA 125.327 1.451 . . . . 0.0 111.381 177.562 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.54 -32.76 74.55 Favored 'General case' 0 CA--C 1.544 0.734 0 N-CA-C 114.118 1.155 . . . . 0.0 114.118 -165.954 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 67.2 m-80 -146.2 172.84 12.85 Favored 'General case' 0 CA--C 1.543 0.688 0 C-N-CA 127.399 2.28 . . . . 0.0 110.467 168.184 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 27.7 p -63.87 -33.27 75.31 Favored 'General case' 0 N--CA 1.472 0.629 0 O-C-N 121.136 -0.977 . . . . 0.0 112.968 165.098 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 33.6 t -57.46 -55.23 37.51 Favored 'General case' 0 N--CA 1.467 0.411 0 C-N-CA 124.404 1.082 . . . . 0.0 112.623 176.029 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 6.5 tp -62.84 -31.68 53.2 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.742 0 N-CA-C 112.325 0.491 . . . . 0.0 112.325 -179.112 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -59.39 -48.8 80.27 Favored 'General case' 0 CA--C 1.542 0.658 0 O-C-N 121.482 -0.761 . . . . 0.0 111.35 170.907 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 24.0 mtp-105 -62.3 -33.61 75.0 Favored 'General case' 0 N--CA 1.479 0.992 0 C-N-CA 123.619 0.768 . . . . 0.0 113.031 175.492 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 46.9 t -62.88 -48.47 78.83 Favored 'General case' 0 CA--C 1.542 0.635 0 C-N-CA 124.302 1.041 . . . . 0.0 111.52 171.373 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 19.5 m120 -66.79 -31.6 72.35 Favored 'General case' 0 CA--C 1.546 0.822 0 C-N-CA 124.583 1.153 . . . . 0.0 113.526 178.515 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 116.86 28.81 2.36 Favored Glycine 0 CA--C 1.539 1.537 0 C-N-CA 125.602 1.572 . . . . 0.0 115.01 178.782 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 18.1 t -129.32 153.99 39.48 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.5 0 C-N-CA 127.528 2.331 . . . . 0.0 108.809 -176.335 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 68.6 m -119.73 156.07 31.25 Favored 'General case' 0 N--CA 1.474 0.761 0 C-N-CA 125.858 1.663 . . . . 0.0 112.445 179.285 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 22.0 mm . . . . . 0 N--CA 1.481 1.114 0 C-N-CA 126.111 1.765 . . . . 0.0 112.373 -171.864 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 32.9 m . . . . . 0 CA--C 1.542 0.647 0 CA-C-O 121.041 0.448 . . . . 0.0 110.81 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -75.06 54.34 0.67 Allowed 'General case' 0 CA--C 1.554 1.119 0 C-N-CA 125.525 1.53 . . . . 0.0 113.021 178.938 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 64.7 m -65.22 152.19 92.23 Favored Pre-proline 0 CA--C 1.552 1.023 0 C-N-CA 125.437 1.495 . . . . 0.0 112.893 -177.901 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -72.03 151.99 56.56 Favored 'Trans proline' 0 CA--C 1.539 0.763 0 C-N-CA 122.957 2.438 . . . . 0.0 112.57 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 32.3 mmtp -72.49 -21.67 61.17 Favored 'General case' 0 N--CA 1.479 1.014 0 C-N-CA 125.232 1.413 . . . . 0.0 113.605 174.664 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.473 ' H ' HD12 ' A' ' 9' ' ' ILE . 4.9 mp -67.8 127.26 29.17 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.548 0 C-N-CA 125.508 1.523 . . . . 0.0 110.198 178.879 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 2.0 pt? -68.55 131.41 45.19 Favored 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 124.912 1.285 . . . . 0.0 111.6 173.72 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 37.0 ttmt -152.08 64.86 5.91 Favored Pre-proline 0 N--CA 1.474 0.745 0 C-N-CA 124.323 1.049 . . . . 0.0 111.114 175.181 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -66.85 153.04 79.29 Favored 'Trans proline' 0 CA--C 1.536 0.619 0 C-N-CA 122.552 2.168 . . . . 0.0 112.199 -176.049 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 18.4 t -134.84 -68.91 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.059 0 C-N-CA 123.695 0.798 . . . . 0.0 112.071 -173.818 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 31.1 p -143.18 -173.9 4.05 Favored 'General case' 0 CA--C 1.544 0.72 0 C-N-CA 126.355 1.862 . . . . 0.0 112.156 -173.812 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -163.75 87.57 0.1 Allowed Glycine 0 CA--C 1.528 0.882 0 C-N-CA 124.098 0.856 . . . . 0.0 114.126 -175.543 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 11.4 t -55.7 -38.17 69.35 Favored 'General case' 0 N--CA 1.478 0.969 0 C-N-CA 124.132 0.973 . . . . 0.0 113.261 176.781 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 54.6 m-20 -78.39 -5.69 53.04 Favored 'General case' 0 N--CA 1.478 0.942 0 C-N-CA 125.141 1.376 . . . . 0.0 113.953 174.541 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 93.86 9.93 59.29 Favored Glycine 0 CA--C 1.537 1.467 0 C-N-CA 125.532 1.539 . . . . 0.0 114.321 -174.018 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 13.5 ptp180 -122.19 135.86 54.83 Favored 'General case' 0 N--CA 1.477 0.898 0 C-N-CA 126.738 2.015 . . . . 0.0 112.21 -177.03 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.1 p -66.64 110.84 3.36 Favored 'General case' 0 N--CA 1.474 0.728 0 C-N-CA 125.347 1.459 . . . . 0.0 111.783 175.657 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 44.6 m-85 -76.86 154.37 33.87 Favored 'General case' 0 N--CA 1.472 0.636 0 O-C-N 121.628 -0.67 . . . . 0.0 111.829 174.794 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.96 -43.83 82.1 Favored 'General case' 0 CA--C 1.542 0.662 0 N-CA-C 113.238 0.829 . . . . 0.0 113.238 -169.416 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 21.2 p30 -160.98 178.68 9.13 Favored 'General case' 0 CA--C 1.548 0.866 0 C-N-CA 126.755 2.022 . . . . 0.0 111.569 173.487 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 16.2 m -63.36 -27.62 69.44 Favored 'General case' 0 N--CA 1.475 0.815 0 O-C-N 120.625 -1.297 . . . . 0.0 113.913 179.833 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 38.6 t -63.1 -56.41 17.07 Favored 'General case' 0 CA--C 1.532 0.257 0 C-N-CA 124.708 1.203 . . . . 0.0 111.555 177.166 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 8.3 tp -59.17 -35.24 56.54 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.87 0 N-CA-C 112.54 0.571 . . . . 0.0 112.54 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -59.3 -57.83 11.31 Favored 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 123.937 0.895 . . . . 0.0 111.993 175.332 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 73.6 mtp180 -60.56 -38.92 86.13 Favored 'General case' 0 N--CA 1.479 1.001 0 N-CA-C 113.058 0.762 . . . . 0.0 113.058 176.561 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 47.7 t -59.83 -50.38 74.04 Favored 'General case' 0 CA--C 1.542 0.646 0 C-N-CA 124.422 1.089 . . . . 0.0 112.179 176.048 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 63.3 t30 -69.95 -40.26 75.56 Favored 'General case' 0 CA--C 1.545 0.767 0 C-N-CA 125.01 1.324 . . . . 0.0 112.925 -176.911 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 129.26 30.2 0.68 Allowed Glycine 0 CA--C 1.536 1.375 0 C-N-CA 124.676 1.131 . . . . 0.0 115.161 178.369 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -120.14 178.49 2.49 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.545 0 C-N-CA 126.943 2.097 . . . . 0.0 110.037 -176.411 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 83.8 p -138.04 159.69 41.34 Favored 'General case' 0 N--CA 1.476 0.854 0 C-N-CA 124.843 1.257 . . . . 0.0 113.466 -178.135 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 16.0 mm . . . . . 0 N--CA 1.478 0.965 0 C-N-CA 124.545 1.138 . . . . 0.0 112.509 -175.003 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 8.5 t . . . . . 0 CA--C 1.543 0.676 0 N-CA-C 112.805 0.668 . . . . 0.0 112.805 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -75.24 32.4 0.1 Allowed 'General case' 0 CA--C 1.553 1.077 0 C-N-CA 126.873 2.069 . . . . 0.0 115.214 -174.132 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 58.4 m -62.96 157.48 60.75 Favored Pre-proline 0 CA--C 1.549 0.912 0 C-N-CA 124.851 1.26 . . . . 0.0 113.15 176.062 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 97.1 Cg_endo -70.58 172.13 14.03 Favored 'Trans proline' 0 CA--C 1.54 0.799 0 C-N-CA 123.419 2.746 . . . . 0.0 112.176 173.141 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 29.9 mtpp -121.05 3.09 10.47 Favored 'General case' 0 N--CA 1.481 1.112 0 C-N-CA 126.2 1.8 . . . . 0.0 114.011 179.765 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -53.0 138.63 12.0 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.785 0 C-N-CA 126.366 1.867 . . . . 0.0 112.347 179.649 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 3.2 tt -70.69 77.61 0.6 Allowed 'General case' 0 CA--C 1.547 0.849 0 C-N-CA 126.72 2.008 . . . . 0.0 111.382 -178.773 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 25.7 tptp -140.15 68.86 34.42 Favored Pre-proline 0 N--CA 1.473 0.722 0 C-N-CA 125.875 1.67 . . . . 0.0 110.893 179.6 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -64.86 148.55 89.98 Favored 'Trans proline' 0 CA--C 1.534 0.524 0 C-N-CA 122.326 2.017 . . . . 0.0 111.868 -178.676 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 1.7 t -137.75 161.0 33.8 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.804 0 C-N-CA 125.542 1.537 . . . . 0.0 109.99 -177.501 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 21.6 p -73.35 130.64 40.61 Favored 'General case' 0 CA--C 1.543 0.683 0 C-N-CA 124.582 1.153 . . . . 0.0 111.669 176.1 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -110.59 159.96 13.57 Favored Glycine 0 CA--C 1.535 1.325 0 C-N-CA 125.135 1.35 . . . . 0.0 112.026 170.729 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 56.6 p -63.53 -30.68 71.76 Favored 'General case' 0 N--CA 1.475 0.781 0 N-CA-C 114.28 1.215 . . . . 0.0 114.28 -172.822 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 17.0 t70 -77.17 -20.37 55.55 Favored 'General case' 0 N--CA 1.477 0.906 0 C-N-CA 124.437 1.095 . . . . 0.0 113.69 177.078 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 106.34 1.27 38.05 Favored Glycine 0 CA--C 1.537 1.411 0 C-N-CA 126.876 2.179 . . . . 0.0 114.789 176.325 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 56.2 mtt180 -85.78 156.21 20.69 Favored 'General case' 0 N--CA 1.476 0.866 0 C-N-CA 125.221 1.408 . . . . 0.0 112.974 -173.688 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 9.6 p -81.58 126.67 32.0 Favored 'General case' 0 N--CA 1.467 0.418 0 C-N-CA 125.959 1.703 . . . . 0.0 111.319 169.799 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 86.1 m-85 -126.13 159.28 33.3 Favored 'General case' 0 N--CA 1.47 0.566 0 C-N-CA 125.71 1.604 . . . . 0.0 110.789 171.99 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -62.57 -42.39 99.52 Favored 'General case' 0 CA--C 1.543 0.701 0 N-CA-C 113.078 0.77 . . . . 0.0 113.078 -168.381 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 14.2 p30 -155.47 178.36 10.32 Favored 'General case' 0 CA--C 1.545 0.78 0 C-N-CA 126.179 1.792 . . . . 0.0 112.258 173.56 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 33.1 t -62.48 -38.25 89.11 Favored 'General case' 0 N--CA 1.473 0.696 0 O-C-N 121.148 -0.97 . . . . 0.0 113.088 178.904 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 24.6 t -59.18 -57.64 12.15 Favored 'General case' 0 N--CA 1.467 0.377 0 C-N-CA 123.974 0.91 . . . . 0.0 111.25 179.749 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 8.4 tt -57.68 -39.45 70.26 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.618 0 N-CA-C 111.783 0.29 . . . . 0.0 111.783 -179.074 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -65.65 -45.73 81.87 Favored 'General case' 0 CA--C 1.542 0.663 0 C-N-CA 123.561 0.745 . . . . 0.0 112.42 179.411 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 16.7 ttp180 -62.87 -44.93 94.8 Favored 'General case' 0 N--CA 1.474 0.728 0 O-C-N 121.372 -0.83 . . . . 0.0 112.198 174.318 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -65.59 -32.54 74.18 Favored 'General case' 0 CA--C 1.545 0.756 0 N-CA-C 113.173 0.805 . . . . 0.0 113.173 177.67 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 51.9 t30 -65.7 -44.06 87.28 Favored 'General case' 0 CA--C 1.544 0.719 0 C-N-CA 124.698 1.199 . . . . 0.0 112.591 173.574 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 159.35 1.29 0.07 OUTLIER Glycine 0 CA--C 1.537 1.409 0 N-CA-C 117.519 1.767 . . . . 0.0 117.519 175.098 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -90.65 178.18 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.453 0 CA-C-N 119.823 1.812 . . . . 0.0 112.036 -176.288 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 66.1 m -133.03 108.36 8.82 Favored 'General case' 0 N--CA 1.477 0.881 0 C-N-CA 125.918 1.687 . . . . 0.0 111.986 177.995 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 16.4 mt . . . . . 0 N--CA 1.485 1.3 0 C-N-CA 125.065 1.346 . . . . 0.0 112.377 178.899 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 64.3 m . . . . . 0 CA--C 1.542 0.637 0 N-CA-C 111.517 0.191 . . . . 0.0 111.517 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -73.8 42.88 0.14 Allowed 'General case' 0 CA--C 1.554 1.115 0 C-N-CA 125.928 1.691 . . . . 0.0 113.96 179.093 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 56.4 m -60.52 153.56 60.26 Favored Pre-proline 0 CA--C 1.55 0.955 0 C-N-CA 125.254 1.422 . . . . 0.0 113.125 177.908 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 88.3 Cg_endo -71.74 158.15 53.88 Favored 'Trans proline' 0 CA--C 1.539 0.735 0 C-N-CA 123.146 2.564 . . . . 0.0 112.309 179.568 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 1.4 mptm? -73.31 -8.56 56.36 Favored 'General case' 0 N--CA 1.48 1.039 0 C-N-CA 125.469 1.508 . . . . 0.0 113.88 179.631 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 51.1 mm -52.95 125.46 7.01 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.668 0 C-N-CA 126.442 1.897 . . . . 0.0 111.498 177.233 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 50.3 tp -95.35 100.44 12.21 Favored 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 127.339 2.256 . . . . 0.0 109.033 176.382 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 29.4 ttmt -146.76 82.34 8.69 Favored Pre-proline 0 N--CA 1.472 0.655 0 C-N-CA 124.565 1.146 . . . . 0.0 110.66 171.22 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 70.2 Cg_endo -68.69 148.32 71.56 Favored 'Trans proline' 0 N--CA 1.459 -0.549 0 C-N-CA 121.805 1.67 . . . . 0.0 110.926 177.543 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 1.4 t -138.41 160.52 31.59 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.752 0 C-N-CA 124.879 1.271 . . . . 0.0 109.966 -179.12 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 49.8 t -75.88 96.34 3.69 Favored 'General case' 0 CA--C 1.54 0.585 0 C-N-CA 124.334 1.054 . . . . 0.0 110.097 173.0 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -62.78 153.3 44.64 Favored Glycine 0 CA--C 1.534 1.265 0 C-N-CA 123.427 0.537 . . . . 0.0 112.113 174.084 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 21.1 t -53.93 -36.09 62.4 Favored 'General case' 0 N--CA 1.477 0.887 0 C-N-CA 125.256 1.422 . . . . 0.0 114.315 -171.51 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 17.8 m-20 -78.67 -2.77 40.77 Favored 'General case' 0 CA--C 1.55 0.945 0 C-N-CA 125.276 1.43 . . . . 0.0 114.589 178.781 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 92.96 37.27 5.76 Favored Glycine 0 CA--C 1.535 1.295 0 C-N-CA 125.503 1.525 . . . . 0.0 113.321 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 13.3 mmm180 -129.52 125.46 36.37 Favored 'General case' 0 N--CA 1.477 0.911 0 C-N-CA 126.604 1.962 . . . . 0.0 111.025 -166.125 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 2.8 p -83.74 90.35 7.3 Favored 'General case' 0 N--CA 1.474 0.746 0 C-N-CA 125.6 1.56 . . . . 0.0 112.074 177.292 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -77.34 154.9 32.36 Favored 'General case' 0 N--CA 1.473 0.691 0 C-N-CA 124.385 1.074 . . . . 0.0 111.851 172.348 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -67.69 -40.82 84.35 Favored 'General case' 0 CA--C 1.545 0.779 0 N-CA-C 113.458 0.91 . . . . 0.0 113.458 -168.705 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 62.1 t30 -144.77 172.27 13.24 Favored 'General case' 0 CA--C 1.548 0.885 0 C-N-CA 125.171 1.388 . . . . 0.0 110.898 169.955 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 88.3 p -62.07 -34.52 76.43 Favored 'General case' 0 N--CA 1.472 0.66 0 O-C-N 120.574 -1.329 . . . . 0.0 113.317 176.365 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 35.4 t -59.72 -57.41 13.03 Favored 'General case' 0 N--CA 1.467 0.414 0 C-N-CA 124.604 1.162 . . . . 0.0 112.669 177.341 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 7.6 tp -58.21 -34.1 48.82 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 CA-C-O 119.06 -0.495 . . . . 0.0 112.286 179.591 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -58.29 -53.6 56.49 Favored 'General case' 0 CA--C 1.544 0.734 0 CA-C-N 118.929 0.786 . . . . 0.0 111.934 172.986 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -58.98 -46.05 89.06 Favored 'General case' 0 N--CA 1.48 1.032 0 N-CA-C 112.666 0.617 . . . . 0.0 112.666 175.338 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -65.3 -32.58 74.31 Favored 'General case' 0 CA--C 1.545 0.776 0 N-CA-C 113.301 0.852 . . . . 0.0 113.301 -179.948 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 25.6 t-20 -71.61 -49.03 44.07 Favored 'General case' 0 CA--C 1.543 0.701 0 C-N-CA 124.758 1.223 . . . . 0.0 112.62 173.86 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 145.47 21.18 0.14 Allowed Glycine 0 CA--C 1.537 1.46 0 N-CA-C 116.813 1.485 . . . . 0.0 116.813 178.965 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 21.7 t -127.48 150.05 33.0 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.607 0 C-N-CA 126.067 1.747 . . . . 0.0 109.548 -176.966 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 80.0 p -124.42 138.69 54.33 Favored 'General case' 0 N--CA 1.47 0.542 0 C-N-CA 126.157 1.783 . . . . 0.0 112.129 -179.499 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 23.5 mm . . . . . 0 N--CA 1.477 0.917 0 C-N-CA 124.961 1.304 . . . . 0.0 111.854 -179.03 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 60.1 m . . . . . 0 CA--C 1.545 0.762 0 CA-C-O 121.069 0.461 . . . . 0.0 111.69 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -75.3 67.6 1.92 Allowed 'General case' 0 CA--C 1.551 1.006 0 C-N-CA 125.56 1.544 . . . . 0.0 113.091 179.802 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 72.8 m -68.92 155.57 93.16 Favored Pre-proline 0 CA--C 1.552 1.027 0 C-N-CA 124.882 1.273 . . . . 0.0 113.586 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 90.4 Cg_endo -74.11 168.01 25.81 Favored 'Trans proline' 0 CA--C 1.541 0.849 0 C-N-CA 123.591 2.861 . . . . 0.0 113.173 179.38 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -76.59 -3.23 36.56 Favored 'General case' 0 N--CA 1.482 1.155 0 C-N-CA 125.619 1.567 . . . . 0.0 114.447 177.927 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 85.6 mt -55.69 151.42 2.22 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.899 0 C-N-CA 126.868 2.067 . . . . 0.0 110.744 174.555 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 50.8 tp -136.9 93.49 2.85 Favored 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 125.914 1.686 . . . . 0.0 109.401 -175.538 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 16.7 mmtm -135.21 82.1 42.44 Favored Pre-proline 0 N--CA 1.475 0.779 0 C-N-CA 125.828 1.651 . . . . 0.0 110.129 174.307 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 65.0 Cg_endo -69.83 91.17 0.52 Allowed 'Trans proline' 0 CA--C 1.54 0.805 0 C-N-CA 123.809 3.006 . . . . 0.0 112.061 -177.238 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 5.0 m -87.11 157.87 3.19 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.522 0 C-N-CA 126.723 2.009 . . . . 0.0 112.882 -177.356 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 45.0 t -68.23 143.29 55.36 Favored 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 124.05 0.94 . . . . 0.0 111.064 171.366 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -111.72 148.97 18.1 Favored Glycine 0 CA--C 1.532 1.108 0 C-N-CA 125.472 1.51 . . . . 0.0 112.786 177.803 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 68.9 m -59.58 -22.81 62.29 Favored 'General case' 0 N--CA 1.477 0.878 0 N-CA-C 115.564 1.69 . . . . 0.0 115.564 -170.498 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 33.4 t70 -77.89 -10.74 59.73 Favored 'General case' 0 CA--C 1.549 0.929 0 C-N-CA 124.904 1.282 . . . . 0.0 114.15 175.238 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 98.39 31.85 6.3 Favored Glycine 0 CA--C 1.536 1.391 0 C-N-CA 125.422 1.487 . . . . 0.0 113.111 -172.097 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 15.3 mmp_? -121.91 -175.0 3.01 Favored 'General case' 0 N--CA 1.478 0.969 0 C-N-CA 127.743 2.417 . . . . 0.0 111.281 -169.734 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 9.3 t -136.84 143.95 43.36 Favored 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 125.191 1.396 . . . . 0.0 111.427 173.007 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 85.4 m-85 -142.39 147.94 37.04 Favored 'General case' 0 N--CA 1.473 0.705 0 C-N-CA 125.22 1.408 . . . . 0.0 112.217 -175.713 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -61.14 -44.81 96.74 Favored 'General case' 0 CA--C 1.542 0.667 0 N-CA-C 114.003 1.112 . . . . 0.0 114.003 -164.608 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 65.6 m-80 -146.85 175.06 10.93 Favored 'General case' 0 CA--C 1.548 0.886 0 C-N-CA 126.461 1.904 . . . . 0.0 110.633 167.576 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 20.0 m -57.76 -30.09 65.33 Favored 'General case' 0 N--CA 1.477 0.903 0 O-C-N 120.945 -1.097 . . . . 0.0 113.599 171.666 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 46.7 t -58.56 -61.1 2.85 Favored 'General case' 0 N--CA 1.466 0.368 0 C-N-CA 124.964 1.306 . . . . 0.0 112.312 175.557 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 8.5 tp -62.56 -33.3 58.85 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.744 0 N-CA-C 112.039 0.385 . . . . 0.0 112.039 179.995 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -57.41 -54.51 46.0 Favored 'General case' 0 CA--C 1.542 0.661 0 C-N-CA 123.348 0.659 . . . . 0.0 111.556 171.56 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 5.5 mtp85 -58.95 -40.22 84.03 Favored 'General case' 0 N--CA 1.48 1.031 0 N-CA-C 113.243 0.831 . . . . 0.0 113.243 174.907 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 33.0 t -59.95 -46.64 88.77 Favored 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 124.517 1.127 . . . . 0.0 111.628 177.17 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 95.4 m-20 -69.15 -48.07 63.31 Favored 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 125.546 1.538 . . . . 0.0 112.786 179.116 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 129.6 39.84 0.28 Allowed Glycine 0 CA--C 1.536 1.36 0 C-N-CA 125.212 1.387 . . . . 0.0 114.652 -176.867 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 44.7 t -133.25 158.18 42.94 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.597 0 C-N-CA 126.938 2.095 . . . . 0.0 108.494 174.528 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 42.7 t -123.57 143.29 50.3 Favored 'General case' 0 N--CA 1.47 0.572 0 C-N-CA 125.545 1.538 . . . . 0.0 111.937 175.492 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 17.1 mm . . . . . 0 N--CA 1.475 0.79 0 C-N-CA 126.034 1.734 . . . . 0.0 111.331 175.889 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 57.2 m . . . . . 0 N--CA 1.476 0.839 0 N-CA-C 113.6 0.963 . . . . 0.0 113.6 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . 50.07 26.32 2.04 Favored 'General case' 0 CA--C 1.552 1.023 0 C-N-CA 127.254 2.222 . . . . 0.0 115.285 -171.032 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 61.9 m -70.22 160.72 79.8 Favored Pre-proline 0 CA--C 1.548 0.869 0 C-N-CA 125.363 1.465 . . . . 0.0 112.922 177.157 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -67.58 167.59 20.48 Favored 'Trans proline' 0 CA--C 1.54 0.798 0 C-N-CA 123.295 2.663 . . . . 0.0 112.231 169.736 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 10.2 mtpm? -112.53 1.38 15.83 Favored 'General case' 0 N--CA 1.48 1.059 0 C-N-CA 126.282 1.833 . . . . 0.0 113.28 173.672 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 48.9 mm -55.93 133.03 19.99 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.593 0 C-N-CA 126.386 1.874 . . . . 0.0 111.082 178.587 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 5.4 tt -69.87 96.0 0.97 Allowed 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 127.771 2.428 . . . . 0.0 111.08 -176.723 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 34.7 ttpt -144.45 73.97 15.53 Favored Pre-proline 0 CA--C 1.546 0.801 0 C-N-CA 124.467 1.107 . . . . 0.0 111.901 -179.427 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -68.21 89.43 0.39 Allowed 'Trans proline' 0 CA--C 1.538 0.708 0 C-N-CA 124.188 3.259 . . . . 0.0 112.922 -175.996 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 16.3 m -73.73 160.24 5.36 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.412 0 C-N-CA 126.084 1.754 . . . . 0.0 112.244 175.273 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 16.5 t -69.36 165.95 19.65 Favored 'General case' 0 CA--C 1.549 0.908 0 C-N-CA 123.625 0.77 . . . . 0.0 111.141 166.998 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -143.6 134.55 5.9 Favored Glycine 0 CA--C 1.53 0.973 0 C-N-CA 124.778 1.18 . . . . 0.0 112.151 177.783 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 63.7 m -57.22 -24.48 54.9 Favored 'General case' 0 N--CA 1.477 0.886 0 C-N-CA 125.847 1.659 . . . . 0.0 114.906 -176.993 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -83.29 -4.58 58.58 Favored 'General case' 0 CA--C 1.548 0.887 0 C-N-CA 125.775 1.63 . . . . 0.0 113.955 176.985 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 94.65 20.21 29.8 Favored Glycine 0 CA--C 1.535 1.311 0 C-N-CA 125.38 1.467 . . . . 0.0 114.284 179.111 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 43.7 mtt180 -121.01 178.18 4.83 Favored 'General case' 0 N--CA 1.477 0.908 0 C-N-CA 126.169 1.788 . . . . 0.0 112.536 -173.88 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 31.8 m -128.35 142.64 51.06 Favored 'General case' 0 N--CA 1.477 0.9 0 C-N-CA 126.107 1.763 . . . . 0.0 110.049 -179.584 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 86.8 m-85 -135.57 155.64 50.15 Favored 'General case' 0 N--CA 1.471 0.588 0 C-N-CA 125.171 1.388 . . . . 0.0 111.651 -175.438 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -61.66 -38.63 88.46 Favored 'General case' 0 CA--C 1.544 0.742 0 N-CA-C 113.212 0.819 . . . . 0.0 113.212 -167.956 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 14.8 p30 -150.33 179.33 8.21 Favored 'General case' 0 CA--C 1.548 0.876 0 C-N-CA 126.213 1.805 . . . . 0.0 111.901 166.441 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 25.0 p -65.63 -34.83 79.12 Favored 'General case' 0 N--CA 1.474 0.745 0 O-C-N 121.007 -1.058 . . . . 0.0 113.755 177.298 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 34.4 t -62.93 -54.04 44.77 Favored 'General case' 0 N--CA 1.466 0.361 0 C-N-CA 124.083 0.953 . . . . 0.0 111.481 179.057 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 9.3 tp -59.0 -37.18 66.14 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.553 0 N-CA-C 112.143 0.423 . . . . 0.0 112.143 -179.277 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -63.32 -42.62 99.02 Favored 'General case' 0 CA--C 1.544 0.717 0 CA-C-N 118.851 0.75 . . . . 0.0 112.927 176.216 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 8.7 tpm_? -62.98 -41.96 99.7 Favored 'General case' 0 N--CA 1.475 0.816 0 C-N-CA 123.828 0.851 . . . . 0.0 112.278 173.82 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 7.3 t -65.06 -39.72 93.67 Favored 'General case' 0 CA--C 1.547 0.839 0 C-N-CA 123.025 0.53 . . . . 0.0 112.245 174.286 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 23.0 t-20 -63.93 -52.03 61.66 Favored 'General case' 0 CA--C 1.544 0.716 0 C-N-CA 125.82 1.648 . . . . 0.0 112.464 178.739 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 149.81 18.12 0.08 OUTLIER Glycine 0 CA--C 1.537 1.436 0 N-CA-C 117.344 1.698 . . . . 0.0 117.344 179.095 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 14.5 t -124.43 144.38 34.51 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.672 0 CA-C-N 119.98 1.89 . . . . 0.0 109.882 -176.828 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 72.3 m -89.47 128.53 35.98 Favored 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 125.805 1.642 . . . . 0.0 111.322 -179.024 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 14.3 mm . . . . . 0 N--CA 1.484 1.23 0 C-N-CA 124.687 1.195 . . . . 0.0 112.486 -175.778 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 22.4 m . . . . . 0 CA--C 1.545 0.776 0 N-CA-C 110.447 -0.205 . . . . 0.0 110.447 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -72.84 35.88 0.07 Allowed 'General case' 0 CA--C 1.556 1.195 0 C-N-CA 125.702 1.601 . . . . 0.0 114.321 178.257 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 63.8 m -64.85 159.03 66.45 Favored Pre-proline 0 CA--C 1.549 0.932 0 C-N-CA 126.499 1.92 . . . . 0.0 113.934 -178.232 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -70.81 158.96 54.15 Favored 'Trans proline' 0 C--N 1.352 0.736 0 C-N-CA 123.293 2.662 . . . . 0.0 112.785 -179.64 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 48.3 tttm -71.54 -21.17 61.94 Favored 'General case' 0 N--CA 1.478 0.953 0 C-N-CA 125.272 1.429 . . . . 0.0 113.397 176.401 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 43.7 mm -57.32 130.61 20.45 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.652 0 C-N-CA 126.257 1.823 . . . . 0.0 110.994 -179.651 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.416 HD23 ' H ' ' A' ' 10' ' ' LEU . 2.0 pt? -93.05 133.95 35.68 Favored 'General case' 0 CA--C 1.539 0.548 0 C-N-CA 125.312 1.445 . . . . 0.0 111.981 176.426 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 54.2 mttm -144.17 81.39 11.56 Favored Pre-proline 0 N--CA 1.471 0.611 0 C-N-CA 126.87 2.068 . . . . 0.0 109.236 166.748 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -71.53 85.03 0.93 Allowed 'Trans proline' 0 CA--C 1.539 0.729 0 C-N-CA 123.522 2.815 . . . . 0.0 111.915 178.836 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 35.2 m -110.96 166.72 5.37 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.344 0 C-N-CA 126.987 2.115 . . . . 0.0 112.609 -176.877 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 24.4 p -76.38 130.82 38.61 Favored 'General case' 0 CA--C 1.544 0.717 0 C-N-CA 124.124 0.97 . . . . 0.0 111.961 176.338 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -89.29 160.14 29.15 Favored Glycine 0 CA--C 1.534 1.255 0 C-N-CA 124.925 1.25 . . . . 0.0 111.974 168.239 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 91.2 p -59.39 -26.19 64.91 Favored 'General case' 0 N--CA 1.476 0.873 0 N-CA-C 115.252 1.575 . . . . 0.0 115.252 -171.928 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 32.2 m-20 -81.56 -2.77 51.18 Favored 'General case' 0 CA--C 1.547 0.858 0 C-N-CA 125.321 1.448 . . . . 0.0 114.451 176.585 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 89.59 31.4 11.48 Favored Glycine 0 CA--C 1.536 1.387 0 C-N-CA 124.772 1.177 . . . . 0.0 113.089 -176.285 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 42.9 mmm-85 -114.68 172.24 7.16 Favored 'General case' 0 N--CA 1.477 0.877 0 C-N-CA 127.808 2.443 . . . . 0.0 111.022 -170.873 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 31.7 m -128.68 133.53 48.23 Favored 'General case' 0 N--CA 1.481 1.086 0 C-N-CA 124.717 1.207 . . . . 0.0 110.748 178.921 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 87.3 m-85 -135.73 156.15 49.28 Favored 'General case' 0 N--CA 1.473 0.682 0 C-N-CA 125.186 1.394 . . . . 0.0 112.155 -178.106 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.99 -40.76 95.44 Favored 'General case' 0 CA--C 1.543 0.689 0 N-CA-C 113.499 0.926 . . . . 0.0 113.499 -166.965 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 23' ' ' ASN . . . . . 0.438 ' H ' HG22 ' A' ' 26' ' ' ILE . 28.7 p30 -148.4 179.7 7.59 Favored 'General case' 0 CA--C 1.547 0.847 0 C-N-CA 125.326 1.45 . . . . 0.0 112.194 164.813 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 44.6 p -62.64 -34.12 76.42 Favored 'General case' 0 N--CA 1.474 0.76 0 C-N-CA 124.228 1.011 . . . . 0.0 113.531 176.772 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 47.3 t -62.39 -55.1 31.08 Favored 'General case' 0 N--CA 1.465 0.276 0 C-N-CA 124.321 1.049 . . . . 0.0 111.917 178.093 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.438 HG22 ' H ' ' A' ' 23' ' ' ASN . 9.3 tp -61.26 -35.71 67.87 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.611 0 N-CA-C 112.25 0.463 . . . . 0.0 112.25 179.576 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -58.99 -51.37 70.38 Favored 'General case' 0 CA--C 1.544 0.73 0 C-N-CA 123.698 0.799 . . . . 0.0 111.885 172.499 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 77.5 mtp85 -57.92 -45.55 86.36 Favored 'General case' 0 N--CA 1.477 0.925 0 C-N-CA 124.644 1.177 . . . . 0.0 112.772 174.85 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 6.7 t -62.48 -40.83 97.95 Favored 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 123.766 0.826 . . . . 0.0 112.275 177.139 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 43.9 t30 -67.67 -42.04 82.79 Favored 'General case' 0 CA--C 1.543 0.681 0 C-N-CA 125.026 1.33 . . . . 0.0 113.245 178.32 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 134.43 23.79 0.64 Allowed Glycine 0 CA--C 1.538 1.476 0 N-CA-C 116.046 1.178 . . . . 0.0 116.046 178.013 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 38.0 t -125.01 154.47 33.06 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.448 0 C-N-CA 126.835 2.054 . . . . 0.0 108.379 -178.147 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 91.3 p -135.79 166.97 22.05 Favored 'General case' 0 N--CA 1.472 0.646 0 C-N-CA 124.618 1.167 . . . . 0.0 112.875 175.918 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 2.0 mt . . . . . 0 N--CA 1.48 1.04 0 C-N-CA 124.862 1.265 . . . . 0.0 112.006 -172.193 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 81.0 m . . . . . 0 CA--C 1.544 0.736 0 CA-C-O 120.693 0.282 . . . . 0.0 110.782 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -74.95 68.62 1.82 Allowed 'General case' 0 CA--C 1.549 0.935 0 C-N-CA 125.686 1.595 . . . . 0.0 113.17 -177.672 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 62.6 m -69.05 154.89 94.57 Favored Pre-proline 0 CA--C 1.549 0.909 0 C-N-CA 124.536 1.134 . . . . 0.0 113.431 -179.404 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -68.5 152.77 74.82 Favored 'Trans proline' 0 CA--C 1.54 0.811 0 C-N-CA 123.201 2.601 . . . . 0.0 111.854 172.637 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 15.2 ptmt -63.86 -26.03 68.43 Favored 'General case' 0 N--CA 1.479 1.023 0 C-N-CA 125.685 1.594 . . . . 0.0 114.678 177.571 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 9.5 tt -57.78 158.32 1.35 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.614 0 C-N-CA 126.673 1.989 . . . . 0.0 112.301 176.079 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 16.8 tp -126.96 114.78 18.29 Favored 'General case' 0 CA--C 1.538 0.487 0 C-N-CA 126.433 1.893 . . . . 0.0 108.518 -178.07 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 31.1 mmmt -127.61 80.18 72.29 Favored Pre-proline 0 N--CA 1.473 0.716 0 C-N-CA 126.125 1.77 . . . . 0.0 109.792 -176.362 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -72.78 84.28 1.27 Allowed 'Trans proline' 0 CA--C 1.541 0.83 0 C-N-CA 124.274 3.316 . . . . 0.0 112.402 -175.427 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 14.4 m -73.78 164.76 3.41 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.598 0 C-N-CA 126.883 2.073 . . . . 0.0 112.832 177.556 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 10.0 t -79.79 -5.21 54.92 Favored 'General case' 0 CA--C 1.551 0.995 0 C-N-CA 124.539 1.135 . . . . 0.0 113.983 174.406 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 57.29 -155.19 18.24 Favored Glycine 0 CA--C 1.539 1.548 0 C-N-CA 125.338 1.447 . . . . 0.0 113.984 179.211 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 38.0 m -121.22 -20.54 6.7 Favored 'General case' 0 N--CA 1.475 0.776 0 C-N-CA 124.94 1.296 . . . . 0.0 114.223 174.454 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -80.81 -13.88 58.56 Favored 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 124.252 1.021 . . . . 0.0 113.102 171.703 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 98.51 -14.91 61.71 Favored Glycine 0 CA--C 1.537 1.456 0 C-N-CA 126.782 2.134 . . . . 0.0 114.008 -177.945 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 9.8 ptm180 -77.96 168.83 19.28 Favored 'General case' 0 N--CA 1.474 0.747 0 C-N-CA 125.378 1.471 . . . . 0.0 112.279 168.269 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 54.7 m -95.22 149.36 21.4 Favored 'General case' 0 N--CA 1.475 0.779 0 C-N-CA 124.452 1.101 . . . . 0.0 111.708 174.823 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 56.1 m-85 -131.63 151.99 51.18 Favored 'General case' 0 N--CA 1.47 0.562 0 C-N-CA 126.249 1.819 . . . . 0.0 110.676 173.797 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.89 -40.54 87.79 Favored 'General case' 0 CA--C 1.544 0.713 0 N-CA-C 113.273 0.842 . . . . 0.0 113.273 -169.855 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 23' ' ' ASN . . . . . 0.41 ' H ' HG22 ' A' ' 26' ' ' ILE . 16.5 m120 -144.61 170.96 15.07 Favored 'General case' 0 CA--C 1.545 0.786 0 C-N-CA 126.29 1.836 . . . . 0.0 110.954 174.894 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 28.4 p -61.41 -32.06 72.0 Favored 'General case' 0 N--CA 1.475 0.797 0 C-N-CA 124.152 0.981 . . . . 0.0 112.618 162.073 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 42.3 t -54.84 -64.25 0.89 Allowed 'General case' 0 CA--C 1.535 0.374 0 C-N-CA 125.699 1.599 . . . . 0.0 112.366 173.264 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.41 HG22 ' H ' ' A' ' 23' ' ' ASN . 13.6 tt -58.54 -35.62 55.6 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.812 0 N-CA-C 112.211 0.449 . . . . 0.0 112.211 -178.021 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -59.07 -56.63 19.72 Favored 'General case' 0 CA--C 1.541 0.617 0 C-N-CA 123.5 0.72 . . . . 0.0 111.505 174.671 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 69.6 mtm180 -64.55 -37.5 87.77 Favored 'General case' 0 N--CA 1.479 0.977 0 N-CA-C 113.209 0.818 . . . . 0.0 113.209 179.009 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 35.9 t -58.35 -45.25 88.54 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 125.233 1.413 . . . . 0.0 111.833 172.695 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 23.0 t-20 -71.57 -48.84 45.73 Favored 'General case' 0 CA--C 1.546 0.816 0 C-N-CA 125.03 1.332 . . . . 0.0 112.79 179.911 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 144.7 23.43 0.14 Allowed Glycine 0 CA--C 1.54 1.629 0 N-CA-C 116.523 1.369 . . . . 0.0 116.523 179.765 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 18.4 t -130.88 151.56 36.12 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.603 0 C-N-CA 126.637 1.975 . . . . 0.0 109.179 -174.789 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 95.0 p -144.91 124.81 13.45 Favored 'General case' 0 N--CA 1.47 0.562 0 C-N-CA 125.106 1.362 . . . . 0.0 112.108 -179.724 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 6.3 mt . . . . . 0 N--CA 1.482 1.149 0 C-N-CA 124.306 1.042 . . . . 0.0 112.132 -178.805 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 61.2 m . . . . . 0 CA--C 1.541 0.605 0 CA-C-O 120.868 0.366 . . . . 0.0 110.832 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -73.99 52.89 0.45 Allowed 'General case' 0 CA--C 1.554 1.123 0 C-N-CA 125.612 1.565 . . . . 0.0 113.131 177.36 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 92.8 m -62.86 157.03 62.98 Favored Pre-proline 0 CA--C 1.551 1.001 0 C-N-CA 125.791 1.636 . . . . 0.0 113.232 178.977 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -71.82 167.7 25.87 Favored 'Trans proline' 0 CA--C 1.542 0.881 0 C-N-CA 123.29 2.66 . . . . 0.0 113.283 -177.24 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 61.7 mtpt -66.46 -16.8 64.39 Favored 'General case' 0 N--CA 1.481 1.088 0 C-N-CA 126.033 1.733 . . . . 0.0 114.097 176.171 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 79.8 mt -58.47 136.36 21.96 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.722 0 C-N-CA 126.489 1.916 . . . . 0.0 110.24 178.064 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.9 pt? -130.98 26.42 4.93 Favored 'General case' 0 CA--C 1.546 0.816 0 C-N-CA 125.416 1.487 . . . . 0.0 113.951 -178.48 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 26.4 mmtp -52.59 107.22 0.79 Allowed Pre-proline 0 N--CA 1.477 0.893 0 C-N-CA 126.516 1.926 . . . . 0.0 111.553 175.182 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 91.6 Cg_endo -73.61 87.76 1.08 Allowed 'Trans proline' 0 CA--C 1.539 0.729 0 C-N-CA 123.526 2.818 . . . . 0.0 112.01 -173.816 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 13.6 m -73.8 157.85 6.17 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.459 0 C-N-CA 125.636 1.574 . . . . 0.0 112.297 179.246 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 30.3 p -63.44 165.2 8.1 Favored 'General case' 0 CA--C 1.544 0.741 0 C-N-CA 123.412 0.685 . . . . 0.0 111.835 165.637 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -133.97 143.29 14.93 Favored Glycine 0 CA--C 1.527 0.798 0 C-N-CA 125.058 1.313 . . . . 0.0 111.972 179.999 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 55.6 m -65.08 -15.82 62.79 Favored 'General case' 0 N--CA 1.473 0.706 0 C-N-CA 125.362 1.465 . . . . 0.0 114.913 -174.598 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 42.0 m-20 -95.32 5.78 50.78 Favored 'General case' 0 CA--C 1.553 1.082 0 C-N-CA 125.972 1.709 . . . . 0.0 113.514 171.955 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 88.91 24.81 31.27 Favored Glycine 0 N--CA 1.473 1.108 0 C-N-CA 125.05 1.309 . . . . 0.0 114.157 179.921 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 24.0 mtp85 -120.47 -170.53 2.0 Favored 'General case' 0 N--CA 1.481 1.098 0 C-N-CA 126.297 1.839 . . . . 0.0 112.348 -171.409 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 41.2 m -134.42 139.04 45.27 Favored 'General case' 0 N--CA 1.478 0.964 0 C-N-CA 125.952 1.701 . . . . 0.0 110.37 -179.34 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 65.6 m-85 -134.3 159.4 41.09 Favored 'General case' 0 N--CA 1.473 0.694 0 C-N-CA 124.921 1.288 . . . . 0.0 111.603 179.036 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -63.97 -40.53 96.6 Favored 'General case' 0 CA--C 1.543 0.682 0 N-CA-C 112.92 0.711 . . . . 0.0 112.92 -168.075 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 28.5 p30 -154.77 -178.39 7.17 Favored 'General case' 0 CA--C 1.551 0.991 0 C-N-CA 125.314 1.445 . . . . 0.0 111.635 168.877 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 83.4 p -73.12 -16.79 61.45 Favored 'General case' 0 N--CA 1.48 1.046 0 N-CA-C 114.753 1.39 . . . . 0.0 114.753 177.843 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 38.8 t -76.6 -56.06 4.95 Favored 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 124.77 1.228 . . . . 0.0 111.136 173.861 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 7.7 tp -57.85 -34.63 48.77 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.859 0 C-N-CA 123.528 0.731 . . . . 0.0 112.406 179.115 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -55.24 -53.35 57.17 Favored 'General case' 0 CA--C 1.541 0.627 0 C-N-CA 123.885 0.874 . . . . 0.0 111.484 172.967 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 81.3 mtm180 -67.02 -37.42 84.13 Favored 'General case' 0 N--CA 1.475 0.786 0 C-N-CA 125.031 1.332 . . . . 0.0 113.49 178.317 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 42.5 t -57.22 -47.0 82.43 Favored 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 124.325 1.05 . . . . 0.0 111.599 170.844 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 63.6 t30 -70.96 -49.84 41.09 Favored 'General case' 0 CA--C 1.546 0.797 0 C-N-CA 125.502 1.521 . . . . 0.0 112.961 -178.172 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 145.42 23.22 0.12 Allowed Glycine 0 CA--C 1.539 1.561 0 N-CA-C 116.792 1.477 . . . . 0.0 116.792 178.663 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 19.3 t -125.55 150.84 31.06 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.613 0 C-N-CA 126.714 2.006 . . . . 0.0 108.839 -178.069 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 32.5 t -144.61 118.54 9.35 Favored 'General case' 0 N--CA 1.472 0.666 0 C-N-CA 124.907 1.283 . . . . 0.0 112.698 179.197 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.471 ' H ' HD12 ' A' ' 34' ' ' ILE . 0.7 OUTLIER . . . . . 0 CA--C 1.555 1.16 0 C-N-CA 126.789 2.035 . . . . 0.0 111.469 -178.638 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 4.9 m . . . . . 0 CA--C 1.547 0.843 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -74.44 51.19 0.44 Allowed 'General case' 0 CA--C 1.554 1.101 0 C-N-CA 125.571 1.549 . . . . 0.0 113.58 -177.588 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 81.2 m -71.5 156.07 91.88 Favored Pre-proline 0 CA--C 1.548 0.885 0 C-N-CA 125.624 1.569 . . . . 0.0 114.039 -172.704 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -68.93 158.83 56.34 Favored 'Trans proline' 0 CA--C 1.54 0.814 0 C-N-CA 123.63 2.887 . . . . 0.0 113.213 177.979 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 64.8 mttm -69.98 -14.02 62.5 Favored 'General case' 0 N--CA 1.481 1.093 0 C-N-CA 126.399 1.88 . . . . 0.0 114.142 177.813 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 10.3 tp -62.41 146.49 12.42 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 C-N-CA 126.438 1.895 . . . . 0.0 113.446 -177.114 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 62.7 tp -116.8 88.36 2.88 Favored 'General case' 0 CA--C 1.539 0.544 0 C-N-CA 127.138 2.175 . . . . 0.0 108.881 -175.677 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 13.1 mmmm -134.38 74.12 67.28 Favored Pre-proline 0 N--CA 1.474 0.739 0 C-N-CA 126.519 1.928 . . . . 0.0 109.179 175.536 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -67.21 120.02 7.07 Favored 'Trans proline' 0 CA--C 1.536 0.611 0 C-N-CA 122.929 2.419 . . . . 0.0 111.12 -175.732 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -107.51 155.75 8.17 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.747 0 C-N-CA 124.929 1.291 . . . . 0.0 110.961 -175.8 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 8.8 p -81.98 106.33 13.81 Favored 'General case' 0 CA--C 1.545 0.754 0 C-N-CA 125.792 1.637 . . . . 0.0 110.813 171.582 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -69.11 154.07 53.11 Favored Glycine 0 CA--C 1.534 1.272 0 O-C-N 121.45 -0.781 . . . . 0.0 112.085 172.063 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 73.2 m -61.69 -18.71 60.73 Favored 'General case' 0 N--CA 1.479 0.982 0 N-CA-C 116.084 1.883 . . . . 0.0 116.084 -168.854 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 31.8 t70 -82.14 -11.29 58.82 Favored 'General case' 0 CA--C 1.548 0.902 0 N-CA-C 114.105 1.15 . . . . 0.0 114.105 175.252 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 107.42 6.13 33.73 Favored Glycine 0 CA--C 1.536 1.377 0 C-N-CA 126.3 1.905 . . . . 0.0 114.418 -179.452 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 40.2 mtp180 -104.39 138.55 40.63 Favored 'General case' 0 N--CA 1.475 0.798 0 C-N-CA 126.073 1.749 . . . . 0.0 111.211 -175.139 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 8.1 p -77.91 141.9 38.75 Favored 'General case' 0 N--CA 1.47 0.55 0 C-N-CA 123.901 0.88 . . . . 0.0 112.39 175.961 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 92.8 m-85 -135.49 144.05 46.16 Favored 'General case' 0 N--CA 1.472 0.666 0 C-N-CA 125.437 1.495 . . . . 0.0 111.742 175.786 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -60.33 -40.98 92.56 Favored 'General case' 0 CA--C 1.543 0.688 0 N-CA-C 114.145 1.165 . . . . 0.0 114.145 -163.402 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 14.1 p30 -155.3 174.28 15.44 Favored 'General case' 0 CA--C 1.55 0.971 0 C-N-CA 126.282 1.833 . . . . 0.0 110.175 163.818 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 73.8 p -60.82 -25.98 66.99 Favored 'General case' 0 N--CA 1.48 1.037 0 N-CA-C 114.391 1.256 . . . . 0.0 114.391 -175.883 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 48.7 t -57.91 -62.25 1.94 Allowed 'General case' 0 CA--C 1.532 0.277 0 C-N-CA 124.923 1.289 . . . . 0.0 111.742 172.344 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 6.4 tt -59.91 -36.09 64.61 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.773 0 N-CA-C 112.289 0.477 . . . . 0.0 112.289 -177.336 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -58.26 -58.18 9.61 Favored 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 124.179 0.992 . . . . 0.0 111.518 174.589 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 65.2 mtm180 -64.17 -36.06 82.82 Favored 'General case' 0 N--CA 1.477 0.881 0 N-CA-C 113.271 0.841 . . . . 0.0 113.271 179.417 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 6.6 t -61.93 -42.97 99.71 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 124.009 0.924 . . . . 0.0 111.631 174.197 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 26.9 t-20 -69.37 -49.08 58.82 Favored 'General case' 0 CA--C 1.546 0.792 0 C-N-CA 124.851 1.26 . . . . 0.0 112.68 176.679 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 139.52 24.38 0.3 Allowed Glycine 0 CA--C 1.539 1.568 0 N-CA-C 116.16 1.224 . . . . 0.0 116.16 179.595 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 32.5 t -129.74 153.23 38.52 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.636 0 C-N-CA 126.373 1.869 . . . . 0.0 109.385 -177.927 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 68.9 m -134.41 170.48 15.67 Favored 'General case' 0 N--CA 1.47 0.575 0 C-N-CA 126.312 1.845 . . . . 0.0 112.099 -179.582 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 1.9 mp . . . . . 0 CA--C 1.554 1.1 0 C-N-CA 126.414 1.886 . . . . 0.0 111.443 -178.924 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 61.8 m . . . . . 0 CA--C 1.551 0.999 0 N-CA-C 113.248 0.833 . . . . 0.0 113.248 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . 54.41 30.85 13.46 Favored 'General case' 0 CA--C 1.551 1.002 0 C-N-CA 127.795 2.438 . . . . 0.0 114.408 -170.016 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 64.1 m -64.42 156.83 75.15 Favored Pre-proline 0 CA--C 1.55 0.958 0 C-N-CA 125.388 1.475 . . . . 0.0 113.387 177.321 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 95.3 Cg_endo -74.18 165.18 32.55 Favored 'Trans proline' 0 CA--C 1.542 0.894 0 C-N-CA 123.419 2.746 . . . . 0.0 113.522 -174.682 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 73.9 mmtt -78.87 -0.26 29.98 Favored 'General case' 0 N--CA 1.482 1.146 0 C-N-CA 126.28 1.832 . . . . 0.0 114.746 178.632 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 50.8 mm -56.86 157.97 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.766 0 C-N-CA 126.696 1.998 . . . . 0.0 111.146 170.536 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 51.5 tp -135.7 92.71 2.85 Favored 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 126.515 1.926 . . . . 0.0 108.583 -178.857 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 53.5 tptt -139.2 80.77 22.43 Favored Pre-proline 0 N--CA 1.471 0.595 0 C-N-CA 125.327 1.451 . . . . 0.0 110.124 174.186 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 62.1 Cg_endo -68.92 146.92 66.99 Favored 'Trans proline' 0 CA--C 1.537 0.67 0 C-N-CA 121.919 1.746 . . . . 0.0 111.102 177.68 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 1.4 t -137.08 159.81 36.41 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.977 0 C-N-CA 124.933 1.293 . . . . 0.0 110.518 -176.589 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 29.9 p -85.83 -7.47 58.71 Favored 'General case' 0 CA--C 1.547 0.828 0 C-N-CA 125.85 1.66 . . . . 0.0 114.764 -174.487 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 56.86 -178.38 0.78 Allowed Glycine 0 CA--C 1.537 1.442 0 C-N-CA 127.136 2.303 . . . . 0.0 116.447 177.274 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 11.2 t -79.46 -36.36 38.93 Favored 'General case' 0 CA--C 1.543 0.692 0 C-N-CA 123.653 0.781 . . . . 0.0 112.166 170.732 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -75.63 -12.22 60.17 Favored 'General case' 0 CA--C 1.548 0.877 0 C-N-CA 125.441 1.497 . . . . 0.0 114.596 -177.857 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 92.26 7.44 63.79 Favored Glycine 0 CA--C 1.536 1.373 0 C-N-CA 125.745 1.641 . . . . 0.0 114.723 176.13 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 38.3 mtt180 -95.84 -178.08 4.25 Favored 'General case' 0 N--CA 1.477 0.902 0 C-N-CA 126.353 1.861 . . . . 0.0 112.172 -177.046 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 47.3 m -122.24 128.19 50.84 Favored 'General case' 0 N--CA 1.476 0.85 0 C-N-CA 124.573 1.149 . . . . 0.0 110.505 179.32 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 56.4 m-85 -131.85 156.34 46.24 Favored 'General case' 0 N--CA 1.47 0.566 0 C-N-CA 125.491 1.517 . . . . 0.0 111.483 179.243 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.19 -43.83 85.7 Favored 'General case' 0 CA--C 1.544 0.748 0 N-CA-C 113.307 0.854 . . . . 0.0 113.307 -169.197 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 70.6 m-80 -139.66 175.9 9.18 Favored 'General case' 0 CA--C 1.544 0.729 0 C-N-CA 125.739 1.616 . . . . 0.0 111.557 171.184 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 42.4 t -61.34 -40.44 94.25 Favored 'General case' 0 N--CA 1.473 0.723 0 O-C-N 121.339 -0.851 . . . . 0.0 112.199 167.018 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 46.0 t -53.49 -57.42 10.76 Favored 'General case' 0 N--CA 1.467 0.398 0 C-N-CA 125.095 1.358 . . . . 0.0 112.795 -179.782 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 10.8 tp -59.97 -39.37 80.01 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.694 0 C-N-CA 122.791 0.436 . . . . 0.0 112.108 -179.099 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -68.76 -40.15 79.88 Favored 'General case' 0 CA--C 1.542 0.635 0 O-C-N 121.525 -0.735 . . . . 0.0 112.386 178.2 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 20.8 tpt180 -68.85 -35.66 77.2 Favored 'General case' 0 N--CA 1.472 0.654 0 C-N-CA 124.57 1.148 . . . . 0.0 112.691 176.107 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 47.8 t -59.45 -49.29 78.37 Favored 'General case' 0 CA--C 1.542 0.648 0 C-N-CA 125.059 1.344 . . . . 0.0 111.083 167.479 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 25.9 t-20 -62.97 -45.35 92.83 Favored 'General case' 0 CA--C 1.546 0.796 0 C-N-CA 124.814 1.246 . . . . 0.0 113.324 -179.535 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 143.66 17.22 0.24 Allowed Glycine 0 CA--C 1.54 1.614 0 N-CA-C 117.191 1.636 . . . . 0.0 117.191 175.386 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 21.7 t -115.7 144.15 23.98 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.704 0 CA-C-N 119.882 1.841 . . . . 0.0 110.232 -176.27 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 23.0 t -91.11 126.84 36.32 Favored 'General case' 0 N--CA 1.472 0.65 0 C-N-CA 126.48 1.912 . . . . 0.0 111.525 176.041 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 22.8 mm . . . . . 0 N--CA 1.479 0.991 0 C-N-CA 125.08 1.352 . . . . 0.0 112.686 -174.655 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 21.0 pttp . . . . . 0 N--CA 1.495 1.797 0 N-CA-C 115.539 1.681 . . . . 0.0 115.539 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 23.4 pttp -61.8 160.57 11.69 Favored 'General case' 0 N--CA 1.482 1.175 0 CA-C-N 120.605 1.548 . . . . 0.0 113.569 -176.733 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 13.2 p -141.66 144.57 25.62 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.844 0 C-N-CA 125.556 1.542 . . . . 0.0 111.307 179.837 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 67.9 m -77.24 98.27 5.08 Favored 'General case' 0 CA--C 1.541 0.612 0 C-N-CA 125.1 1.36 . . . . 0.0 111.364 179.108 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -73.34 48.76 0.25 Allowed 'General case' 0 CA--C 1.554 1.13 0 C-N-CA 126.371 1.868 . . . . 0.0 113.54 177.627 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 85.4 m -61.99 156.79 55.65 Favored Pre-proline 0 CA--C 1.548 0.897 0 C-N-CA 125.718 1.607 . . . . 0.0 113.724 179.853 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_endo -68.62 151.82 74.88 Favored 'Trans proline' 0 C--N 1.351 0.7 0 C-N-CA 123.275 2.65 . . . . 0.0 112.137 177.17 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 10.4 ptpp? -74.28 -30.71 62.22 Favored 'General case' 0 N--CA 1.478 0.964 0 C-N-CA 125.058 1.343 . . . . 0.0 114.198 176.399 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 40.8 mm -58.05 126.95 16.47 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.741 0 C-N-CA 126.893 2.077 . . . . 0.0 111.457 -176.571 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 2.0 pt? -61.6 126.67 28.17 Favored 'General case' 0 CA--C 1.542 0.662 0 C-N-CA 125.128 1.371 . . . . 0.0 112.851 -179.777 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 74.9 mmtt -136.33 71.91 59.6 Favored Pre-proline 0 N--CA 1.479 1.004 0 C-N-CA 125.314 1.446 . . . . 0.0 111.604 173.25 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 75.1 Cg_endo -72.85 84.59 1.25 Allowed 'Trans proline' 0 CA--C 1.54 0.817 0 C-N-CA 123.84 3.027 . . . . 0.0 112.818 -178.058 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 15.1 m -76.99 162.13 4.35 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.589 0 C-N-CA 126.739 2.016 . . . . 0.0 113.296 178.824 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 10.6 t -80.19 -5.54 56.26 Favored 'General case' 0 CA--C 1.553 1.068 0 C-N-CA 125.492 1.517 . . . . 0.0 114.166 174.321 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 64.71 -164.67 34.45 Favored Glycine 0 CA--C 1.538 1.504 0 C-N-CA 125.072 1.32 . . . . 0.0 113.974 -178.371 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 25.1 t -111.27 -38.9 4.87 Favored 'General case' 0 N--CA 1.477 0.901 0 C-N-CA 124.775 1.23 . . . . 0.0 112.591 172.57 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 29.5 t70 -72.29 -13.42 61.5 Favored 'General case' 0 N--CA 1.478 0.955 0 N-CA-C 114.249 1.203 . . . . 0.0 114.249 177.718 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 98.15 39.27 3.81 Favored Glycine 0 CA--C 1.533 1.202 0 C-N-CA 125.92 1.724 . . . . 0.0 112.827 -178.745 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 16.2 mmm180 -135.33 150.88 50.07 Favored 'General case' 0 N--CA 1.475 0.776 0 C-N-CA 127.366 2.266 . . . . 0.0 110.822 -168.716 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 27.9 m -95.82 134.45 38.76 Favored 'General case' 0 N--CA 1.476 0.866 0 C-N-CA 124.209 1.004 . . . . 0.0 110.569 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 73.5 m-85 -128.67 160.92 30.94 Favored 'General case' 0 N--CA 1.471 0.613 0 C-N-CA 125.541 1.537 . . . . 0.0 111.215 178.666 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.9 -60.95 2.49 Favored 'General case' 0 CA--C 1.542 0.658 0 N-CA-C 111.784 0.29 . . . . 0.0 111.784 -172.247 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 30.1 m-20 -129.04 162.49 27.53 Favored 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 125.962 1.705 . . . . 0.0 110.322 170.896 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 26.7 p -63.24 -40.98 98.98 Favored 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 124.637 1.175 . . . . 0.0 113.684 177.299 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 49.5 t -57.89 -48.2 80.56 Favored 'General case' 0 N--CA 1.468 0.441 0 C-N-CA 125.303 1.441 . . . . 0.0 112.372 177.049 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 1.4 mp -52.31 -45.91 44.95 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.727 0 C-N-CA 124.815 1.246 . . . . 0.0 111.669 174.224 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -59.67 -46.63 88.46 Favored 'General case' 0 CA--C 1.545 0.753 0 CA-C-N 119.631 1.105 . . . . 0.0 112.14 177.281 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -57.69 -47.65 81.74 Favored 'General case' 0 N--CA 1.478 0.937 0 C-N-CA 124.877 1.271 . . . . 0.0 111.615 175.639 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 50.7 t -56.31 -48.21 77.13 Favored 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 125.38 1.472 . . . . 0.0 112.297 174.099 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -67.8 -30.06 69.39 Favored 'General case' 0 CA--C 1.548 0.882 0 C-N-CA 124.718 1.207 . . . . 0.0 112.792 -177.516 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 123.32 22.25 2.36 Favored Glycine 0 CA--C 1.537 1.409 0 C-N-CA 124.911 1.243 . . . . 0.0 115.954 175.401 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 5.0 t -124.27 143.59 37.09 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.568 0 C-N-CA 125.906 1.682 . . . . 0.0 109.315 -179.216 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 16.0 t -97.54 169.97 9.36 Favored 'General case' 0 N--CA 1.473 0.721 0 C-N-CA 125.362 1.465 . . . . 0.0 112.134 178.121 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 2.4 mt -141.17 12.74 0.49 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.054 0 C-N-CA 126.999 2.12 . . . . 0.0 110.494 -179.225 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 58.22 18.95 5.76 Favored 'General case' 0 N--CA 1.485 1.295 0 C-N-CA 126.916 2.086 . . . . 0.0 114.495 -174.285 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 1.4 t -116.7 22.18 12.88 Favored 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 126.924 2.09 . . . . 0.0 113.717 -174.521 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 52.9 mt-10 -54.35 -22.77 13.06 Favored 'General case' 0 CA--C 1.546 0.804 0 C-N-CA 126.082 1.753 . . . . 0.0 114.622 177.507 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -76.99 -10.07 86.43 Favored Glycine 0 CA--C 1.54 1.605 0 C-N-CA 124.857 1.218 . . . . 0.0 115.446 176.04 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 12.6 t -146.07 89.91 1.92 Allowed 'General case' 0 N--CA 1.472 0.667 0 CA-C-N 118.975 1.388 . . . . 0.0 111.369 178.83 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 29.5 p -139.6 160.58 60.79 Favored Pre-proline 0 CA--C 1.549 0.94 0 C-N-CA 125.581 1.552 . . . . 0.0 111.994 -177.049 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -74.13 -14.6 23.34 Favored 'Trans proline' 0 CA--C 1.542 0.897 0 C-N-CA 123.15 2.567 . . . . 0.0 113.953 179.179 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 13.7 m -60.7 112.65 2.1 Favored 'General case' 0 N--CA 1.473 0.717 0 C-N-CA 126.454 1.902 . . . . 0.0 111.685 178.338 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -156.58 68.75 0.29 Allowed Glycine 0 CA--C 1.531 1.084 0 C-N-CA 124.4 1.0 . . . . 0.0 113.432 -175.421 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.255 1.353 0 C-N-CA 125.656 1.582 . . . . 0.0 111.529 174.383 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 4.1 mppt? . . . . . 0 N--CA 1.491 1.612 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 11.5 ptmm? -157.34 175.17 14.36 Favored 'General case' 0 N--CA 1.484 1.238 0 C-N-CA 127.068 2.147 . . . . 0.0 111.488 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 12.6 p -141.52 149.98 19.93 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.009 0 C-N-CA 125.317 1.447 . . . . 0.0 111.532 175.84 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 58.5 m -71.47 105.95 3.77 Favored 'General case' 0 CA--C 1.544 0.722 0 C-N-CA 125.486 1.514 . . . . 0.0 110.963 175.301 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -74.6 53.5 0.56 Allowed 'General case' 0 CA--C 1.553 1.059 0 C-N-CA 126.101 1.76 . . . . 0.0 113.629 -178.503 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 80.0 m -67.14 153.99 93.54 Favored Pre-proline 0 CA--C 1.551 0.982 0 C-N-CA 125.373 1.469 . . . . 0.0 113.306 -178.071 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -72.59 157.37 52.65 Favored 'Trans proline' 0 CA--C 1.541 0.847 0 C-N-CA 123.05 2.5 . . . . 0.0 112.514 179.459 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -88.72 -9.54 51.59 Favored 'General case' 0 N--CA 1.48 1.045 0 C-N-CA 124.927 1.291 . . . . 0.0 113.678 176.649 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 79.9 mt -62.02 139.82 20.2 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.756 0 C-N-CA 125.106 1.362 . . . . 0.0 109.692 174.176 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 10.4 mp -82.53 97.8 8.62 Favored 'General case' 0 CA--C 1.538 0.507 0 C-N-CA 124.744 1.218 . . . . 0.0 110.354 172.806 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 2.4 mmmp? -126.47 65.99 61.36 Favored Pre-proline 0 CA--C 1.546 0.815 0 C-N-CA 125.331 1.452 . . . . 0.0 110.632 170.147 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 66.5 Cg_endo -66.32 154.29 74.78 Favored 'Trans proline' 0 C--N 1.352 0.747 0 C-N-CA 122.813 2.342 . . . . 0.0 112.169 -179.263 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -142.18 160.2 20.1 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.757 0 C-N-CA 125.088 1.355 . . . . 0.0 110.476 -178.746 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 47.3 t -73.41 105.04 4.61 Favored 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 124.735 1.214 . . . . 0.0 110.283 169.97 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -65.99 148.02 50.65 Favored Glycine 0 CA--C 1.531 1.041 0 C-N-CA 124.1 0.857 . . . . 0.0 112.416 174.136 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 69.5 m -65.56 -17.58 64.68 Favored 'General case' 0 N--CA 1.475 0.819 0 N-CA-C 114.941 1.46 . . . . 0.0 114.941 -174.8 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 32.1 t70 -79.81 -8.12 59.08 Favored 'General case' 0 CA--C 1.552 1.032 0 C-N-CA 124.698 1.199 . . . . 0.0 113.569 169.148 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 97.34 27.38 9.29 Favored Glycine 0 CA--C 1.536 1.39 0 C-N-CA 126.548 2.023 . . . . 0.0 114.084 -179.593 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 64.3 mtt-85 -127.31 170.57 12.33 Favored 'General case' 0 N--CA 1.481 1.075 0 C-N-CA 125.241 1.416 . . . . 0.0 113.826 -166.385 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 33.1 m -103.45 125.36 49.99 Favored 'General case' 0 N--CA 1.475 0.78 0 C-N-CA 125.761 1.625 . . . . 0.0 110.674 -177.293 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 77.6 m-85 -131.57 157.43 43.62 Favored 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 125.097 1.359 . . . . 0.0 111.631 174.789 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.21 -48.82 74.39 Favored 'General case' 0 CA--C 1.542 0.645 0 N-CA-C 113.211 0.819 . . . . 0.0 113.211 -166.993 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' ASN . . . . . 0.407 ' H ' HG22 ' A' ' 26' ' ' ILE . 71.8 m-80 -144.32 174.23 11.09 Favored 'General case' 0 CA--C 1.549 0.936 0 C-N-CA 126.754 2.021 . . . . 0.0 111.08 174.865 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 69.5 m -65.58 -27.92 68.77 Favored 'General case' 0 N--CA 1.483 1.194 0 O-C-N 120.485 -1.385 . . . . 0.0 112.992 171.61 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 46.0 t -58.57 -58.36 8.9 Favored 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 125.414 1.486 . . . . 0.0 112.218 175.652 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.407 HG22 ' H ' ' A' ' 23' ' ' ASN . 10.5 tp -60.7 -33.95 56.94 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 N-CA-C 112.219 0.452 . . . . 0.0 112.219 -179.619 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -59.24 -53.89 53.13 Favored 'General case' 0 CA--C 1.542 0.663 0 CA-C-N 118.684 0.675 . . . . 0.0 111.852 173.152 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 18.4 mmm180 -62.9 -33.56 75.56 Favored 'General case' 0 N--CA 1.48 1.031 0 C-N-CA 123.812 0.845 . . . . 0.0 113.217 176.088 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 19.3 t -62.83 -46.69 86.74 Favored 'General case' 0 CA--C 1.545 0.762 0 C-N-CA 124.513 1.125 . . . . 0.0 111.741 172.554 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 88.1 m-20 -69.34 -49.66 53.64 Favored 'General case' 0 CA--C 1.542 0.654 0 C-N-CA 125.552 1.541 . . . . 0.0 113.015 -179.691 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 142.63 24.5 0.19 Allowed Glycine 0 CA--C 1.538 1.518 0 N-CA-C 116.484 1.353 . . . . 0.0 116.484 -177.867 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 6.6 t -128.4 147.02 32.97 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.706 0 C-N-CA 126.211 1.804 . . . . 0.0 108.878 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 68.8 m -117.43 133.33 56.09 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 125.337 1.455 . . . . 0.0 112.231 -175.369 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 9.9 mm -121.62 8.14 5.9 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.04 0 C-N-CA 126.375 1.87 . . . . 0.0 111.582 -166.631 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 26.0 mmmt 60.3 14.22 4.5 Favored 'General case' 0 N--CA 1.488 1.46 0 C-N-CA 127.208 2.203 . . . . 0.0 115.162 -170.38 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 75.7 m -118.97 41.24 3.1 Favored 'General case' 0 N--CA 1.473 0.698 0 C-N-CA 127.083 2.153 . . . . 0.0 112.05 -179.577 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 39.4 mt-10 -58.99 160.01 6.47 Favored 'General case' 0 CA--C 1.547 0.856 0 C-N-CA 125.196 1.398 . . . . 0.0 113.104 171.437 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -179.54 -65.76 0.07 OUTLIER Glycine 0 CA--C 1.532 1.109 0 C-N-CA 124.653 1.12 . . . . 0.0 112.313 177.876 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 46.6 m -63.27 106.5 0.9 Allowed 'General case' 0 N--CA 1.472 0.653 0 C-N-CA 125.408 1.483 . . . . 0.0 111.36 172.966 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 46.6 t -60.41 118.96 38.8 Favored Pre-proline 0 CA--C 1.552 1.026 0 C-N-CA 124.473 1.109 . . . . 0.0 112.083 -177.983 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 85.6 Cg_endo -75.84 -15.74 18.79 Favored 'Trans proline' 0 CA--C 1.54 0.824 0 C-N-CA 122.948 2.432 . . . . 0.0 113.978 -177.224 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 5.1 m 55.86 36.66 27.71 Favored 'General case' 0 N--CA 1.483 1.217 0 C-N-CA 125.949 1.699 . . . . 0.0 112.478 -176.87 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -102.25 -97.05 2.34 Favored Glycine 0 CA--C 1.536 1.373 0 C-N-CA 125.646 1.593 . . . . 0.0 112.578 179.599 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 67.6 mt . . . . . 0 C--O 1.254 1.31 0 C-N-CA 126.178 1.791 . . . . 0.0 110.863 178.319 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 70.3 mmtt . . . . . 0 N--CA 1.491 1.617 0 N-CA-C 110.681 -0.118 . . . . 0.0 110.681 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 6.3 ttpm? -69.24 141.63 54.38 Favored 'General case' 0 N--CA 1.481 1.097 0 C-N-CA 124.307 1.043 . . . . 0.0 110.678 174.226 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 13.8 p -144.28 143.47 23.33 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.796 0 C-N-CA 125.022 1.329 . . . . 0.0 111.371 -179.669 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 34.2 m -111.87 -18.33 12.71 Favored 'General case' 0 CA--C 1.547 0.834 0 C-N-CA 125.426 1.49 . . . . 0.0 112.981 178.346 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . 46.46 34.33 2.31 Favored 'General case' 0 CA--C 1.549 0.931 0 C-N-CA 127.366 2.266 . . . . 0.0 114.612 -174.462 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 53.2 m -63.22 152.78 83.77 Favored Pre-proline 0 CA--C 1.548 0.891 0 C-N-CA 124.264 1.026 . . . . 0.0 113.285 -176.658 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -67.75 157.54 61.32 Favored 'Trans proline' 0 CA--C 1.54 0.78 0 C-N-CA 123.595 2.863 . . . . 0.0 112.942 179.873 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 32.1 mmmt -74.24 -8.91 57.85 Favored 'General case' 0 N--CA 1.481 1.085 0 C-N-CA 126.353 1.861 . . . . 0.0 114.116 -179.05 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -54.89 138.52 14.93 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.691 0 C-N-CA 127.43 2.292 . . . . 0.0 112.838 179.396 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 42.5 tp -114.0 101.05 8.88 Favored 'General case' 0 CA--C 1.539 0.52 0 C-N-CA 127.269 2.228 . . . . 0.0 109.127 -176.588 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 59.0 tttm -148.74 78.17 9.15 Favored Pre-proline 0 N--CA 1.473 0.7 0 C-N-CA 124.635 1.174 . . . . 0.0 110.662 175.646 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 67.0 Cg_endo -72.26 108.24 2.45 Favored 'Trans proline' 0 N--CA 1.458 -0.612 0 C-N-CA 123.035 2.49 . . . . 0.0 111.913 -177.871 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 14.9 m -107.09 172.65 1.82 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.463 0 C-N-CA 126.867 2.067 . . . . 0.0 111.793 -179.836 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 24.2 t -75.75 154.07 36.59 Favored 'General case' 0 CA--C 1.541 0.599 0 C-N-CA 123.981 0.912 . . . . 0.0 111.184 -179.851 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -121.48 152.82 16.76 Favored Glycine 0 CA--C 1.531 1.061 0 C-N-CA 125.012 1.292 . . . . 0.0 113.239 177.002 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 9.2 t -55.98 -36.05 67.43 Favored 'General case' 0 N--CA 1.476 0.841 0 C-N-CA 125.86 1.664 . . . . 0.0 114.064 -173.783 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 32.8 t70 -80.04 -9.31 59.69 Favored 'General case' 0 CA--C 1.551 1.0 0 C-N-CA 125.027 1.331 . . . . 0.0 114.368 179.119 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 89.88 53.4 2.4 Favored Glycine 0 CA--C 1.532 1.136 0 C-N-CA 125.311 1.434 . . . . 0.0 112.068 -175.203 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 4.0 mmp_? -137.81 174.89 10.1 Favored 'General case' 0 N--CA 1.477 0.91 0 C-N-CA 127.658 2.383 . . . . 0.0 110.916 -172.462 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 9.4 m -137.71 140.49 40.76 Favored 'General case' 0 N--CA 1.48 1.025 0 C-N-CA 125.301 1.44 . . . . 0.0 110.512 179.7 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 49.1 m-85 -139.25 161.33 37.68 Favored 'General case' 0 N--CA 1.473 0.699 0 C-N-CA 125.533 1.533 . . . . 0.0 111.32 -176.894 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.39 -45.42 87.77 Favored 'General case' 0 CA--C 1.545 0.772 0 N-CA-C 113.525 0.935 . . . . 0.0 113.525 -167.553 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' ASN . . . . . 0.433 ' H ' HG22 ' A' ' 26' ' ' ILE . 28.0 p30 -146.08 -178.42 6.12 Favored 'General case' 0 CA--C 1.548 0.886 0 C-N-CA 125.226 1.411 . . . . 0.0 111.864 166.984 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 29.0 p -66.28 -30.16 70.53 Favored 'General case' 0 N--CA 1.472 0.629 0 N-CA-C 114.226 1.195 . . . . 0.0 114.226 179.094 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 49.1 t -64.98 -56.58 12.32 Favored 'General case' 0 N--CA 1.47 0.526 0 C-N-CA 124.058 0.943 . . . . 0.0 111.524 177.401 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.433 HG22 ' H ' ' A' ' 23' ' ' ASN . 11.2 tp -57.6 -38.88 66.59 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.618 0 CA-C-O 119.354 -0.355 . . . . 0.0 111.757 179.853 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -61.11 -45.09 96.12 Favored 'General case' 0 CA--C 1.543 0.683 0 C-N-CA 123.949 0.9 . . . . 0.0 112.797 175.809 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 5.1 tpt180 -64.8 -42.06 95.31 Favored 'General case' 0 N--CA 1.474 0.734 0 C-N-CA 123.448 0.699 . . . . 0.0 112.524 176.203 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 2.9 t -65.35 -36.08 82.94 Favored 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 123.117 0.567 . . . . 0.0 112.164 174.858 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 24.7 t-20 -66.68 -53.71 30.82 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 125.594 1.558 . . . . 0.0 112.486 176.674 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 151.49 19.4 0.06 OUTLIER Glycine 0 CA--C 1.538 1.526 0 N-CA-C 117.602 1.801 . . . . 0.0 117.602 179.284 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 3.7 t -127.78 138.69 53.99 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.814 0 CA-C-N 120.25 2.025 . . . . 0.0 110.309 -177.659 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 8.6 t -91.87 94.65 9.42 Favored 'General case' 0 N--CA 1.472 0.658 0 C-N-CA 125.245 1.418 . . . . 0.0 112.324 -173.987 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 19.6 mm -98.28 -25.55 4.03 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.006 0 C-N-CA 124.368 1.067 . . . . 0.0 112.972 -176.861 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -78.94 -25.02 43.6 Favored 'General case' 0 N--CA 1.48 1.048 0 C-N-CA 125.065 1.346 . . . . 0.0 113.848 178.501 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER 53.83 36.23 23.57 Favored 'General case' 0 N--CA 1.48 1.025 0 C-N-CA 125.15 1.38 . . . . 0.0 113.231 -169.92 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -60.1 164.36 4.13 Favored 'General case' 0 CA--C 1.548 0.903 0 C-N-CA 127.045 2.138 . . . . 0.0 113.726 178.93 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 109.43 -11.03 33.3 Favored Glycine 0 CA--C 1.539 1.572 0 C-N-CA 126.805 2.145 . . . . 0.0 114.919 -177.85 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 62.4 m -110.55 -40.48 4.6 Favored 'General case' 0 N--CA 1.478 0.962 0 C-N-CA 125.281 1.432 . . . . 0.0 113.773 -178.182 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 84.9 m -132.9 155.63 80.95 Favored Pre-proline 0 CA--C 1.545 0.773 0 C-N-CA 126.393 1.877 . . . . 0.0 110.599 179.179 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -72.19 -13.14 28.32 Favored 'Trans proline' 0 CA--C 1.544 1.023 0 C-N-CA 123.18 2.587 . . . . 0.0 114.222 -176.562 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.8 m -66.13 133.27 50.35 Favored 'General case' 0 N--CA 1.473 0.709 0 C-N-CA 125.769 1.628 . . . . 0.0 111.254 176.618 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -160.07 -83.07 0.05 OUTLIER Glycine 0 CA--C 1.533 1.161 0 O-C-N 121.756 -0.59 . . . . 0.0 113.6 179.943 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 44.1 mt . . . . . 0 C--O 1.254 1.326 0 C-N-CA 125.213 1.405 . . . . 0.0 110.74 175.821 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 13.6 tmtt? . . . . . 0 N--CA 1.49 1.575 0 N-CA-C 110.436 -0.209 . . . . 0.0 110.436 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 46.7 tttp 48.99 57.53 6.35 Favored 'General case' 0 N--CA 1.483 1.223 0 C-N-CA 126.826 2.05 . . . . 0.0 113.885 -177.392 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 47.9 t -129.44 127.16 64.65 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.072 0 C-N-CA 125.871 1.668 . . . . 0.0 110.497 176.386 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 3.7 m -77.58 103.13 7.34 Favored 'General case' 0 CA--C 1.544 0.737 0 C-N-CA 125.699 1.6 . . . . 0.0 110.002 175.022 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -74.66 60.22 0.9 Allowed 'General case' 0 CA--C 1.553 1.085 0 C-N-CA 124.607 1.163 . . . . 0.0 112.827 179.351 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 84.3 m -64.12 156.11 76.15 Favored Pre-proline 0 CA--C 1.55 0.947 0 C-N-CA 125.78 1.632 . . . . 0.0 112.96 179.497 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 93.0 Cg_endo -71.35 168.42 23.5 Favored 'Trans proline' 0 CA--C 1.54 0.819 0 C-N-CA 123.056 2.504 . . . . 0.0 112.334 176.589 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 38.0 tttp -64.09 -20.33 65.88 Favored 'General case' 0 N--CA 1.479 0.977 0 C-N-CA 124.761 1.224 . . . . 0.0 113.188 174.721 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 61.7 mt -57.89 120.05 3.62 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.589 0 C-N-CA 126.715 2.006 . . . . 0.0 111.066 179.908 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 15.9 tp -99.44 117.41 33.79 Favored 'General case' 0 CA--C 1.538 0.508 0 C-N-CA 129.048 2.939 . . . . 0.0 108.363 174.533 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -132.18 78.27 69.14 Favored Pre-proline 0 N--CA 1.473 0.704 0 C-N-CA 125.786 1.634 . . . . 0.0 108.882 -178.695 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 66.2 Cg_endo -71.38 102.66 1.3 Allowed 'Trans proline' 0 CA--C 1.537 0.67 0 C-N-CA 123.831 3.021 . . . . 0.0 112.181 -168.527 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -100.2 158.13 3.91 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.003 0 C-N-CA 124.332 1.053 . . . . 0.0 112.245 -176.162 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 18.0 t -72.94 -18.2 61.41 Favored 'General case' 0 CA--C 1.547 0.843 0 N-CA-C 114.209 1.189 . . . . 0.0 114.209 -178.896 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 63.51 -178.63 6.68 Favored Glycine 0 CA--C 1.537 1.457 0 C-N-CA 126.416 1.96 . . . . 0.0 115.514 176.971 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 14.1 m -84.53 -38.46 20.0 Favored 'General case' 0 N--CA 1.476 0.857 0 C-N-CA 124.066 0.947 . . . . 0.0 113.083 173.484 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 20.4 m-20 -77.03 -14.97 59.76 Favored 'General case' 0 N--CA 1.479 0.98 0 N-CA-C 113.581 0.956 . . . . 0.0 113.581 179.695 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 98.07 -11.77 63.91 Favored Glycine 0 CA--C 1.536 1.353 0 C-N-CA 126.391 1.948 . . . . 0.0 114.392 179.842 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -78.41 156.53 29.4 Favored 'General case' 0 N--CA 1.474 0.761 0 C-N-CA 125.262 1.425 . . . . 0.0 112.084 171.239 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -84.26 113.14 20.9 Favored 'General case' 0 N--CA 1.472 0.638 0 C-N-CA 124.88 1.272 . . . . 0.0 112.857 178.069 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 79.0 m-85 -91.45 149.53 21.66 Favored 'General case' 0 N--CA 1.475 0.785 0 C-N-CA 124.792 1.237 . . . . 0.0 111.599 173.489 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.69 -46.75 77.84 Favored 'General case' 0 CA--C 1.542 0.665 0 N-CA-C 113.355 0.872 . . . . 0.0 113.355 -168.936 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 26.0 p30 -157.06 -179.35 8.12 Favored 'General case' 0 CA--C 1.545 0.773 0 C-N-CA 125.441 1.496 . . . . 0.0 111.88 174.348 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 36.7 p -61.69 -32.57 72.78 Favored 'General case' 0 N--CA 1.473 0.708 0 O-C-N 120.977 -1.077 . . . . 0.0 113.342 173.956 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 49.5 t -58.82 -60.51 3.73 Favored 'General case' 0 CA--C 1.533 0.299 0 C-N-CA 124.85 1.26 . . . . 0.0 111.765 176.75 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 9.8 tp -56.98 -40.45 72.64 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.881 0 N-CA-C 112.431 0.53 . . . . 0.0 112.431 178.943 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -57.32 -59.34 5.27 Favored 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 123.886 0.874 . . . . 0.0 111.461 176.498 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 46.3 mmm-85 -59.27 -41.85 89.84 Favored 'General case' 0 N--CA 1.475 0.799 0 C-N-CA 124.773 1.229 . . . . 0.0 113.028 178.775 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 2.9 t -66.6 -41.33 88.62 Favored 'General case' 0 CA--C 1.545 0.757 0 C-N-CA 123.609 0.763 . . . . 0.0 112.536 179.579 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 53.1 t30 -71.52 -42.0 68.51 Favored 'General case' 0 CA--C 1.543 0.7 0 C-N-CA 124.655 1.182 . . . . 0.0 113.181 178.833 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 129.71 30.1 0.66 Allowed Glycine 0 CA--C 1.538 1.475 0 C-N-CA 124.611 1.1 . . . . 0.0 115.206 -179.333 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -123.08 169.7 14.16 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 C-N-CA 127.37 2.268 . . . . 0.0 109.192 -177.866 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 29.8 t -145.77 161.52 39.74 Favored 'General case' 0 N--CA 1.471 0.614 0 C-N-CA 125.259 1.423 . . . . 0.0 112.42 -179.005 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 18.7 mm -100.91 -7.36 9.08 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.86 0 C-N-CA 125.956 1.703 . . . . 0.0 111.69 178.019 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 8.4 mmpt? -62.37 -28.73 69.97 Favored 'General case' 0 N--CA 1.481 1.078 0 C-N-CA 125.22 1.408 . . . . 0.0 113.323 -178.986 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 21.8 t -62.78 -54.54 37.5 Favored 'General case' 0 N--CA 1.471 0.576 0 C-N-CA 124.84 1.256 . . . . 0.0 111.609 172.522 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 4.3 mt-10 -165.07 151.07 9.94 Favored 'General case' 0 N--CA 1.473 0.718 0 C-N-CA 126.239 1.816 . . . . 0.0 111.41 -179.231 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 133.85 93.1 0.48 Allowed Glycine 0 CA--C 1.531 1.06 0 C-N-CA 125.272 1.415 . . . . 0.0 112.276 179.531 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 34.1 m -55.95 145.86 23.91 Favored 'General case' 0 N--CA 1.474 0.754 0 C-N-CA 124.676 1.191 . . . . 0.0 112.649 178.747 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 28.9 p -146.42 158.7 46.73 Favored Pre-proline 0 CA--C 1.547 0.855 0 C-N-CA 125.084 1.354 . . . . 0.0 112.289 -176.938 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -69.98 124.13 10.69 Favored 'Trans proline' 0 CA--C 1.541 0.846 0 C-N-CA 123.141 2.561 . . . . 0.0 111.134 174.675 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 22.5 p -65.54 129.12 38.62 Favored 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 124.0 0.92 . . . . 0.0 111.389 174.998 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -112.32 -68.38 0.53 Allowed Glycine 0 CA--C 1.532 1.114 0 C-N-CA 125.284 1.421 . . . . 0.0 113.27 -175.237 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 10.7 tp . . . . . 0 C--O 1.253 1.263 0 C-N-CA 126.989 2.115 . . . . 0.0 112.202 -178.207 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 14.8 ptpt . . . . . 0 N--CA 1.497 1.901 0 N-CA-C 114.63 1.344 . . . . 0.0 114.63 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 12.4 mmmm 52.05 37.51 21.58 Favored 'General case' 0 N--CA 1.491 1.579 0 C-N-CA 126.284 1.834 . . . . 0.0 114.538 179.491 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.9 p -119.43 -4.17 10.17 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.315 0 C-N-CA 125.885 1.674 . . . . 0.0 113.954 -177.293 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 29.2 m -63.15 103.81 0.52 Allowed 'General case' 0 CA--C 1.54 0.585 0 C-N-CA 126.446 1.899 . . . . 0.0 110.532 177.752 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -71.64 55.78 0.26 Allowed 'General case' 0 CA--C 1.552 1.045 0 C-N-CA 126.516 1.926 . . . . 0.0 113.101 -179.961 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 93.0 m -63.59 157.59 64.79 Favored Pre-proline 0 CA--C 1.549 0.937 0 C-N-CA 126.083 1.753 . . . . 0.0 112.739 178.496 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -64.89 155.02 70.14 Favored 'Trans proline' 0 CA--C 1.537 0.671 0 C-N-CA 123.281 2.654 . . . . 0.0 112.803 -179.871 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 19.5 ptpt -59.75 -25.59 64.99 Favored 'General case' 0 N--CA 1.48 1.074 0 C-N-CA 125.707 1.603 . . . . 0.0 114.497 178.029 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 8.9 tp -57.11 144.47 9.34 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.473 0 C-N-CA 127.089 2.155 . . . . 0.0 113.212 -178.68 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 23.8 tp -119.66 108.24 14.21 Favored 'General case' 0 CA--C 1.535 0.402 0 C-N-CA 126.708 2.003 . . . . 0.0 108.292 -178.283 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 39.5 ttpt -128.95 79.03 75.34 Favored Pre-proline 0 CA--C 1.54 0.576 0 C-N-CA 126.38 1.872 . . . . 0.0 108.511 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -73.68 90.34 0.94 Allowed 'Trans proline' 0 CA--C 1.539 0.742 0 C-N-CA 123.72 2.947 . . . . 0.0 111.909 -171.442 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 1.1 t -83.56 161.26 3.38 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 C-N-CA 124.421 1.089 . . . . 0.0 111.03 -177.56 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 46.3 t -72.44 111.59 7.76 Favored 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 124.342 1.057 . . . . 0.0 109.839 170.448 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -65.51 146.01 49.25 Favored Glycine 0 CA--C 1.532 1.118 0 C-N-CA 123.778 0.704 . . . . 0.0 112.422 177.988 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 82.7 p -61.39 -29.86 70.19 Favored 'General case' 0 N--CA 1.476 0.865 0 N-CA-C 113.935 1.087 . . . . 0.0 113.935 -174.072 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 31.8 t70 -84.98 -8.19 58.84 Favored 'General case' 0 CA--C 1.551 0.993 0 C-N-CA 125.964 1.706 . . . . 0.0 113.894 176.92 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 107.51 1.04 34.96 Favored Glycine 0 CA--C 1.536 1.386 0 C-N-CA 126.504 2.002 . . . . 0.0 114.674 -178.623 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 22.1 mtm180 -90.32 -172.21 3.37 Favored 'General case' 0 N--CA 1.479 0.988 0 C-N-CA 126.355 1.862 . . . . 0.0 112.387 -177.269 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 23.0 m -128.8 135.26 48.91 Favored 'General case' 0 N--CA 1.479 1.01 0 C-N-CA 125.487 1.515 . . . . 0.0 110.492 -178.274 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 81.8 m-85 -135.94 150.39 49.27 Favored 'General case' 0 N--CA 1.474 0.74 0 C-N-CA 125.055 1.342 . . . . 0.0 111.488 -177.573 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.31 -45.08 89.52 Favored 'General case' 0 CA--C 1.543 0.683 0 N-CA-C 113.929 1.085 . . . . 0.0 113.929 -165.242 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 27.0 p30 -157.74 178.62 10.05 Favored 'General case' 0 CA--C 1.549 0.932 0 C-N-CA 125.927 1.691 . . . . 0.0 111.124 170.298 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 89.0 p -60.54 -29.69 69.29 Favored 'General case' 0 N--CA 1.478 0.973 0 N-CA-C 114.015 1.117 . . . . 0.0 114.015 179.052 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 45.4 t -61.66 -57.93 10.05 Favored 'General case' 0 N--CA 1.465 0.312 0 C-N-CA 124.24 1.016 . . . . 0.0 111.704 176.888 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 7.6 tp -59.75 -37.89 73.38 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.819 0 N-CA-C 112.062 0.393 . . . . 0.0 112.062 -179.878 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -57.3 -55.96 28.02 Favored 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 124.199 1.0 . . . . 0.0 111.583 173.967 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 70.4 mtp85 -61.23 -40.63 94.73 Favored 'General case' 0 N--CA 1.475 0.809 0 N-CA-C 113.297 0.851 . . . . 0.0 113.297 178.341 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -65.41 -36.35 83.68 Favored 'General case' 0 CA--C 1.546 0.819 0 N-CA-C 112.57 0.582 . . . . 0.0 112.57 177.132 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 25.9 t-20 -72.37 -47.53 48.68 Favored 'General case' 0 CA--C 1.546 0.815 0 C-N-CA 124.798 1.239 . . . . 0.0 113.003 175.926 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 135.8 29.5 0.36 Allowed Glycine 0 CA--C 1.538 1.53 0 C-N-CA 124.911 1.243 . . . . 0.0 115.469 -178.437 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 34.6 t -127.87 152.32 35.8 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.464 0 C-N-CA 127.416 2.286 . . . . 0.0 108.645 -176.992 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 58.2 m -141.72 160.06 40.95 Favored 'General case' 0 N--CA 1.476 0.838 0 C-N-CA 125.878 1.671 . . . . 0.0 112.302 -179.343 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 16.3 mt -113.17 -12.84 11.64 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.108 0 C-N-CA 125.102 1.361 . . . . 0.0 111.828 -175.067 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -58.21 -26.06 62.38 Favored 'General case' 0 N--CA 1.482 1.157 0 C-N-CA 125.699 1.6 . . . . 0.0 114.255 176.25 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 20.8 m -63.59 -49.74 72.15 Favored 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 125.654 1.582 . . . . 0.0 112.349 179.114 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -156.93 133.68 10.14 Favored 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 125.912 1.685 . . . . 0.0 111.511 175.086 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.82 -64.24 0.48 Allowed Glycine 0 CA--C 1.531 1.081 0 C-N-CA 124.985 1.279 . . . . 0.0 112.504 -178.41 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 95.6 p -150.43 165.71 32.33 Favored 'General case' 0 N--CA 1.473 0.694 0 C-N-CA 125.089 1.356 . . . . 0.0 113.018 178.312 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 13.2 p -149.38 66.17 8.29 Favored Pre-proline 0 CA--C 1.553 1.085 0 C-N-CA 125.495 1.518 . . . . 0.0 112.045 175.626 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -70.83 103.86 1.4 Allowed 'Trans proline' 0 CA--C 1.542 0.911 0 C-N-CA 123.875 3.05 . . . . 0.0 112.387 -177.179 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 16.1 m -61.21 139.16 58.19 Favored 'General case' 0 N--CA 1.477 0.887 0 C-N-CA 125.252 1.421 . . . . 0.0 111.976 178.207 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -166.1 165.21 38.02 Favored Glycine 0 CA--C 1.535 1.321 0 C-N-CA 125.059 1.314 . . . . 0.0 112.75 172.819 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 19.9 tt . . . . . 0 C--O 1.252 1.228 0 C-N-CA 126.571 1.948 . . . . 0.0 112.184 -179.596 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 18.8 ptpt . . . . . 0 N--CA 1.492 1.638 0 N-CA-C 111.6 0.222 . . . . 0.0 111.6 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 4.0 mppt? -114.35 130.71 56.69 Favored 'General case' 0 N--CA 1.478 0.968 0 C-N-CA 125.711 1.604 . . . . 0.0 110.248 172.9 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 33.2 t -136.36 128.21 44.16 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.942 0 C-N-CA 125.922 1.689 . . . . 0.0 109.481 179.153 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 4.7 t -124.99 -4.92 7.45 Favored 'General case' 0 CA--C 1.548 0.87 0 C-N-CA 124.726 1.211 . . . . 0.0 114.111 -178.118 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . 49.34 30.73 3.39 Favored 'General case' 0 CA--C 1.549 0.921 0 C-N-CA 127.018 2.127 . . . . 0.0 115.603 178.421 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 58.0 m -61.8 151.29 79.76 Favored Pre-proline 0 CA--C 1.547 0.828 0 C-N-CA 124.368 1.067 . . . . 0.0 112.379 177.141 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -75.1 -4.13 14.93 Favored 'Trans proline' 0 CA--C 1.543 0.955 0 C-N-CA 124.135 3.223 . . . . 0.0 115.735 -168.769 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 37.8 mmtm 58.86 6.93 0.7 Allowed 'General case' 0 N--CA 1.481 1.093 0 C-N-CA 128.247 2.619 . . . . 0.0 116.299 179.839 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 11.2 tp -51.76 142.47 4.27 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.631 0 C-N-CA 126.698 1.999 . . . . 0.0 112.329 178.436 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 4.5 tt -78.46 89.99 4.45 Favored 'General case' 0 CA--C 1.545 0.772 0 C-N-CA 127.209 2.204 . . . . 0.0 110.907 -177.706 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 3.8 ttmp? -143.83 74.83 16.34 Favored Pre-proline 0 N--CA 1.477 0.897 0 C-N-CA 124.992 1.317 . . . . 0.0 111.843 178.33 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -67.8 91.1 0.36 Allowed 'Trans proline' 0 CA--C 1.54 0.809 0 C-N-CA 124.347 3.364 . . . . 0.0 112.754 -175.995 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 5.7 m -87.27 143.08 12.05 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 C-N-CA 126.32 1.848 . . . . 0.0 112.101 179.652 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 47.3 t -63.7 119.82 10.65 Favored 'General case' 0 CA--C 1.542 0.653 0 C-N-CA 124.125 0.97 . . . . 0.0 110.988 172.475 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -92.23 154.79 22.53 Favored Glycine 0 CA--C 1.533 1.17 0 C-N-CA 124.597 1.094 . . . . 0.0 112.861 177.911 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 7.5 t -61.74 -27.26 68.6 Favored 'General case' 0 N--CA 1.475 0.781 0 N-CA-C 114.463 1.283 . . . . 0.0 114.463 -173.943 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 10.5 t0 -76.52 -10.25 59.25 Favored 'General case' 0 CA--C 1.547 0.841 0 N-CA-C 113.69 0.996 . . . . 0.0 113.69 176.216 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 105.09 -10.11 47.3 Favored Glycine 0 CA--C 1.536 1.354 0 C-N-CA 126.586 2.041 . . . . 0.0 114.048 178.21 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 5.9 ptp85 -82.31 -171.13 3.27 Favored 'General case' 0 N--CA 1.473 0.706 0 C-N-CA 126.067 1.747 . . . . 0.0 112.723 173.365 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 11.5 t -123.34 157.62 32.86 Favored 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 125.595 1.558 . . . . 0.0 111.688 174.307 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -137.51 148.53 46.08 Favored 'General case' 0 N--CA 1.471 0.6 0 C-N-CA 126.263 1.825 . . . . 0.0 110.917 -179.9 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -60.28 -36.86 78.8 Favored 'General case' 0 CA--C 1.543 0.673 0 N-CA-C 114.049 1.129 . . . . 0.0 114.049 -164.277 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 12.4 p30 -156.89 177.54 11.39 Favored 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 126.443 1.897 . . . . 0.0 111.848 168.889 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 27.6 t -58.73 -38.95 79.49 Favored 'General case' 0 N--CA 1.472 0.637 0 O-C-N 121.345 -0.847 . . . . 0.0 113.099 176.486 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 20.0 t -60.14 -55.94 27.66 Favored 'General case' 0 N--CA 1.468 0.47 0 O-C-N 121.493 -0.755 . . . . 0.0 111.806 -179.886 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 7.4 tt -59.4 -38.71 76.42 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.698 0 CA-C-O 118.996 -0.526 . . . . 0.0 112.292 178.437 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -59.61 -53.6 56.12 Favored 'General case' 0 CA--C 1.543 0.684 0 CA-C-N 119.132 0.878 . . . . 0.0 111.904 174.814 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 5.7 mtp-105 -57.41 -44.07 84.27 Favored 'General case' 0 N--CA 1.477 0.884 0 C-N-CA 124.824 1.25 . . . . 0.0 112.3 178.034 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -71.51 -34.0 69.71 Favored 'General case' 0 CA--C 1.544 0.737 0 N-CA-C 113.448 0.907 . . . . 0.0 113.448 178.748 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 28.8 t-20 -66.85 -40.39 87.91 Favored 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 124.277 1.031 . . . . 0.0 112.541 174.056 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 135.29 22.59 0.63 Allowed Glycine 0 CA--C 1.538 1.471 0 C-N-CA 125.051 1.31 . . . . 0.0 115.896 176.366 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 40.4 t -128.26 149.54 33.2 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.525 0 C-N-CA 126.26 1.824 . . . . 0.0 109.866 -174.556 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 58.8 m -121.92 171.81 8.66 Favored 'General case' 0 N--CA 1.475 0.78 0 C-N-CA 126.857 2.063 . . . . 0.0 112.063 -176.702 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -138.82 108.37 4.07 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.447 0 C-N-CA 125.513 1.525 . . . . 0.0 108.92 -176.37 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 47.6 mmtm -58.32 -39.08 78.45 Favored 'General case' 0 N--CA 1.478 0.957 0 C-N-CA 125.808 1.643 . . . . 0.0 112.729 177.719 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER 55.43 24.02 6.33 Favored 'General case' 0 N--CA 1.478 0.951 0 C-N-CA 126.746 2.018 . . . . 0.0 114.928 176.024 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 33.8 tt0 -59.79 -33.81 72.21 Favored 'General case' 0 N--CA 1.474 0.765 0 C-N-CA 125.858 1.663 . . . . 0.0 113.8 -171.98 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -89.37 -2.53 76.66 Favored Glycine 0 CA--C 1.537 1.448 0 C-N-CA 124.975 1.274 . . . . 0.0 115.218 179.233 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 44.4 m -89.05 173.59 8.37 Favored 'General case' 0 N--CA 1.472 0.657 0 C-N-CA 125.161 1.384 . . . . 0.0 113.404 -173.933 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 73.7 m -125.15 70.92 62.45 Favored Pre-proline 0 CA--C 1.549 0.904 0 C-N-CA 126.103 1.761 . . . . 0.0 111.225 174.676 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 76.6 Cg_endo -70.83 157.79 57.34 Favored 'Trans proline' 0 CA--C 1.541 0.851 0 C-N-CA 123.077 2.518 . . . . 0.0 112.465 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 6.3 t -108.2 -12.58 15.07 Favored 'General case' 0 N--CA 1.481 1.114 0 C-N-CA 125.051 1.34 . . . . 0.0 113.724 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -110.58 -59.84 0.49 Allowed Glycine 0 CA--C 1.535 1.286 0 C-N-CA 125.585 1.564 . . . . 0.0 114.349 -176.557 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 19.5 tt . . . . . 0 C--O 1.253 1.264 0 C-N-CA 126.608 1.963 . . . . 0.0 112.619 -173.433 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.723 0 N-CA-C 111.781 0.289 . . . . 0.0 111.781 . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 57.0 mtpt -126.52 171.73 10.82 Favored 'General case' 0 N--CA 1.482 1.17 0 C-N-CA 126.47 1.908 . . . . 0.0 111.12 173.683 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 49.2 t -142.85 141.49 27.05 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.17 0 C-N-CA 126.725 2.01 . . . . 0.0 109.258 176.121 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 10.9 t -67.61 123.89 21.72 Favored 'General case' 0 CA--C 1.544 0.746 0 C-N-CA 123.324 0.65 . . . . 0.0 111.83 176.212 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -74.04 32.36 0.08 Allowed 'General case' 0 CA--C 1.554 1.128 0 C-N-CA 126.588 1.955 . . . . 0.0 115.668 -172.654 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 62.8 m -64.25 152.65 87.9 Favored Pre-proline 0 CA--C 1.549 0.926 0 C-N-CA 124.907 1.283 . . . . 0.0 113.67 179.275 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 89.1 Cg_endo -72.6 153.86 54.71 Favored 'Trans proline' 0 C--N 1.352 0.742 0 C-N-CA 123.359 2.706 . . . . 0.0 112.326 176.581 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 57.3 mtmt -76.38 -1.93 29.33 Favored 'General case' 0 N--CA 1.48 1.053 0 C-N-CA 125.708 1.603 . . . . 0.0 114.685 -179.361 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 46.9 mm -51.18 120.59 1.34 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.715 0 C-N-CA 126.145 1.778 . . . . 0.0 111.181 174.716 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 54.9 tp -84.71 102.27 12.85 Favored 'General case' 0 CA--C 1.539 0.546 0 C-N-CA 127.401 2.28 . . . . 0.0 109.614 177.935 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 20.8 tptp -147.07 91.94 5.04 Favored Pre-proline 0 N--CA 1.471 0.582 0 C-N-CA 124.098 0.959 . . . . 0.0 110.753 166.432 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -64.47 137.89 57.35 Favored 'Trans proline' 0 N--CA 1.456 -0.689 0 C-N-CA 121.191 1.261 . . . . 0.0 111.024 172.266 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 8.7 m -140.79 159.09 23.98 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.361 0 C-N-CA 127.373 2.269 . . . . 0.0 110.845 -179.346 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 37.6 t -72.78 149.52 43.58 Favored 'General case' 0 CA--C 1.545 0.763 0 C-N-CA 123.822 0.849 . . . . 0.0 111.785 171.973 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -123.76 156.21 17.93 Favored Glycine 0 CA--C 1.535 1.325 0 C-N-CA 125.859 1.695 . . . . 0.0 112.544 169.974 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 14.6 t -51.53 -40.64 60.05 Favored 'General case' 0 N--CA 1.478 0.966 0 C-N-CA 126.059 1.744 . . . . 0.0 115.431 -166.119 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 13.9 m-20 -71.1 -5.86 34.79 Favored 'General case' 0 CA--C 1.548 0.879 0 N-CA-C 114.863 1.431 . . . . 0.0 114.863 -179.193 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 86.83 61.32 1.61 Allowed Glycine 0 CA--C 1.527 0.805 0 C-N-CA 125.107 1.337 . . . . 0.0 110.592 -173.387 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 89.5 mmt-85 -142.18 168.29 20.09 Favored 'General case' 0 N--CA 1.472 0.671 0 C-N-CA 127.36 2.264 . . . . 0.0 111.103 -172.806 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 6.6 p -132.14 145.23 51.24 Favored 'General case' 0 C--O 1.235 0.322 0 C-N-CA 126.301 1.84 . . . . 0.0 111.089 172.455 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 92.8 m-85 -141.63 157.04 45.59 Favored 'General case' 0 N--CA 1.471 0.62 0 C-N-CA 125.604 1.561 . . . . 0.0 111.454 -179.461 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.69 -32.89 74.77 Favored 'General case' 0 CA--C 1.545 0.788 0 N-CA-C 114.451 1.278 . . . . 0.0 114.451 -165.222 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 60.5 t30 -149.37 168.13 24.24 Favored 'General case' 0 CA--C 1.544 0.747 0 C-N-CA 125.558 1.543 . . . . 0.0 111.17 171.26 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 34.6 p -57.19 -42.63 81.56 Favored 'General case' 0 N--CA 1.472 0.653 0 C-N-CA 124.769 1.228 . . . . 0.0 113.106 175.216 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 38.1 t -56.51 -55.76 29.68 Favored 'General case' 0 CA--C 1.533 0.292 0 C-N-CA 124.376 1.07 . . . . 0.0 112.11 177.507 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.8 tt -62.21 -35.25 68.08 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.672 0 CA-C-O 118.684 -0.674 . . . . 0.0 112.407 -177.679 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -57.82 -53.43 58.27 Favored 'General case' 0 CA--C 1.54 0.563 0 CA-C-N 119.288 0.949 . . . . 0.0 111.443 173.516 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -56.38 -49.78 73.47 Favored 'General case' 0 N--CA 1.474 0.768 0 C-N-CA 125.042 1.337 . . . . 0.0 111.282 176.124 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -63.7 -39.84 95.29 Favored 'General case' 0 CA--C 1.541 0.622 0 C-N-CA 123.786 0.834 . . . . 0.0 113.089 -177.68 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 88.8 m-20 -66.27 -33.44 75.74 Favored 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 124.86 1.264 . . . . 0.0 112.79 174.458 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 130.17 17.21 1.64 Allowed Glycine 0 CA--C 1.536 1.369 0 N-CA-C 116.389 1.316 . . . . 0.0 116.389 171.618 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 7.4 t -118.63 132.97 66.96 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.666 0 CA-C-N 119.629 1.714 . . . . 0.0 110.608 -178.229 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 38.5 m -78.54 164.69 24.48 Favored 'General case' 0 C--N 1.322 -0.597 0 C-N-CA 126.826 2.05 . . . . 0.0 112.714 -179.583 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -134.36 98.8 2.51 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.525 0 C-N-CA 125.873 1.669 . . . . 0.0 109.1 -178.959 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -87.93 -13.74 41.06 Favored 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 125.849 1.66 . . . . 0.0 113.405 -179.723 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 22.7 t -84.88 119.59 25.51 Favored 'General case' 0 CA--C 1.532 0.273 0 C-N-CA 125.954 1.701 . . . . 0.0 110.935 173.608 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 8.2 tp10 -63.43 -15.08 56.6 Favored 'General case' 0 CA--C 1.551 1.015 0 C-N-CA 125.478 1.511 . . . . 0.0 113.169 169.844 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -78.22 58.43 4.01 Favored Glycine 0 CA--C 1.536 1.366 0 C-N-CA 126.135 1.826 . . . . 0.0 113.79 178.434 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 71.6 p -140.2 168.46 19.75 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 126.299 1.84 . . . . 0.0 112.491 179.681 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 1.9 m -65.1 159.16 67.28 Favored Pre-proline 0 CA--C 1.549 0.909 0 C-N-CA 123.575 0.75 . . . . 0.0 112.792 174.036 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -68.8 164.88 31.68 Favored 'Trans proline' 0 CA--C 1.541 0.836 0 C-N-CA 123.182 2.588 . . . . 0.0 112.462 175.945 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 20.7 m -137.49 143.82 41.9 Favored 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 125.521 1.528 . . . . 0.0 110.651 -175.691 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -81.75 -171.4 45.71 Favored Glycine 0 CA--C 1.538 1.496 0 C-N-CA 125.138 1.351 . . . . 0.0 114.044 178.179 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 4.6 mp . . . . . 0 C--O 1.252 1.227 0 C-N-CA 126.728 2.011 . . . . 0.0 110.191 179.068 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 68.4 mttm . . . . . 0 N--CA 1.492 1.654 0 N-CA-C 110.537 -0.171 . . . . 0.0 110.537 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 37.7 ttpt -72.38 94.74 1.66 Allowed 'General case' 0 N--CA 1.48 1.037 0 C-N-CA 125.224 1.41 . . . . 0.0 111.31 175.776 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 13.8 p -143.41 147.1 20.59 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.028 0 C-N-CA 125.043 1.337 . . . . 0.0 112.304 179.737 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 3.2 m -66.8 113.25 4.74 Favored 'General case' 0 CA--C 1.548 0.884 0 C-N-CA 125.515 1.526 . . . . 0.0 110.377 173.77 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -75.89 58.45 1.15 Allowed 'General case' 0 CA--C 1.554 1.1 0 C-N-CA 124.798 1.239 . . . . 0.0 113.24 -179.519 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 76.3 m -69.75 159.32 84.39 Favored Pre-proline 0 CA--C 1.553 1.082 0 C-N-CA 126.048 1.739 . . . . 0.0 113.746 -177.413 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -71.06 165.44 32.39 Favored 'Trans proline' 0 CA--C 1.542 0.877 0 C-N-CA 123.497 2.798 . . . . 0.0 113.407 179.141 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 7.9 ptpp? -68.35 -27.56 66.36 Favored 'General case' 0 N--CA 1.482 1.161 0 C-N-CA 125.072 1.349 . . . . 0.0 114.613 175.501 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 34.9 mm -60.08 161.88 1.24 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.83 0 C-N-CA 128.162 2.585 . . . . 0.0 111.294 176.295 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 20.1 tp -141.98 101.89 4.03 Favored 'General case' 0 CA--C 1.537 0.472 0 C-N-CA 126.257 1.823 . . . . 0.0 109.879 -170.646 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -115.52 84.92 12.77 Favored Pre-proline 0 N--CA 1.474 0.726 0 C-N-CA 126.096 1.759 . . . . 0.0 109.42 175.399 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 93.7 Cg_endo -74.52 81.14 2.14 Favored 'Trans proline' 0 CA--C 1.541 0.848 0 C-N-CA 124.043 3.162 . . . . 0.0 111.717 -176.616 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 9.0 m -85.84 164.24 2.48 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 C-N-CA 127.195 2.198 . . . . 0.0 113.003 -175.938 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 30.1 p -68.29 173.97 4.37 Favored 'General case' 0 CA--C 1.549 0.933 0 C-N-CA 124.231 1.012 . . . . 0.0 112.294 159.289 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -148.48 155.98 26.66 Favored Glycine 0 CA--C 1.532 1.132 0 C-N-CA 125.691 1.615 . . . . 0.0 111.392 173.712 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 19.0 t -57.09 -35.55 69.54 Favored 'General case' 0 N--CA 1.476 0.872 0 N-CA-C 115.144 1.535 . . . . 0.0 115.144 -163.138 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 31.5 t70 -71.86 -9.1 57.84 Favored 'General case' 0 CA--C 1.551 1.008 0 N-CA-C 114.415 1.265 . . . . 0.0 114.415 179.305 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 106.84 12.58 23.94 Favored Glycine 0 CA--C 1.535 1.286 0 C-N-CA 126.063 1.792 . . . . 0.0 114.073 179.35 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 31.2 mtm180 -120.99 134.46 55.3 Favored 'General case' 0 N--CA 1.476 0.844 0 C-N-CA 126.225 1.81 . . . . 0.0 111.181 -171.542 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 18.0 p -75.23 151.55 38.41 Favored 'General case' 0 N--CA 1.471 0.597 0 C-N-CA 124.622 1.169 . . . . 0.0 112.614 177.927 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 76.5 m-85 -139.69 149.03 43.19 Favored 'General case' 0 N--CA 1.471 0.592 0 C-N-CA 125.434 1.494 . . . . 0.0 112.93 -179.87 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -69.74 -33.72 72.84 Favored 'General case' 0 CA--C 1.545 0.76 0 N-CA-C 113.902 1.075 . . . . 0.0 113.902 -165.895 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' ASN . . . . . 0.463 ' H ' HG22 ' A' ' 26' ' ' ILE . 14.7 m-20 -145.87 170.85 15.76 Favored 'General case' 0 CA--C 1.543 0.703 0 C-N-CA 125.813 1.645 . . . . 0.0 110.946 166.116 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 40.7 p -59.46 -35.55 74.27 Favored 'General case' 0 N--CA 1.473 0.722 0 O-C-N 121.368 -0.832 . . . . 0.0 112.45 165.824 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 43.5 t -52.87 -63.33 1.18 Allowed 'General case' 0 CA--C 1.533 0.316 0 C-N-CA 126.01 1.724 . . . . 0.0 112.369 174.064 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.463 HG22 ' H ' ' A' ' 23' ' ' ASN . 9.1 tp -58.38 -37.3 62.85 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.788 0 N-CA-C 112.592 0.59 . . . . 0.0 112.592 -178.583 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -59.94 -54.59 44.32 Favored 'General case' 0 CA--C 1.544 0.716 0 CA-C-N 118.697 0.68 . . . . 0.0 111.836 173.961 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 25.4 mmm180 -61.57 -39.98 93.09 Favored 'General case' 0 N--CA 1.478 0.975 0 C-N-CA 124.707 1.203 . . . . 0.0 113.207 177.933 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 9.2 t -62.15 -43.92 97.76 Favored 'General case' 0 CA--C 1.544 0.729 0 C-N-CA 124.832 1.253 . . . . 0.0 111.644 175.128 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 28.7 t-20 -68.79 -46.62 68.21 Favored 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 124.837 1.255 . . . . 0.0 113.179 178.263 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 136.11 26.42 0.45 Allowed Glycine 0 CA--C 1.539 1.534 0 C-N-CA 124.787 1.184 . . . . 0.0 115.964 -179.528 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 40.1 t -124.29 156.12 31.9 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.512 0 C-N-CA 127.11 2.164 . . . . 0.0 108.607 -179.658 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 6.2 t -134.21 177.8 7.47 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 126.25 1.82 . . . . 0.0 112.216 179.143 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -141.61 107.13 1.74 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.299 0 C-N-CA 126.438 1.895 . . . . 0.0 108.869 -170.52 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 2.5 tppp? -61.67 -27.69 68.86 Favored 'General case' 0 N--CA 1.475 0.821 0 C-N-CA 124.617 1.167 . . . . 0.0 112.868 175.033 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 8.2 t -62.33 -47.12 85.66 Favored 'General case' 0 N--CA 1.472 0.644 0 C-N-CA 125.77 1.628 . . . . 0.0 113.28 179.217 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -153.48 131.15 11.52 Favored 'General case' 0 CA--C 1.542 0.661 0 C-N-CA 124.94 1.296 . . . . 0.0 112.196 179.059 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 164.57 57.44 0.02 OUTLIER Glycine 0 CA--C 1.533 1.157 0 C-N-CA 123.787 0.708 . . . . 0.0 113.647 -177.139 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 51.6 p -67.48 160.54 27.35 Favored 'General case' 0 N--CA 1.473 0.685 0 C-N-CA 124.722 1.209 . . . . 0.0 113.362 176.787 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 74.6 m -71.45 156.13 91.87 Favored Pre-proline 0 CA--C 1.549 0.94 0 C-N-CA 124.273 1.029 . . . . 0.0 112.483 176.716 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 96.2 Cg_endo -71.8 164.3 36.12 Favored 'Trans proline' 0 CA--C 1.54 0.78 0 C-N-CA 123.147 2.564 . . . . 0.0 112.357 174.011 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 38.7 p -77.22 -15.7 59.37 Favored 'General case' 0 N--CA 1.48 1.057 0 C-N-CA 124.991 1.316 . . . . 0.0 113.772 174.755 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -113.37 -157.72 12.7 Favored Glycine 0 CA--C 1.537 1.427 0 C-N-CA 127.092 2.282 . . . . 0.0 113.485 -178.76 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 4.1 mp . . . . . 0 C--O 1.253 1.265 0 C-N-CA 126.589 1.956 . . . . 0.0 110.318 178.622 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 26.1 mmmt . . . . . 0 N--CA 1.492 1.643 0 CA-C-O 120.462 0.173 . . . . 0.0 111.118 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 60.4 mttm -62.29 141.81 58.07 Favored 'General case' 0 N--CA 1.48 1.031 0 C-N-CA 125.522 1.529 . . . . 0.0 111.452 172.792 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 40.1 t -140.77 129.84 25.41 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.062 0 C-N-CA 125.789 1.635 . . . . 0.0 109.775 175.972 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 31.2 m -68.25 126.54 29.87 Favored 'General case' 0 CA--C 1.542 0.665 0 C-N-CA 124.632 1.173 . . . . 0.0 110.968 175.384 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -73.27 31.78 0.07 Allowed 'General case' 0 CA--C 1.555 1.163 0 C-N-CA 125.629 1.572 . . . . 0.0 114.37 177.777 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 60.1 m -63.32 160.76 38.6 Favored Pre-proline 0 CA--C 1.549 0.924 0 C-N-CA 126.335 1.854 . . . . 0.0 113.237 177.439 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -67.61 169.77 15.18 Favored 'Trans proline' 0 CA--C 1.541 0.872 0 C-N-CA 123.254 2.636 . . . . 0.0 112.156 170.899 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 10.1 tppt? -107.89 1.98 23.1 Favored 'General case' 0 N--CA 1.482 1.145 0 C-N-CA 125.968 1.707 . . . . 0.0 112.946 172.186 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 83.2 mt -52.24 131.76 13.88 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.762 0 C-N-CA 126.632 1.973 . . . . 0.0 110.821 179.426 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 5.2 tt -69.74 97.85 1.13 Allowed 'General case' 0 CA--C 1.542 0.652 0 C-N-CA 127.399 2.28 . . . . 0.0 111.497 -174.823 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 86.8 tttt -140.6 74.45 27.86 Favored Pre-proline 0 N--CA 1.476 0.828 0 C-N-CA 125.719 1.608 . . . . 0.0 111.101 -177.882 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -66.14 101.33 0.49 Allowed 'Trans proline' 0 CA--C 1.54 0.818 0 C-N-CA 123.956 3.104 . . . . 0.0 112.343 -178.605 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 15.9 m -127.21 159.52 37.33 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.479 0 C-N-CA 126.001 1.72 . . . . 0.0 112.859 -176.98 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 24.4 p -88.4 123.29 32.81 Favored 'General case' 0 CA--C 1.539 0.529 0 C-N-CA 124.358 1.063 . . . . 0.0 111.889 176.572 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -79.17 55.68 4.34 Favored Glycine 0 CA--C 1.53 0.977 0 C-N-CA 124.665 1.126 . . . . 0.0 112.117 172.673 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 3.9 t 54.81 -11.68 0.01 OUTLIER 'General case' 0 CA--C 1.55 0.979 0 C-N-CA 129.385 3.074 . . . . 0.0 117.268 -175.009 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 63.5 m-20 -95.11 -17.8 21.52 Favored 'General case' 0 N--CA 1.475 0.775 0 C-N-CA 126.041 1.736 . . . . 0.0 114.545 -179.148 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 105.66 2.99 40.36 Favored Glycine 0 CA--C 1.538 1.505 0 C-N-CA 125.498 1.523 . . . . 0.0 114.84 177.713 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 2.1 mmp_? -67.37 -177.98 0.79 Allowed 'General case' 0 N--CA 1.476 0.841 0 C-N-CA 128.541 2.736 . . . . 0.0 112.195 172.501 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 24.1 m -128.58 85.72 2.37 Favored 'General case' 0 N--CA 1.476 0.841 0 C-N-CA 124.92 1.288 . . . . 0.0 110.157 176.318 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 26.8 m-85 -76.12 154.17 35.71 Favored 'General case' 0 N--CA 1.47 0.541 0 C-N-CA 123.94 0.896 . . . . 0.0 112.252 173.389 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.15 -37.63 88.15 Favored 'General case' 0 CA--C 1.542 0.643 0 N-CA-C 113.288 0.847 . . . . 0.0 113.288 -170.447 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 14.3 p30 -152.56 179.42 8.61 Favored 'General case' 0 CA--C 1.545 0.765 0 C-N-CA 126.172 1.789 . . . . 0.0 111.968 172.283 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 9.1 p -70.67 -32.03 69.15 Favored 'General case' 0 N--CA 1.473 0.7 0 O-C-N 121.018 -1.051 . . . . 0.0 113.788 176.369 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 34.8 t -62.42 -49.99 73.27 Favored 'General case' 0 N--CA 1.469 0.484 0 C-N-CA 124.31 1.044 . . . . 0.0 112.269 178.627 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 8.5 tt -58.82 -39.77 78.1 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 N-CA-C 112.194 0.442 . . . . 0.0 112.194 179.338 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -64.88 -44.62 89.05 Favored 'General case' 0 CA--C 1.543 0.712 0 C-N-CA 124.285 1.034 . . . . 0.0 112.599 175.051 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 25.1 mmt180 -55.67 -52.5 63.64 Favored 'General case' 0 N--CA 1.478 0.941 0 C-N-CA 124.378 1.071 . . . . 0.0 111.734 170.814 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 4.9 t -63.08 -37.36 86.89 Favored 'General case' 0 CA--C 1.544 0.714 0 C-N-CA 124.13 0.972 . . . . 0.0 113.023 -178.59 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 28.4 t30 -62.66 -30.55 71.46 Favored 'General case' 0 CA--C 1.545 0.762 0 C-N-CA 124.43 1.092 . . . . 0.0 113.351 176.888 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 135.21 9.97 1.57 Allowed Glycine 0 CA--C 1.536 1.373 0 N-CA-C 116.13 1.212 . . . . 0.0 116.13 175.471 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.612 HG12 ' H ' ' A' ' 33' ' ' SER . 0.5 OUTLIER -107.51 -170.16 0.34 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.653 0 CA-C-N 119.351 1.576 . . . . 0.0 110.689 -177.242 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 33' ' ' SER . . . . . 0.612 ' H ' HG12 ' A' ' 32' ' ' VAL . 27.7 m -147.91 166.96 26.07 Favored 'General case' 0 N--CA 1.471 0.599 0 C-N-CA 128.258 2.623 . . . . 0.0 110.529 174.863 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 1.1 mt -141.31 105.36 1.54 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.622 0 C-N-CA 125.069 1.347 . . . . 0.0 108.765 172.43 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -95.92 -14.66 22.93 Favored 'General case' 0 N--CA 1.481 1.081 0 C-N-CA 125.552 1.541 . . . . 0.0 113.35 176.794 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 1.5 t -78.49 31.28 0.19 Allowed 'General case' 0 N--CA 1.478 0.971 0 C-N-CA 127.382 2.273 . . . . 0.0 114.215 -176.854 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 3.3 mm-40 -61.05 159.99 10.76 Favored 'General case' 0 CA--C 1.543 0.704 0 C-N-CA 125.171 1.388 . . . . 0.0 113.635 176.863 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -75.83 -15.78 81.1 Favored Glycine 0 CA--C 1.538 1.472 0 C-N-CA 124.446 1.022 . . . . 0.0 115.077 -175.824 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 88.4 p -154.98 -178.6 7.35 Favored 'General case' 0 N--CA 1.473 0.7 0 C-N-CA 126.893 2.077 . . . . 0.0 111.061 174.79 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 73.5 m 48.37 69.66 2.56 Favored Pre-proline 0 CA--C 1.553 1.09 0 C-N-CA 126.335 1.854 . . . . 0.0 114.197 178.359 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -67.96 164.32 32.25 Favored 'Trans proline' 0 CA--C 1.54 0.811 0 C-N-CA 123.351 2.701 . . . . 0.0 112.977 -179.113 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 6.4 t -129.51 2.38 5.04 Favored 'General case' 0 N--CA 1.481 1.111 0 C-N-CA 125.189 1.396 . . . . 0.0 114.064 -172.567 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 133.62 -77.86 0.37 Allowed Glycine 0 CA--C 1.532 1.152 0 C-N-CA 125.923 1.725 . . . . 0.0 112.351 175.282 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 43.5 pt . . . . . 0 C--O 1.251 1.134 0 C-N-CA 127.102 2.161 . . . . 0.0 112.675 178.61 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 12.2 tmtt? . . . . . 0 N--CA 1.49 1.539 0 N-CA-C 110.151 -0.314 . . . . 0.0 110.151 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -141.62 162.6 35.09 Favored 'General case' 0 N--CA 1.483 1.21 0 C-N-CA 126.847 2.059 . . . . 0.0 111.138 176.978 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 41.1 t -140.27 146.73 24.2 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.099 0 C-N-CA 125.962 1.705 . . . . 0.0 110.473 -179.607 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 80.9 m -60.67 117.54 5.48 Favored 'General case' 0 CA--C 1.544 0.749 0 C-N-CA 125.559 1.544 . . . . 0.0 111.809 172.974 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -73.49 37.52 0.09 Allowed 'General case' 0 CA--C 1.556 1.175 0 C-N-CA 126.462 1.905 . . . . 0.0 114.841 -177.161 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 98.8 m -63.92 156.67 72.49 Favored Pre-proline 0 CA--C 1.55 0.956 0 C-N-CA 125.726 1.61 . . . . 0.0 113.742 -179.555 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -71.78 159.42 50.75 Favored 'Trans proline' 0 CA--C 1.54 0.811 0 C-N-CA 123.411 2.741 . . . . 0.0 113.2 -178.677 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 34.5 ttmt -86.37 -11.11 52.95 Favored 'General case' 0 N--CA 1.48 1.066 0 C-N-CA 125.786 1.634 . . . . 0.0 113.751 177.501 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 80.3 mt -55.85 146.3 5.27 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.883 0 C-N-CA 126.662 1.985 . . . . 0.0 110.444 178.862 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 11.1 mp -89.68 113.27 24.74 Favored 'General case' 0 CA--C 1.539 0.548 0 C-N-CA 124.229 1.012 . . . . 0.0 110.809 175.161 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 33.2 ttmt -135.02 75.3 61.12 Favored Pre-proline 0 CA--C 1.545 0.77 0 C-N-CA 124.874 1.27 . . . . 0.0 110.277 167.734 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 62.5 Cg_endo -68.88 86.15 0.47 Allowed 'Trans proline' 0 CA--C 1.541 0.85 0 C-N-CA 123.978 3.119 . . . . 0.0 112.535 -177.68 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 10.5 m -85.63 154.94 3.46 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.534 0 C-N-CA 126.527 1.931 . . . . 0.0 112.785 -178.391 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 46.0 t -78.2 108.49 11.55 Favored 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 124.861 1.264 . . . . 0.0 110.74 168.429 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -76.57 153.53 42.66 Favored Glycine 0 CA--C 1.531 1.079 0 C-N-CA 124.603 1.097 . . . . 0.0 113.357 174.697 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 13.5 t -58.72 -33.96 70.79 Favored 'General case' 0 N--CA 1.476 0.833 0 C-N-CA 124.595 1.158 . . . . 0.0 114.123 -172.096 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 10.4 m-20 -73.73 -3.56 29.16 Favored 'General case' 0 CA--C 1.549 0.923 0 N-CA-C 114.667 1.358 . . . . 0.0 114.667 176.359 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 95.79 18.01 33.71 Favored Glycine 0 CA--C 1.533 1.21 0 C-N-CA 125.318 1.437 . . . . 0.0 114.11 178.205 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 29.5 mtp85 -121.52 154.49 36.58 Favored 'General case' 0 N--CA 1.476 0.857 0 C-N-CA 126.164 1.786 . . . . 0.0 111.308 -173.79 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 13.5 p -87.91 146.48 25.54 Favored 'General case' 0 N--CA 1.469 0.513 0 C-N-CA 124.173 0.989 . . . . 0.0 112.185 177.162 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 97.9 m-85 -138.74 147.7 43.0 Favored 'General case' 0 N--CA 1.472 0.668 0 C-N-CA 125.327 1.451 . . . . 0.0 111.381 177.562 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.54 -32.76 74.55 Favored 'General case' 0 CA--C 1.544 0.734 0 N-CA-C 114.118 1.155 . . . . 0.0 114.118 -165.954 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 67.2 m-80 -146.2 172.84 12.85 Favored 'General case' 0 CA--C 1.543 0.688 0 C-N-CA 127.399 2.28 . . . . 0.0 110.467 168.184 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 27.7 p -63.87 -33.27 75.31 Favored 'General case' 0 N--CA 1.472 0.629 0 O-C-N 121.136 -0.977 . . . . 0.0 112.968 165.098 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 33.6 t -57.46 -55.23 37.51 Favored 'General case' 0 N--CA 1.467 0.411 0 C-N-CA 124.404 1.082 . . . . 0.0 112.623 176.029 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 6.5 tp -62.84 -31.68 53.2 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.742 0 N-CA-C 112.325 0.491 . . . . 0.0 112.325 -179.112 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -59.39 -48.8 80.27 Favored 'General case' 0 CA--C 1.542 0.658 0 O-C-N 121.482 -0.761 . . . . 0.0 111.35 170.907 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 24.0 mtp-105 -62.3 -33.61 75.0 Favored 'General case' 0 N--CA 1.479 0.992 0 C-N-CA 123.619 0.768 . . . . 0.0 113.031 175.492 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 46.9 t -62.88 -48.47 78.83 Favored 'General case' 0 CA--C 1.542 0.635 0 C-N-CA 124.302 1.041 . . . . 0.0 111.52 171.373 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 19.5 m120 -66.79 -31.6 72.35 Favored 'General case' 0 CA--C 1.546 0.822 0 C-N-CA 124.583 1.153 . . . . 0.0 113.526 178.515 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 116.86 28.81 2.36 Favored Glycine 0 CA--C 1.539 1.537 0 C-N-CA 125.602 1.572 . . . . 0.0 115.01 178.782 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 18.1 t -129.32 153.99 39.48 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.5 0 C-N-CA 127.528 2.331 . . . . 0.0 108.809 -176.335 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 68.6 m -119.73 156.07 31.25 Favored 'General case' 0 N--CA 1.474 0.761 0 C-N-CA 125.858 1.663 . . . . 0.0 112.445 179.285 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 22.0 mm -126.21 -14.02 4.16 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.114 0 C-N-CA 126.111 1.765 . . . . 0.0 112.373 -171.864 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 63.4 pttt 46.66 21.48 0.14 Allowed 'General case' 0 N--CA 1.487 1.406 0 C-N-CA 129.872 3.269 . . . . 0.0 117.96 175.78 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 19.6 t -57.53 -41.0 80.02 Favored 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 127.437 2.295 . . . . 0.0 113.683 -174.454 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 27.3 tt0 -146.18 159.91 42.67 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 124.898 1.279 . . . . 0.0 111.592 175.61 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -84.5 60.59 4.81 Favored Glycine 0 CA--C 1.532 1.15 0 C-N-CA 125.721 1.629 . . . . 0.0 113.298 -178.781 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 8.6 t -63.84 158.47 21.92 Favored 'General case' 0 N--CA 1.474 0.74 0 C-N-CA 124.325 1.05 . . . . 0.0 112.835 177.878 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 13.8 p -141.84 69.82 24.45 Favored Pre-proline 0 CA--C 1.551 1.004 0 C-N-CA 125.588 1.555 . . . . 0.0 112.235 -178.324 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_endo -70.16 162.38 42.48 Favored 'Trans proline' 0 CA--C 1.541 0.863 0 C-N-CA 123.163 2.575 . . . . 0.0 112.5 177.495 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 26.8 p -79.45 171.14 15.57 Favored 'General case' 0 N--CA 1.477 0.915 0 C-N-CA 125.215 1.406 . . . . 0.0 112.359 172.159 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 77.9 18.59 76.76 Favored Glycine 0 CA--C 1.539 1.58 0 N-CA-C 115.313 0.885 . . . . 0.0 115.313 174.573 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 20.6 tt . . . . . 0 C--O 1.255 1.345 0 C-N-CA 127.356 2.262 . . . . 0.0 112.696 -176.929 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 9.8 mtpm? . . . . . 0 N--CA 1.491 1.619 0 N-CA-C 110.307 -0.257 . . . . 0.0 110.307 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -76.65 91.17 3.41 Favored 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 125.612 1.565 . . . . 0.0 111.052 179.443 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 11.7 p -140.73 146.79 23.62 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.027 0 C-N-CA 124.959 1.304 . . . . 0.0 112.399 -177.685 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 32.9 m -94.64 91.68 6.67 Favored 'General case' 0 CA--C 1.542 0.647 0 C-N-CA 125.737 1.615 . . . . 0.0 110.81 179.712 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -75.06 54.34 0.67 Allowed 'General case' 0 CA--C 1.554 1.119 0 C-N-CA 125.525 1.53 . . . . 0.0 113.021 178.938 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 64.7 m -65.22 152.19 92.23 Favored Pre-proline 0 CA--C 1.552 1.023 0 C-N-CA 125.437 1.495 . . . . 0.0 112.893 -177.901 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -72.03 151.99 56.56 Favored 'Trans proline' 0 CA--C 1.539 0.763 0 C-N-CA 122.957 2.438 . . . . 0.0 112.57 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 32.3 mmtp -72.49 -21.67 61.17 Favored 'General case' 0 N--CA 1.479 1.014 0 C-N-CA 125.232 1.413 . . . . 0.0 113.605 174.664 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.473 ' H ' HD12 ' A' ' 9' ' ' ILE . 4.9 mp -67.8 127.26 29.17 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.548 0 C-N-CA 125.508 1.523 . . . . 0.0 110.198 178.879 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 2.0 pt? -68.55 131.41 45.19 Favored 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 124.912 1.285 . . . . 0.0 111.6 173.72 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 37.0 ttmt -152.08 64.86 5.91 Favored Pre-proline 0 N--CA 1.474 0.745 0 C-N-CA 124.323 1.049 . . . . 0.0 111.114 175.181 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -66.85 153.04 79.29 Favored 'Trans proline' 0 CA--C 1.536 0.619 0 C-N-CA 122.552 2.168 . . . . 0.0 112.199 -176.049 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 18.4 t -134.84 -68.91 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.059 0 C-N-CA 123.695 0.798 . . . . 0.0 112.071 -173.818 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 31.1 p -143.18 -173.9 4.05 Favored 'General case' 0 CA--C 1.544 0.72 0 C-N-CA 126.355 1.862 . . . . 0.0 112.156 -173.812 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -163.75 87.57 0.1 Allowed Glycine 0 CA--C 1.528 0.882 0 C-N-CA 124.098 0.856 . . . . 0.0 114.126 -175.543 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 11.4 t -55.7 -38.17 69.35 Favored 'General case' 0 N--CA 1.478 0.969 0 C-N-CA 124.132 0.973 . . . . 0.0 113.261 176.781 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 54.6 m-20 -78.39 -5.69 53.04 Favored 'General case' 0 N--CA 1.478 0.942 0 C-N-CA 125.141 1.376 . . . . 0.0 113.953 174.541 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 93.86 9.93 59.29 Favored Glycine 0 CA--C 1.537 1.467 0 C-N-CA 125.532 1.539 . . . . 0.0 114.321 -174.018 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 13.5 ptp180 -122.19 135.86 54.83 Favored 'General case' 0 N--CA 1.477 0.898 0 C-N-CA 126.738 2.015 . . . . 0.0 112.21 -177.03 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.1 p -66.64 110.84 3.36 Favored 'General case' 0 N--CA 1.474 0.728 0 C-N-CA 125.347 1.459 . . . . 0.0 111.783 175.657 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 44.6 m-85 -76.86 154.37 33.87 Favored 'General case' 0 N--CA 1.472 0.636 0 O-C-N 121.628 -0.67 . . . . 0.0 111.829 174.794 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.96 -43.83 82.1 Favored 'General case' 0 CA--C 1.542 0.662 0 N-CA-C 113.238 0.829 . . . . 0.0 113.238 -169.416 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 21.2 p30 -160.98 178.68 9.13 Favored 'General case' 0 CA--C 1.548 0.866 0 C-N-CA 126.755 2.022 . . . . 0.0 111.569 173.487 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 16.2 m -63.36 -27.62 69.44 Favored 'General case' 0 N--CA 1.475 0.815 0 O-C-N 120.625 -1.297 . . . . 0.0 113.913 179.833 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 38.6 t -63.1 -56.41 17.07 Favored 'General case' 0 CA--C 1.532 0.257 0 C-N-CA 124.708 1.203 . . . . 0.0 111.555 177.166 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 8.3 tp -59.17 -35.24 56.54 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.87 0 N-CA-C 112.54 0.571 . . . . 0.0 112.54 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -59.3 -57.83 11.31 Favored 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 123.937 0.895 . . . . 0.0 111.993 175.332 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 73.6 mtp180 -60.56 -38.92 86.13 Favored 'General case' 0 N--CA 1.479 1.001 0 N-CA-C 113.058 0.762 . . . . 0.0 113.058 176.561 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 47.7 t -59.83 -50.38 74.04 Favored 'General case' 0 CA--C 1.542 0.646 0 C-N-CA 124.422 1.089 . . . . 0.0 112.179 176.048 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 63.3 t30 -69.95 -40.26 75.56 Favored 'General case' 0 CA--C 1.545 0.767 0 C-N-CA 125.01 1.324 . . . . 0.0 112.925 -176.911 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 129.26 30.2 0.68 Allowed Glycine 0 CA--C 1.536 1.375 0 C-N-CA 124.676 1.131 . . . . 0.0 115.161 178.369 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -120.14 178.49 2.49 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.545 0 C-N-CA 126.943 2.097 . . . . 0.0 110.037 -176.411 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 83.8 p -138.04 159.69 41.34 Favored 'General case' 0 N--CA 1.476 0.854 0 C-N-CA 124.843 1.257 . . . . 0.0 113.466 -178.135 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 16.0 mm -87.53 -23.5 6.56 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.965 0 C-N-CA 124.545 1.138 . . . . 0.0 112.509 -175.003 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 8.3 tptm -68.69 -3.04 10.61 Favored 'General case' 0 N--CA 1.477 0.913 0 C-N-CA 127.102 2.161 . . . . 0.0 114.292 178.921 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 18.6 t -51.27 -41.84 60.69 Favored 'General case' 0 N--CA 1.473 0.686 0 C-N-CA 127.014 2.126 . . . . 0.0 113.591 179.998 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 7.4 tp10 -153.02 -52.71 0.11 Allowed 'General case' 0 N--CA 1.474 0.74 0 C-N-CA 124.365 1.066 . . . . 0.0 111.476 173.099 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -76.82 65.81 2.85 Favored Glycine 0 CA--C 1.533 1.196 0 C-N-CA 125.615 1.578 . . . . 0.0 113.474 -179.661 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 25.7 t -57.76 119.1 6.06 Favored 'General case' 0 N--CA 1.47 0.552 0 C-N-CA 125.462 1.505 . . . . 0.0 111.83 175.493 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 93.7 m -119.07 159.22 45.81 Favored Pre-proline 0 CA--C 1.549 0.906 0 C-N-CA 125.928 1.691 . . . . 0.0 111.787 -179.239 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -72.8 95.56 0.82 Allowed 'Trans proline' 0 CA--C 1.542 0.91 0 C-N-CA 123.672 2.914 . . . . 0.0 112.057 178.244 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 27.9 m -57.94 130.66 47.56 Favored 'General case' 0 N--CA 1.476 0.869 0 C-N-CA 125.695 1.598 . . . . 0.0 111.773 177.112 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -78.42 -69.95 1.35 Allowed Glycine 0 CA--C 1.536 1.365 0 C-N-CA 124.634 1.111 . . . . 0.0 113.696 -177.068 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 21.3 tt . . . . . 0 C--O 1.252 1.198 0 C-N-CA 126.863 2.065 . . . . 0.0 112.251 -178.301 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 65.8 mttm . . . . . 0 N--CA 1.493 1.719 0 CA-C-O 120.834 0.349 . . . . 0.0 110.593 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 9.5 mtmp? -97.05 104.09 16.08 Favored 'General case' 0 N--CA 1.482 1.161 0 C-N-CA 125.109 1.363 . . . . 0.0 110.818 -178.833 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 40.9 t -129.62 140.28 49.49 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.065 0 C-N-CA 125.841 1.656 . . . . 0.0 110.029 -178.867 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 8.5 t -66.37 118.07 9.51 Favored 'General case' 0 CA--C 1.543 0.676 0 C-N-CA 124.401 1.08 . . . . 0.0 112.805 -174.787 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -75.24 32.4 0.1 Allowed 'General case' 0 CA--C 1.553 1.077 0 C-N-CA 126.873 2.069 . . . . 0.0 115.214 -174.132 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 58.4 m -62.96 157.48 60.75 Favored Pre-proline 0 CA--C 1.549 0.912 0 C-N-CA 124.851 1.26 . . . . 0.0 113.15 176.062 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 97.1 Cg_endo -70.58 172.13 14.03 Favored 'Trans proline' 0 CA--C 1.54 0.799 0 C-N-CA 123.419 2.746 . . . . 0.0 112.176 173.141 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 29.9 mtpp -121.05 3.09 10.47 Favored 'General case' 0 N--CA 1.481 1.112 0 C-N-CA 126.2 1.8 . . . . 0.0 114.011 179.765 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -53.0 138.63 12.0 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.785 0 C-N-CA 126.366 1.867 . . . . 0.0 112.347 179.649 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 3.2 tt -70.69 77.61 0.6 Allowed 'General case' 0 CA--C 1.547 0.849 0 C-N-CA 126.72 2.008 . . . . 0.0 111.382 -178.773 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 25.7 tptp -140.15 68.86 34.42 Favored Pre-proline 0 N--CA 1.473 0.722 0 C-N-CA 125.875 1.67 . . . . 0.0 110.893 179.6 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -64.86 148.55 89.98 Favored 'Trans proline' 0 CA--C 1.534 0.524 0 C-N-CA 122.326 2.017 . . . . 0.0 111.868 -178.676 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 1.7 t -137.75 161.0 33.8 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.804 0 C-N-CA 125.542 1.537 . . . . 0.0 109.99 -177.501 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 21.6 p -73.35 130.64 40.61 Favored 'General case' 0 CA--C 1.543 0.683 0 C-N-CA 124.582 1.153 . . . . 0.0 111.669 176.1 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -110.59 159.96 13.57 Favored Glycine 0 CA--C 1.535 1.325 0 C-N-CA 125.135 1.35 . . . . 0.0 112.026 170.729 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 56.6 p -63.53 -30.68 71.76 Favored 'General case' 0 N--CA 1.475 0.781 0 N-CA-C 114.28 1.215 . . . . 0.0 114.28 -172.822 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 17.0 t70 -77.17 -20.37 55.55 Favored 'General case' 0 N--CA 1.477 0.906 0 C-N-CA 124.437 1.095 . . . . 0.0 113.69 177.078 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 106.34 1.27 38.05 Favored Glycine 0 CA--C 1.537 1.411 0 C-N-CA 126.876 2.179 . . . . 0.0 114.789 176.325 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 56.2 mtt180 -85.78 156.21 20.69 Favored 'General case' 0 N--CA 1.476 0.866 0 C-N-CA 125.221 1.408 . . . . 0.0 112.974 -173.688 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 9.6 p -81.58 126.67 32.0 Favored 'General case' 0 N--CA 1.467 0.418 0 C-N-CA 125.959 1.703 . . . . 0.0 111.319 169.799 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 86.1 m-85 -126.13 159.28 33.3 Favored 'General case' 0 N--CA 1.47 0.566 0 C-N-CA 125.71 1.604 . . . . 0.0 110.789 171.99 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -62.57 -42.39 99.52 Favored 'General case' 0 CA--C 1.543 0.701 0 N-CA-C 113.078 0.77 . . . . 0.0 113.078 -168.381 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 14.2 p30 -155.47 178.36 10.32 Favored 'General case' 0 CA--C 1.545 0.78 0 C-N-CA 126.179 1.792 . . . . 0.0 112.258 173.56 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 33.1 t -62.48 -38.25 89.11 Favored 'General case' 0 N--CA 1.473 0.696 0 O-C-N 121.148 -0.97 . . . . 0.0 113.088 178.904 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 24.6 t -59.18 -57.64 12.15 Favored 'General case' 0 N--CA 1.467 0.377 0 C-N-CA 123.974 0.91 . . . . 0.0 111.25 179.749 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 8.4 tt -57.68 -39.45 70.26 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.618 0 N-CA-C 111.783 0.29 . . . . 0.0 111.783 -179.074 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -65.65 -45.73 81.87 Favored 'General case' 0 CA--C 1.542 0.663 0 C-N-CA 123.561 0.745 . . . . 0.0 112.42 179.411 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 16.7 ttp180 -62.87 -44.93 94.8 Favored 'General case' 0 N--CA 1.474 0.728 0 O-C-N 121.372 -0.83 . . . . 0.0 112.198 174.318 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -65.59 -32.54 74.18 Favored 'General case' 0 CA--C 1.545 0.756 0 N-CA-C 113.173 0.805 . . . . 0.0 113.173 177.67 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 51.9 t30 -65.7 -44.06 87.28 Favored 'General case' 0 CA--C 1.544 0.719 0 C-N-CA 124.698 1.199 . . . . 0.0 112.591 173.574 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 159.35 1.29 0.07 OUTLIER Glycine 0 CA--C 1.537 1.409 0 N-CA-C 117.519 1.767 . . . . 0.0 117.519 175.098 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -90.65 178.18 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.453 0 CA-C-N 119.823 1.812 . . . . 0.0 112.036 -176.288 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 66.1 m -133.03 108.36 8.82 Favored 'General case' 0 N--CA 1.477 0.881 0 C-N-CA 125.918 1.687 . . . . 0.0 111.986 177.995 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 16.4 mt -117.43 -34.05 1.77 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.3 0 C-N-CA 125.065 1.346 . . . . 0.0 112.377 178.899 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 9.2 tptm -69.49 -16.74 63.52 Favored 'General case' 0 N--CA 1.479 0.988 0 C-N-CA 125.568 1.547 . . . . 0.0 113.702 179.643 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 13.1 p -66.79 97.44 0.47 Allowed 'General case' 0 CA--C 1.538 0.501 0 C-N-CA 126.727 2.011 . . . . 0.0 111.704 167.877 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 26.8 tt0 -62.39 168.99 3.15 Favored 'General case' 0 CA--C 1.551 0.993 0 C-N-CA 125.077 1.351 . . . . 0.0 112.175 172.457 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -69.1 -9.73 60.77 Favored Glycine 0 CA--C 1.54 1.638 0 C-N-CA 124.74 1.162 . . . . 0.0 115.797 -177.863 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 63.2 p -70.4 162.47 28.59 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 125.009 1.324 . . . . 0.0 112.743 170.341 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 71.7 m -133.38 71.24 76.47 Favored Pre-proline 0 CA--C 1.547 0.856 0 C-N-CA 124.913 1.285 . . . . 0.0 111.301 179.078 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 93.3 Cg_endo -72.65 163.06 39.58 Favored 'Trans proline' 0 CA--C 1.54 0.815 0 C-N-CA 123.168 2.579 . . . . 0.0 112.542 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 6.5 t -75.77 -14.84 60.32 Favored 'General case' 0 N--CA 1.48 1.065 0 N-CA-C 113.903 1.075 . . . . 0.0 113.903 178.764 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -171.56 -82.97 0.05 OUTLIER Glycine 0 CA--C 1.534 1.254 0 C-N-CA 124.468 1.032 . . . . 0.0 113.301 176.13 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 21.4 tt . . . . . 0 C--O 1.254 1.314 0 C-N-CA 126.127 1.771 . . . . 0.0 113.668 179.894 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 64.2 mttm . . . . . 0 N--CA 1.496 1.863 0 N-CA-C 113.67 0.989 . . . . 0.0 113.67 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -119.8 90.38 3.32 Favored 'General case' 0 N--CA 1.483 1.192 0 O-C-N 120.12 -1.613 . . . . 0.0 110.673 179.126 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 46.3 t -137.35 132.89 46.27 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.953 0 C-N-CA 126.255 1.822 . . . . 0.0 109.746 179.179 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 64.3 m -67.78 126.03 28.12 Favored 'General case' 0 CA--C 1.542 0.637 0 C-N-CA 123.846 0.858 . . . . 0.0 111.517 175.423 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -73.8 42.88 0.14 Allowed 'General case' 0 CA--C 1.554 1.115 0 C-N-CA 125.928 1.691 . . . . 0.0 113.96 179.093 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 56.4 m -60.52 153.56 60.26 Favored Pre-proline 0 CA--C 1.55 0.955 0 C-N-CA 125.254 1.422 . . . . 0.0 113.125 177.908 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 88.3 Cg_endo -71.74 158.15 53.88 Favored 'Trans proline' 0 CA--C 1.539 0.735 0 C-N-CA 123.146 2.564 . . . . 0.0 112.309 179.568 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 1.4 mptm? -73.31 -8.56 56.36 Favored 'General case' 0 N--CA 1.48 1.039 0 C-N-CA 125.469 1.508 . . . . 0.0 113.88 179.631 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 51.1 mm -52.95 125.46 7.01 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.668 0 C-N-CA 126.442 1.897 . . . . 0.0 111.498 177.233 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 50.3 tp -95.35 100.44 12.21 Favored 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 127.339 2.256 . . . . 0.0 109.033 176.382 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 29.4 ttmt -146.76 82.34 8.69 Favored Pre-proline 0 N--CA 1.472 0.655 0 C-N-CA 124.565 1.146 . . . . 0.0 110.66 171.22 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 70.2 Cg_endo -68.69 148.32 71.56 Favored 'Trans proline' 0 N--CA 1.459 -0.549 0 C-N-CA 121.805 1.67 . . . . 0.0 110.926 177.543 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 1.4 t -138.41 160.52 31.59 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.752 0 C-N-CA 124.879 1.271 . . . . 0.0 109.966 -179.12 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 49.8 t -75.88 96.34 3.69 Favored 'General case' 0 CA--C 1.54 0.585 0 C-N-CA 124.334 1.054 . . . . 0.0 110.097 173.0 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -62.78 153.3 44.64 Favored Glycine 0 CA--C 1.534 1.265 0 C-N-CA 123.427 0.537 . . . . 0.0 112.113 174.084 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 21.1 t -53.93 -36.09 62.4 Favored 'General case' 0 N--CA 1.477 0.887 0 C-N-CA 125.256 1.422 . . . . 0.0 114.315 -171.51 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 17.8 m-20 -78.67 -2.77 40.77 Favored 'General case' 0 CA--C 1.55 0.945 0 C-N-CA 125.276 1.43 . . . . 0.0 114.589 178.781 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 92.96 37.27 5.76 Favored Glycine 0 CA--C 1.535 1.295 0 C-N-CA 125.503 1.525 . . . . 0.0 113.321 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 13.3 mmm180 -129.52 125.46 36.37 Favored 'General case' 0 N--CA 1.477 0.911 0 C-N-CA 126.604 1.962 . . . . 0.0 111.025 -166.125 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 2.8 p -83.74 90.35 7.3 Favored 'General case' 0 N--CA 1.474 0.746 0 C-N-CA 125.6 1.56 . . . . 0.0 112.074 177.292 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -77.34 154.9 32.36 Favored 'General case' 0 N--CA 1.473 0.691 0 C-N-CA 124.385 1.074 . . . . 0.0 111.851 172.348 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -67.69 -40.82 84.35 Favored 'General case' 0 CA--C 1.545 0.779 0 N-CA-C 113.458 0.91 . . . . 0.0 113.458 -168.705 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 62.1 t30 -144.77 172.27 13.24 Favored 'General case' 0 CA--C 1.548 0.885 0 C-N-CA 125.171 1.388 . . . . 0.0 110.898 169.955 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 88.3 p -62.07 -34.52 76.43 Favored 'General case' 0 N--CA 1.472 0.66 0 O-C-N 120.574 -1.329 . . . . 0.0 113.317 176.365 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 35.4 t -59.72 -57.41 13.03 Favored 'General case' 0 N--CA 1.467 0.414 0 C-N-CA 124.604 1.162 . . . . 0.0 112.669 177.341 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 7.6 tp -58.21 -34.1 48.82 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 CA-C-O 119.06 -0.495 . . . . 0.0 112.286 179.591 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -58.29 -53.6 56.49 Favored 'General case' 0 CA--C 1.544 0.734 0 CA-C-N 118.929 0.786 . . . . 0.0 111.934 172.986 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -58.98 -46.05 89.06 Favored 'General case' 0 N--CA 1.48 1.032 0 N-CA-C 112.666 0.617 . . . . 0.0 112.666 175.338 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -65.3 -32.58 74.31 Favored 'General case' 0 CA--C 1.545 0.776 0 N-CA-C 113.301 0.852 . . . . 0.0 113.301 -179.948 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 25.6 t-20 -71.61 -49.03 44.07 Favored 'General case' 0 CA--C 1.543 0.701 0 C-N-CA 124.758 1.223 . . . . 0.0 112.62 173.86 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 145.47 21.18 0.14 Allowed Glycine 0 CA--C 1.537 1.46 0 N-CA-C 116.813 1.485 . . . . 0.0 116.813 178.965 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 21.7 t -127.48 150.05 33.0 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.607 0 C-N-CA 126.067 1.747 . . . . 0.0 109.548 -176.966 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 80.0 p -124.42 138.69 54.33 Favored 'General case' 0 N--CA 1.47 0.542 0 C-N-CA 126.157 1.783 . . . . 0.0 112.129 -179.499 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 23.5 mm -91.66 -18.93 7.18 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.917 0 C-N-CA 124.961 1.304 . . . . 0.0 111.854 -179.03 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 10.0 mtpm? -83.38 15.21 3.11 Favored 'General case' 0 N--CA 1.482 1.132 0 C-N-CA 128.276 2.631 . . . . 0.0 113.543 173.135 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 8.2 p -68.77 61.56 0.1 Allowed 'General case' 0 N--CA 1.476 0.851 0 C-N-CA 128.464 2.706 . . . . 0.0 114.314 179.919 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 57.6 mm-40 -80.17 165.76 22.11 Favored 'General case' 0 CA--C 1.547 0.828 0 C-N-CA 126.784 2.034 . . . . 0.0 112.766 176.163 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -154.9 41.04 0.61 Allowed Glycine 0 CA--C 1.534 1.271 0 C-N-CA 125.185 1.374 . . . . 0.0 113.615 -177.206 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 13.4 t -129.73 168.95 15.74 Favored 'General case' 0 N--CA 1.473 0.722 0 C-N-CA 126.084 1.754 . . . . 0.0 111.822 -179.725 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 81.8 m 37.13 68.68 1.5 Allowed Pre-proline 0 CA--C 1.552 1.024 0 C-N-CA 127.818 2.447 . . . . 0.0 114.036 -177.448 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -63.48 140.0 73.62 Favored 'Trans proline' 0 CA--C 1.538 0.692 0 C-N-CA 123.056 2.504 . . . . 0.0 111.696 -176.983 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 78.0 p -67.64 162.04 24.47 Favored 'General case' 0 N--CA 1.477 0.9 0 C-N-CA 123.849 0.86 . . . . 0.0 112.676 -178.398 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -170.94 175.39 44.66 Favored Glycine 0 CA--C 1.534 1.237 0 C-N-CA 124.435 1.017 . . . . 0.0 113.553 -178.331 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 17.5 tt . . . . . 0 C--O 1.254 1.341 0 C-N-CA 126.317 1.847 . . . . 0.0 113.416 178.466 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 56.0 mttp . . . . . 0 N--CA 1.49 1.565 0 N-CA-C 109.692 -0.485 . . . . 0.0 109.692 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -142.84 168.41 19.79 Favored 'General case' 0 N--CA 1.484 1.23 0 C-N-CA 125.713 1.605 . . . . 0.0 112.8 -177.298 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 11.7 p -148.63 151.83 12.85 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.093 0 C-N-CA 125.301 1.44 . . . . 0.0 112.184 -178.159 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 60.1 m -77.93 97.51 5.34 Favored 'General case' 0 CA--C 1.545 0.762 0 C-N-CA 126.017 1.727 . . . . 0.0 111.69 177.408 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -75.3 67.6 1.92 Allowed 'General case' 0 CA--C 1.551 1.006 0 C-N-CA 125.56 1.544 . . . . 0.0 113.091 179.802 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 72.8 m -68.92 155.57 93.16 Favored Pre-proline 0 CA--C 1.552 1.027 0 C-N-CA 124.882 1.273 . . . . 0.0 113.586 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 90.4 Cg_endo -74.11 168.01 25.81 Favored 'Trans proline' 0 CA--C 1.541 0.849 0 C-N-CA 123.591 2.861 . . . . 0.0 113.173 179.38 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -76.59 -3.23 36.56 Favored 'General case' 0 N--CA 1.482 1.155 0 C-N-CA 125.619 1.567 . . . . 0.0 114.447 177.927 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 85.6 mt -55.69 151.42 2.22 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.899 0 C-N-CA 126.868 2.067 . . . . 0.0 110.744 174.555 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 50.8 tp -136.9 93.49 2.85 Favored 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 125.914 1.686 . . . . 0.0 109.401 -175.538 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 16.7 mmtm -135.21 82.1 42.44 Favored Pre-proline 0 N--CA 1.475 0.779 0 C-N-CA 125.828 1.651 . . . . 0.0 110.129 174.307 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 65.0 Cg_endo -69.83 91.17 0.52 Allowed 'Trans proline' 0 CA--C 1.54 0.805 0 C-N-CA 123.809 3.006 . . . . 0.0 112.061 -177.238 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 5.0 m -87.11 157.87 3.19 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.522 0 C-N-CA 126.723 2.009 . . . . 0.0 112.882 -177.356 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 45.0 t -68.23 143.29 55.36 Favored 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 124.05 0.94 . . . . 0.0 111.064 171.366 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -111.72 148.97 18.1 Favored Glycine 0 CA--C 1.532 1.108 0 C-N-CA 125.472 1.51 . . . . 0.0 112.786 177.803 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 68.9 m -59.58 -22.81 62.29 Favored 'General case' 0 N--CA 1.477 0.878 0 N-CA-C 115.564 1.69 . . . . 0.0 115.564 -170.498 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 33.4 t70 -77.89 -10.74 59.73 Favored 'General case' 0 CA--C 1.549 0.929 0 C-N-CA 124.904 1.282 . . . . 0.0 114.15 175.238 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 98.39 31.85 6.3 Favored Glycine 0 CA--C 1.536 1.391 0 C-N-CA 125.422 1.487 . . . . 0.0 113.111 -172.097 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 15.3 mmp_? -121.91 -175.0 3.01 Favored 'General case' 0 N--CA 1.478 0.969 0 C-N-CA 127.743 2.417 . . . . 0.0 111.281 -169.734 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 9.3 t -136.84 143.95 43.36 Favored 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 125.191 1.396 . . . . 0.0 111.427 173.007 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 85.4 m-85 -142.39 147.94 37.04 Favored 'General case' 0 N--CA 1.473 0.705 0 C-N-CA 125.22 1.408 . . . . 0.0 112.217 -175.713 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -61.14 -44.81 96.74 Favored 'General case' 0 CA--C 1.542 0.667 0 N-CA-C 114.003 1.112 . . . . 0.0 114.003 -164.608 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 65.6 m-80 -146.85 175.06 10.93 Favored 'General case' 0 CA--C 1.548 0.886 0 C-N-CA 126.461 1.904 . . . . 0.0 110.633 167.576 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 20.0 m -57.76 -30.09 65.33 Favored 'General case' 0 N--CA 1.477 0.903 0 O-C-N 120.945 -1.097 . . . . 0.0 113.599 171.666 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 46.7 t -58.56 -61.1 2.85 Favored 'General case' 0 N--CA 1.466 0.368 0 C-N-CA 124.964 1.306 . . . . 0.0 112.312 175.557 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 8.5 tp -62.56 -33.3 58.85 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.744 0 N-CA-C 112.039 0.385 . . . . 0.0 112.039 179.995 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -57.41 -54.51 46.0 Favored 'General case' 0 CA--C 1.542 0.661 0 C-N-CA 123.348 0.659 . . . . 0.0 111.556 171.56 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 5.5 mtp85 -58.95 -40.22 84.03 Favored 'General case' 0 N--CA 1.48 1.031 0 N-CA-C 113.243 0.831 . . . . 0.0 113.243 174.907 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 33.0 t -59.95 -46.64 88.77 Favored 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 124.517 1.127 . . . . 0.0 111.628 177.17 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 95.4 m-20 -69.15 -48.07 63.31 Favored 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 125.546 1.538 . . . . 0.0 112.786 179.116 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 129.6 39.84 0.28 Allowed Glycine 0 CA--C 1.536 1.36 0 C-N-CA 125.212 1.387 . . . . 0.0 114.652 -176.867 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 44.7 t -133.25 158.18 42.94 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.597 0 C-N-CA 126.938 2.095 . . . . 0.0 108.494 174.528 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 42.7 t -123.57 143.29 50.3 Favored 'General case' 0 N--CA 1.47 0.572 0 C-N-CA 125.545 1.538 . . . . 0.0 111.937 175.492 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 17.1 mm -100.76 -15.58 7.52 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.79 0 C-N-CA 126.034 1.734 . . . . 0.0 111.331 175.889 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 10.7 mmmm -101.7 -24.13 14.13 Favored 'General case' 0 N--CA 1.479 0.984 0 C-N-CA 126.642 1.977 . . . . 0.0 113.877 -177.359 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 1.4 t 55.26 32.53 18.78 Favored 'General case' 0 N--CA 1.478 0.953 0 C-N-CA 126.024 1.73 . . . . 0.0 114.647 178.396 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 14.3 mm-40 -65.52 -13.3 58.61 Favored 'General case' 0 N--CA 1.477 0.911 0 C-N-CA 125.852 1.661 . . . . 0.0 114.735 178.828 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 149.23 2.85 0.31 Allowed Glycine 0 CA--C 1.538 1.496 0 C-N-CA 124.875 1.226 . . . . 0.0 116.032 178.121 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 12.1 m -59.11 -33.51 70.94 Favored 'General case' 0 N--CA 1.475 0.799 0 C-N-CA 125.457 1.503 . . . . 0.0 114.927 -172.302 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 83.9 m 30.64 66.56 0.85 Allowed Pre-proline 0 CA--C 1.555 1.157 0 C-N-CA 128.345 2.658 . . . . 0.0 114.956 177.723 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo -68.56 116.33 4.35 Favored 'Trans proline' 0 CA--C 1.539 0.733 0 C-N-CA 123.666 2.911 . . . . 0.0 112.979 -171.444 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 24.1 p -76.08 -45.96 31.41 Favored 'General case' 0 N--CA 1.476 0.845 0 C-N-CA 125.629 1.571 . . . . 0.0 113.614 -178.437 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 151.57 -126.59 2.11 Favored Glycine 0 CA--C 1.535 1.324 0 C-N-CA 125.366 1.46 . . . . 0.0 112.744 -176.648 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 34.6 pt . . . . . 0 C--O 1.254 1.308 0 C-N-CA 126.091 1.757 . . . . 0.0 114.082 177.978 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 83.4 tttt . . . . . 0 N--CA 1.491 1.575 0 N-CA-C 110.416 -0.216 . . . . 0.0 110.416 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 1.9 mptp? -71.9 142.56 49.51 Favored 'General case' 0 N--CA 1.481 1.09 0 C-N-CA 124.111 0.964 . . . . 0.0 110.733 173.717 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 13.7 p -149.86 145.26 17.48 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.917 0 C-N-CA 124.939 1.296 . . . . 0.0 111.564 179.285 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 57.2 m -107.88 -18.86 13.7 Favored 'General case' 0 N--CA 1.476 0.839 0 C-N-CA 125.095 1.358 . . . . 0.0 113.6 179.481 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . 50.07 26.32 2.04 Favored 'General case' 0 CA--C 1.552 1.023 0 C-N-CA 127.254 2.222 . . . . 0.0 115.285 -171.032 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 61.9 m -70.22 160.72 79.8 Favored Pre-proline 0 CA--C 1.548 0.869 0 C-N-CA 125.363 1.465 . . . . 0.0 112.922 177.157 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -67.58 167.59 20.48 Favored 'Trans proline' 0 CA--C 1.54 0.798 0 C-N-CA 123.295 2.663 . . . . 0.0 112.231 169.736 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 10.2 mtpm? -112.53 1.38 15.83 Favored 'General case' 0 N--CA 1.48 1.059 0 C-N-CA 126.282 1.833 . . . . 0.0 113.28 173.672 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 48.9 mm -55.93 133.03 19.99 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.593 0 C-N-CA 126.386 1.874 . . . . 0.0 111.082 178.587 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 5.4 tt -69.87 96.0 0.97 Allowed 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 127.771 2.428 . . . . 0.0 111.08 -176.723 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 34.7 ttpt -144.45 73.97 15.53 Favored Pre-proline 0 CA--C 1.546 0.801 0 C-N-CA 124.467 1.107 . . . . 0.0 111.901 -179.427 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -68.21 89.43 0.39 Allowed 'Trans proline' 0 CA--C 1.538 0.708 0 C-N-CA 124.188 3.259 . . . . 0.0 112.922 -175.996 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 16.3 m -73.73 160.24 5.36 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.412 0 C-N-CA 126.084 1.754 . . . . 0.0 112.244 175.273 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 16.5 t -69.36 165.95 19.65 Favored 'General case' 0 CA--C 1.549 0.908 0 C-N-CA 123.625 0.77 . . . . 0.0 111.141 166.998 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -143.6 134.55 5.9 Favored Glycine 0 CA--C 1.53 0.973 0 C-N-CA 124.778 1.18 . . . . 0.0 112.151 177.783 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 63.7 m -57.22 -24.48 54.9 Favored 'General case' 0 N--CA 1.477 0.886 0 C-N-CA 125.847 1.659 . . . . 0.0 114.906 -176.993 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -83.29 -4.58 58.58 Favored 'General case' 0 CA--C 1.548 0.887 0 C-N-CA 125.775 1.63 . . . . 0.0 113.955 176.985 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 94.65 20.21 29.8 Favored Glycine 0 CA--C 1.535 1.311 0 C-N-CA 125.38 1.467 . . . . 0.0 114.284 179.111 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 43.7 mtt180 -121.01 178.18 4.83 Favored 'General case' 0 N--CA 1.477 0.908 0 C-N-CA 126.169 1.788 . . . . 0.0 112.536 -173.88 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 31.8 m -128.35 142.64 51.06 Favored 'General case' 0 N--CA 1.477 0.9 0 C-N-CA 126.107 1.763 . . . . 0.0 110.049 -179.584 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 86.8 m-85 -135.57 155.64 50.15 Favored 'General case' 0 N--CA 1.471 0.588 0 C-N-CA 125.171 1.388 . . . . 0.0 111.651 -175.438 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -61.66 -38.63 88.46 Favored 'General case' 0 CA--C 1.544 0.742 0 N-CA-C 113.212 0.819 . . . . 0.0 113.212 -167.956 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 14.8 p30 -150.33 179.33 8.21 Favored 'General case' 0 CA--C 1.548 0.876 0 C-N-CA 126.213 1.805 . . . . 0.0 111.901 166.441 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 25.0 p -65.63 -34.83 79.12 Favored 'General case' 0 N--CA 1.474 0.745 0 O-C-N 121.007 -1.058 . . . . 0.0 113.755 177.298 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 34.4 t -62.93 -54.04 44.77 Favored 'General case' 0 N--CA 1.466 0.361 0 C-N-CA 124.083 0.953 . . . . 0.0 111.481 179.057 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 9.3 tp -59.0 -37.18 66.14 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.553 0 N-CA-C 112.143 0.423 . . . . 0.0 112.143 -179.277 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -63.32 -42.62 99.02 Favored 'General case' 0 CA--C 1.544 0.717 0 CA-C-N 118.851 0.75 . . . . 0.0 112.927 176.216 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 8.7 tpm_? -62.98 -41.96 99.7 Favored 'General case' 0 N--CA 1.475 0.816 0 C-N-CA 123.828 0.851 . . . . 0.0 112.278 173.82 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 7.3 t -65.06 -39.72 93.67 Favored 'General case' 0 CA--C 1.547 0.839 0 C-N-CA 123.025 0.53 . . . . 0.0 112.245 174.286 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 23.0 t-20 -63.93 -52.03 61.66 Favored 'General case' 0 CA--C 1.544 0.716 0 C-N-CA 125.82 1.648 . . . . 0.0 112.464 178.739 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 149.81 18.12 0.08 OUTLIER Glycine 0 CA--C 1.537 1.436 0 N-CA-C 117.344 1.698 . . . . 0.0 117.344 179.095 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 14.5 t -124.43 144.38 34.51 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.672 0 CA-C-N 119.98 1.89 . . . . 0.0 109.882 -176.828 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 72.3 m -89.47 128.53 35.98 Favored 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 125.805 1.642 . . . . 0.0 111.322 -179.024 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 14.3 mm -117.48 -9.33 11.99 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.23 0 C-N-CA 124.687 1.195 . . . . 0.0 112.486 -175.778 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 84.3 tttt -59.6 -33.05 70.98 Favored 'General case' 0 N--CA 1.477 0.9 0 C-N-CA 126.018 1.727 . . . . 0.0 113.409 173.707 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 18.5 t -131.48 113.4 13.64 Favored 'General case' 0 N--CA 1.468 0.446 0 C-N-CA 125.852 1.661 . . . . 0.0 110.495 -179.512 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 78.2 mm-40 -61.75 136.71 58.1 Favored 'General case' 0 N--CA 1.474 0.743 0 C-N-CA 124.698 1.199 . . . . 0.0 112.796 179.91 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -86.37 -31.85 18.15 Favored Glycine 0 CA--C 1.537 1.418 0 C-N-CA 123.912 0.768 . . . . 0.0 114.683 -179.06 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 66.2 m -76.69 93.72 3.69 Favored 'General case' 0 N--CA 1.473 0.688 0 C-N-CA 124.97 1.308 . . . . 0.0 112.045 -179.485 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 48.8 t -60.53 132.25 90.96 Favored Pre-proline 0 CA--C 1.551 1.001 0 C-N-CA 124.33 1.052 . . . . 0.0 111.607 174.979 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -71.64 161.61 44.72 Favored 'Trans proline' 0 CA--C 1.542 0.913 0 C-N-CA 123.125 2.55 . . . . 0.0 112.652 178.656 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 34.5 m -127.29 -37.42 2.04 Favored 'General case' 0 N--CA 1.483 1.202 0 C-N-CA 124.965 1.306 . . . . 0.0 112.912 -175.559 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 172.94 -168.08 41.05 Favored Glycine 0 CA--C 1.534 1.219 0 C-N-CA 125.03 1.3 . . . . 0.0 112.72 -173.177 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 11.2 tp . . . . . 0 C--O 1.254 1.301 0 C-N-CA 126.41 1.884 . . . . 0.0 112.98 -179.877 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.489 1.512 0 CA-C-O 120.491 0.186 . . . . 0.0 111.172 . . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -79.76 74.86 6.45 Favored 'General case' 0 N--CA 1.482 1.127 0 C-N-CA 125.204 1.402 . . . . 0.0 111.738 179.087 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 24.7 t -137.34 123.82 28.31 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.999 0 C-N-CA 125.486 1.515 . . . . 0.0 110.588 179.91 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 22.4 m -71.14 114.37 9.13 Favored 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 125.285 1.434 . . . . 0.0 110.447 173.426 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -72.84 35.88 0.07 Allowed 'General case' 0 CA--C 1.556 1.195 0 C-N-CA 125.702 1.601 . . . . 0.0 114.321 178.257 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 63.8 m -64.85 159.03 66.45 Favored Pre-proline 0 CA--C 1.549 0.932 0 C-N-CA 126.499 1.92 . . . . 0.0 113.934 -178.232 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -70.81 158.96 54.15 Favored 'Trans proline' 0 C--N 1.352 0.736 0 C-N-CA 123.293 2.662 . . . . 0.0 112.785 -179.64 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 48.3 tttm -71.54 -21.17 61.94 Favored 'General case' 0 N--CA 1.478 0.953 0 C-N-CA 125.272 1.429 . . . . 0.0 113.397 176.401 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 43.7 mm -57.32 130.61 20.45 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.652 0 C-N-CA 126.257 1.823 . . . . 0.0 110.994 -179.651 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.416 HD23 ' H ' ' A' ' 10' ' ' LEU . 2.0 pt? -93.05 133.95 35.68 Favored 'General case' 0 CA--C 1.539 0.548 0 C-N-CA 125.312 1.445 . . . . 0.0 111.981 176.426 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 54.2 mttm -144.17 81.39 11.56 Favored Pre-proline 0 N--CA 1.471 0.611 0 C-N-CA 126.87 2.068 . . . . 0.0 109.236 166.748 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -71.53 85.03 0.93 Allowed 'Trans proline' 0 CA--C 1.539 0.729 0 C-N-CA 123.522 2.815 . . . . 0.0 111.915 178.836 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 35.2 m -110.96 166.72 5.37 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.344 0 C-N-CA 126.987 2.115 . . . . 0.0 112.609 -176.877 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 24.4 p -76.38 130.82 38.61 Favored 'General case' 0 CA--C 1.544 0.717 0 C-N-CA 124.124 0.97 . . . . 0.0 111.961 176.338 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -89.29 160.14 29.15 Favored Glycine 0 CA--C 1.534 1.255 0 C-N-CA 124.925 1.25 . . . . 0.0 111.974 168.239 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 91.2 p -59.39 -26.19 64.91 Favored 'General case' 0 N--CA 1.476 0.873 0 N-CA-C 115.252 1.575 . . . . 0.0 115.252 -171.928 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 32.2 m-20 -81.56 -2.77 51.18 Favored 'General case' 0 CA--C 1.547 0.858 0 C-N-CA 125.321 1.448 . . . . 0.0 114.451 176.585 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 89.59 31.4 11.48 Favored Glycine 0 CA--C 1.536 1.387 0 C-N-CA 124.772 1.177 . . . . 0.0 113.089 -176.285 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 42.9 mmm-85 -114.68 172.24 7.16 Favored 'General case' 0 N--CA 1.477 0.877 0 C-N-CA 127.808 2.443 . . . . 0.0 111.022 -170.873 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 31.7 m -128.68 133.53 48.23 Favored 'General case' 0 N--CA 1.481 1.086 0 C-N-CA 124.717 1.207 . . . . 0.0 110.748 178.921 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 87.3 m-85 -135.73 156.15 49.28 Favored 'General case' 0 N--CA 1.473 0.682 0 C-N-CA 125.186 1.394 . . . . 0.0 112.155 -178.106 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.99 -40.76 95.44 Favored 'General case' 0 CA--C 1.543 0.689 0 N-CA-C 113.499 0.926 . . . . 0.0 113.499 -166.965 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' ASN . . . . . 0.438 ' H ' HG22 ' A' ' 26' ' ' ILE . 28.7 p30 -148.4 179.7 7.59 Favored 'General case' 0 CA--C 1.547 0.847 0 C-N-CA 125.326 1.45 . . . . 0.0 112.194 164.813 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 44.6 p -62.64 -34.12 76.42 Favored 'General case' 0 N--CA 1.474 0.76 0 C-N-CA 124.228 1.011 . . . . 0.0 113.531 176.772 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 47.3 t -62.39 -55.1 31.08 Favored 'General case' 0 N--CA 1.465 0.276 0 C-N-CA 124.321 1.049 . . . . 0.0 111.917 178.093 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.438 HG22 ' H ' ' A' ' 23' ' ' ASN . 9.3 tp -61.26 -35.71 67.87 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.611 0 N-CA-C 112.25 0.463 . . . . 0.0 112.25 179.576 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -58.99 -51.37 70.38 Favored 'General case' 0 CA--C 1.544 0.73 0 C-N-CA 123.698 0.799 . . . . 0.0 111.885 172.499 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 77.5 mtp85 -57.92 -45.55 86.36 Favored 'General case' 0 N--CA 1.477 0.925 0 C-N-CA 124.644 1.177 . . . . 0.0 112.772 174.85 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 6.7 t -62.48 -40.83 97.95 Favored 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 123.766 0.826 . . . . 0.0 112.275 177.139 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 43.9 t30 -67.67 -42.04 82.79 Favored 'General case' 0 CA--C 1.543 0.681 0 C-N-CA 125.026 1.33 . . . . 0.0 113.245 178.32 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 134.43 23.79 0.64 Allowed Glycine 0 CA--C 1.538 1.476 0 N-CA-C 116.046 1.178 . . . . 0.0 116.046 178.013 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 38.0 t -125.01 154.47 33.06 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.448 0 C-N-CA 126.835 2.054 . . . . 0.0 108.379 -178.147 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 91.3 p -135.79 166.97 22.05 Favored 'General case' 0 N--CA 1.472 0.646 0 C-N-CA 124.618 1.167 . . . . 0.0 112.875 175.918 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 2.0 mt -125.98 -8.71 5.38 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.04 0 C-N-CA 124.862 1.265 . . . . 0.0 112.006 -172.193 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 25.7 pttm -60.46 -30.78 69.88 Favored 'General case' 0 N--CA 1.479 0.981 0 C-N-CA 126.366 1.866 . . . . 0.0 113.584 174.291 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 33.8 m -83.62 83.19 7.99 Favored 'General case' 0 N--CA 1.468 0.467 0 C-N-CA 126.263 1.825 . . . . 0.0 110.551 -179.559 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 16.9 pt-20 -130.01 163.45 26.45 Favored 'General case' 0 CA--C 1.543 0.709 0 C-N-CA 125.949 1.7 . . . . 0.0 112.657 -177.049 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -91.67 -27.89 15.87 Favored Glycine 0 CA--C 1.537 1.418 0 C-N-CA 123.953 0.787 . . . . 0.0 115.037 -173.848 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 25.6 p -85.05 166.37 16.75 Favored 'General case' 0 N--CA 1.473 0.676 0 C-N-CA 125.209 1.403 . . . . 0.0 113.127 177.365 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 48.6 t -65.6 127.98 93.45 Favored Pre-proline 0 CA--C 1.55 0.96 0 C-N-CA 123.91 0.884 . . . . 0.0 111.593 176.917 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -71.34 94.08 0.67 Allowed 'Trans proline' 0 CA--C 1.543 0.945 0 C-N-CA 123.886 3.057 . . . . 0.0 112.211 -178.089 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 8.6 m -138.6 147.26 42.75 Favored 'General case' 0 N--CA 1.48 1.032 0 C-N-CA 126.029 1.732 . . . . 0.0 110.86 -177.441 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 143.7 -62.28 0.5 Allowed Glycine 0 CA--C 1.532 1.154 0 C-N-CA 124.891 1.234 . . . . 0.0 113.63 171.452 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 21.1 tt . . . . . 0 C--O 1.252 1.204 0 C-N-CA 126.954 2.102 . . . . 0.0 112.273 -178.011 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.636 0 N-CA-C 111.622 0.231 . . . . 0.0 111.622 . . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 48.5 tttm 51.05 47.46 24.82 Favored 'General case' 0 N--CA 1.484 1.241 0 C-N-CA 127.084 2.154 . . . . 0.0 113.586 178.912 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 12.8 p -142.41 144.93 24.18 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.966 0 C-N-CA 126.047 1.739 . . . . 0.0 111.69 -179.414 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 81.0 m -80.92 110.27 16.29 Favored 'General case' 0 CA--C 1.544 0.736 0 C-N-CA 125.584 1.554 . . . . 0.0 110.782 175.736 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -74.95 68.62 1.82 Allowed 'General case' 0 CA--C 1.549 0.935 0 C-N-CA 125.686 1.595 . . . . 0.0 113.17 -177.672 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 62.6 m -69.05 154.89 94.57 Favored Pre-proline 0 CA--C 1.549 0.909 0 C-N-CA 124.536 1.134 . . . . 0.0 113.431 -179.404 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -68.5 152.77 74.82 Favored 'Trans proline' 0 CA--C 1.54 0.811 0 C-N-CA 123.201 2.601 . . . . 0.0 111.854 172.637 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 15.2 ptmt -63.86 -26.03 68.43 Favored 'General case' 0 N--CA 1.479 1.023 0 C-N-CA 125.685 1.594 . . . . 0.0 114.678 177.571 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 9.5 tt -57.78 158.32 1.35 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.614 0 C-N-CA 126.673 1.989 . . . . 0.0 112.301 176.079 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 16.8 tp -126.96 114.78 18.29 Favored 'General case' 0 CA--C 1.538 0.487 0 C-N-CA 126.433 1.893 . . . . 0.0 108.518 -178.07 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 31.1 mmmt -127.61 80.18 72.29 Favored Pre-proline 0 N--CA 1.473 0.716 0 C-N-CA 126.125 1.77 . . . . 0.0 109.792 -176.362 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -72.78 84.28 1.27 Allowed 'Trans proline' 0 CA--C 1.541 0.83 0 C-N-CA 124.274 3.316 . . . . 0.0 112.402 -175.427 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 14.4 m -73.78 164.76 3.41 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.598 0 C-N-CA 126.883 2.073 . . . . 0.0 112.832 177.556 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 10.0 t -79.79 -5.21 54.92 Favored 'General case' 0 CA--C 1.551 0.995 0 C-N-CA 124.539 1.135 . . . . 0.0 113.983 174.406 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 57.29 -155.19 18.24 Favored Glycine 0 CA--C 1.539 1.548 0 C-N-CA 125.338 1.447 . . . . 0.0 113.984 179.211 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 38.0 m -121.22 -20.54 6.7 Favored 'General case' 0 N--CA 1.475 0.776 0 C-N-CA 124.94 1.296 . . . . 0.0 114.223 174.454 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -80.81 -13.88 58.56 Favored 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 124.252 1.021 . . . . 0.0 113.102 171.703 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 98.51 -14.91 61.71 Favored Glycine 0 CA--C 1.537 1.456 0 C-N-CA 126.782 2.134 . . . . 0.0 114.008 -177.945 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 9.8 ptm180 -77.96 168.83 19.28 Favored 'General case' 0 N--CA 1.474 0.747 0 C-N-CA 125.378 1.471 . . . . 0.0 112.279 168.269 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 54.7 m -95.22 149.36 21.4 Favored 'General case' 0 N--CA 1.475 0.779 0 C-N-CA 124.452 1.101 . . . . 0.0 111.708 174.823 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 56.1 m-85 -131.63 151.99 51.18 Favored 'General case' 0 N--CA 1.47 0.562 0 C-N-CA 126.249 1.819 . . . . 0.0 110.676 173.797 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.89 -40.54 87.79 Favored 'General case' 0 CA--C 1.544 0.713 0 N-CA-C 113.273 0.842 . . . . 0.0 113.273 -169.855 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 23' ' ' ASN . . . . . 0.41 ' H ' HG22 ' A' ' 26' ' ' ILE . 16.5 m120 -144.61 170.96 15.07 Favored 'General case' 0 CA--C 1.545 0.786 0 C-N-CA 126.29 1.836 . . . . 0.0 110.954 174.894 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 28.4 p -61.41 -32.06 72.0 Favored 'General case' 0 N--CA 1.475 0.797 0 C-N-CA 124.152 0.981 . . . . 0.0 112.618 162.073 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 42.3 t -54.84 -64.25 0.89 Allowed 'General case' 0 CA--C 1.535 0.374 0 C-N-CA 125.699 1.599 . . . . 0.0 112.366 173.264 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.41 HG22 ' H ' ' A' ' 23' ' ' ASN . 13.6 tt -58.54 -35.62 55.6 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.812 0 N-CA-C 112.211 0.449 . . . . 0.0 112.211 -178.021 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -59.07 -56.63 19.72 Favored 'General case' 0 CA--C 1.541 0.617 0 C-N-CA 123.5 0.72 . . . . 0.0 111.505 174.671 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 69.6 mtm180 -64.55 -37.5 87.77 Favored 'General case' 0 N--CA 1.479 0.977 0 N-CA-C 113.209 0.818 . . . . 0.0 113.209 179.009 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 35.9 t -58.35 -45.25 88.54 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 125.233 1.413 . . . . 0.0 111.833 172.695 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 23.0 t-20 -71.57 -48.84 45.73 Favored 'General case' 0 CA--C 1.546 0.816 0 C-N-CA 125.03 1.332 . . . . 0.0 112.79 179.911 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 144.7 23.43 0.14 Allowed Glycine 0 CA--C 1.54 1.629 0 N-CA-C 116.523 1.369 . . . . 0.0 116.523 179.765 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 18.4 t -130.88 151.56 36.12 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.603 0 C-N-CA 126.637 1.975 . . . . 0.0 109.179 -174.789 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 95.0 p -144.91 124.81 13.45 Favored 'General case' 0 N--CA 1.47 0.562 0 C-N-CA 125.106 1.362 . . . . 0.0 112.108 -179.724 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 6.3 mt -63.57 -20.88 27.23 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.149 0 C-N-CA 124.306 1.042 . . . . 0.0 112.132 -178.805 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -67.29 -16.1 64.08 Favored 'General case' 0 N--CA 1.475 0.813 0 C-N-CA 126.808 2.043 . . . . 0.0 113.254 173.014 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 1.1 t 61.93 20.21 11.33 Favored 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 126.402 1.881 . . . . 0.0 114.768 -179.372 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -147.59 166.41 27.45 Favored 'General case' 0 CA--C 1.541 0.622 0 C-N-CA 124.913 1.285 . . . . 0.0 113.298 -178.391 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -80.0 52.5 4.25 Favored Glycine 0 CA--C 1.534 1.252 0 C-N-CA 125.581 1.562 . . . . 0.0 113.794 -179.581 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 10.8 t -72.44 88.68 1.22 Allowed 'General case' 0 CA--C 1.54 0.594 0 C-N-CA 124.851 1.261 . . . . 0.0 111.128 176.802 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 17.7 t 40.87 75.02 0.64 Allowed Pre-proline 0 CA--C 1.556 1.177 0 C-N-CA 127.884 2.474 . . . . 0.0 114.358 -175.398 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 74.9 Cg_endo -72.35 89.16 0.82 Allowed 'Trans proline' 0 CA--C 1.543 0.962 0 C-N-CA 124.174 3.249 . . . . 0.0 112.605 -177.318 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 22.1 p -71.75 102.12 2.74 Favored 'General case' 0 N--CA 1.475 0.791 0 C-N-CA 126.074 1.75 . . . . 0.0 112.307 176.911 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 97.39 114.1 3.18 Favored Glycine 0 CA--C 1.535 1.313 0 C-N-CA 124.848 1.213 . . . . 0.0 113.1 176.673 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 27.6 mm . . . . . 0 C--O 1.254 1.309 0 C-N-CA 126.025 1.73 . . . . 0.0 111.391 177.304 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 62.8 pttt . . . . . 0 N--CA 1.491 1.611 0 N-CA-C 111.606 0.224 . . . . 0.0 111.606 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 8.8 mtmp? 48.21 46.74 19.82 Favored 'General case' 0 N--CA 1.487 1.401 0 C-N-CA 126.983 2.113 . . . . 0.0 113.975 -179.027 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 11.1 p -138.8 142.53 34.16 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.003 0 C-N-CA 125.002 1.321 . . . . 0.0 112.046 -179.036 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 61.2 m -82.05 100.41 9.72 Favored 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 125.494 1.518 . . . . 0.0 110.832 177.266 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -73.99 52.89 0.45 Allowed 'General case' 0 CA--C 1.554 1.123 0 C-N-CA 125.612 1.565 . . . . 0.0 113.131 177.36 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 92.8 m -62.86 157.03 62.98 Favored Pre-proline 0 CA--C 1.551 1.001 0 C-N-CA 125.791 1.636 . . . . 0.0 113.232 178.977 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -71.82 167.7 25.87 Favored 'Trans proline' 0 CA--C 1.542 0.881 0 C-N-CA 123.29 2.66 . . . . 0.0 113.283 -177.24 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 61.7 mtpt -66.46 -16.8 64.39 Favored 'General case' 0 N--CA 1.481 1.088 0 C-N-CA 126.033 1.733 . . . . 0.0 114.097 176.171 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 79.8 mt -58.47 136.36 21.96 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.722 0 C-N-CA 126.489 1.916 . . . . 0.0 110.24 178.064 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.9 pt? -130.98 26.42 4.93 Favored 'General case' 0 CA--C 1.546 0.816 0 C-N-CA 125.416 1.487 . . . . 0.0 113.951 -178.48 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 26.4 mmtp -52.59 107.22 0.79 Allowed Pre-proline 0 N--CA 1.477 0.893 0 C-N-CA 126.516 1.926 . . . . 0.0 111.553 175.182 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 91.6 Cg_endo -73.61 87.76 1.08 Allowed 'Trans proline' 0 CA--C 1.539 0.729 0 C-N-CA 123.526 2.818 . . . . 0.0 112.01 -173.816 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 13.6 m -73.8 157.85 6.17 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.459 0 C-N-CA 125.636 1.574 . . . . 0.0 112.297 179.246 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 30.3 p -63.44 165.2 8.1 Favored 'General case' 0 CA--C 1.544 0.741 0 C-N-CA 123.412 0.685 . . . . 0.0 111.835 165.637 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -133.97 143.29 14.93 Favored Glycine 0 CA--C 1.527 0.798 0 C-N-CA 125.058 1.313 . . . . 0.0 111.972 179.999 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 55.6 m -65.08 -15.82 62.79 Favored 'General case' 0 N--CA 1.473 0.706 0 C-N-CA 125.362 1.465 . . . . 0.0 114.913 -174.598 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 42.0 m-20 -95.32 5.78 50.78 Favored 'General case' 0 CA--C 1.553 1.082 0 C-N-CA 125.972 1.709 . . . . 0.0 113.514 171.955 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 88.91 24.81 31.27 Favored Glycine 0 N--CA 1.473 1.108 0 C-N-CA 125.05 1.309 . . . . 0.0 114.157 179.921 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 24.0 mtp85 -120.47 -170.53 2.0 Favored 'General case' 0 N--CA 1.481 1.098 0 C-N-CA 126.297 1.839 . . . . 0.0 112.348 -171.409 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 41.2 m -134.42 139.04 45.27 Favored 'General case' 0 N--CA 1.478 0.964 0 C-N-CA 125.952 1.701 . . . . 0.0 110.37 -179.34 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 65.6 m-85 -134.3 159.4 41.09 Favored 'General case' 0 N--CA 1.473 0.694 0 C-N-CA 124.921 1.288 . . . . 0.0 111.603 179.036 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -63.97 -40.53 96.6 Favored 'General case' 0 CA--C 1.543 0.682 0 N-CA-C 112.92 0.711 . . . . 0.0 112.92 -168.075 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 28.5 p30 -154.77 -178.39 7.17 Favored 'General case' 0 CA--C 1.551 0.991 0 C-N-CA 125.314 1.445 . . . . 0.0 111.635 168.877 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 83.4 p -73.12 -16.79 61.45 Favored 'General case' 0 N--CA 1.48 1.046 0 N-CA-C 114.753 1.39 . . . . 0.0 114.753 177.843 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 38.8 t -76.6 -56.06 4.95 Favored 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 124.77 1.228 . . . . 0.0 111.136 173.861 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 7.7 tp -57.85 -34.63 48.77 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.859 0 C-N-CA 123.528 0.731 . . . . 0.0 112.406 179.115 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -55.24 -53.35 57.17 Favored 'General case' 0 CA--C 1.541 0.627 0 C-N-CA 123.885 0.874 . . . . 0.0 111.484 172.967 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 81.3 mtm180 -67.02 -37.42 84.13 Favored 'General case' 0 N--CA 1.475 0.786 0 C-N-CA 125.031 1.332 . . . . 0.0 113.49 178.317 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 42.5 t -57.22 -47.0 82.43 Favored 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 124.325 1.05 . . . . 0.0 111.599 170.844 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 63.6 t30 -70.96 -49.84 41.09 Favored 'General case' 0 CA--C 1.546 0.797 0 C-N-CA 125.502 1.521 . . . . 0.0 112.961 -178.172 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 145.42 23.22 0.12 Allowed Glycine 0 CA--C 1.539 1.561 0 N-CA-C 116.792 1.477 . . . . 0.0 116.792 178.663 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 19.3 t -125.55 150.84 31.06 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.613 0 C-N-CA 126.714 2.006 . . . . 0.0 108.839 -178.069 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 32.5 t -144.61 118.54 9.35 Favored 'General case' 0 N--CA 1.472 0.666 0 C-N-CA 124.907 1.283 . . . . 0.0 112.698 179.197 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.471 ' H ' HD12 ' A' ' 34' ' ' ILE . 0.7 OUTLIER -86.51 13.12 0.96 Allowed 'Isoleucine or valine' 0 CA--C 1.555 1.16 0 C-N-CA 126.789 2.035 . . . . 0.0 111.469 -178.638 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 1.1 mptm? 60.99 5.13 0.92 Allowed 'General case' 0 N--CA 1.487 1.392 0 C-N-CA 128.728 2.811 . . . . 0.0 115.433 -174.978 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 7.5 t -67.98 -21.23 65.07 Favored 'General case' 0 N--CA 1.474 0.727 0 C-N-CA 125.181 1.393 . . . . 0.0 114.58 -178.45 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 14.1 tt0 -144.62 162.12 37.45 Favored 'General case' 0 CA--C 1.548 0.87 0 C-N-CA 124.659 1.184 . . . . 0.0 111.546 177.021 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -79.54 47.92 3.34 Favored Glycine 0 CA--C 1.536 1.392 0 C-N-CA 125.711 1.624 . . . . 0.0 116.044 -166.077 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 21.3 t -78.18 -59.74 2.66 Favored 'General case' 0 N--CA 1.475 0.784 0 C-N-CA 124.617 1.167 . . . . 0.0 112.661 -179.361 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 13.2 p -143.14 70.39 18.26 Favored Pre-proline 0 CA--C 1.551 1.005 0 C-N-CA 125.234 1.414 . . . . 0.0 111.869 -178.363 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 79.3 Cg_endo -70.11 162.34 42.62 Favored 'Trans proline' 0 CA--C 1.543 0.95 0 C-N-CA 123.173 2.582 . . . . 0.0 112.544 178.475 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 21.3 m -130.0 77.67 1.8 Allowed 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 125.287 1.435 . . . . 0.0 109.959 -178.922 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -84.28 71.68 2.94 Favored Glycine 0 CA--C 1.533 1.187 0 C-N-CA 125.154 1.359 . . . . 0.0 113.476 -175.296 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 54.2 mt . . . . . 0 C--O 1.254 1.311 0 C-N-CA 126.171 1.789 . . . . 0.0 111.085 176.172 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 74.6 tttt . . . . . 0 N--CA 1.492 1.648 0 N-CA-C 111.503 0.186 . . . . 0.0 111.503 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 10.4 ptpp? -166.15 167.31 16.37 Favored 'General case' 0 N--CA 1.487 1.388 0 C-N-CA 127.17 2.188 . . . . 0.0 111.122 167.923 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 45.8 t -139.77 133.08 36.34 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.042 0 C-N-CA 125.675 1.59 . . . . 0.0 110.172 177.51 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 4.9 m -68.99 104.05 2.0 Allowed 'General case' 0 CA--C 1.547 0.843 0 C-N-CA 124.686 1.194 . . . . 0.0 109.888 171.139 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -74.44 51.19 0.44 Allowed 'General case' 0 CA--C 1.554 1.101 0 C-N-CA 125.571 1.549 . . . . 0.0 113.58 -177.588 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 81.2 m -71.5 156.07 91.88 Favored Pre-proline 0 CA--C 1.548 0.885 0 C-N-CA 125.624 1.569 . . . . 0.0 114.039 -172.704 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -68.93 158.83 56.34 Favored 'Trans proline' 0 CA--C 1.54 0.814 0 C-N-CA 123.63 2.887 . . . . 0.0 113.213 177.979 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 64.8 mttm -69.98 -14.02 62.5 Favored 'General case' 0 N--CA 1.481 1.093 0 C-N-CA 126.399 1.88 . . . . 0.0 114.142 177.813 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 10.3 tp -62.41 146.49 12.42 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 C-N-CA 126.438 1.895 . . . . 0.0 113.446 -177.114 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 62.7 tp -116.8 88.36 2.88 Favored 'General case' 0 CA--C 1.539 0.544 0 C-N-CA 127.138 2.175 . . . . 0.0 108.881 -175.677 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 13.1 mmmm -134.38 74.12 67.28 Favored Pre-proline 0 N--CA 1.474 0.739 0 C-N-CA 126.519 1.928 . . . . 0.0 109.179 175.536 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -67.21 120.02 7.07 Favored 'Trans proline' 0 CA--C 1.536 0.611 0 C-N-CA 122.929 2.419 . . . . 0.0 111.12 -175.732 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -107.51 155.75 8.17 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.747 0 C-N-CA 124.929 1.291 . . . . 0.0 110.961 -175.8 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 8.8 p -81.98 106.33 13.81 Favored 'General case' 0 CA--C 1.545 0.754 0 C-N-CA 125.792 1.637 . . . . 0.0 110.813 171.582 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -69.11 154.07 53.11 Favored Glycine 0 CA--C 1.534 1.272 0 O-C-N 121.45 -0.781 . . . . 0.0 112.085 172.063 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 73.2 m -61.69 -18.71 60.73 Favored 'General case' 0 N--CA 1.479 0.982 0 N-CA-C 116.084 1.883 . . . . 0.0 116.084 -168.854 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 31.8 t70 -82.14 -11.29 58.82 Favored 'General case' 0 CA--C 1.548 0.902 0 N-CA-C 114.105 1.15 . . . . 0.0 114.105 175.252 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 107.42 6.13 33.73 Favored Glycine 0 CA--C 1.536 1.377 0 C-N-CA 126.3 1.905 . . . . 0.0 114.418 -179.452 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 40.2 mtp180 -104.39 138.55 40.63 Favored 'General case' 0 N--CA 1.475 0.798 0 C-N-CA 126.073 1.749 . . . . 0.0 111.211 -175.139 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 8.1 p -77.91 141.9 38.75 Favored 'General case' 0 N--CA 1.47 0.55 0 C-N-CA 123.901 0.88 . . . . 0.0 112.39 175.961 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 92.8 m-85 -135.49 144.05 46.16 Favored 'General case' 0 N--CA 1.472 0.666 0 C-N-CA 125.437 1.495 . . . . 0.0 111.742 175.786 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -60.33 -40.98 92.56 Favored 'General case' 0 CA--C 1.543 0.688 0 N-CA-C 114.145 1.165 . . . . 0.0 114.145 -163.402 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 14.1 p30 -155.3 174.28 15.44 Favored 'General case' 0 CA--C 1.55 0.971 0 C-N-CA 126.282 1.833 . . . . 0.0 110.175 163.818 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 73.8 p -60.82 -25.98 66.99 Favored 'General case' 0 N--CA 1.48 1.037 0 N-CA-C 114.391 1.256 . . . . 0.0 114.391 -175.883 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 48.7 t -57.91 -62.25 1.94 Allowed 'General case' 0 CA--C 1.532 0.277 0 C-N-CA 124.923 1.289 . . . . 0.0 111.742 172.344 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 6.4 tt -59.91 -36.09 64.61 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.773 0 N-CA-C 112.289 0.477 . . . . 0.0 112.289 -177.336 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -58.26 -58.18 9.61 Favored 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 124.179 0.992 . . . . 0.0 111.518 174.589 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 65.2 mtm180 -64.17 -36.06 82.82 Favored 'General case' 0 N--CA 1.477 0.881 0 N-CA-C 113.271 0.841 . . . . 0.0 113.271 179.417 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 6.6 t -61.93 -42.97 99.71 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 124.009 0.924 . . . . 0.0 111.631 174.197 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 26.9 t-20 -69.37 -49.08 58.82 Favored 'General case' 0 CA--C 1.546 0.792 0 C-N-CA 124.851 1.26 . . . . 0.0 112.68 176.679 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 139.52 24.38 0.3 Allowed Glycine 0 CA--C 1.539 1.568 0 N-CA-C 116.16 1.224 . . . . 0.0 116.16 179.595 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 32.5 t -129.74 153.23 38.52 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.636 0 C-N-CA 126.373 1.869 . . . . 0.0 109.385 -177.927 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 68.9 m -134.41 170.48 15.67 Favored 'General case' 0 N--CA 1.47 0.575 0 C-N-CA 126.312 1.845 . . . . 0.0 112.099 -179.582 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 1.9 mp -118.01 3.34 7.28 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.1 0 C-N-CA 126.414 1.886 . . . . 0.0 111.443 -178.924 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 28.0 tptp -49.72 -61.88 1.87 Allowed 'General case' 0 N--CA 1.479 1.017 0 C-N-CA 127.044 2.137 . . . . 0.0 112.96 -178.904 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 13.4 t -156.29 129.75 8.22 Favored 'General case' 0 N--CA 1.466 0.328 0 C-N-CA 125.737 1.615 . . . . 0.0 110.054 -179.533 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 44.4 mt-10 -68.04 168.74 11.35 Favored 'General case' 0 CA--C 1.547 0.834 0 C-N-CA 124.857 1.263 . . . . 0.0 113.175 -179.444 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -69.12 -12.24 65.17 Favored Glycine 0 CA--C 1.54 1.642 0 N-CA-C 115.63 1.012 . . . . 0.0 115.63 -178.771 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 89.1 p -147.97 165.27 31.22 Favored 'General case' 0 N--CA 1.473 0.715 0 C-N-CA 126.069 1.748 . . . . 0.0 112.064 174.197 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 10.8 p -147.9 72.67 11.37 Favored Pre-proline 0 CA--C 1.551 1.017 0 C-N-CA 125.044 1.338 . . . . 0.0 112.052 178.589 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_endo -76.1 84.48 1.81 Allowed 'Trans proline' 0 CA--C 1.545 1.039 0 C-N-CA 123.811 3.007 . . . . 0.0 112.177 -179.551 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 2.0 m -74.27 43.12 0.17 Allowed 'General case' 0 N--CA 1.485 1.281 0 C-N-CA 126.701 2.0 . . . . 0.0 112.651 176.899 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 82.92 142.98 4.75 Favored Glycine 0 CA--C 1.537 1.422 0 C-N-CA 126.545 2.021 . . . . 0.0 113.034 -171.172 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 37.9 pt . . . . . 0 C--O 1.252 1.203 0 C-N-CA 127.447 2.299 . . . . 0.0 112.593 179.67 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 60.2 mtpt . . . . . 0 N--CA 1.494 1.738 0 CA-C-O 119.731 -0.176 . . . . 0.0 110.82 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 59.5 pttt 48.29 26.2 1.04 Allowed 'General case' 0 N--CA 1.49 1.568 0 C-N-CA 128.682 2.793 . . . . 0.0 117.27 179.236 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 25.0 t -77.63 124.13 35.5 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.853 0 C-N-CA 124.531 1.132 . . . . 0.0 111.049 -179.185 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 61.8 m -115.3 4.11 14.37 Favored 'General case' 0 CA--C 1.551 0.999 0 C-N-CA 126.351 1.861 . . . . 0.0 113.248 174.897 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . 54.41 30.85 13.46 Favored 'General case' 0 CA--C 1.551 1.002 0 C-N-CA 127.795 2.438 . . . . 0.0 114.408 -170.016 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 64.1 m -64.42 156.83 75.15 Favored Pre-proline 0 CA--C 1.55 0.958 0 C-N-CA 125.388 1.475 . . . . 0.0 113.387 177.321 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 95.3 Cg_endo -74.18 165.18 32.55 Favored 'Trans proline' 0 CA--C 1.542 0.894 0 C-N-CA 123.419 2.746 . . . . 0.0 113.522 -174.682 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 73.9 mmtt -78.87 -0.26 29.98 Favored 'General case' 0 N--CA 1.482 1.146 0 C-N-CA 126.28 1.832 . . . . 0.0 114.746 178.632 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 50.8 mm -56.86 157.97 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.766 0 C-N-CA 126.696 1.998 . . . . 0.0 111.146 170.536 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 51.5 tp -135.7 92.71 2.85 Favored 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 126.515 1.926 . . . . 0.0 108.583 -178.857 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 53.5 tptt -139.2 80.77 22.43 Favored Pre-proline 0 N--CA 1.471 0.595 0 C-N-CA 125.327 1.451 . . . . 0.0 110.124 174.186 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 62.1 Cg_endo -68.92 146.92 66.99 Favored 'Trans proline' 0 CA--C 1.537 0.67 0 C-N-CA 121.919 1.746 . . . . 0.0 111.102 177.68 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 1.4 t -137.08 159.81 36.41 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.977 0 C-N-CA 124.933 1.293 . . . . 0.0 110.518 -176.589 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 29.9 p -85.83 -7.47 58.71 Favored 'General case' 0 CA--C 1.547 0.828 0 C-N-CA 125.85 1.66 . . . . 0.0 114.764 -174.487 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 56.86 -178.38 0.78 Allowed Glycine 0 CA--C 1.537 1.442 0 C-N-CA 127.136 2.303 . . . . 0.0 116.447 177.274 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 11.2 t -79.46 -36.36 38.93 Favored 'General case' 0 CA--C 1.543 0.692 0 C-N-CA 123.653 0.781 . . . . 0.0 112.166 170.732 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -75.63 -12.22 60.17 Favored 'General case' 0 CA--C 1.548 0.877 0 C-N-CA 125.441 1.497 . . . . 0.0 114.596 -177.857 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 92.26 7.44 63.79 Favored Glycine 0 CA--C 1.536 1.373 0 C-N-CA 125.745 1.641 . . . . 0.0 114.723 176.13 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 38.3 mtt180 -95.84 -178.08 4.25 Favored 'General case' 0 N--CA 1.477 0.902 0 C-N-CA 126.353 1.861 . . . . 0.0 112.172 -177.046 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 47.3 m -122.24 128.19 50.84 Favored 'General case' 0 N--CA 1.476 0.85 0 C-N-CA 124.573 1.149 . . . . 0.0 110.505 179.32 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 56.4 m-85 -131.85 156.34 46.24 Favored 'General case' 0 N--CA 1.47 0.566 0 C-N-CA 125.491 1.517 . . . . 0.0 111.483 179.243 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.19 -43.83 85.7 Favored 'General case' 0 CA--C 1.544 0.748 0 N-CA-C 113.307 0.854 . . . . 0.0 113.307 -169.197 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 70.6 m-80 -139.66 175.9 9.18 Favored 'General case' 0 CA--C 1.544 0.729 0 C-N-CA 125.739 1.616 . . . . 0.0 111.557 171.184 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 42.4 t -61.34 -40.44 94.25 Favored 'General case' 0 N--CA 1.473 0.723 0 O-C-N 121.339 -0.851 . . . . 0.0 112.199 167.018 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 46.0 t -53.49 -57.42 10.76 Favored 'General case' 0 N--CA 1.467 0.398 0 C-N-CA 125.095 1.358 . . . . 0.0 112.795 -179.782 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 10.8 tp -59.97 -39.37 80.01 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.694 0 C-N-CA 122.791 0.436 . . . . 0.0 112.108 -179.099 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -68.76 -40.15 79.88 Favored 'General case' 0 CA--C 1.542 0.635 0 O-C-N 121.525 -0.735 . . . . 0.0 112.386 178.2 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 20.8 tpt180 -68.85 -35.66 77.2 Favored 'General case' 0 N--CA 1.472 0.654 0 C-N-CA 124.57 1.148 . . . . 0.0 112.691 176.107 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 47.8 t -59.45 -49.29 78.37 Favored 'General case' 0 CA--C 1.542 0.648 0 C-N-CA 125.059 1.344 . . . . 0.0 111.083 167.479 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 25.9 t-20 -62.97 -45.35 92.83 Favored 'General case' 0 CA--C 1.546 0.796 0 C-N-CA 124.814 1.246 . . . . 0.0 113.324 -179.535 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 143.66 17.22 0.24 Allowed Glycine 0 CA--C 1.54 1.614 0 N-CA-C 117.191 1.636 . . . . 0.0 117.191 175.386 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 21.7 t -115.7 144.15 23.98 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.704 0 CA-C-N 119.882 1.841 . . . . 0.0 110.232 -176.27 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 23.0 t -91.11 126.84 36.32 Favored 'General case' 0 N--CA 1.472 0.65 0 C-N-CA 126.48 1.912 . . . . 0.0 111.525 176.041 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 22.8 mm -116.65 -23.02 4.15 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.991 0 C-N-CA 125.08 1.352 . . . . 0.0 112.686 -174.655 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 26.5 mmmt -65.46 -21.08 66.61 Favored 'General case' 0 N--CA 1.48 1.027 0 C-N-CA 126.183 1.793 . . . . 0.0 113.72 173.548 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 1.7 t -76.11 9.55 2.44 Favored 'General case' 0 N--CA 1.476 0.868 0 C-N-CA 126.336 1.854 . . . . 0.0 114.982 -177.669 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 37.5 tp10 -48.85 -40.77 30.77 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 126.942 2.097 . . . . 0.0 115.179 -176.568 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -156.23 55.54 0.4 Allowed Glycine 0 CA--C 1.53 0.975 0 C-N-CA 124.098 0.856 . . . . 0.0 113.616 -174.77 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 43.0 m -64.05 -30.28 71.37 Favored 'General case' 0 N--CA 1.475 0.819 0 C-N-CA 124.618 1.167 . . . . 0.0 114.021 179.902 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 38.2 t -149.29 83.07 6.69 Favored Pre-proline 0 CA--C 1.551 0.997 0 C-N-CA 125.448 1.499 . . . . 0.0 111.07 175.661 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 95.1 Cg_endo -75.9 170.4 20.22 Favored 'Trans proline' 0 CA--C 1.542 0.909 0 C-N-CA 123.423 2.748 . . . . 0.0 112.37 178.9 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 6.2 t -70.6 171.86 9.58 Favored 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 123.94 0.896 . . . . 0.0 112.456 170.716 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -92.66 -110.63 1.91 Allowed Glycine 0 CA--C 1.535 1.296 0 C-N-CA 125.486 1.517 . . . . 0.0 112.919 -179.135 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 33.9 pt . . . . . 0 C--O 1.252 1.217 0 C-N-CA 125.874 1.67 . . . . 0.0 113.748 177.705 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 67.9 m . . . . . 0 CA--C 1.541 0.612 0 CA-C-O 121.064 0.459 . . . . 0.0 111.364 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -73.34 48.76 0.25 Allowed 'General case' 0 CA--C 1.554 1.13 0 C-N-CA 126.371 1.868 . . . . 0.0 113.54 177.627 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 85.4 m -61.99 156.79 55.65 Favored Pre-proline 0 CA--C 1.548 0.897 0 C-N-CA 125.718 1.607 . . . . 0.0 113.724 179.853 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_endo -68.62 151.82 74.88 Favored 'Trans proline' 0 C--N 1.351 0.7 0 C-N-CA 123.275 2.65 . . . . 0.0 112.137 177.17 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 10.4 ptpp? -74.28 -30.71 62.22 Favored 'General case' 0 N--CA 1.478 0.964 0 C-N-CA 125.058 1.343 . . . . 0.0 114.198 176.399 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 40.8 mm -58.05 126.95 16.47 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.741 0 C-N-CA 126.893 2.077 . . . . 0.0 111.457 -176.571 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 2.0 pt? -61.6 126.67 28.17 Favored 'General case' 0 CA--C 1.542 0.662 0 C-N-CA 125.128 1.371 . . . . 0.0 112.851 -179.777 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 74.9 mmtt -136.33 71.91 59.6 Favored Pre-proline 0 N--CA 1.479 1.004 0 C-N-CA 125.314 1.446 . . . . 0.0 111.604 173.25 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 75.1 Cg_endo -72.85 84.59 1.25 Allowed 'Trans proline' 0 CA--C 1.54 0.817 0 C-N-CA 123.84 3.027 . . . . 0.0 112.818 -178.058 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 15.1 m -76.99 162.13 4.35 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.589 0 C-N-CA 126.739 2.016 . . . . 0.0 113.296 178.824 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 10.6 t -80.19 -5.54 56.26 Favored 'General case' 0 CA--C 1.553 1.068 0 C-N-CA 125.492 1.517 . . . . 0.0 114.166 174.321 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 64.71 -164.67 34.45 Favored Glycine 0 CA--C 1.538 1.504 0 C-N-CA 125.072 1.32 . . . . 0.0 113.974 -178.371 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 25.1 t -111.27 -38.9 4.87 Favored 'General case' 0 N--CA 1.477 0.901 0 C-N-CA 124.775 1.23 . . . . 0.0 112.591 172.57 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 29.5 t70 -72.29 -13.42 61.5 Favored 'General case' 0 N--CA 1.478 0.955 0 N-CA-C 114.249 1.203 . . . . 0.0 114.249 177.718 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 98.15 39.27 3.81 Favored Glycine 0 CA--C 1.533 1.202 0 C-N-CA 125.92 1.724 . . . . 0.0 112.827 -178.745 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 16.2 mmm180 -135.33 150.88 50.07 Favored 'General case' 0 N--CA 1.475 0.776 0 C-N-CA 127.366 2.266 . . . . 0.0 110.822 -168.716 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 27.9 m -95.82 134.45 38.76 Favored 'General case' 0 N--CA 1.476 0.866 0 C-N-CA 124.209 1.004 . . . . 0.0 110.569 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 73.5 m-85 -128.67 160.92 30.94 Favored 'General case' 0 N--CA 1.471 0.613 0 C-N-CA 125.541 1.537 . . . . 0.0 111.215 178.666 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.9 -60.95 2.49 Favored 'General case' 0 CA--C 1.542 0.658 0 N-CA-C 111.784 0.29 . . . . 0.0 111.784 -172.247 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 30.1 m-20 -129.04 162.49 27.53 Favored 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 125.962 1.705 . . . . 0.0 110.322 170.896 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 26.7 p -63.24 -40.98 98.98 Favored 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 124.637 1.175 . . . . 0.0 113.684 177.299 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 49.5 t -57.89 -48.2 80.56 Favored 'General case' 0 N--CA 1.468 0.441 0 C-N-CA 125.303 1.441 . . . . 0.0 112.372 177.049 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 1.4 mp -52.31 -45.91 44.95 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.727 0 C-N-CA 124.815 1.246 . . . . 0.0 111.669 174.224 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -59.67 -46.63 88.46 Favored 'General case' 0 CA--C 1.545 0.753 0 CA-C-N 119.631 1.105 . . . . 0.0 112.14 177.281 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -57.69 -47.65 81.74 Favored 'General case' 0 N--CA 1.478 0.937 0 C-N-CA 124.877 1.271 . . . . 0.0 111.615 175.639 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 50.7 t -56.31 -48.21 77.13 Favored 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 125.38 1.472 . . . . 0.0 112.297 174.099 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -67.8 -30.06 69.39 Favored 'General case' 0 CA--C 1.548 0.882 0 C-N-CA 124.718 1.207 . . . . 0.0 112.792 -177.516 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 123.32 22.25 2.36 Favored Glycine 0 CA--C 1.537 1.409 0 C-N-CA 124.911 1.243 . . . . 0.0 115.954 175.401 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 5.0 t -124.27 143.59 37.09 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.568 0 C-N-CA 125.906 1.682 . . . . 0.0 109.315 -179.216 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 16.0 t -97.54 169.97 9.36 Favored 'General case' 0 N--CA 1.473 0.721 0 C-N-CA 125.362 1.465 . . . . 0.0 112.134 178.121 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 2.4 mt . . . . . 0 CA--C 1.552 1.054 0 C-N-CA 126.999 2.12 . . . . 0.0 110.494 -179.225 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 58.5 m . . . . . 0 CA--C 1.544 0.722 0 CA-C-O 120.651 0.262 . . . . 0.0 110.963 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -74.6 53.5 0.56 Allowed 'General case' 0 CA--C 1.553 1.059 0 C-N-CA 126.101 1.76 . . . . 0.0 113.629 -178.503 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 80.0 m -67.14 153.99 93.54 Favored Pre-proline 0 CA--C 1.551 0.982 0 C-N-CA 125.373 1.469 . . . . 0.0 113.306 -178.071 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -72.59 157.37 52.65 Favored 'Trans proline' 0 CA--C 1.541 0.847 0 C-N-CA 123.05 2.5 . . . . 0.0 112.514 179.459 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -88.72 -9.54 51.59 Favored 'General case' 0 N--CA 1.48 1.045 0 C-N-CA 124.927 1.291 . . . . 0.0 113.678 176.649 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 79.9 mt -62.02 139.82 20.2 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.756 0 C-N-CA 125.106 1.362 . . . . 0.0 109.692 174.176 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 10.4 mp -82.53 97.8 8.62 Favored 'General case' 0 CA--C 1.538 0.507 0 C-N-CA 124.744 1.218 . . . . 0.0 110.354 172.806 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 2.4 mmmp? -126.47 65.99 61.36 Favored Pre-proline 0 CA--C 1.546 0.815 0 C-N-CA 125.331 1.452 . . . . 0.0 110.632 170.147 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 66.5 Cg_endo -66.32 154.29 74.78 Favored 'Trans proline' 0 C--N 1.352 0.747 0 C-N-CA 122.813 2.342 . . . . 0.0 112.169 -179.263 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -142.18 160.2 20.1 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.757 0 C-N-CA 125.088 1.355 . . . . 0.0 110.476 -178.746 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 47.3 t -73.41 105.04 4.61 Favored 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 124.735 1.214 . . . . 0.0 110.283 169.97 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -65.99 148.02 50.65 Favored Glycine 0 CA--C 1.531 1.041 0 C-N-CA 124.1 0.857 . . . . 0.0 112.416 174.136 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 69.5 m -65.56 -17.58 64.68 Favored 'General case' 0 N--CA 1.475 0.819 0 N-CA-C 114.941 1.46 . . . . 0.0 114.941 -174.8 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 32.1 t70 -79.81 -8.12 59.08 Favored 'General case' 0 CA--C 1.552 1.032 0 C-N-CA 124.698 1.199 . . . . 0.0 113.569 169.148 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 97.34 27.38 9.29 Favored Glycine 0 CA--C 1.536 1.39 0 C-N-CA 126.548 2.023 . . . . 0.0 114.084 -179.593 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 64.3 mtt-85 -127.31 170.57 12.33 Favored 'General case' 0 N--CA 1.481 1.075 0 C-N-CA 125.241 1.416 . . . . 0.0 113.826 -166.385 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 33.1 m -103.45 125.36 49.99 Favored 'General case' 0 N--CA 1.475 0.78 0 C-N-CA 125.761 1.625 . . . . 0.0 110.674 -177.293 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 77.6 m-85 -131.57 157.43 43.62 Favored 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 125.097 1.359 . . . . 0.0 111.631 174.789 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.21 -48.82 74.39 Favored 'General case' 0 CA--C 1.542 0.645 0 N-CA-C 113.211 0.819 . . . . 0.0 113.211 -166.993 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . 0.407 ' H ' HG22 ' A' ' 26' ' ' ILE . 71.8 m-80 -144.32 174.23 11.09 Favored 'General case' 0 CA--C 1.549 0.936 0 C-N-CA 126.754 2.021 . . . . 0.0 111.08 174.865 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 69.5 m -65.58 -27.92 68.77 Favored 'General case' 0 N--CA 1.483 1.194 0 O-C-N 120.485 -1.385 . . . . 0.0 112.992 171.61 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 46.0 t -58.57 -58.36 8.9 Favored 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 125.414 1.486 . . . . 0.0 112.218 175.652 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.407 HG22 ' H ' ' A' ' 23' ' ' ASN . 10.5 tp -60.7 -33.95 56.94 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 N-CA-C 112.219 0.452 . . . . 0.0 112.219 -179.619 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -59.24 -53.89 53.13 Favored 'General case' 0 CA--C 1.542 0.663 0 CA-C-N 118.684 0.675 . . . . 0.0 111.852 173.152 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 18.4 mmm180 -62.9 -33.56 75.56 Favored 'General case' 0 N--CA 1.48 1.031 0 C-N-CA 123.812 0.845 . . . . 0.0 113.217 176.088 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 19.3 t -62.83 -46.69 86.74 Favored 'General case' 0 CA--C 1.545 0.762 0 C-N-CA 124.513 1.125 . . . . 0.0 111.741 172.554 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 88.1 m-20 -69.34 -49.66 53.64 Favored 'General case' 0 CA--C 1.542 0.654 0 C-N-CA 125.552 1.541 . . . . 0.0 113.015 -179.691 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 142.63 24.5 0.19 Allowed Glycine 0 CA--C 1.538 1.518 0 N-CA-C 116.484 1.353 . . . . 0.0 116.484 -177.867 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 6.6 t -128.4 147.02 32.97 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.706 0 C-N-CA 126.211 1.804 . . . . 0.0 108.878 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 68.8 m -117.43 133.33 56.09 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 125.337 1.455 . . . . 0.0 112.231 -175.369 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 9.9 mm . . . . . 0 N--CA 1.48 1.04 0 C-N-CA 126.375 1.87 . . . . 0.0 111.582 -166.631 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 34.2 m . . . . . 0 CA--C 1.547 0.834 0 N-CA-C 112.981 0.734 . . . . 0.0 112.981 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . 46.46 34.33 2.31 Favored 'General case' 0 CA--C 1.549 0.931 0 C-N-CA 127.366 2.266 . . . . 0.0 114.612 -174.462 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 53.2 m -63.22 152.78 83.77 Favored Pre-proline 0 CA--C 1.548 0.891 0 C-N-CA 124.264 1.026 . . . . 0.0 113.285 -176.658 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -67.75 157.54 61.32 Favored 'Trans proline' 0 CA--C 1.54 0.78 0 C-N-CA 123.595 2.863 . . . . 0.0 112.942 179.873 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 32.1 mmmt -74.24 -8.91 57.85 Favored 'General case' 0 N--CA 1.481 1.085 0 C-N-CA 126.353 1.861 . . . . 0.0 114.116 -179.05 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -54.89 138.52 14.93 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.691 0 C-N-CA 127.43 2.292 . . . . 0.0 112.838 179.396 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 42.5 tp -114.0 101.05 8.88 Favored 'General case' 0 CA--C 1.539 0.52 0 C-N-CA 127.269 2.228 . . . . 0.0 109.127 -176.588 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 59.0 tttm -148.74 78.17 9.15 Favored Pre-proline 0 N--CA 1.473 0.7 0 C-N-CA 124.635 1.174 . . . . 0.0 110.662 175.646 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 67.0 Cg_endo -72.26 108.24 2.45 Favored 'Trans proline' 0 N--CA 1.458 -0.612 0 C-N-CA 123.035 2.49 . . . . 0.0 111.913 -177.871 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 14.9 m -107.09 172.65 1.82 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.463 0 C-N-CA 126.867 2.067 . . . . 0.0 111.793 -179.836 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 24.2 t -75.75 154.07 36.59 Favored 'General case' 0 CA--C 1.541 0.599 0 C-N-CA 123.981 0.912 . . . . 0.0 111.184 -179.851 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -121.48 152.82 16.76 Favored Glycine 0 CA--C 1.531 1.061 0 C-N-CA 125.012 1.292 . . . . 0.0 113.239 177.002 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 9.2 t -55.98 -36.05 67.43 Favored 'General case' 0 N--CA 1.476 0.841 0 C-N-CA 125.86 1.664 . . . . 0.0 114.064 -173.783 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 32.8 t70 -80.04 -9.31 59.69 Favored 'General case' 0 CA--C 1.551 1.0 0 C-N-CA 125.027 1.331 . . . . 0.0 114.368 179.119 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 89.88 53.4 2.4 Favored Glycine 0 CA--C 1.532 1.136 0 C-N-CA 125.311 1.434 . . . . 0.0 112.068 -175.203 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 4.0 mmp_? -137.81 174.89 10.1 Favored 'General case' 0 N--CA 1.477 0.91 0 C-N-CA 127.658 2.383 . . . . 0.0 110.916 -172.462 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 9.4 m -137.71 140.49 40.76 Favored 'General case' 0 N--CA 1.48 1.025 0 C-N-CA 125.301 1.44 . . . . 0.0 110.512 179.7 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 49.1 m-85 -139.25 161.33 37.68 Favored 'General case' 0 N--CA 1.473 0.699 0 C-N-CA 125.533 1.533 . . . . 0.0 111.32 -176.894 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.39 -45.42 87.77 Favored 'General case' 0 CA--C 1.545 0.772 0 N-CA-C 113.525 0.935 . . . . 0.0 113.525 -167.553 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . 0.433 ' H ' HG22 ' A' ' 26' ' ' ILE . 28.0 p30 -146.08 -178.42 6.12 Favored 'General case' 0 CA--C 1.548 0.886 0 C-N-CA 125.226 1.411 . . . . 0.0 111.864 166.984 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 29.0 p -66.28 -30.16 70.53 Favored 'General case' 0 N--CA 1.472 0.629 0 N-CA-C 114.226 1.195 . . . . 0.0 114.226 179.094 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 49.1 t -64.98 -56.58 12.32 Favored 'General case' 0 N--CA 1.47 0.526 0 C-N-CA 124.058 0.943 . . . . 0.0 111.524 177.401 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.433 HG22 ' H ' ' A' ' 23' ' ' ASN . 11.2 tp -57.6 -38.88 66.59 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.618 0 CA-C-O 119.354 -0.355 . . . . 0.0 111.757 179.853 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -61.11 -45.09 96.12 Favored 'General case' 0 CA--C 1.543 0.683 0 C-N-CA 123.949 0.9 . . . . 0.0 112.797 175.809 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 5.1 tpt180 -64.8 -42.06 95.31 Favored 'General case' 0 N--CA 1.474 0.734 0 C-N-CA 123.448 0.699 . . . . 0.0 112.524 176.203 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 2.9 t -65.35 -36.08 82.94 Favored 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 123.117 0.567 . . . . 0.0 112.164 174.858 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 24.7 t-20 -66.68 -53.71 30.82 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 125.594 1.558 . . . . 0.0 112.486 176.674 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 151.49 19.4 0.06 OUTLIER Glycine 0 CA--C 1.538 1.526 0 N-CA-C 117.602 1.801 . . . . 0.0 117.602 179.284 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 3.7 t -127.78 138.69 53.99 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.814 0 CA-C-N 120.25 2.025 . . . . 0.0 110.309 -177.659 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 8.6 t -91.87 94.65 9.42 Favored 'General case' 0 N--CA 1.472 0.658 0 C-N-CA 125.245 1.418 . . . . 0.0 112.324 -173.987 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 19.6 mm . . . . . 0 N--CA 1.479 1.006 0 C-N-CA 124.368 1.067 . . . . 0.0 112.972 -176.861 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 3.7 m . . . . . 0 CA--C 1.544 0.737 0 N-CA-C 110.002 -0.37 . . . . 0.0 110.002 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -74.66 60.22 0.9 Allowed 'General case' 0 CA--C 1.553 1.085 0 C-N-CA 124.607 1.163 . . . . 0.0 112.827 179.351 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 84.3 m -64.12 156.11 76.15 Favored Pre-proline 0 CA--C 1.55 0.947 0 C-N-CA 125.78 1.632 . . . . 0.0 112.96 179.497 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 93.0 Cg_endo -71.35 168.42 23.5 Favored 'Trans proline' 0 CA--C 1.54 0.819 0 C-N-CA 123.056 2.504 . . . . 0.0 112.334 176.589 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 38.0 tttp -64.09 -20.33 65.88 Favored 'General case' 0 N--CA 1.479 0.977 0 C-N-CA 124.761 1.224 . . . . 0.0 113.188 174.721 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 61.7 mt -57.89 120.05 3.62 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.589 0 C-N-CA 126.715 2.006 . . . . 0.0 111.066 179.908 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 15.9 tp -99.44 117.41 33.79 Favored 'General case' 0 CA--C 1.538 0.508 0 C-N-CA 129.048 2.939 . . . . 0.0 108.363 174.533 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -132.18 78.27 69.14 Favored Pre-proline 0 N--CA 1.473 0.704 0 C-N-CA 125.786 1.634 . . . . 0.0 108.882 -178.695 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 66.2 Cg_endo -71.38 102.66 1.3 Allowed 'Trans proline' 0 CA--C 1.537 0.67 0 C-N-CA 123.831 3.021 . . . . 0.0 112.181 -168.527 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -100.2 158.13 3.91 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.003 0 C-N-CA 124.332 1.053 . . . . 0.0 112.245 -176.162 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 18.0 t -72.94 -18.2 61.41 Favored 'General case' 0 CA--C 1.547 0.843 0 N-CA-C 114.209 1.189 . . . . 0.0 114.209 -178.896 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 63.51 -178.63 6.68 Favored Glycine 0 CA--C 1.537 1.457 0 C-N-CA 126.416 1.96 . . . . 0.0 115.514 176.971 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 14.1 m -84.53 -38.46 20.0 Favored 'General case' 0 N--CA 1.476 0.857 0 C-N-CA 124.066 0.947 . . . . 0.0 113.083 173.484 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 20.4 m-20 -77.03 -14.97 59.76 Favored 'General case' 0 N--CA 1.479 0.98 0 N-CA-C 113.581 0.956 . . . . 0.0 113.581 179.695 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 98.07 -11.77 63.91 Favored Glycine 0 CA--C 1.536 1.353 0 C-N-CA 126.391 1.948 . . . . 0.0 114.392 179.842 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -78.41 156.53 29.4 Favored 'General case' 0 N--CA 1.474 0.761 0 C-N-CA 125.262 1.425 . . . . 0.0 112.084 171.239 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -84.26 113.14 20.9 Favored 'General case' 0 N--CA 1.472 0.638 0 C-N-CA 124.88 1.272 . . . . 0.0 112.857 178.069 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 79.0 m-85 -91.45 149.53 21.66 Favored 'General case' 0 N--CA 1.475 0.785 0 C-N-CA 124.792 1.237 . . . . 0.0 111.599 173.489 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.69 -46.75 77.84 Favored 'General case' 0 CA--C 1.542 0.665 0 N-CA-C 113.355 0.872 . . . . 0.0 113.355 -168.936 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 26.0 p30 -157.06 -179.35 8.12 Favored 'General case' 0 CA--C 1.545 0.773 0 C-N-CA 125.441 1.496 . . . . 0.0 111.88 174.348 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 36.7 p -61.69 -32.57 72.78 Favored 'General case' 0 N--CA 1.473 0.708 0 O-C-N 120.977 -1.077 . . . . 0.0 113.342 173.956 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 49.5 t -58.82 -60.51 3.73 Favored 'General case' 0 CA--C 1.533 0.299 0 C-N-CA 124.85 1.26 . . . . 0.0 111.765 176.75 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 9.8 tp -56.98 -40.45 72.64 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.881 0 N-CA-C 112.431 0.53 . . . . 0.0 112.431 178.943 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -57.32 -59.34 5.27 Favored 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 123.886 0.874 . . . . 0.0 111.461 176.498 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 46.3 mmm-85 -59.27 -41.85 89.84 Favored 'General case' 0 N--CA 1.475 0.799 0 C-N-CA 124.773 1.229 . . . . 0.0 113.028 178.775 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 2.9 t -66.6 -41.33 88.62 Favored 'General case' 0 CA--C 1.545 0.757 0 C-N-CA 123.609 0.763 . . . . 0.0 112.536 179.579 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 53.1 t30 -71.52 -42.0 68.51 Favored 'General case' 0 CA--C 1.543 0.7 0 C-N-CA 124.655 1.182 . . . . 0.0 113.181 178.833 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 129.71 30.1 0.66 Allowed Glycine 0 CA--C 1.538 1.475 0 C-N-CA 124.611 1.1 . . . . 0.0 115.206 -179.333 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -123.08 169.7 14.16 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 C-N-CA 127.37 2.268 . . . . 0.0 109.192 -177.866 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 29.8 t -145.77 161.52 39.74 Favored 'General case' 0 N--CA 1.471 0.614 0 C-N-CA 125.259 1.423 . . . . 0.0 112.42 -179.005 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 18.7 mm . . . . . 0 N--CA 1.476 0.86 0 C-N-CA 125.956 1.703 . . . . 0.0 111.69 178.019 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 29.2 m . . . . . 0 CA--C 1.54 0.585 0 CA-C-O 120.548 0.213 . . . . 0.0 110.532 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -71.64 55.78 0.26 Allowed 'General case' 0 CA--C 1.552 1.045 0 C-N-CA 126.516 1.926 . . . . 0.0 113.101 -179.961 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 93.0 m -63.59 157.59 64.79 Favored Pre-proline 0 CA--C 1.549 0.937 0 C-N-CA 126.083 1.753 . . . . 0.0 112.739 178.496 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -64.89 155.02 70.14 Favored 'Trans proline' 0 CA--C 1.537 0.671 0 C-N-CA 123.281 2.654 . . . . 0.0 112.803 -179.871 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 19.5 ptpt -59.75 -25.59 64.99 Favored 'General case' 0 N--CA 1.48 1.074 0 C-N-CA 125.707 1.603 . . . . 0.0 114.497 178.029 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 8.9 tp -57.11 144.47 9.34 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.473 0 C-N-CA 127.089 2.155 . . . . 0.0 113.212 -178.68 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 23.8 tp -119.66 108.24 14.21 Favored 'General case' 0 CA--C 1.535 0.402 0 C-N-CA 126.708 2.003 . . . . 0.0 108.292 -178.283 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 39.5 ttpt -128.95 79.03 75.34 Favored Pre-proline 0 CA--C 1.54 0.576 0 C-N-CA 126.38 1.872 . . . . 0.0 108.511 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -73.68 90.34 0.94 Allowed 'Trans proline' 0 CA--C 1.539 0.742 0 C-N-CA 123.72 2.947 . . . . 0.0 111.909 -171.442 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 1.1 t -83.56 161.26 3.38 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 C-N-CA 124.421 1.089 . . . . 0.0 111.03 -177.56 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 46.3 t -72.44 111.59 7.76 Favored 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 124.342 1.057 . . . . 0.0 109.839 170.448 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -65.51 146.01 49.25 Favored Glycine 0 CA--C 1.532 1.118 0 C-N-CA 123.778 0.704 . . . . 0.0 112.422 177.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 82.7 p -61.39 -29.86 70.19 Favored 'General case' 0 N--CA 1.476 0.865 0 N-CA-C 113.935 1.087 . . . . 0.0 113.935 -174.072 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 31.8 t70 -84.98 -8.19 58.84 Favored 'General case' 0 CA--C 1.551 0.993 0 C-N-CA 125.964 1.706 . . . . 0.0 113.894 176.92 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 107.51 1.04 34.96 Favored Glycine 0 CA--C 1.536 1.386 0 C-N-CA 126.504 2.002 . . . . 0.0 114.674 -178.623 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 22.1 mtm180 -90.32 -172.21 3.37 Favored 'General case' 0 N--CA 1.479 0.988 0 C-N-CA 126.355 1.862 . . . . 0.0 112.387 -177.269 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 23.0 m -128.8 135.26 48.91 Favored 'General case' 0 N--CA 1.479 1.01 0 C-N-CA 125.487 1.515 . . . . 0.0 110.492 -178.274 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 81.8 m-85 -135.94 150.39 49.27 Favored 'General case' 0 N--CA 1.474 0.74 0 C-N-CA 125.055 1.342 . . . . 0.0 111.488 -177.573 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.31 -45.08 89.52 Favored 'General case' 0 CA--C 1.543 0.683 0 N-CA-C 113.929 1.085 . . . . 0.0 113.929 -165.242 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 27.0 p30 -157.74 178.62 10.05 Favored 'General case' 0 CA--C 1.549 0.932 0 C-N-CA 125.927 1.691 . . . . 0.0 111.124 170.298 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 89.0 p -60.54 -29.69 69.29 Favored 'General case' 0 N--CA 1.478 0.973 0 N-CA-C 114.015 1.117 . . . . 0.0 114.015 179.052 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 45.4 t -61.66 -57.93 10.05 Favored 'General case' 0 N--CA 1.465 0.312 0 C-N-CA 124.24 1.016 . . . . 0.0 111.704 176.888 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 7.6 tp -59.75 -37.89 73.38 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.819 0 N-CA-C 112.062 0.393 . . . . 0.0 112.062 -179.878 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -57.3 -55.96 28.02 Favored 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 124.199 1.0 . . . . 0.0 111.583 173.967 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 70.4 mtp85 -61.23 -40.63 94.73 Favored 'General case' 0 N--CA 1.475 0.809 0 N-CA-C 113.297 0.851 . . . . 0.0 113.297 178.341 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -65.41 -36.35 83.68 Favored 'General case' 0 CA--C 1.546 0.819 0 N-CA-C 112.57 0.582 . . . . 0.0 112.57 177.132 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 25.9 t-20 -72.37 -47.53 48.68 Favored 'General case' 0 CA--C 1.546 0.815 0 C-N-CA 124.798 1.239 . . . . 0.0 113.003 175.926 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 135.8 29.5 0.36 Allowed Glycine 0 CA--C 1.538 1.53 0 C-N-CA 124.911 1.243 . . . . 0.0 115.469 -178.437 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 34.6 t -127.87 152.32 35.8 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.464 0 C-N-CA 127.416 2.286 . . . . 0.0 108.645 -176.992 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 58.2 m -141.72 160.06 40.95 Favored 'General case' 0 N--CA 1.476 0.838 0 C-N-CA 125.878 1.671 . . . . 0.0 112.302 -179.343 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 16.3 mt . . . . . 0 N--CA 1.481 1.108 0 C-N-CA 125.102 1.361 . . . . 0.0 111.828 -175.067 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 4.7 t . . . . . 0 CA--C 1.548 0.87 0 N-CA-C 114.111 1.152 . . . . 0.0 114.111 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . 49.34 30.73 3.39 Favored 'General case' 0 CA--C 1.549 0.921 0 C-N-CA 127.018 2.127 . . . . 0.0 115.603 178.421 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 58.0 m -61.8 151.29 79.76 Favored Pre-proline 0 CA--C 1.547 0.828 0 C-N-CA 124.368 1.067 . . . . 0.0 112.379 177.141 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -75.1 -4.13 14.93 Favored 'Trans proline' 0 CA--C 1.543 0.955 0 C-N-CA 124.135 3.223 . . . . 0.0 115.735 -168.769 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 37.8 mmtm 58.86 6.93 0.7 Allowed 'General case' 0 N--CA 1.481 1.093 0 C-N-CA 128.247 2.619 . . . . 0.0 116.299 179.839 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 11.2 tp -51.76 142.47 4.27 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.631 0 C-N-CA 126.698 1.999 . . . . 0.0 112.329 178.436 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 4.5 tt -78.46 89.99 4.45 Favored 'General case' 0 CA--C 1.545 0.772 0 C-N-CA 127.209 2.204 . . . . 0.0 110.907 -177.706 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 3.8 ttmp? -143.83 74.83 16.34 Favored Pre-proline 0 N--CA 1.477 0.897 0 C-N-CA 124.992 1.317 . . . . 0.0 111.843 178.33 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -67.8 91.1 0.36 Allowed 'Trans proline' 0 CA--C 1.54 0.809 0 C-N-CA 124.347 3.364 . . . . 0.0 112.754 -175.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 5.7 m -87.27 143.08 12.05 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 C-N-CA 126.32 1.848 . . . . 0.0 112.101 179.652 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 47.3 t -63.7 119.82 10.65 Favored 'General case' 0 CA--C 1.542 0.653 0 C-N-CA 124.125 0.97 . . . . 0.0 110.988 172.475 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -92.23 154.79 22.53 Favored Glycine 0 CA--C 1.533 1.17 0 C-N-CA 124.597 1.094 . . . . 0.0 112.861 177.911 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 7.5 t -61.74 -27.26 68.6 Favored 'General case' 0 N--CA 1.475 0.781 0 N-CA-C 114.463 1.283 . . . . 0.0 114.463 -173.943 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 10.5 t0 -76.52 -10.25 59.25 Favored 'General case' 0 CA--C 1.547 0.841 0 N-CA-C 113.69 0.996 . . . . 0.0 113.69 176.216 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 105.09 -10.11 47.3 Favored Glycine 0 CA--C 1.536 1.354 0 C-N-CA 126.586 2.041 . . . . 0.0 114.048 178.21 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 5.9 ptp85 -82.31 -171.13 3.27 Favored 'General case' 0 N--CA 1.473 0.706 0 C-N-CA 126.067 1.747 . . . . 0.0 112.723 173.365 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 11.5 t -123.34 157.62 32.86 Favored 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 125.595 1.558 . . . . 0.0 111.688 174.307 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -137.51 148.53 46.08 Favored 'General case' 0 N--CA 1.471 0.6 0 C-N-CA 126.263 1.825 . . . . 0.0 110.917 -179.9 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -60.28 -36.86 78.8 Favored 'General case' 0 CA--C 1.543 0.673 0 N-CA-C 114.049 1.129 . . . . 0.0 114.049 -164.277 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 12.4 p30 -156.89 177.54 11.39 Favored 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 126.443 1.897 . . . . 0.0 111.848 168.889 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 27.6 t -58.73 -38.95 79.49 Favored 'General case' 0 N--CA 1.472 0.637 0 O-C-N 121.345 -0.847 . . . . 0.0 113.099 176.486 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 20.0 t -60.14 -55.94 27.66 Favored 'General case' 0 N--CA 1.468 0.47 0 O-C-N 121.493 -0.755 . . . . 0.0 111.806 -179.886 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 7.4 tt -59.4 -38.71 76.42 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.698 0 CA-C-O 118.996 -0.526 . . . . 0.0 112.292 178.437 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -59.61 -53.6 56.12 Favored 'General case' 0 CA--C 1.543 0.684 0 CA-C-N 119.132 0.878 . . . . 0.0 111.904 174.814 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 5.7 mtp-105 -57.41 -44.07 84.27 Favored 'General case' 0 N--CA 1.477 0.884 0 C-N-CA 124.824 1.25 . . . . 0.0 112.3 178.034 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -71.51 -34.0 69.71 Favored 'General case' 0 CA--C 1.544 0.737 0 N-CA-C 113.448 0.907 . . . . 0.0 113.448 178.748 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 28.8 t-20 -66.85 -40.39 87.91 Favored 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 124.277 1.031 . . . . 0.0 112.541 174.056 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 135.29 22.59 0.63 Allowed Glycine 0 CA--C 1.538 1.471 0 C-N-CA 125.051 1.31 . . . . 0.0 115.896 176.366 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 40.4 t -128.26 149.54 33.2 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.525 0 C-N-CA 126.26 1.824 . . . . 0.0 109.866 -174.556 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 58.8 m -121.92 171.81 8.66 Favored 'General case' 0 N--CA 1.475 0.78 0 C-N-CA 126.857 2.063 . . . . 0.0 112.063 -176.702 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.468 0.447 0 C-N-CA 125.513 1.525 . . . . 0.0 108.92 -176.37 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 10.9 t . . . . . 0 CA--C 1.544 0.746 0 N-CA-C 111.83 0.307 . . . . 0.0 111.83 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -74.04 32.36 0.08 Allowed 'General case' 0 CA--C 1.554 1.128 0 C-N-CA 126.588 1.955 . . . . 0.0 115.668 -172.654 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 62.8 m -64.25 152.65 87.9 Favored Pre-proline 0 CA--C 1.549 0.926 0 C-N-CA 124.907 1.283 . . . . 0.0 113.67 179.275 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 89.1 Cg_endo -72.6 153.86 54.71 Favored 'Trans proline' 0 C--N 1.352 0.742 0 C-N-CA 123.359 2.706 . . . . 0.0 112.326 176.581 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 57.3 mtmt -76.38 -1.93 29.33 Favored 'General case' 0 N--CA 1.48 1.053 0 C-N-CA 125.708 1.603 . . . . 0.0 114.685 -179.361 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 46.9 mm -51.18 120.59 1.34 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.715 0 C-N-CA 126.145 1.778 . . . . 0.0 111.181 174.716 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 54.9 tp -84.71 102.27 12.85 Favored 'General case' 0 CA--C 1.539 0.546 0 C-N-CA 127.401 2.28 . . . . 0.0 109.614 177.935 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 20.8 tptp -147.07 91.94 5.04 Favored Pre-proline 0 N--CA 1.471 0.582 0 C-N-CA 124.098 0.959 . . . . 0.0 110.753 166.432 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -64.47 137.89 57.35 Favored 'Trans proline' 0 N--CA 1.456 -0.689 0 C-N-CA 121.191 1.261 . . . . 0.0 111.024 172.266 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 8.7 m -140.79 159.09 23.98 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.361 0 C-N-CA 127.373 2.269 . . . . 0.0 110.845 -179.346 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 37.6 t -72.78 149.52 43.58 Favored 'General case' 0 CA--C 1.545 0.763 0 C-N-CA 123.822 0.849 . . . . 0.0 111.785 171.973 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -123.76 156.21 17.93 Favored Glycine 0 CA--C 1.535 1.325 0 C-N-CA 125.859 1.695 . . . . 0.0 112.544 169.974 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 14.6 t -51.53 -40.64 60.05 Favored 'General case' 0 N--CA 1.478 0.966 0 C-N-CA 126.059 1.744 . . . . 0.0 115.431 -166.119 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 13.9 m-20 -71.1 -5.86 34.79 Favored 'General case' 0 CA--C 1.548 0.879 0 N-CA-C 114.863 1.431 . . . . 0.0 114.863 -179.193 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 86.83 61.32 1.61 Allowed Glycine 0 CA--C 1.527 0.805 0 C-N-CA 125.107 1.337 . . . . 0.0 110.592 -173.387 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 89.5 mmt-85 -142.18 168.29 20.09 Favored 'General case' 0 N--CA 1.472 0.671 0 C-N-CA 127.36 2.264 . . . . 0.0 111.103 -172.806 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 6.6 p -132.14 145.23 51.24 Favored 'General case' 0 C--O 1.235 0.322 0 C-N-CA 126.301 1.84 . . . . 0.0 111.089 172.455 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 92.8 m-85 -141.63 157.04 45.59 Favored 'General case' 0 N--CA 1.471 0.62 0 C-N-CA 125.604 1.561 . . . . 0.0 111.454 -179.461 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.69 -32.89 74.77 Favored 'General case' 0 CA--C 1.545 0.788 0 N-CA-C 114.451 1.278 . . . . 0.0 114.451 -165.222 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 60.5 t30 -149.37 168.13 24.24 Favored 'General case' 0 CA--C 1.544 0.747 0 C-N-CA 125.558 1.543 . . . . 0.0 111.17 171.26 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 34.6 p -57.19 -42.63 81.56 Favored 'General case' 0 N--CA 1.472 0.653 0 C-N-CA 124.769 1.228 . . . . 0.0 113.106 175.216 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 38.1 t -56.51 -55.76 29.68 Favored 'General case' 0 CA--C 1.533 0.292 0 C-N-CA 124.376 1.07 . . . . 0.0 112.11 177.507 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.8 tt -62.21 -35.25 68.08 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.672 0 CA-C-O 118.684 -0.674 . . . . 0.0 112.407 -177.679 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -57.82 -53.43 58.27 Favored 'General case' 0 CA--C 1.54 0.563 0 CA-C-N 119.288 0.949 . . . . 0.0 111.443 173.516 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -56.38 -49.78 73.47 Favored 'General case' 0 N--CA 1.474 0.768 0 C-N-CA 125.042 1.337 . . . . 0.0 111.282 176.124 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -63.7 -39.84 95.29 Favored 'General case' 0 CA--C 1.541 0.622 0 C-N-CA 123.786 0.834 . . . . 0.0 113.089 -177.68 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 88.8 m-20 -66.27 -33.44 75.74 Favored 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 124.86 1.264 . . . . 0.0 112.79 174.458 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 130.17 17.21 1.64 Allowed Glycine 0 CA--C 1.536 1.369 0 N-CA-C 116.389 1.316 . . . . 0.0 116.389 171.618 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 7.4 t -118.63 132.97 66.96 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.666 0 CA-C-N 119.629 1.714 . . . . 0.0 110.608 -178.229 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 38.5 m -78.54 164.69 24.48 Favored 'General case' 0 C--N 1.322 -0.597 0 C-N-CA 126.826 2.05 . . . . 0.0 112.714 -179.583 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.469 0.525 0 C-N-CA 125.873 1.669 . . . . 0.0 109.1 -178.959 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 3.2 m . . . . . 0 CA--C 1.548 0.884 0 N-CA-C 110.377 -0.231 . . . . 0.0 110.377 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -75.89 58.45 1.15 Allowed 'General case' 0 CA--C 1.554 1.1 0 C-N-CA 124.798 1.239 . . . . 0.0 113.24 -179.519 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 76.3 m -69.75 159.32 84.39 Favored Pre-proline 0 CA--C 1.553 1.082 0 C-N-CA 126.048 1.739 . . . . 0.0 113.746 -177.413 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -71.06 165.44 32.39 Favored 'Trans proline' 0 CA--C 1.542 0.877 0 C-N-CA 123.497 2.798 . . . . 0.0 113.407 179.141 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 7.9 ptpp? -68.35 -27.56 66.36 Favored 'General case' 0 N--CA 1.482 1.161 0 C-N-CA 125.072 1.349 . . . . 0.0 114.613 175.501 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 34.9 mm -60.08 161.88 1.24 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.83 0 C-N-CA 128.162 2.585 . . . . 0.0 111.294 176.295 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 20.1 tp -141.98 101.89 4.03 Favored 'General case' 0 CA--C 1.537 0.472 0 C-N-CA 126.257 1.823 . . . . 0.0 109.879 -170.646 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -115.52 84.92 12.77 Favored Pre-proline 0 N--CA 1.474 0.726 0 C-N-CA 126.096 1.759 . . . . 0.0 109.42 175.399 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 93.7 Cg_endo -74.52 81.14 2.14 Favored 'Trans proline' 0 CA--C 1.541 0.848 0 C-N-CA 124.043 3.162 . . . . 0.0 111.717 -176.616 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 9.0 m -85.84 164.24 2.48 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 C-N-CA 127.195 2.198 . . . . 0.0 113.003 -175.938 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 30.1 p -68.29 173.97 4.37 Favored 'General case' 0 CA--C 1.549 0.933 0 C-N-CA 124.231 1.012 . . . . 0.0 112.294 159.289 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -148.48 155.98 26.66 Favored Glycine 0 CA--C 1.532 1.132 0 C-N-CA 125.691 1.615 . . . . 0.0 111.392 173.712 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 19.0 t -57.09 -35.55 69.54 Favored 'General case' 0 N--CA 1.476 0.872 0 N-CA-C 115.144 1.535 . . . . 0.0 115.144 -163.138 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 31.5 t70 -71.86 -9.1 57.84 Favored 'General case' 0 CA--C 1.551 1.008 0 N-CA-C 114.415 1.265 . . . . 0.0 114.415 179.305 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 106.84 12.58 23.94 Favored Glycine 0 CA--C 1.535 1.286 0 C-N-CA 126.063 1.792 . . . . 0.0 114.073 179.35 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 31.2 mtm180 -120.99 134.46 55.3 Favored 'General case' 0 N--CA 1.476 0.844 0 C-N-CA 126.225 1.81 . . . . 0.0 111.181 -171.542 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 18.0 p -75.23 151.55 38.41 Favored 'General case' 0 N--CA 1.471 0.597 0 C-N-CA 124.622 1.169 . . . . 0.0 112.614 177.927 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 76.5 m-85 -139.69 149.03 43.19 Favored 'General case' 0 N--CA 1.471 0.592 0 C-N-CA 125.434 1.494 . . . . 0.0 112.93 -179.87 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -69.74 -33.72 72.84 Favored 'General case' 0 CA--C 1.545 0.76 0 N-CA-C 113.902 1.075 . . . . 0.0 113.902 -165.895 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . 0.463 ' H ' HG22 ' A' ' 26' ' ' ILE . 14.7 m-20 -145.87 170.85 15.76 Favored 'General case' 0 CA--C 1.543 0.703 0 C-N-CA 125.813 1.645 . . . . 0.0 110.946 166.116 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 40.7 p -59.46 -35.55 74.27 Favored 'General case' 0 N--CA 1.473 0.722 0 O-C-N 121.368 -0.832 . . . . 0.0 112.45 165.824 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 43.5 t -52.87 -63.33 1.18 Allowed 'General case' 0 CA--C 1.533 0.316 0 C-N-CA 126.01 1.724 . . . . 0.0 112.369 174.064 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.463 HG22 ' H ' ' A' ' 23' ' ' ASN . 9.1 tp -58.38 -37.3 62.85 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.788 0 N-CA-C 112.592 0.59 . . . . 0.0 112.592 -178.583 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -59.94 -54.59 44.32 Favored 'General case' 0 CA--C 1.544 0.716 0 CA-C-N 118.697 0.68 . . . . 0.0 111.836 173.961 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 25.4 mmm180 -61.57 -39.98 93.09 Favored 'General case' 0 N--CA 1.478 0.975 0 C-N-CA 124.707 1.203 . . . . 0.0 113.207 177.933 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 9.2 t -62.15 -43.92 97.76 Favored 'General case' 0 CA--C 1.544 0.729 0 C-N-CA 124.832 1.253 . . . . 0.0 111.644 175.128 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 28.7 t-20 -68.79 -46.62 68.21 Favored 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 124.837 1.255 . . . . 0.0 113.179 178.263 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 136.11 26.42 0.45 Allowed Glycine 0 CA--C 1.539 1.534 0 C-N-CA 124.787 1.184 . . . . 0.0 115.964 -179.528 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 40.1 t -124.29 156.12 31.9 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.512 0 C-N-CA 127.11 2.164 . . . . 0.0 108.607 -179.658 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 6.2 t -134.21 177.8 7.47 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 126.25 1.82 . . . . 0.0 112.216 179.143 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 CA--C 1.533 0.299 0 C-N-CA 126.438 1.895 . . . . 0.0 108.869 -170.52 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 31.2 m . . . . . 0 CA--C 1.542 0.665 0 N-CA-C 110.968 -0.012 . . . . 0.0 110.968 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -73.27 31.78 0.07 Allowed 'General case' 0 CA--C 1.555 1.163 0 C-N-CA 125.629 1.572 . . . . 0.0 114.37 177.777 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 60.1 m -63.32 160.76 38.6 Favored Pre-proline 0 CA--C 1.549 0.924 0 C-N-CA 126.335 1.854 . . . . 0.0 113.237 177.439 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -67.61 169.77 15.18 Favored 'Trans proline' 0 CA--C 1.541 0.872 0 C-N-CA 123.254 2.636 . . . . 0.0 112.156 170.899 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 10.1 tppt? -107.89 1.98 23.1 Favored 'General case' 0 N--CA 1.482 1.145 0 C-N-CA 125.968 1.707 . . . . 0.0 112.946 172.186 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 83.2 mt -52.24 131.76 13.88 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.762 0 C-N-CA 126.632 1.973 . . . . 0.0 110.821 179.426 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 5.2 tt -69.74 97.85 1.13 Allowed 'General case' 0 CA--C 1.542 0.652 0 C-N-CA 127.399 2.28 . . . . 0.0 111.497 -174.823 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 86.8 tttt -140.6 74.45 27.86 Favored Pre-proline 0 N--CA 1.476 0.828 0 C-N-CA 125.719 1.608 . . . . 0.0 111.101 -177.882 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -66.14 101.33 0.49 Allowed 'Trans proline' 0 CA--C 1.54 0.818 0 C-N-CA 123.956 3.104 . . . . 0.0 112.343 -178.605 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 15.9 m -127.21 159.52 37.33 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.479 0 C-N-CA 126.001 1.72 . . . . 0.0 112.859 -176.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 24.4 p -88.4 123.29 32.81 Favored 'General case' 0 CA--C 1.539 0.529 0 C-N-CA 124.358 1.063 . . . . 0.0 111.889 176.572 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -79.17 55.68 4.34 Favored Glycine 0 CA--C 1.53 0.977 0 C-N-CA 124.665 1.126 . . . . 0.0 112.117 172.673 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 3.9 t 54.81 -11.68 0.01 OUTLIER 'General case' 0 CA--C 1.55 0.979 0 C-N-CA 129.385 3.074 . . . . 0.0 117.268 -175.009 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 63.5 m-20 -95.11 -17.8 21.52 Favored 'General case' 0 N--CA 1.475 0.775 0 C-N-CA 126.041 1.736 . . . . 0.0 114.545 -179.148 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 105.66 2.99 40.36 Favored Glycine 0 CA--C 1.538 1.505 0 C-N-CA 125.498 1.523 . . . . 0.0 114.84 177.713 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 2.1 mmp_? -67.37 -177.98 0.79 Allowed 'General case' 0 N--CA 1.476 0.841 0 C-N-CA 128.541 2.736 . . . . 0.0 112.195 172.501 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 24.1 m -128.58 85.72 2.37 Favored 'General case' 0 N--CA 1.476 0.841 0 C-N-CA 124.92 1.288 . . . . 0.0 110.157 176.318 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 26.8 m-85 -76.12 154.17 35.71 Favored 'General case' 0 N--CA 1.47 0.541 0 C-N-CA 123.94 0.896 . . . . 0.0 112.252 173.389 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.15 -37.63 88.15 Favored 'General case' 0 CA--C 1.542 0.643 0 N-CA-C 113.288 0.847 . . . . 0.0 113.288 -170.447 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 14.3 p30 -152.56 179.42 8.61 Favored 'General case' 0 CA--C 1.545 0.765 0 C-N-CA 126.172 1.789 . . . . 0.0 111.968 172.283 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 9.1 p -70.67 -32.03 69.15 Favored 'General case' 0 N--CA 1.473 0.7 0 O-C-N 121.018 -1.051 . . . . 0.0 113.788 176.369 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 34.8 t -62.42 -49.99 73.27 Favored 'General case' 0 N--CA 1.469 0.484 0 C-N-CA 124.31 1.044 . . . . 0.0 112.269 178.627 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 8.5 tt -58.82 -39.77 78.1 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 N-CA-C 112.194 0.442 . . . . 0.0 112.194 179.338 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -64.88 -44.62 89.05 Favored 'General case' 0 CA--C 1.543 0.712 0 C-N-CA 124.285 1.034 . . . . 0.0 112.599 175.051 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 25.1 mmt180 -55.67 -52.5 63.64 Favored 'General case' 0 N--CA 1.478 0.941 0 C-N-CA 124.378 1.071 . . . . 0.0 111.734 170.814 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 4.9 t -63.08 -37.36 86.89 Favored 'General case' 0 CA--C 1.544 0.714 0 C-N-CA 124.13 0.972 . . . . 0.0 113.023 -178.59 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 28.4 t30 -62.66 -30.55 71.46 Favored 'General case' 0 CA--C 1.545 0.762 0 C-N-CA 124.43 1.092 . . . . 0.0 113.351 176.888 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 135.21 9.97 1.57 Allowed Glycine 0 CA--C 1.536 1.373 0 N-CA-C 116.13 1.212 . . . . 0.0 116.13 175.471 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.612 HG12 ' H ' ' A' ' 33' ' ' SER . 0.5 OUTLIER -107.51 -170.16 0.34 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.653 0 CA-C-N 119.351 1.576 . . . . 0.0 110.689 -177.242 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . 0.612 ' H ' HG12 ' A' ' 32' ' ' VAL . 27.7 m -147.91 166.96 26.07 Favored 'General case' 0 N--CA 1.471 0.599 0 C-N-CA 128.258 2.623 . . . . 0.0 110.529 174.863 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 1.1 mt . . . . . 0 N--CA 1.471 0.622 0 C-N-CA 125.069 1.347 . . . . 0.0 108.765 172.43 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 80.9 m . . . . . 0 CA--C 1.544 0.749 0 N-CA-C 111.809 0.3 . . . . 0.0 111.809 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -73.49 37.52 0.09 Allowed 'General case' 0 CA--C 1.556 1.175 0 C-N-CA 126.462 1.905 . . . . 0.0 114.841 -177.161 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 98.8 m -63.92 156.67 72.49 Favored Pre-proline 0 CA--C 1.55 0.956 0 C-N-CA 125.726 1.61 . . . . 0.0 113.742 -179.555 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -71.78 159.42 50.75 Favored 'Trans proline' 0 CA--C 1.54 0.811 0 C-N-CA 123.411 2.741 . . . . 0.0 113.2 -178.677 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 34.5 ttmt -86.37 -11.11 52.95 Favored 'General case' 0 N--CA 1.48 1.066 0 C-N-CA 125.786 1.634 . . . . 0.0 113.751 177.501 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 80.3 mt -55.85 146.3 5.27 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.883 0 C-N-CA 126.662 1.985 . . . . 0.0 110.444 178.862 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 11.1 mp -89.68 113.27 24.74 Favored 'General case' 0 CA--C 1.539 0.548 0 C-N-CA 124.229 1.012 . . . . 0.0 110.809 175.161 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 33.2 ttmt -135.02 75.3 61.12 Favored Pre-proline 0 CA--C 1.545 0.77 0 C-N-CA 124.874 1.27 . . . . 0.0 110.277 167.734 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 62.5 Cg_endo -68.88 86.15 0.47 Allowed 'Trans proline' 0 CA--C 1.541 0.85 0 C-N-CA 123.978 3.119 . . . . 0.0 112.535 -177.68 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 10.5 m -85.63 154.94 3.46 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.534 0 C-N-CA 126.527 1.931 . . . . 0.0 112.785 -178.391 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 46.0 t -78.2 108.49 11.55 Favored 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 124.861 1.264 . . . . 0.0 110.74 168.429 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -76.57 153.53 42.66 Favored Glycine 0 CA--C 1.531 1.079 0 C-N-CA 124.603 1.097 . . . . 0.0 113.357 174.697 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 13.5 t -58.72 -33.96 70.79 Favored 'General case' 0 N--CA 1.476 0.833 0 C-N-CA 124.595 1.158 . . . . 0.0 114.123 -172.096 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 10.4 m-20 -73.73 -3.56 29.16 Favored 'General case' 0 CA--C 1.549 0.923 0 N-CA-C 114.667 1.358 . . . . 0.0 114.667 176.359 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 95.79 18.01 33.71 Favored Glycine 0 CA--C 1.533 1.21 0 C-N-CA 125.318 1.437 . . . . 0.0 114.11 178.205 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 29.5 mtp85 -121.52 154.49 36.58 Favored 'General case' 0 N--CA 1.476 0.857 0 C-N-CA 126.164 1.786 . . . . 0.0 111.308 -173.79 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 13.5 p -87.91 146.48 25.54 Favored 'General case' 0 N--CA 1.469 0.513 0 C-N-CA 124.173 0.989 . . . . 0.0 112.185 177.162 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 97.9 m-85 -138.74 147.7 43.0 Favored 'General case' 0 N--CA 1.472 0.668 0 C-N-CA 125.327 1.451 . . . . 0.0 111.381 177.562 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.54 -32.76 74.55 Favored 'General case' 0 CA--C 1.544 0.734 0 N-CA-C 114.118 1.155 . . . . 0.0 114.118 -165.954 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 67.2 m-80 -146.2 172.84 12.85 Favored 'General case' 0 CA--C 1.543 0.688 0 C-N-CA 127.399 2.28 . . . . 0.0 110.467 168.184 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 27.7 p -63.87 -33.27 75.31 Favored 'General case' 0 N--CA 1.472 0.629 0 O-C-N 121.136 -0.977 . . . . 0.0 112.968 165.098 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 33.6 t -57.46 -55.23 37.51 Favored 'General case' 0 N--CA 1.467 0.411 0 C-N-CA 124.404 1.082 . . . . 0.0 112.623 176.029 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 6.5 tp -62.84 -31.68 53.2 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.742 0 N-CA-C 112.325 0.491 . . . . 0.0 112.325 -179.112 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -59.39 -48.8 80.27 Favored 'General case' 0 CA--C 1.542 0.658 0 O-C-N 121.482 -0.761 . . . . 0.0 111.35 170.907 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 24.0 mtp-105 -62.3 -33.61 75.0 Favored 'General case' 0 N--CA 1.479 0.992 0 C-N-CA 123.619 0.768 . . . . 0.0 113.031 175.492 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 46.9 t -62.88 -48.47 78.83 Favored 'General case' 0 CA--C 1.542 0.635 0 C-N-CA 124.302 1.041 . . . . 0.0 111.52 171.373 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 19.5 m120 -66.79 -31.6 72.35 Favored 'General case' 0 CA--C 1.546 0.822 0 C-N-CA 124.583 1.153 . . . . 0.0 113.526 178.515 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 116.86 28.81 2.36 Favored Glycine 0 CA--C 1.539 1.537 0 C-N-CA 125.602 1.572 . . . . 0.0 115.01 178.782 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 18.1 t -129.32 153.99 39.48 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.5 0 C-N-CA 127.528 2.331 . . . . 0.0 108.809 -176.335 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 68.6 m -119.73 156.07 31.25 Favored 'General case' 0 N--CA 1.474 0.761 0 C-N-CA 125.858 1.663 . . . . 0.0 112.445 179.285 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 22.0 mm . . . . . 0 N--CA 1.481 1.114 0 C-N-CA 126.111 1.765 . . . . 0.0 112.373 -171.864 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 32.9 m . . . . . 0 CA--C 1.542 0.647 0 CA-C-O 121.041 0.448 . . . . 0.0 110.81 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -75.06 54.34 0.67 Allowed 'General case' 0 CA--C 1.554 1.119 0 C-N-CA 125.525 1.53 . . . . 0.0 113.021 178.938 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 64.7 m -65.22 152.19 92.23 Favored Pre-proline 0 CA--C 1.552 1.023 0 C-N-CA 125.437 1.495 . . . . 0.0 112.893 -177.901 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -72.03 151.99 56.56 Favored 'Trans proline' 0 CA--C 1.539 0.763 0 C-N-CA 122.957 2.438 . . . . 0.0 112.57 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 32.3 mmtp -72.49 -21.67 61.17 Favored 'General case' 0 N--CA 1.479 1.014 0 C-N-CA 125.232 1.413 . . . . 0.0 113.605 174.664 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.473 ' H ' HD12 ' A' ' 9' ' ' ILE . 4.9 mp -67.8 127.26 29.17 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.548 0 C-N-CA 125.508 1.523 . . . . 0.0 110.198 178.879 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 2.0 pt? -68.55 131.41 45.19 Favored 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 124.912 1.285 . . . . 0.0 111.6 173.72 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 37.0 ttmt -152.08 64.86 5.91 Favored Pre-proline 0 N--CA 1.474 0.745 0 C-N-CA 124.323 1.049 . . . . 0.0 111.114 175.181 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -66.85 153.04 79.29 Favored 'Trans proline' 0 CA--C 1.536 0.619 0 C-N-CA 122.552 2.168 . . . . 0.0 112.199 -176.049 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 18.4 t -134.84 -68.91 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.059 0 C-N-CA 123.695 0.798 . . . . 0.0 112.071 -173.818 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 31.1 p -143.18 -173.9 4.05 Favored 'General case' 0 CA--C 1.544 0.72 0 C-N-CA 126.355 1.862 . . . . 0.0 112.156 -173.812 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -163.75 87.57 0.1 Allowed Glycine 0 CA--C 1.528 0.882 0 C-N-CA 124.098 0.856 . . . . 0.0 114.126 -175.543 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 11.4 t -55.7 -38.17 69.35 Favored 'General case' 0 N--CA 1.478 0.969 0 C-N-CA 124.132 0.973 . . . . 0.0 113.261 176.781 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 54.6 m-20 -78.39 -5.69 53.04 Favored 'General case' 0 N--CA 1.478 0.942 0 C-N-CA 125.141 1.376 . . . . 0.0 113.953 174.541 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 93.86 9.93 59.29 Favored Glycine 0 CA--C 1.537 1.467 0 C-N-CA 125.532 1.539 . . . . 0.0 114.321 -174.018 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 13.5 ptp180 -122.19 135.86 54.83 Favored 'General case' 0 N--CA 1.477 0.898 0 C-N-CA 126.738 2.015 . . . . 0.0 112.21 -177.03 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.1 p -66.64 110.84 3.36 Favored 'General case' 0 N--CA 1.474 0.728 0 C-N-CA 125.347 1.459 . . . . 0.0 111.783 175.657 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 44.6 m-85 -76.86 154.37 33.87 Favored 'General case' 0 N--CA 1.472 0.636 0 O-C-N 121.628 -0.67 . . . . 0.0 111.829 174.794 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.96 -43.83 82.1 Favored 'General case' 0 CA--C 1.542 0.662 0 N-CA-C 113.238 0.829 . . . . 0.0 113.238 -169.416 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 21.2 p30 -160.98 178.68 9.13 Favored 'General case' 0 CA--C 1.548 0.866 0 C-N-CA 126.755 2.022 . . . . 0.0 111.569 173.487 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 16.2 m -63.36 -27.62 69.44 Favored 'General case' 0 N--CA 1.475 0.815 0 O-C-N 120.625 -1.297 . . . . 0.0 113.913 179.833 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 38.6 t -63.1 -56.41 17.07 Favored 'General case' 0 CA--C 1.532 0.257 0 C-N-CA 124.708 1.203 . . . . 0.0 111.555 177.166 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 8.3 tp -59.17 -35.24 56.54 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.87 0 N-CA-C 112.54 0.571 . . . . 0.0 112.54 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -59.3 -57.83 11.31 Favored 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 123.937 0.895 . . . . 0.0 111.993 175.332 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 73.6 mtp180 -60.56 -38.92 86.13 Favored 'General case' 0 N--CA 1.479 1.001 0 N-CA-C 113.058 0.762 . . . . 0.0 113.058 176.561 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 47.7 t -59.83 -50.38 74.04 Favored 'General case' 0 CA--C 1.542 0.646 0 C-N-CA 124.422 1.089 . . . . 0.0 112.179 176.048 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 63.3 t30 -69.95 -40.26 75.56 Favored 'General case' 0 CA--C 1.545 0.767 0 C-N-CA 125.01 1.324 . . . . 0.0 112.925 -176.911 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 129.26 30.2 0.68 Allowed Glycine 0 CA--C 1.536 1.375 0 C-N-CA 124.676 1.131 . . . . 0.0 115.161 178.369 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -120.14 178.49 2.49 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.545 0 C-N-CA 126.943 2.097 . . . . 0.0 110.037 -176.411 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 83.8 p -138.04 159.69 41.34 Favored 'General case' 0 N--CA 1.476 0.854 0 C-N-CA 124.843 1.257 . . . . 0.0 113.466 -178.135 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 16.0 mm . . . . . 0 N--CA 1.478 0.965 0 C-N-CA 124.545 1.138 . . . . 0.0 112.509 -175.003 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 8.5 t . . . . . 0 CA--C 1.543 0.676 0 N-CA-C 112.805 0.668 . . . . 0.0 112.805 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -75.24 32.4 0.1 Allowed 'General case' 0 CA--C 1.553 1.077 0 C-N-CA 126.873 2.069 . . . . 0.0 115.214 -174.132 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 58.4 m -62.96 157.48 60.75 Favored Pre-proline 0 CA--C 1.549 0.912 0 C-N-CA 124.851 1.26 . . . . 0.0 113.15 176.062 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 97.1 Cg_endo -70.58 172.13 14.03 Favored 'Trans proline' 0 CA--C 1.54 0.799 0 C-N-CA 123.419 2.746 . . . . 0.0 112.176 173.141 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 29.9 mtpp -121.05 3.09 10.47 Favored 'General case' 0 N--CA 1.481 1.112 0 C-N-CA 126.2 1.8 . . . . 0.0 114.011 179.765 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -53.0 138.63 12.0 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.785 0 C-N-CA 126.366 1.867 . . . . 0.0 112.347 179.649 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 3.2 tt -70.69 77.61 0.6 Allowed 'General case' 0 CA--C 1.547 0.849 0 C-N-CA 126.72 2.008 . . . . 0.0 111.382 -178.773 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 25.7 tptp -140.15 68.86 34.42 Favored Pre-proline 0 N--CA 1.473 0.722 0 C-N-CA 125.875 1.67 . . . . 0.0 110.893 179.6 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -64.86 148.55 89.98 Favored 'Trans proline' 0 CA--C 1.534 0.524 0 C-N-CA 122.326 2.017 . . . . 0.0 111.868 -178.676 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 1.7 t -137.75 161.0 33.8 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.804 0 C-N-CA 125.542 1.537 . . . . 0.0 109.99 -177.501 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 21.6 p -73.35 130.64 40.61 Favored 'General case' 0 CA--C 1.543 0.683 0 C-N-CA 124.582 1.153 . . . . 0.0 111.669 176.1 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -110.59 159.96 13.57 Favored Glycine 0 CA--C 1.535 1.325 0 C-N-CA 125.135 1.35 . . . . 0.0 112.026 170.729 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 56.6 p -63.53 -30.68 71.76 Favored 'General case' 0 N--CA 1.475 0.781 0 N-CA-C 114.28 1.215 . . . . 0.0 114.28 -172.822 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 17.0 t70 -77.17 -20.37 55.55 Favored 'General case' 0 N--CA 1.477 0.906 0 C-N-CA 124.437 1.095 . . . . 0.0 113.69 177.078 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 106.34 1.27 38.05 Favored Glycine 0 CA--C 1.537 1.411 0 C-N-CA 126.876 2.179 . . . . 0.0 114.789 176.325 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 56.2 mtt180 -85.78 156.21 20.69 Favored 'General case' 0 N--CA 1.476 0.866 0 C-N-CA 125.221 1.408 . . . . 0.0 112.974 -173.688 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 9.6 p -81.58 126.67 32.0 Favored 'General case' 0 N--CA 1.467 0.418 0 C-N-CA 125.959 1.703 . . . . 0.0 111.319 169.799 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 86.1 m-85 -126.13 159.28 33.3 Favored 'General case' 0 N--CA 1.47 0.566 0 C-N-CA 125.71 1.604 . . . . 0.0 110.789 171.99 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -62.57 -42.39 99.52 Favored 'General case' 0 CA--C 1.543 0.701 0 N-CA-C 113.078 0.77 . . . . 0.0 113.078 -168.381 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 14.2 p30 -155.47 178.36 10.32 Favored 'General case' 0 CA--C 1.545 0.78 0 C-N-CA 126.179 1.792 . . . . 0.0 112.258 173.56 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 33.1 t -62.48 -38.25 89.11 Favored 'General case' 0 N--CA 1.473 0.696 0 O-C-N 121.148 -0.97 . . . . 0.0 113.088 178.904 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 24.6 t -59.18 -57.64 12.15 Favored 'General case' 0 N--CA 1.467 0.377 0 C-N-CA 123.974 0.91 . . . . 0.0 111.25 179.749 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 8.4 tt -57.68 -39.45 70.26 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.618 0 N-CA-C 111.783 0.29 . . . . 0.0 111.783 -179.074 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -65.65 -45.73 81.87 Favored 'General case' 0 CA--C 1.542 0.663 0 C-N-CA 123.561 0.745 . . . . 0.0 112.42 179.411 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 16.7 ttp180 -62.87 -44.93 94.8 Favored 'General case' 0 N--CA 1.474 0.728 0 O-C-N 121.372 -0.83 . . . . 0.0 112.198 174.318 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -65.59 -32.54 74.18 Favored 'General case' 0 CA--C 1.545 0.756 0 N-CA-C 113.173 0.805 . . . . 0.0 113.173 177.67 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 51.9 t30 -65.7 -44.06 87.28 Favored 'General case' 0 CA--C 1.544 0.719 0 C-N-CA 124.698 1.199 . . . . 0.0 112.591 173.574 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 159.35 1.29 0.07 OUTLIER Glycine 0 CA--C 1.537 1.409 0 N-CA-C 117.519 1.767 . . . . 0.0 117.519 175.098 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -90.65 178.18 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.453 0 CA-C-N 119.823 1.812 . . . . 0.0 112.036 -176.288 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 66.1 m -133.03 108.36 8.82 Favored 'General case' 0 N--CA 1.477 0.881 0 C-N-CA 125.918 1.687 . . . . 0.0 111.986 177.995 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 16.4 mt . . . . . 0 N--CA 1.485 1.3 0 C-N-CA 125.065 1.346 . . . . 0.0 112.377 178.899 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 64.3 m . . . . . 0 CA--C 1.542 0.637 0 N-CA-C 111.517 0.191 . . . . 0.0 111.517 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -73.8 42.88 0.14 Allowed 'General case' 0 CA--C 1.554 1.115 0 C-N-CA 125.928 1.691 . . . . 0.0 113.96 179.093 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 56.4 m -60.52 153.56 60.26 Favored Pre-proline 0 CA--C 1.55 0.955 0 C-N-CA 125.254 1.422 . . . . 0.0 113.125 177.908 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 88.3 Cg_endo -71.74 158.15 53.88 Favored 'Trans proline' 0 CA--C 1.539 0.735 0 C-N-CA 123.146 2.564 . . . . 0.0 112.309 179.568 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 1.4 mptm? -73.31 -8.56 56.36 Favored 'General case' 0 N--CA 1.48 1.039 0 C-N-CA 125.469 1.508 . . . . 0.0 113.88 179.631 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 51.1 mm -52.95 125.46 7.01 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.668 0 C-N-CA 126.442 1.897 . . . . 0.0 111.498 177.233 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 50.3 tp -95.35 100.44 12.21 Favored 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 127.339 2.256 . . . . 0.0 109.033 176.382 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 29.4 ttmt -146.76 82.34 8.69 Favored Pre-proline 0 N--CA 1.472 0.655 0 C-N-CA 124.565 1.146 . . . . 0.0 110.66 171.22 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 70.2 Cg_endo -68.69 148.32 71.56 Favored 'Trans proline' 0 N--CA 1.459 -0.549 0 C-N-CA 121.805 1.67 . . . . 0.0 110.926 177.543 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 1.4 t -138.41 160.52 31.59 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.752 0 C-N-CA 124.879 1.271 . . . . 0.0 109.966 -179.12 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 49.8 t -75.88 96.34 3.69 Favored 'General case' 0 CA--C 1.54 0.585 0 C-N-CA 124.334 1.054 . . . . 0.0 110.097 173.0 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -62.78 153.3 44.64 Favored Glycine 0 CA--C 1.534 1.265 0 C-N-CA 123.427 0.537 . . . . 0.0 112.113 174.084 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 21.1 t -53.93 -36.09 62.4 Favored 'General case' 0 N--CA 1.477 0.887 0 C-N-CA 125.256 1.422 . . . . 0.0 114.315 -171.51 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 17.8 m-20 -78.67 -2.77 40.77 Favored 'General case' 0 CA--C 1.55 0.945 0 C-N-CA 125.276 1.43 . . . . 0.0 114.589 178.781 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 92.96 37.27 5.76 Favored Glycine 0 CA--C 1.535 1.295 0 C-N-CA 125.503 1.525 . . . . 0.0 113.321 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 13.3 mmm180 -129.52 125.46 36.37 Favored 'General case' 0 N--CA 1.477 0.911 0 C-N-CA 126.604 1.962 . . . . 0.0 111.025 -166.125 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 2.8 p -83.74 90.35 7.3 Favored 'General case' 0 N--CA 1.474 0.746 0 C-N-CA 125.6 1.56 . . . . 0.0 112.074 177.292 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -77.34 154.9 32.36 Favored 'General case' 0 N--CA 1.473 0.691 0 C-N-CA 124.385 1.074 . . . . 0.0 111.851 172.348 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -67.69 -40.82 84.35 Favored 'General case' 0 CA--C 1.545 0.779 0 N-CA-C 113.458 0.91 . . . . 0.0 113.458 -168.705 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 62.1 t30 -144.77 172.27 13.24 Favored 'General case' 0 CA--C 1.548 0.885 0 C-N-CA 125.171 1.388 . . . . 0.0 110.898 169.955 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 88.3 p -62.07 -34.52 76.43 Favored 'General case' 0 N--CA 1.472 0.66 0 O-C-N 120.574 -1.329 . . . . 0.0 113.317 176.365 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 35.4 t -59.72 -57.41 13.03 Favored 'General case' 0 N--CA 1.467 0.414 0 C-N-CA 124.604 1.162 . . . . 0.0 112.669 177.341 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 7.6 tp -58.21 -34.1 48.82 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 CA-C-O 119.06 -0.495 . . . . 0.0 112.286 179.591 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -58.29 -53.6 56.49 Favored 'General case' 0 CA--C 1.544 0.734 0 CA-C-N 118.929 0.786 . . . . 0.0 111.934 172.986 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -58.98 -46.05 89.06 Favored 'General case' 0 N--CA 1.48 1.032 0 N-CA-C 112.666 0.617 . . . . 0.0 112.666 175.338 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -65.3 -32.58 74.31 Favored 'General case' 0 CA--C 1.545 0.776 0 N-CA-C 113.301 0.852 . . . . 0.0 113.301 -179.948 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 25.6 t-20 -71.61 -49.03 44.07 Favored 'General case' 0 CA--C 1.543 0.701 0 C-N-CA 124.758 1.223 . . . . 0.0 112.62 173.86 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 145.47 21.18 0.14 Allowed Glycine 0 CA--C 1.537 1.46 0 N-CA-C 116.813 1.485 . . . . 0.0 116.813 178.965 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 21.7 t -127.48 150.05 33.0 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.607 0 C-N-CA 126.067 1.747 . . . . 0.0 109.548 -176.966 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 80.0 p -124.42 138.69 54.33 Favored 'General case' 0 N--CA 1.47 0.542 0 C-N-CA 126.157 1.783 . . . . 0.0 112.129 -179.499 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 23.5 mm . . . . . 0 N--CA 1.477 0.917 0 C-N-CA 124.961 1.304 . . . . 0.0 111.854 -179.03 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 60.1 m . . . . . 0 CA--C 1.545 0.762 0 CA-C-O 121.069 0.461 . . . . 0.0 111.69 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -75.3 67.6 1.92 Allowed 'General case' 0 CA--C 1.551 1.006 0 C-N-CA 125.56 1.544 . . . . 0.0 113.091 179.802 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 72.8 m -68.92 155.57 93.16 Favored Pre-proline 0 CA--C 1.552 1.027 0 C-N-CA 124.882 1.273 . . . . 0.0 113.586 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 90.4 Cg_endo -74.11 168.01 25.81 Favored 'Trans proline' 0 CA--C 1.541 0.849 0 C-N-CA 123.591 2.861 . . . . 0.0 113.173 179.38 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -76.59 -3.23 36.56 Favored 'General case' 0 N--CA 1.482 1.155 0 C-N-CA 125.619 1.567 . . . . 0.0 114.447 177.927 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 85.6 mt -55.69 151.42 2.22 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.899 0 C-N-CA 126.868 2.067 . . . . 0.0 110.744 174.555 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 50.8 tp -136.9 93.49 2.85 Favored 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 125.914 1.686 . . . . 0.0 109.401 -175.538 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 16.7 mmtm -135.21 82.1 42.44 Favored Pre-proline 0 N--CA 1.475 0.779 0 C-N-CA 125.828 1.651 . . . . 0.0 110.129 174.307 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 65.0 Cg_endo -69.83 91.17 0.52 Allowed 'Trans proline' 0 CA--C 1.54 0.805 0 C-N-CA 123.809 3.006 . . . . 0.0 112.061 -177.238 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 5.0 m -87.11 157.87 3.19 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.522 0 C-N-CA 126.723 2.009 . . . . 0.0 112.882 -177.356 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 45.0 t -68.23 143.29 55.36 Favored 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 124.05 0.94 . . . . 0.0 111.064 171.366 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -111.72 148.97 18.1 Favored Glycine 0 CA--C 1.532 1.108 0 C-N-CA 125.472 1.51 . . . . 0.0 112.786 177.803 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 68.9 m -59.58 -22.81 62.29 Favored 'General case' 0 N--CA 1.477 0.878 0 N-CA-C 115.564 1.69 . . . . 0.0 115.564 -170.498 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 33.4 t70 -77.89 -10.74 59.73 Favored 'General case' 0 CA--C 1.549 0.929 0 C-N-CA 124.904 1.282 . . . . 0.0 114.15 175.238 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 98.39 31.85 6.3 Favored Glycine 0 CA--C 1.536 1.391 0 C-N-CA 125.422 1.487 . . . . 0.0 113.111 -172.097 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 15.3 mmp_? -121.91 -175.0 3.01 Favored 'General case' 0 N--CA 1.478 0.969 0 C-N-CA 127.743 2.417 . . . . 0.0 111.281 -169.734 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 9.3 t -136.84 143.95 43.36 Favored 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 125.191 1.396 . . . . 0.0 111.427 173.007 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 85.4 m-85 -142.39 147.94 37.04 Favored 'General case' 0 N--CA 1.473 0.705 0 C-N-CA 125.22 1.408 . . . . 0.0 112.217 -175.713 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -61.14 -44.81 96.74 Favored 'General case' 0 CA--C 1.542 0.667 0 N-CA-C 114.003 1.112 . . . . 0.0 114.003 -164.608 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 65.6 m-80 -146.85 175.06 10.93 Favored 'General case' 0 CA--C 1.548 0.886 0 C-N-CA 126.461 1.904 . . . . 0.0 110.633 167.576 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 20.0 m -57.76 -30.09 65.33 Favored 'General case' 0 N--CA 1.477 0.903 0 O-C-N 120.945 -1.097 . . . . 0.0 113.599 171.666 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 46.7 t -58.56 -61.1 2.85 Favored 'General case' 0 N--CA 1.466 0.368 0 C-N-CA 124.964 1.306 . . . . 0.0 112.312 175.557 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 8.5 tp -62.56 -33.3 58.85 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.744 0 N-CA-C 112.039 0.385 . . . . 0.0 112.039 179.995 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -57.41 -54.51 46.0 Favored 'General case' 0 CA--C 1.542 0.661 0 C-N-CA 123.348 0.659 . . . . 0.0 111.556 171.56 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 5.5 mtp85 -58.95 -40.22 84.03 Favored 'General case' 0 N--CA 1.48 1.031 0 N-CA-C 113.243 0.831 . . . . 0.0 113.243 174.907 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 33.0 t -59.95 -46.64 88.77 Favored 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 124.517 1.127 . . . . 0.0 111.628 177.17 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 95.4 m-20 -69.15 -48.07 63.31 Favored 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 125.546 1.538 . . . . 0.0 112.786 179.116 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 129.6 39.84 0.28 Allowed Glycine 0 CA--C 1.536 1.36 0 C-N-CA 125.212 1.387 . . . . 0.0 114.652 -176.867 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 44.7 t -133.25 158.18 42.94 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.597 0 C-N-CA 126.938 2.095 . . . . 0.0 108.494 174.528 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 42.7 t -123.57 143.29 50.3 Favored 'General case' 0 N--CA 1.47 0.572 0 C-N-CA 125.545 1.538 . . . . 0.0 111.937 175.492 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 17.1 mm . . . . . 0 N--CA 1.475 0.79 0 C-N-CA 126.034 1.734 . . . . 0.0 111.331 175.889 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 57.2 m . . . . . 0 N--CA 1.476 0.839 0 N-CA-C 113.6 0.963 . . . . 0.0 113.6 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . 50.07 26.32 2.04 Favored 'General case' 0 CA--C 1.552 1.023 0 C-N-CA 127.254 2.222 . . . . 0.0 115.285 -171.032 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 61.9 m -70.22 160.72 79.8 Favored Pre-proline 0 CA--C 1.548 0.869 0 C-N-CA 125.363 1.465 . . . . 0.0 112.922 177.157 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -67.58 167.59 20.48 Favored 'Trans proline' 0 CA--C 1.54 0.798 0 C-N-CA 123.295 2.663 . . . . 0.0 112.231 169.736 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 10.2 mtpm? -112.53 1.38 15.83 Favored 'General case' 0 N--CA 1.48 1.059 0 C-N-CA 126.282 1.833 . . . . 0.0 113.28 173.672 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 48.9 mm -55.93 133.03 19.99 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.593 0 C-N-CA 126.386 1.874 . . . . 0.0 111.082 178.587 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 5.4 tt -69.87 96.0 0.97 Allowed 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 127.771 2.428 . . . . 0.0 111.08 -176.723 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 34.7 ttpt -144.45 73.97 15.53 Favored Pre-proline 0 CA--C 1.546 0.801 0 C-N-CA 124.467 1.107 . . . . 0.0 111.901 -179.427 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -68.21 89.43 0.39 Allowed 'Trans proline' 0 CA--C 1.538 0.708 0 C-N-CA 124.188 3.259 . . . . 0.0 112.922 -175.996 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 16.3 m -73.73 160.24 5.36 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.412 0 C-N-CA 126.084 1.754 . . . . 0.0 112.244 175.273 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 16.5 t -69.36 165.95 19.65 Favored 'General case' 0 CA--C 1.549 0.908 0 C-N-CA 123.625 0.77 . . . . 0.0 111.141 166.998 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -143.6 134.55 5.9 Favored Glycine 0 CA--C 1.53 0.973 0 C-N-CA 124.778 1.18 . . . . 0.0 112.151 177.783 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 63.7 m -57.22 -24.48 54.9 Favored 'General case' 0 N--CA 1.477 0.886 0 C-N-CA 125.847 1.659 . . . . 0.0 114.906 -176.993 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -83.29 -4.58 58.58 Favored 'General case' 0 CA--C 1.548 0.887 0 C-N-CA 125.775 1.63 . . . . 0.0 113.955 176.985 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 94.65 20.21 29.8 Favored Glycine 0 CA--C 1.535 1.311 0 C-N-CA 125.38 1.467 . . . . 0.0 114.284 179.111 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 43.7 mtt180 -121.01 178.18 4.83 Favored 'General case' 0 N--CA 1.477 0.908 0 C-N-CA 126.169 1.788 . . . . 0.0 112.536 -173.88 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 31.8 m -128.35 142.64 51.06 Favored 'General case' 0 N--CA 1.477 0.9 0 C-N-CA 126.107 1.763 . . . . 0.0 110.049 -179.584 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 86.8 m-85 -135.57 155.64 50.15 Favored 'General case' 0 N--CA 1.471 0.588 0 C-N-CA 125.171 1.388 . . . . 0.0 111.651 -175.438 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -61.66 -38.63 88.46 Favored 'General case' 0 CA--C 1.544 0.742 0 N-CA-C 113.212 0.819 . . . . 0.0 113.212 -167.956 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 14.8 p30 -150.33 179.33 8.21 Favored 'General case' 0 CA--C 1.548 0.876 0 C-N-CA 126.213 1.805 . . . . 0.0 111.901 166.441 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 25.0 p -65.63 -34.83 79.12 Favored 'General case' 0 N--CA 1.474 0.745 0 O-C-N 121.007 -1.058 . . . . 0.0 113.755 177.298 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 34.4 t -62.93 -54.04 44.77 Favored 'General case' 0 N--CA 1.466 0.361 0 C-N-CA 124.083 0.953 . . . . 0.0 111.481 179.057 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 9.3 tp -59.0 -37.18 66.14 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.553 0 N-CA-C 112.143 0.423 . . . . 0.0 112.143 -179.277 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -63.32 -42.62 99.02 Favored 'General case' 0 CA--C 1.544 0.717 0 CA-C-N 118.851 0.75 . . . . 0.0 112.927 176.216 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 8.7 tpm_? -62.98 -41.96 99.7 Favored 'General case' 0 N--CA 1.475 0.816 0 C-N-CA 123.828 0.851 . . . . 0.0 112.278 173.82 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 7.3 t -65.06 -39.72 93.67 Favored 'General case' 0 CA--C 1.547 0.839 0 C-N-CA 123.025 0.53 . . . . 0.0 112.245 174.286 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 23.0 t-20 -63.93 -52.03 61.66 Favored 'General case' 0 CA--C 1.544 0.716 0 C-N-CA 125.82 1.648 . . . . 0.0 112.464 178.739 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 149.81 18.12 0.08 OUTLIER Glycine 0 CA--C 1.537 1.436 0 N-CA-C 117.344 1.698 . . . . 0.0 117.344 179.095 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 14.5 t -124.43 144.38 34.51 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.672 0 CA-C-N 119.98 1.89 . . . . 0.0 109.882 -176.828 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 72.3 m -89.47 128.53 35.98 Favored 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 125.805 1.642 . . . . 0.0 111.322 -179.024 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 14.3 mm . . . . . 0 N--CA 1.484 1.23 0 C-N-CA 124.687 1.195 . . . . 0.0 112.486 -175.778 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 22.4 m . . . . . 0 CA--C 1.545 0.776 0 N-CA-C 110.447 -0.205 . . . . 0.0 110.447 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -72.84 35.88 0.07 Allowed 'General case' 0 CA--C 1.556 1.195 0 C-N-CA 125.702 1.601 . . . . 0.0 114.321 178.257 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 63.8 m -64.85 159.03 66.45 Favored Pre-proline 0 CA--C 1.549 0.932 0 C-N-CA 126.499 1.92 . . . . 0.0 113.934 -178.232 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -70.81 158.96 54.15 Favored 'Trans proline' 0 C--N 1.352 0.736 0 C-N-CA 123.293 2.662 . . . . 0.0 112.785 -179.64 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 48.3 tttm -71.54 -21.17 61.94 Favored 'General case' 0 N--CA 1.478 0.953 0 C-N-CA 125.272 1.429 . . . . 0.0 113.397 176.401 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 43.7 mm -57.32 130.61 20.45 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.652 0 C-N-CA 126.257 1.823 . . . . 0.0 110.994 -179.651 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.416 HD23 ' H ' ' A' ' 10' ' ' LEU . 2.0 pt? -93.05 133.95 35.68 Favored 'General case' 0 CA--C 1.539 0.548 0 C-N-CA 125.312 1.445 . . . . 0.0 111.981 176.426 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 54.2 mttm -144.17 81.39 11.56 Favored Pre-proline 0 N--CA 1.471 0.611 0 C-N-CA 126.87 2.068 . . . . 0.0 109.236 166.748 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -71.53 85.03 0.93 Allowed 'Trans proline' 0 CA--C 1.539 0.729 0 C-N-CA 123.522 2.815 . . . . 0.0 111.915 178.836 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 35.2 m -110.96 166.72 5.37 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.344 0 C-N-CA 126.987 2.115 . . . . 0.0 112.609 -176.877 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 24.4 p -76.38 130.82 38.61 Favored 'General case' 0 CA--C 1.544 0.717 0 C-N-CA 124.124 0.97 . . . . 0.0 111.961 176.338 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -89.29 160.14 29.15 Favored Glycine 0 CA--C 1.534 1.255 0 C-N-CA 124.925 1.25 . . . . 0.0 111.974 168.239 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 91.2 p -59.39 -26.19 64.91 Favored 'General case' 0 N--CA 1.476 0.873 0 N-CA-C 115.252 1.575 . . . . 0.0 115.252 -171.928 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 32.2 m-20 -81.56 -2.77 51.18 Favored 'General case' 0 CA--C 1.547 0.858 0 C-N-CA 125.321 1.448 . . . . 0.0 114.451 176.585 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 89.59 31.4 11.48 Favored Glycine 0 CA--C 1.536 1.387 0 C-N-CA 124.772 1.177 . . . . 0.0 113.089 -176.285 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 42.9 mmm-85 -114.68 172.24 7.16 Favored 'General case' 0 N--CA 1.477 0.877 0 C-N-CA 127.808 2.443 . . . . 0.0 111.022 -170.873 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 31.7 m -128.68 133.53 48.23 Favored 'General case' 0 N--CA 1.481 1.086 0 C-N-CA 124.717 1.207 . . . . 0.0 110.748 178.921 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 87.3 m-85 -135.73 156.15 49.28 Favored 'General case' 0 N--CA 1.473 0.682 0 C-N-CA 125.186 1.394 . . . . 0.0 112.155 -178.106 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.99 -40.76 95.44 Favored 'General case' 0 CA--C 1.543 0.689 0 N-CA-C 113.499 0.926 . . . . 0.0 113.499 -166.965 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . 0.438 ' H ' HG22 ' A' ' 26' ' ' ILE . 28.7 p30 -148.4 179.7 7.59 Favored 'General case' 0 CA--C 1.547 0.847 0 C-N-CA 125.326 1.45 . . . . 0.0 112.194 164.813 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 44.6 p -62.64 -34.12 76.42 Favored 'General case' 0 N--CA 1.474 0.76 0 C-N-CA 124.228 1.011 . . . . 0.0 113.531 176.772 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 47.3 t -62.39 -55.1 31.08 Favored 'General case' 0 N--CA 1.465 0.276 0 C-N-CA 124.321 1.049 . . . . 0.0 111.917 178.093 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.438 HG22 ' H ' ' A' ' 23' ' ' ASN . 9.3 tp -61.26 -35.71 67.87 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.611 0 N-CA-C 112.25 0.463 . . . . 0.0 112.25 179.576 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -58.99 -51.37 70.38 Favored 'General case' 0 CA--C 1.544 0.73 0 C-N-CA 123.698 0.799 . . . . 0.0 111.885 172.499 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 77.5 mtp85 -57.92 -45.55 86.36 Favored 'General case' 0 N--CA 1.477 0.925 0 C-N-CA 124.644 1.177 . . . . 0.0 112.772 174.85 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 6.7 t -62.48 -40.83 97.95 Favored 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 123.766 0.826 . . . . 0.0 112.275 177.139 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 43.9 t30 -67.67 -42.04 82.79 Favored 'General case' 0 CA--C 1.543 0.681 0 C-N-CA 125.026 1.33 . . . . 0.0 113.245 178.32 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 134.43 23.79 0.64 Allowed Glycine 0 CA--C 1.538 1.476 0 N-CA-C 116.046 1.178 . . . . 0.0 116.046 178.013 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 38.0 t -125.01 154.47 33.06 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.448 0 C-N-CA 126.835 2.054 . . . . 0.0 108.379 -178.147 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 91.3 p -135.79 166.97 22.05 Favored 'General case' 0 N--CA 1.472 0.646 0 C-N-CA 124.618 1.167 . . . . 0.0 112.875 175.918 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 2.0 mt . . . . . 0 N--CA 1.48 1.04 0 C-N-CA 124.862 1.265 . . . . 0.0 112.006 -172.193 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 81.0 m . . . . . 0 CA--C 1.544 0.736 0 CA-C-O 120.693 0.282 . . . . 0.0 110.782 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -74.95 68.62 1.82 Allowed 'General case' 0 CA--C 1.549 0.935 0 C-N-CA 125.686 1.595 . . . . 0.0 113.17 -177.672 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 62.6 m -69.05 154.89 94.57 Favored Pre-proline 0 CA--C 1.549 0.909 0 C-N-CA 124.536 1.134 . . . . 0.0 113.431 -179.404 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -68.5 152.77 74.82 Favored 'Trans proline' 0 CA--C 1.54 0.811 0 C-N-CA 123.201 2.601 . . . . 0.0 111.854 172.637 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 15.2 ptmt -63.86 -26.03 68.43 Favored 'General case' 0 N--CA 1.479 1.023 0 C-N-CA 125.685 1.594 . . . . 0.0 114.678 177.571 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 9.5 tt -57.78 158.32 1.35 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.614 0 C-N-CA 126.673 1.989 . . . . 0.0 112.301 176.079 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 16.8 tp -126.96 114.78 18.29 Favored 'General case' 0 CA--C 1.538 0.487 0 C-N-CA 126.433 1.893 . . . . 0.0 108.518 -178.07 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 31.1 mmmt -127.61 80.18 72.29 Favored Pre-proline 0 N--CA 1.473 0.716 0 C-N-CA 126.125 1.77 . . . . 0.0 109.792 -176.362 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -72.78 84.28 1.27 Allowed 'Trans proline' 0 CA--C 1.541 0.83 0 C-N-CA 124.274 3.316 . . . . 0.0 112.402 -175.427 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 14.4 m -73.78 164.76 3.41 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.598 0 C-N-CA 126.883 2.073 . . . . 0.0 112.832 177.556 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 10.0 t -79.79 -5.21 54.92 Favored 'General case' 0 CA--C 1.551 0.995 0 C-N-CA 124.539 1.135 . . . . 0.0 113.983 174.406 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 57.29 -155.19 18.24 Favored Glycine 0 CA--C 1.539 1.548 0 C-N-CA 125.338 1.447 . . . . 0.0 113.984 179.211 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 38.0 m -121.22 -20.54 6.7 Favored 'General case' 0 N--CA 1.475 0.776 0 C-N-CA 124.94 1.296 . . . . 0.0 114.223 174.454 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -80.81 -13.88 58.56 Favored 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 124.252 1.021 . . . . 0.0 113.102 171.703 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 98.51 -14.91 61.71 Favored Glycine 0 CA--C 1.537 1.456 0 C-N-CA 126.782 2.134 . . . . 0.0 114.008 -177.945 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 9.8 ptm180 -77.96 168.83 19.28 Favored 'General case' 0 N--CA 1.474 0.747 0 C-N-CA 125.378 1.471 . . . . 0.0 112.279 168.269 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 54.7 m -95.22 149.36 21.4 Favored 'General case' 0 N--CA 1.475 0.779 0 C-N-CA 124.452 1.101 . . . . 0.0 111.708 174.823 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 56.1 m-85 -131.63 151.99 51.18 Favored 'General case' 0 N--CA 1.47 0.562 0 C-N-CA 126.249 1.819 . . . . 0.0 110.676 173.797 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.89 -40.54 87.79 Favored 'General case' 0 CA--C 1.544 0.713 0 N-CA-C 113.273 0.842 . . . . 0.0 113.273 -169.855 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . 0.41 ' H ' HG22 ' A' ' 26' ' ' ILE . 16.5 m120 -144.61 170.96 15.07 Favored 'General case' 0 CA--C 1.545 0.786 0 C-N-CA 126.29 1.836 . . . . 0.0 110.954 174.894 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 28.4 p -61.41 -32.06 72.0 Favored 'General case' 0 N--CA 1.475 0.797 0 C-N-CA 124.152 0.981 . . . . 0.0 112.618 162.073 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 42.3 t -54.84 -64.25 0.89 Allowed 'General case' 0 CA--C 1.535 0.374 0 C-N-CA 125.699 1.599 . . . . 0.0 112.366 173.264 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.41 HG22 ' H ' ' A' ' 23' ' ' ASN . 13.6 tt -58.54 -35.62 55.6 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.812 0 N-CA-C 112.211 0.449 . . . . 0.0 112.211 -178.021 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -59.07 -56.63 19.72 Favored 'General case' 0 CA--C 1.541 0.617 0 C-N-CA 123.5 0.72 . . . . 0.0 111.505 174.671 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 69.6 mtm180 -64.55 -37.5 87.77 Favored 'General case' 0 N--CA 1.479 0.977 0 N-CA-C 113.209 0.818 . . . . 0.0 113.209 179.009 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 35.9 t -58.35 -45.25 88.54 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 125.233 1.413 . . . . 0.0 111.833 172.695 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 23.0 t-20 -71.57 -48.84 45.73 Favored 'General case' 0 CA--C 1.546 0.816 0 C-N-CA 125.03 1.332 . . . . 0.0 112.79 179.911 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 144.7 23.43 0.14 Allowed Glycine 0 CA--C 1.54 1.629 0 N-CA-C 116.523 1.369 . . . . 0.0 116.523 179.765 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 18.4 t -130.88 151.56 36.12 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.603 0 C-N-CA 126.637 1.975 . . . . 0.0 109.179 -174.789 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 95.0 p -144.91 124.81 13.45 Favored 'General case' 0 N--CA 1.47 0.562 0 C-N-CA 125.106 1.362 . . . . 0.0 112.108 -179.724 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 6.3 mt . . . . . 0 N--CA 1.482 1.149 0 C-N-CA 124.306 1.042 . . . . 0.0 112.132 -178.805 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 61.2 m . . . . . 0 CA--C 1.541 0.605 0 CA-C-O 120.868 0.366 . . . . 0.0 110.832 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -73.99 52.89 0.45 Allowed 'General case' 0 CA--C 1.554 1.123 0 C-N-CA 125.612 1.565 . . . . 0.0 113.131 177.36 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 92.8 m -62.86 157.03 62.98 Favored Pre-proline 0 CA--C 1.551 1.001 0 C-N-CA 125.791 1.636 . . . . 0.0 113.232 178.977 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -71.82 167.7 25.87 Favored 'Trans proline' 0 CA--C 1.542 0.881 0 C-N-CA 123.29 2.66 . . . . 0.0 113.283 -177.24 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 61.7 mtpt -66.46 -16.8 64.39 Favored 'General case' 0 N--CA 1.481 1.088 0 C-N-CA 126.033 1.733 . . . . 0.0 114.097 176.171 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 79.8 mt -58.47 136.36 21.96 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.722 0 C-N-CA 126.489 1.916 . . . . 0.0 110.24 178.064 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.9 pt? -130.98 26.42 4.93 Favored 'General case' 0 CA--C 1.546 0.816 0 C-N-CA 125.416 1.487 . . . . 0.0 113.951 -178.48 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 26.4 mmtp -52.59 107.22 0.79 Allowed Pre-proline 0 N--CA 1.477 0.893 0 C-N-CA 126.516 1.926 . . . . 0.0 111.553 175.182 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 91.6 Cg_endo -73.61 87.76 1.08 Allowed 'Trans proline' 0 CA--C 1.539 0.729 0 C-N-CA 123.526 2.818 . . . . 0.0 112.01 -173.816 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 13.6 m -73.8 157.85 6.17 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.459 0 C-N-CA 125.636 1.574 . . . . 0.0 112.297 179.246 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 30.3 p -63.44 165.2 8.1 Favored 'General case' 0 CA--C 1.544 0.741 0 C-N-CA 123.412 0.685 . . . . 0.0 111.835 165.637 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -133.97 143.29 14.93 Favored Glycine 0 CA--C 1.527 0.798 0 C-N-CA 125.058 1.313 . . . . 0.0 111.972 179.999 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 55.6 m -65.08 -15.82 62.79 Favored 'General case' 0 N--CA 1.473 0.706 0 C-N-CA 125.362 1.465 . . . . 0.0 114.913 -174.598 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 42.0 m-20 -95.32 5.78 50.78 Favored 'General case' 0 CA--C 1.553 1.082 0 C-N-CA 125.972 1.709 . . . . 0.0 113.514 171.955 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 88.91 24.81 31.27 Favored Glycine 0 N--CA 1.473 1.108 0 C-N-CA 125.05 1.309 . . . . 0.0 114.157 179.921 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 24.0 mtp85 -120.47 -170.53 2.0 Favored 'General case' 0 N--CA 1.481 1.098 0 C-N-CA 126.297 1.839 . . . . 0.0 112.348 -171.409 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 41.2 m -134.42 139.04 45.27 Favored 'General case' 0 N--CA 1.478 0.964 0 C-N-CA 125.952 1.701 . . . . 0.0 110.37 -179.34 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 65.6 m-85 -134.3 159.4 41.09 Favored 'General case' 0 N--CA 1.473 0.694 0 C-N-CA 124.921 1.288 . . . . 0.0 111.603 179.036 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -63.97 -40.53 96.6 Favored 'General case' 0 CA--C 1.543 0.682 0 N-CA-C 112.92 0.711 . . . . 0.0 112.92 -168.075 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 28.5 p30 -154.77 -178.39 7.17 Favored 'General case' 0 CA--C 1.551 0.991 0 C-N-CA 125.314 1.445 . . . . 0.0 111.635 168.877 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 83.4 p -73.12 -16.79 61.45 Favored 'General case' 0 N--CA 1.48 1.046 0 N-CA-C 114.753 1.39 . . . . 0.0 114.753 177.843 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 38.8 t -76.6 -56.06 4.95 Favored 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 124.77 1.228 . . . . 0.0 111.136 173.861 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 7.7 tp -57.85 -34.63 48.77 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.859 0 C-N-CA 123.528 0.731 . . . . 0.0 112.406 179.115 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -55.24 -53.35 57.17 Favored 'General case' 0 CA--C 1.541 0.627 0 C-N-CA 123.885 0.874 . . . . 0.0 111.484 172.967 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 81.3 mtm180 -67.02 -37.42 84.13 Favored 'General case' 0 N--CA 1.475 0.786 0 C-N-CA 125.031 1.332 . . . . 0.0 113.49 178.317 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 42.5 t -57.22 -47.0 82.43 Favored 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 124.325 1.05 . . . . 0.0 111.599 170.844 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 63.6 t30 -70.96 -49.84 41.09 Favored 'General case' 0 CA--C 1.546 0.797 0 C-N-CA 125.502 1.521 . . . . 0.0 112.961 -178.172 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 145.42 23.22 0.12 Allowed Glycine 0 CA--C 1.539 1.561 0 N-CA-C 116.792 1.477 . . . . 0.0 116.792 178.663 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 19.3 t -125.55 150.84 31.06 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.613 0 C-N-CA 126.714 2.006 . . . . 0.0 108.839 -178.069 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 32.5 t -144.61 118.54 9.35 Favored 'General case' 0 N--CA 1.472 0.666 0 C-N-CA 124.907 1.283 . . . . 0.0 112.698 179.197 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.471 ' H ' HD12 ' A' ' 34' ' ' ILE . 0.7 OUTLIER . . . . . 0 CA--C 1.555 1.16 0 C-N-CA 126.789 2.035 . . . . 0.0 111.469 -178.638 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 4.9 m . . . . . 0 CA--C 1.547 0.843 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -74.44 51.19 0.44 Allowed 'General case' 0 CA--C 1.554 1.101 0 C-N-CA 125.571 1.549 . . . . 0.0 113.58 -177.588 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 81.2 m -71.5 156.07 91.88 Favored Pre-proline 0 CA--C 1.548 0.885 0 C-N-CA 125.624 1.569 . . . . 0.0 114.039 -172.704 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -68.93 158.83 56.34 Favored 'Trans proline' 0 CA--C 1.54 0.814 0 C-N-CA 123.63 2.887 . . . . 0.0 113.213 177.979 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 64.8 mttm -69.98 -14.02 62.5 Favored 'General case' 0 N--CA 1.481 1.093 0 C-N-CA 126.399 1.88 . . . . 0.0 114.142 177.813 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 10.3 tp -62.41 146.49 12.42 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 C-N-CA 126.438 1.895 . . . . 0.0 113.446 -177.114 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 62.7 tp -116.8 88.36 2.88 Favored 'General case' 0 CA--C 1.539 0.544 0 C-N-CA 127.138 2.175 . . . . 0.0 108.881 -175.677 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 13.1 mmmm -134.38 74.12 67.28 Favored Pre-proline 0 N--CA 1.474 0.739 0 C-N-CA 126.519 1.928 . . . . 0.0 109.179 175.536 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -67.21 120.02 7.07 Favored 'Trans proline' 0 CA--C 1.536 0.611 0 C-N-CA 122.929 2.419 . . . . 0.0 111.12 -175.732 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -107.51 155.75 8.17 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.747 0 C-N-CA 124.929 1.291 . . . . 0.0 110.961 -175.8 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 8.8 p -81.98 106.33 13.81 Favored 'General case' 0 CA--C 1.545 0.754 0 C-N-CA 125.792 1.637 . . . . 0.0 110.813 171.582 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -69.11 154.07 53.11 Favored Glycine 0 CA--C 1.534 1.272 0 O-C-N 121.45 -0.781 . . . . 0.0 112.085 172.063 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 73.2 m -61.69 -18.71 60.73 Favored 'General case' 0 N--CA 1.479 0.982 0 N-CA-C 116.084 1.883 . . . . 0.0 116.084 -168.854 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 31.8 t70 -82.14 -11.29 58.82 Favored 'General case' 0 CA--C 1.548 0.902 0 N-CA-C 114.105 1.15 . . . . 0.0 114.105 175.252 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 107.42 6.13 33.73 Favored Glycine 0 CA--C 1.536 1.377 0 C-N-CA 126.3 1.905 . . . . 0.0 114.418 -179.452 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 40.2 mtp180 -104.39 138.55 40.63 Favored 'General case' 0 N--CA 1.475 0.798 0 C-N-CA 126.073 1.749 . . . . 0.0 111.211 -175.139 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 8.1 p -77.91 141.9 38.75 Favored 'General case' 0 N--CA 1.47 0.55 0 C-N-CA 123.901 0.88 . . . . 0.0 112.39 175.961 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 92.8 m-85 -135.49 144.05 46.16 Favored 'General case' 0 N--CA 1.472 0.666 0 C-N-CA 125.437 1.495 . . . . 0.0 111.742 175.786 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -60.33 -40.98 92.56 Favored 'General case' 0 CA--C 1.543 0.688 0 N-CA-C 114.145 1.165 . . . . 0.0 114.145 -163.402 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 14.1 p30 -155.3 174.28 15.44 Favored 'General case' 0 CA--C 1.55 0.971 0 C-N-CA 126.282 1.833 . . . . 0.0 110.175 163.818 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 73.8 p -60.82 -25.98 66.99 Favored 'General case' 0 N--CA 1.48 1.037 0 N-CA-C 114.391 1.256 . . . . 0.0 114.391 -175.883 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 48.7 t -57.91 -62.25 1.94 Allowed 'General case' 0 CA--C 1.532 0.277 0 C-N-CA 124.923 1.289 . . . . 0.0 111.742 172.344 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 6.4 tt -59.91 -36.09 64.61 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.773 0 N-CA-C 112.289 0.477 . . . . 0.0 112.289 -177.336 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -58.26 -58.18 9.61 Favored 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 124.179 0.992 . . . . 0.0 111.518 174.589 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 65.2 mtm180 -64.17 -36.06 82.82 Favored 'General case' 0 N--CA 1.477 0.881 0 N-CA-C 113.271 0.841 . . . . 0.0 113.271 179.417 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 6.6 t -61.93 -42.97 99.71 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 124.009 0.924 . . . . 0.0 111.631 174.197 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 26.9 t-20 -69.37 -49.08 58.82 Favored 'General case' 0 CA--C 1.546 0.792 0 C-N-CA 124.851 1.26 . . . . 0.0 112.68 176.679 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 139.52 24.38 0.3 Allowed Glycine 0 CA--C 1.539 1.568 0 N-CA-C 116.16 1.224 . . . . 0.0 116.16 179.595 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 32.5 t -129.74 153.23 38.52 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.636 0 C-N-CA 126.373 1.869 . . . . 0.0 109.385 -177.927 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 68.9 m -134.41 170.48 15.67 Favored 'General case' 0 N--CA 1.47 0.575 0 C-N-CA 126.312 1.845 . . . . 0.0 112.099 -179.582 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 1.9 mp . . . . . 0 CA--C 1.554 1.1 0 C-N-CA 126.414 1.886 . . . . 0.0 111.443 -178.924 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 61.8 m . . . . . 0 CA--C 1.551 0.999 0 N-CA-C 113.248 0.833 . . . . 0.0 113.248 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . 54.41 30.85 13.46 Favored 'General case' 0 CA--C 1.551 1.002 0 C-N-CA 127.795 2.438 . . . . 0.0 114.408 -170.016 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 64.1 m -64.42 156.83 75.15 Favored Pre-proline 0 CA--C 1.55 0.958 0 C-N-CA 125.388 1.475 . . . . 0.0 113.387 177.321 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 95.3 Cg_endo -74.18 165.18 32.55 Favored 'Trans proline' 0 CA--C 1.542 0.894 0 C-N-CA 123.419 2.746 . . . . 0.0 113.522 -174.682 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 73.9 mmtt -78.87 -0.26 29.98 Favored 'General case' 0 N--CA 1.482 1.146 0 C-N-CA 126.28 1.832 . . . . 0.0 114.746 178.632 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 50.8 mm -56.86 157.97 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.766 0 C-N-CA 126.696 1.998 . . . . 0.0 111.146 170.536 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 51.5 tp -135.7 92.71 2.85 Favored 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 126.515 1.926 . . . . 0.0 108.583 -178.857 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 53.5 tptt -139.2 80.77 22.43 Favored Pre-proline 0 N--CA 1.471 0.595 0 C-N-CA 125.327 1.451 . . . . 0.0 110.124 174.186 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 62.1 Cg_endo -68.92 146.92 66.99 Favored 'Trans proline' 0 CA--C 1.537 0.67 0 C-N-CA 121.919 1.746 . . . . 0.0 111.102 177.68 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 1.4 t -137.08 159.81 36.41 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.977 0 C-N-CA 124.933 1.293 . . . . 0.0 110.518 -176.589 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 29.9 p -85.83 -7.47 58.71 Favored 'General case' 0 CA--C 1.547 0.828 0 C-N-CA 125.85 1.66 . . . . 0.0 114.764 -174.487 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 56.86 -178.38 0.78 Allowed Glycine 0 CA--C 1.537 1.442 0 C-N-CA 127.136 2.303 . . . . 0.0 116.447 177.274 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 11.2 t -79.46 -36.36 38.93 Favored 'General case' 0 CA--C 1.543 0.692 0 C-N-CA 123.653 0.781 . . . . 0.0 112.166 170.732 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -75.63 -12.22 60.17 Favored 'General case' 0 CA--C 1.548 0.877 0 C-N-CA 125.441 1.497 . . . . 0.0 114.596 -177.857 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 92.26 7.44 63.79 Favored Glycine 0 CA--C 1.536 1.373 0 C-N-CA 125.745 1.641 . . . . 0.0 114.723 176.13 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 38.3 mtt180 -95.84 -178.08 4.25 Favored 'General case' 0 N--CA 1.477 0.902 0 C-N-CA 126.353 1.861 . . . . 0.0 112.172 -177.046 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 47.3 m -122.24 128.19 50.84 Favored 'General case' 0 N--CA 1.476 0.85 0 C-N-CA 124.573 1.149 . . . . 0.0 110.505 179.32 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 56.4 m-85 -131.85 156.34 46.24 Favored 'General case' 0 N--CA 1.47 0.566 0 C-N-CA 125.491 1.517 . . . . 0.0 111.483 179.243 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.19 -43.83 85.7 Favored 'General case' 0 CA--C 1.544 0.748 0 N-CA-C 113.307 0.854 . . . . 0.0 113.307 -169.197 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 70.6 m-80 -139.66 175.9 9.18 Favored 'General case' 0 CA--C 1.544 0.729 0 C-N-CA 125.739 1.616 . . . . 0.0 111.557 171.184 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 42.4 t -61.34 -40.44 94.25 Favored 'General case' 0 N--CA 1.473 0.723 0 O-C-N 121.339 -0.851 . . . . 0.0 112.199 167.018 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 46.0 t -53.49 -57.42 10.76 Favored 'General case' 0 N--CA 1.467 0.398 0 C-N-CA 125.095 1.358 . . . . 0.0 112.795 -179.782 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 10.8 tp -59.97 -39.37 80.01 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.694 0 C-N-CA 122.791 0.436 . . . . 0.0 112.108 -179.099 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -68.76 -40.15 79.88 Favored 'General case' 0 CA--C 1.542 0.635 0 O-C-N 121.525 -0.735 . . . . 0.0 112.386 178.2 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 20.8 tpt180 -68.85 -35.66 77.2 Favored 'General case' 0 N--CA 1.472 0.654 0 C-N-CA 124.57 1.148 . . . . 0.0 112.691 176.107 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 47.8 t -59.45 -49.29 78.37 Favored 'General case' 0 CA--C 1.542 0.648 0 C-N-CA 125.059 1.344 . . . . 0.0 111.083 167.479 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 25.9 t-20 -62.97 -45.35 92.83 Favored 'General case' 0 CA--C 1.546 0.796 0 C-N-CA 124.814 1.246 . . . . 0.0 113.324 -179.535 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 143.66 17.22 0.24 Allowed Glycine 0 CA--C 1.54 1.614 0 N-CA-C 117.191 1.636 . . . . 0.0 117.191 175.386 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 21.7 t -115.7 144.15 23.98 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.704 0 CA-C-N 119.882 1.841 . . . . 0.0 110.232 -176.27 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 23.0 t -91.11 126.84 36.32 Favored 'General case' 0 N--CA 1.472 0.65 0 C-N-CA 126.48 1.912 . . . . 0.0 111.525 176.041 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 22.8 mm . . . . . 0 N--CA 1.479 0.991 0 C-N-CA 125.08 1.352 . . . . 0.0 112.686 -174.655 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 21.0 pttp . . . . . 0 N--CA 1.495 1.797 0 N-CA-C 115.539 1.681 . . . . 0.0 115.539 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 23.4 pttp -61.8 160.57 11.69 Favored 'General case' 0 N--CA 1.482 1.175 0 CA-C-N 120.605 1.548 . . . . 0.0 113.569 -176.733 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 13.2 p -141.66 144.57 25.62 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.844 0 C-N-CA 125.556 1.542 . . . . 0.0 111.307 179.837 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 67.9 m -77.24 98.27 5.08 Favored 'General case' 0 CA--C 1.541 0.612 0 C-N-CA 125.1 1.36 . . . . 0.0 111.364 179.108 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -73.34 48.76 0.25 Allowed 'General case' 0 CA--C 1.554 1.13 0 C-N-CA 126.371 1.868 . . . . 0.0 113.54 177.627 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 85.4 m -61.99 156.79 55.65 Favored Pre-proline 0 CA--C 1.548 0.897 0 C-N-CA 125.718 1.607 . . . . 0.0 113.724 179.853 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_endo -68.62 151.82 74.88 Favored 'Trans proline' 0 C--N 1.351 0.7 0 C-N-CA 123.275 2.65 . . . . 0.0 112.137 177.17 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 10.4 ptpp? -74.28 -30.71 62.22 Favored 'General case' 0 N--CA 1.478 0.964 0 C-N-CA 125.058 1.343 . . . . 0.0 114.198 176.399 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 40.8 mm -58.05 126.95 16.47 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.741 0 C-N-CA 126.893 2.077 . . . . 0.0 111.457 -176.571 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 2.0 pt? -61.6 126.67 28.17 Favored 'General case' 0 CA--C 1.542 0.662 0 C-N-CA 125.128 1.371 . . . . 0.0 112.851 -179.777 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 74.9 mmtt -136.33 71.91 59.6 Favored Pre-proline 0 N--CA 1.479 1.004 0 C-N-CA 125.314 1.446 . . . . 0.0 111.604 173.25 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 75.1 Cg_endo -72.85 84.59 1.25 Allowed 'Trans proline' 0 CA--C 1.54 0.817 0 C-N-CA 123.84 3.027 . . . . 0.0 112.818 -178.058 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 15.1 m -76.99 162.13 4.35 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.589 0 C-N-CA 126.739 2.016 . . . . 0.0 113.296 178.824 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 10.6 t -80.19 -5.54 56.26 Favored 'General case' 0 CA--C 1.553 1.068 0 C-N-CA 125.492 1.517 . . . . 0.0 114.166 174.321 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 64.71 -164.67 34.45 Favored Glycine 0 CA--C 1.538 1.504 0 C-N-CA 125.072 1.32 . . . . 0.0 113.974 -178.371 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 25.1 t -111.27 -38.9 4.87 Favored 'General case' 0 N--CA 1.477 0.901 0 C-N-CA 124.775 1.23 . . . . 0.0 112.591 172.57 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 29.5 t70 -72.29 -13.42 61.5 Favored 'General case' 0 N--CA 1.478 0.955 0 N-CA-C 114.249 1.203 . . . . 0.0 114.249 177.718 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 98.15 39.27 3.81 Favored Glycine 0 CA--C 1.533 1.202 0 C-N-CA 125.92 1.724 . . . . 0.0 112.827 -178.745 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 16.2 mmm180 -135.33 150.88 50.07 Favored 'General case' 0 N--CA 1.475 0.776 0 C-N-CA 127.366 2.266 . . . . 0.0 110.822 -168.716 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 27.9 m -95.82 134.45 38.76 Favored 'General case' 0 N--CA 1.476 0.866 0 C-N-CA 124.209 1.004 . . . . 0.0 110.569 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 73.5 m-85 -128.67 160.92 30.94 Favored 'General case' 0 N--CA 1.471 0.613 0 C-N-CA 125.541 1.537 . . . . 0.0 111.215 178.666 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.9 -60.95 2.49 Favored 'General case' 0 CA--C 1.542 0.658 0 N-CA-C 111.784 0.29 . . . . 0.0 111.784 -172.247 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 30.1 m-20 -129.04 162.49 27.53 Favored 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 125.962 1.705 . . . . 0.0 110.322 170.896 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 26.7 p -63.24 -40.98 98.98 Favored 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 124.637 1.175 . . . . 0.0 113.684 177.299 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 49.5 t -57.89 -48.2 80.56 Favored 'General case' 0 N--CA 1.468 0.441 0 C-N-CA 125.303 1.441 . . . . 0.0 112.372 177.049 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 1.4 mp -52.31 -45.91 44.95 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.727 0 C-N-CA 124.815 1.246 . . . . 0.0 111.669 174.224 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -59.67 -46.63 88.46 Favored 'General case' 0 CA--C 1.545 0.753 0 CA-C-N 119.631 1.105 . . . . 0.0 112.14 177.281 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -57.69 -47.65 81.74 Favored 'General case' 0 N--CA 1.478 0.937 0 C-N-CA 124.877 1.271 . . . . 0.0 111.615 175.639 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 50.7 t -56.31 -48.21 77.13 Favored 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 125.38 1.472 . . . . 0.0 112.297 174.099 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -67.8 -30.06 69.39 Favored 'General case' 0 CA--C 1.548 0.882 0 C-N-CA 124.718 1.207 . . . . 0.0 112.792 -177.516 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 123.32 22.25 2.36 Favored Glycine 0 CA--C 1.537 1.409 0 C-N-CA 124.911 1.243 . . . . 0.0 115.954 175.401 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 5.0 t -124.27 143.59 37.09 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.568 0 C-N-CA 125.906 1.682 . . . . 0.0 109.315 -179.216 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 16.0 t -97.54 169.97 9.36 Favored 'General case' 0 N--CA 1.473 0.721 0 C-N-CA 125.362 1.465 . . . . 0.0 112.134 178.121 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 2.4 mt -141.17 12.74 0.49 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.054 0 C-N-CA 126.999 2.12 . . . . 0.0 110.494 -179.225 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 58.22 18.95 5.76 Favored 'General case' 0 N--CA 1.485 1.295 0 C-N-CA 126.916 2.086 . . . . 0.0 114.495 -174.285 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 1.4 t -116.7 22.18 12.88 Favored 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 126.924 2.09 . . . . 0.0 113.717 -174.521 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 52.9 mt-10 -54.35 -22.77 13.06 Favored 'General case' 0 CA--C 1.546 0.804 0 C-N-CA 126.082 1.753 . . . . 0.0 114.622 177.507 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -76.99 -10.07 86.43 Favored Glycine 0 CA--C 1.54 1.605 0 C-N-CA 124.857 1.218 . . . . 0.0 115.446 176.04 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 12.6 t -146.07 89.91 1.92 Allowed 'General case' 0 N--CA 1.472 0.667 0 CA-C-N 118.975 1.388 . . . . 0.0 111.369 178.83 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 29.5 p -139.6 160.58 60.79 Favored Pre-proline 0 CA--C 1.549 0.94 0 C-N-CA 125.581 1.552 . . . . 0.0 111.994 -177.049 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -74.13 -14.6 23.34 Favored 'Trans proline' 0 CA--C 1.542 0.897 0 C-N-CA 123.15 2.567 . . . . 0.0 113.953 179.179 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 13.7 m -60.7 112.65 2.1 Favored 'General case' 0 N--CA 1.473 0.717 0 C-N-CA 126.454 1.902 . . . . 0.0 111.685 178.338 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -156.58 68.75 0.29 Allowed Glycine 0 CA--C 1.531 1.084 0 C-N-CA 124.4 1.0 . . . . 0.0 113.432 -175.421 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.255 1.353 0 C-N-CA 125.656 1.582 . . . . 0.0 111.529 174.383 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 4.1 mppt? . . . . . 0 N--CA 1.491 1.612 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 11.5 ptmm? -157.34 175.17 14.36 Favored 'General case' 0 N--CA 1.484 1.238 0 C-N-CA 127.068 2.147 . . . . 0.0 111.488 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 12.6 p -141.52 149.98 19.93 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.009 0 C-N-CA 125.317 1.447 . . . . 0.0 111.532 175.84 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 58.5 m -71.47 105.95 3.77 Favored 'General case' 0 CA--C 1.544 0.722 0 C-N-CA 125.486 1.514 . . . . 0.0 110.963 175.301 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -74.6 53.5 0.56 Allowed 'General case' 0 CA--C 1.553 1.059 0 C-N-CA 126.101 1.76 . . . . 0.0 113.629 -178.503 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 80.0 m -67.14 153.99 93.54 Favored Pre-proline 0 CA--C 1.551 0.982 0 C-N-CA 125.373 1.469 . . . . 0.0 113.306 -178.071 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -72.59 157.37 52.65 Favored 'Trans proline' 0 CA--C 1.541 0.847 0 C-N-CA 123.05 2.5 . . . . 0.0 112.514 179.459 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -88.72 -9.54 51.59 Favored 'General case' 0 N--CA 1.48 1.045 0 C-N-CA 124.927 1.291 . . . . 0.0 113.678 176.649 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 79.9 mt -62.02 139.82 20.2 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.756 0 C-N-CA 125.106 1.362 . . . . 0.0 109.692 174.176 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 10.4 mp -82.53 97.8 8.62 Favored 'General case' 0 CA--C 1.538 0.507 0 C-N-CA 124.744 1.218 . . . . 0.0 110.354 172.806 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 2.4 mmmp? -126.47 65.99 61.36 Favored Pre-proline 0 CA--C 1.546 0.815 0 C-N-CA 125.331 1.452 . . . . 0.0 110.632 170.147 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 66.5 Cg_endo -66.32 154.29 74.78 Favored 'Trans proline' 0 C--N 1.352 0.747 0 C-N-CA 122.813 2.342 . . . . 0.0 112.169 -179.263 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -142.18 160.2 20.1 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.757 0 C-N-CA 125.088 1.355 . . . . 0.0 110.476 -178.746 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 47.3 t -73.41 105.04 4.61 Favored 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 124.735 1.214 . . . . 0.0 110.283 169.97 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -65.99 148.02 50.65 Favored Glycine 0 CA--C 1.531 1.041 0 C-N-CA 124.1 0.857 . . . . 0.0 112.416 174.136 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 69.5 m -65.56 -17.58 64.68 Favored 'General case' 0 N--CA 1.475 0.819 0 N-CA-C 114.941 1.46 . . . . 0.0 114.941 -174.8 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 32.1 t70 -79.81 -8.12 59.08 Favored 'General case' 0 CA--C 1.552 1.032 0 C-N-CA 124.698 1.199 . . . . 0.0 113.569 169.148 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 97.34 27.38 9.29 Favored Glycine 0 CA--C 1.536 1.39 0 C-N-CA 126.548 2.023 . . . . 0.0 114.084 -179.593 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 64.3 mtt-85 -127.31 170.57 12.33 Favored 'General case' 0 N--CA 1.481 1.075 0 C-N-CA 125.241 1.416 . . . . 0.0 113.826 -166.385 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 33.1 m -103.45 125.36 49.99 Favored 'General case' 0 N--CA 1.475 0.78 0 C-N-CA 125.761 1.625 . . . . 0.0 110.674 -177.293 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 77.6 m-85 -131.57 157.43 43.62 Favored 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 125.097 1.359 . . . . 0.0 111.631 174.789 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.21 -48.82 74.39 Favored 'General case' 0 CA--C 1.542 0.645 0 N-CA-C 113.211 0.819 . . . . 0.0 113.211 -166.993 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . 0.407 ' H ' HG22 ' A' ' 26' ' ' ILE . 71.8 m-80 -144.32 174.23 11.09 Favored 'General case' 0 CA--C 1.549 0.936 0 C-N-CA 126.754 2.021 . . . . 0.0 111.08 174.865 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 69.5 m -65.58 -27.92 68.77 Favored 'General case' 0 N--CA 1.483 1.194 0 O-C-N 120.485 -1.385 . . . . 0.0 112.992 171.61 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 46.0 t -58.57 -58.36 8.9 Favored 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 125.414 1.486 . . . . 0.0 112.218 175.652 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.407 HG22 ' H ' ' A' ' 23' ' ' ASN . 10.5 tp -60.7 -33.95 56.94 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 N-CA-C 112.219 0.452 . . . . 0.0 112.219 -179.619 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -59.24 -53.89 53.13 Favored 'General case' 0 CA--C 1.542 0.663 0 CA-C-N 118.684 0.675 . . . . 0.0 111.852 173.152 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 18.4 mmm180 -62.9 -33.56 75.56 Favored 'General case' 0 N--CA 1.48 1.031 0 C-N-CA 123.812 0.845 . . . . 0.0 113.217 176.088 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 19.3 t -62.83 -46.69 86.74 Favored 'General case' 0 CA--C 1.545 0.762 0 C-N-CA 124.513 1.125 . . . . 0.0 111.741 172.554 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 88.1 m-20 -69.34 -49.66 53.64 Favored 'General case' 0 CA--C 1.542 0.654 0 C-N-CA 125.552 1.541 . . . . 0.0 113.015 -179.691 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 142.63 24.5 0.19 Allowed Glycine 0 CA--C 1.538 1.518 0 N-CA-C 116.484 1.353 . . . . 0.0 116.484 -177.867 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 6.6 t -128.4 147.02 32.97 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.706 0 C-N-CA 126.211 1.804 . . . . 0.0 108.878 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 68.8 m -117.43 133.33 56.09 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 125.337 1.455 . . . . 0.0 112.231 -175.369 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 9.9 mm -121.62 8.14 5.9 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.04 0 C-N-CA 126.375 1.87 . . . . 0.0 111.582 -166.631 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 26.0 mmmt 60.3 14.22 4.5 Favored 'General case' 0 N--CA 1.488 1.46 0 C-N-CA 127.208 2.203 . . . . 0.0 115.162 -170.38 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 75.7 m -118.97 41.24 3.1 Favored 'General case' 0 N--CA 1.473 0.698 0 C-N-CA 127.083 2.153 . . . . 0.0 112.05 -179.577 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 39.4 mt-10 -58.99 160.01 6.47 Favored 'General case' 0 CA--C 1.547 0.856 0 C-N-CA 125.196 1.398 . . . . 0.0 113.104 171.437 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -179.54 -65.76 0.07 OUTLIER Glycine 0 CA--C 1.532 1.109 0 C-N-CA 124.653 1.12 . . . . 0.0 112.313 177.876 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 46.6 m -63.27 106.5 0.9 Allowed 'General case' 0 N--CA 1.472 0.653 0 C-N-CA 125.408 1.483 . . . . 0.0 111.36 172.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 46.6 t -60.41 118.96 38.8 Favored Pre-proline 0 CA--C 1.552 1.026 0 C-N-CA 124.473 1.109 . . . . 0.0 112.083 -177.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 85.6 Cg_endo -75.84 -15.74 18.79 Favored 'Trans proline' 0 CA--C 1.54 0.824 0 C-N-CA 122.948 2.432 . . . . 0.0 113.978 -177.224 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 5.1 m 55.86 36.66 27.71 Favored 'General case' 0 N--CA 1.483 1.217 0 C-N-CA 125.949 1.699 . . . . 0.0 112.478 -176.87 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -102.25 -97.05 2.34 Favored Glycine 0 CA--C 1.536 1.373 0 C-N-CA 125.646 1.593 . . . . 0.0 112.578 179.599 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 67.6 mt . . . . . 0 C--O 1.254 1.31 0 C-N-CA 126.178 1.791 . . . . 0.0 110.863 178.319 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 70.3 mmtt . . . . . 0 N--CA 1.491 1.617 0 N-CA-C 110.681 -0.118 . . . . 0.0 110.681 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 6.3 ttpm? -69.24 141.63 54.38 Favored 'General case' 0 N--CA 1.481 1.097 0 C-N-CA 124.307 1.043 . . . . 0.0 110.678 174.226 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 13.8 p -144.28 143.47 23.33 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.796 0 C-N-CA 125.022 1.329 . . . . 0.0 111.371 -179.669 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 34.2 m -111.87 -18.33 12.71 Favored 'General case' 0 CA--C 1.547 0.834 0 C-N-CA 125.426 1.49 . . . . 0.0 112.981 178.346 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . 46.46 34.33 2.31 Favored 'General case' 0 CA--C 1.549 0.931 0 C-N-CA 127.366 2.266 . . . . 0.0 114.612 -174.462 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 53.2 m -63.22 152.78 83.77 Favored Pre-proline 0 CA--C 1.548 0.891 0 C-N-CA 124.264 1.026 . . . . 0.0 113.285 -176.658 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -67.75 157.54 61.32 Favored 'Trans proline' 0 CA--C 1.54 0.78 0 C-N-CA 123.595 2.863 . . . . 0.0 112.942 179.873 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 32.1 mmmt -74.24 -8.91 57.85 Favored 'General case' 0 N--CA 1.481 1.085 0 C-N-CA 126.353 1.861 . . . . 0.0 114.116 -179.05 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -54.89 138.52 14.93 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.691 0 C-N-CA 127.43 2.292 . . . . 0.0 112.838 179.396 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 42.5 tp -114.0 101.05 8.88 Favored 'General case' 0 CA--C 1.539 0.52 0 C-N-CA 127.269 2.228 . . . . 0.0 109.127 -176.588 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 59.0 tttm -148.74 78.17 9.15 Favored Pre-proline 0 N--CA 1.473 0.7 0 C-N-CA 124.635 1.174 . . . . 0.0 110.662 175.646 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 67.0 Cg_endo -72.26 108.24 2.45 Favored 'Trans proline' 0 N--CA 1.458 -0.612 0 C-N-CA 123.035 2.49 . . . . 0.0 111.913 -177.871 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 14.9 m -107.09 172.65 1.82 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.463 0 C-N-CA 126.867 2.067 . . . . 0.0 111.793 -179.836 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 24.2 t -75.75 154.07 36.59 Favored 'General case' 0 CA--C 1.541 0.599 0 C-N-CA 123.981 0.912 . . . . 0.0 111.184 -179.851 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -121.48 152.82 16.76 Favored Glycine 0 CA--C 1.531 1.061 0 C-N-CA 125.012 1.292 . . . . 0.0 113.239 177.002 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 9.2 t -55.98 -36.05 67.43 Favored 'General case' 0 N--CA 1.476 0.841 0 C-N-CA 125.86 1.664 . . . . 0.0 114.064 -173.783 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 32.8 t70 -80.04 -9.31 59.69 Favored 'General case' 0 CA--C 1.551 1.0 0 C-N-CA 125.027 1.331 . . . . 0.0 114.368 179.119 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 89.88 53.4 2.4 Favored Glycine 0 CA--C 1.532 1.136 0 C-N-CA 125.311 1.434 . . . . 0.0 112.068 -175.203 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 4.0 mmp_? -137.81 174.89 10.1 Favored 'General case' 0 N--CA 1.477 0.91 0 C-N-CA 127.658 2.383 . . . . 0.0 110.916 -172.462 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 9.4 m -137.71 140.49 40.76 Favored 'General case' 0 N--CA 1.48 1.025 0 C-N-CA 125.301 1.44 . . . . 0.0 110.512 179.7 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 49.1 m-85 -139.25 161.33 37.68 Favored 'General case' 0 N--CA 1.473 0.699 0 C-N-CA 125.533 1.533 . . . . 0.0 111.32 -176.894 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.39 -45.42 87.77 Favored 'General case' 0 CA--C 1.545 0.772 0 N-CA-C 113.525 0.935 . . . . 0.0 113.525 -167.553 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . 0.433 ' H ' HG22 ' A' ' 26' ' ' ILE . 28.0 p30 -146.08 -178.42 6.12 Favored 'General case' 0 CA--C 1.548 0.886 0 C-N-CA 125.226 1.411 . . . . 0.0 111.864 166.984 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 29.0 p -66.28 -30.16 70.53 Favored 'General case' 0 N--CA 1.472 0.629 0 N-CA-C 114.226 1.195 . . . . 0.0 114.226 179.094 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 49.1 t -64.98 -56.58 12.32 Favored 'General case' 0 N--CA 1.47 0.526 0 C-N-CA 124.058 0.943 . . . . 0.0 111.524 177.401 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.433 HG22 ' H ' ' A' ' 23' ' ' ASN . 11.2 tp -57.6 -38.88 66.59 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.618 0 CA-C-O 119.354 -0.355 . . . . 0.0 111.757 179.853 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -61.11 -45.09 96.12 Favored 'General case' 0 CA--C 1.543 0.683 0 C-N-CA 123.949 0.9 . . . . 0.0 112.797 175.809 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 5.1 tpt180 -64.8 -42.06 95.31 Favored 'General case' 0 N--CA 1.474 0.734 0 C-N-CA 123.448 0.699 . . . . 0.0 112.524 176.203 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 2.9 t -65.35 -36.08 82.94 Favored 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 123.117 0.567 . . . . 0.0 112.164 174.858 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 24.7 t-20 -66.68 -53.71 30.82 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 125.594 1.558 . . . . 0.0 112.486 176.674 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 151.49 19.4 0.06 OUTLIER Glycine 0 CA--C 1.538 1.526 0 N-CA-C 117.602 1.801 . . . . 0.0 117.602 179.284 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 3.7 t -127.78 138.69 53.99 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.814 0 CA-C-N 120.25 2.025 . . . . 0.0 110.309 -177.659 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 8.6 t -91.87 94.65 9.42 Favored 'General case' 0 N--CA 1.472 0.658 0 C-N-CA 125.245 1.418 . . . . 0.0 112.324 -173.987 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 19.6 mm -98.28 -25.55 4.03 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.006 0 C-N-CA 124.368 1.067 . . . . 0.0 112.972 -176.861 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -78.94 -25.02 43.6 Favored 'General case' 0 N--CA 1.48 1.048 0 C-N-CA 125.065 1.346 . . . . 0.0 113.848 178.501 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER 53.83 36.23 23.57 Favored 'General case' 0 N--CA 1.48 1.025 0 C-N-CA 125.15 1.38 . . . . 0.0 113.231 -169.92 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -60.1 164.36 4.13 Favored 'General case' 0 CA--C 1.548 0.903 0 C-N-CA 127.045 2.138 . . . . 0.0 113.726 178.93 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 109.43 -11.03 33.3 Favored Glycine 0 CA--C 1.539 1.572 0 C-N-CA 126.805 2.145 . . . . 0.0 114.919 -177.85 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 62.4 m -110.55 -40.48 4.6 Favored 'General case' 0 N--CA 1.478 0.962 0 C-N-CA 125.281 1.432 . . . . 0.0 113.773 -178.182 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 84.9 m -132.9 155.63 80.95 Favored Pre-proline 0 CA--C 1.545 0.773 0 C-N-CA 126.393 1.877 . . . . 0.0 110.599 179.179 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -72.19 -13.14 28.32 Favored 'Trans proline' 0 CA--C 1.544 1.023 0 C-N-CA 123.18 2.587 . . . . 0.0 114.222 -176.562 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.8 m -66.13 133.27 50.35 Favored 'General case' 0 N--CA 1.473 0.709 0 C-N-CA 125.769 1.628 . . . . 0.0 111.254 176.618 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -160.07 -83.07 0.05 OUTLIER Glycine 0 CA--C 1.533 1.161 0 O-C-N 121.756 -0.59 . . . . 0.0 113.6 179.943 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 44.1 mt . . . . . 0 C--O 1.254 1.326 0 C-N-CA 125.213 1.405 . . . . 0.0 110.74 175.821 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 13.6 tmtt? . . . . . 0 N--CA 1.49 1.575 0 N-CA-C 110.436 -0.209 . . . . 0.0 110.436 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 46.7 tttp 48.99 57.53 6.35 Favored 'General case' 0 N--CA 1.483 1.223 0 C-N-CA 126.826 2.05 . . . . 0.0 113.885 -177.392 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 47.9 t -129.44 127.16 64.65 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.072 0 C-N-CA 125.871 1.668 . . . . 0.0 110.497 176.386 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 3.7 m -77.58 103.13 7.34 Favored 'General case' 0 CA--C 1.544 0.737 0 C-N-CA 125.699 1.6 . . . . 0.0 110.002 175.022 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -74.66 60.22 0.9 Allowed 'General case' 0 CA--C 1.553 1.085 0 C-N-CA 124.607 1.163 . . . . 0.0 112.827 179.351 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 84.3 m -64.12 156.11 76.15 Favored Pre-proline 0 CA--C 1.55 0.947 0 C-N-CA 125.78 1.632 . . . . 0.0 112.96 179.497 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 93.0 Cg_endo -71.35 168.42 23.5 Favored 'Trans proline' 0 CA--C 1.54 0.819 0 C-N-CA 123.056 2.504 . . . . 0.0 112.334 176.589 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 38.0 tttp -64.09 -20.33 65.88 Favored 'General case' 0 N--CA 1.479 0.977 0 C-N-CA 124.761 1.224 . . . . 0.0 113.188 174.721 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 61.7 mt -57.89 120.05 3.62 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.589 0 C-N-CA 126.715 2.006 . . . . 0.0 111.066 179.908 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 15.9 tp -99.44 117.41 33.79 Favored 'General case' 0 CA--C 1.538 0.508 0 C-N-CA 129.048 2.939 . . . . 0.0 108.363 174.533 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -132.18 78.27 69.14 Favored Pre-proline 0 N--CA 1.473 0.704 0 C-N-CA 125.786 1.634 . . . . 0.0 108.882 -178.695 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 66.2 Cg_endo -71.38 102.66 1.3 Allowed 'Trans proline' 0 CA--C 1.537 0.67 0 C-N-CA 123.831 3.021 . . . . 0.0 112.181 -168.527 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -100.2 158.13 3.91 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.003 0 C-N-CA 124.332 1.053 . . . . 0.0 112.245 -176.162 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 18.0 t -72.94 -18.2 61.41 Favored 'General case' 0 CA--C 1.547 0.843 0 N-CA-C 114.209 1.189 . . . . 0.0 114.209 -178.896 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 63.51 -178.63 6.68 Favored Glycine 0 CA--C 1.537 1.457 0 C-N-CA 126.416 1.96 . . . . 0.0 115.514 176.971 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 14.1 m -84.53 -38.46 20.0 Favored 'General case' 0 N--CA 1.476 0.857 0 C-N-CA 124.066 0.947 . . . . 0.0 113.083 173.484 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 20.4 m-20 -77.03 -14.97 59.76 Favored 'General case' 0 N--CA 1.479 0.98 0 N-CA-C 113.581 0.956 . . . . 0.0 113.581 179.695 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 98.07 -11.77 63.91 Favored Glycine 0 CA--C 1.536 1.353 0 C-N-CA 126.391 1.948 . . . . 0.0 114.392 179.842 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -78.41 156.53 29.4 Favored 'General case' 0 N--CA 1.474 0.761 0 C-N-CA 125.262 1.425 . . . . 0.0 112.084 171.239 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -84.26 113.14 20.9 Favored 'General case' 0 N--CA 1.472 0.638 0 C-N-CA 124.88 1.272 . . . . 0.0 112.857 178.069 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 79.0 m-85 -91.45 149.53 21.66 Favored 'General case' 0 N--CA 1.475 0.785 0 C-N-CA 124.792 1.237 . . . . 0.0 111.599 173.489 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.69 -46.75 77.84 Favored 'General case' 0 CA--C 1.542 0.665 0 N-CA-C 113.355 0.872 . . . . 0.0 113.355 -168.936 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 26.0 p30 -157.06 -179.35 8.12 Favored 'General case' 0 CA--C 1.545 0.773 0 C-N-CA 125.441 1.496 . . . . 0.0 111.88 174.348 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 36.7 p -61.69 -32.57 72.78 Favored 'General case' 0 N--CA 1.473 0.708 0 O-C-N 120.977 -1.077 . . . . 0.0 113.342 173.956 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 49.5 t -58.82 -60.51 3.73 Favored 'General case' 0 CA--C 1.533 0.299 0 C-N-CA 124.85 1.26 . . . . 0.0 111.765 176.75 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 9.8 tp -56.98 -40.45 72.64 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.881 0 N-CA-C 112.431 0.53 . . . . 0.0 112.431 178.943 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -57.32 -59.34 5.27 Favored 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 123.886 0.874 . . . . 0.0 111.461 176.498 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 46.3 mmm-85 -59.27 -41.85 89.84 Favored 'General case' 0 N--CA 1.475 0.799 0 C-N-CA 124.773 1.229 . . . . 0.0 113.028 178.775 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 2.9 t -66.6 -41.33 88.62 Favored 'General case' 0 CA--C 1.545 0.757 0 C-N-CA 123.609 0.763 . . . . 0.0 112.536 179.579 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 53.1 t30 -71.52 -42.0 68.51 Favored 'General case' 0 CA--C 1.543 0.7 0 C-N-CA 124.655 1.182 . . . . 0.0 113.181 178.833 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 129.71 30.1 0.66 Allowed Glycine 0 CA--C 1.538 1.475 0 C-N-CA 124.611 1.1 . . . . 0.0 115.206 -179.333 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -123.08 169.7 14.16 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 C-N-CA 127.37 2.268 . . . . 0.0 109.192 -177.866 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 29.8 t -145.77 161.52 39.74 Favored 'General case' 0 N--CA 1.471 0.614 0 C-N-CA 125.259 1.423 . . . . 0.0 112.42 -179.005 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 18.7 mm -100.91 -7.36 9.08 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.86 0 C-N-CA 125.956 1.703 . . . . 0.0 111.69 178.019 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 8.4 mmpt? -62.37 -28.73 69.97 Favored 'General case' 0 N--CA 1.481 1.078 0 C-N-CA 125.22 1.408 . . . . 0.0 113.323 -178.986 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 21.8 t -62.78 -54.54 37.5 Favored 'General case' 0 N--CA 1.471 0.576 0 C-N-CA 124.84 1.256 . . . . 0.0 111.609 172.522 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 4.3 mt-10 -165.07 151.07 9.94 Favored 'General case' 0 N--CA 1.473 0.718 0 C-N-CA 126.239 1.816 . . . . 0.0 111.41 -179.231 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 133.85 93.1 0.48 Allowed Glycine 0 CA--C 1.531 1.06 0 C-N-CA 125.272 1.415 . . . . 0.0 112.276 179.531 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 34.1 m -55.95 145.86 23.91 Favored 'General case' 0 N--CA 1.474 0.754 0 C-N-CA 124.676 1.191 . . . . 0.0 112.649 178.747 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 28.9 p -146.42 158.7 46.73 Favored Pre-proline 0 CA--C 1.547 0.855 0 C-N-CA 125.084 1.354 . . . . 0.0 112.289 -176.938 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -69.98 124.13 10.69 Favored 'Trans proline' 0 CA--C 1.541 0.846 0 C-N-CA 123.141 2.561 . . . . 0.0 111.134 174.675 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 22.5 p -65.54 129.12 38.62 Favored 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 124.0 0.92 . . . . 0.0 111.389 174.998 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -112.32 -68.38 0.53 Allowed Glycine 0 CA--C 1.532 1.114 0 C-N-CA 125.284 1.421 . . . . 0.0 113.27 -175.237 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 10.7 tp . . . . . 0 C--O 1.253 1.263 0 C-N-CA 126.989 2.115 . . . . 0.0 112.202 -178.207 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 14.8 ptpt . . . . . 0 N--CA 1.497 1.901 0 N-CA-C 114.63 1.344 . . . . 0.0 114.63 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 12.4 mmmm 52.05 37.51 21.58 Favored 'General case' 0 N--CA 1.491 1.579 0 C-N-CA 126.284 1.834 . . . . 0.0 114.538 179.491 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.9 p -119.43 -4.17 10.17 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.315 0 C-N-CA 125.885 1.674 . . . . 0.0 113.954 -177.293 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 29.2 m -63.15 103.81 0.52 Allowed 'General case' 0 CA--C 1.54 0.585 0 C-N-CA 126.446 1.899 . . . . 0.0 110.532 177.752 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -71.64 55.78 0.26 Allowed 'General case' 0 CA--C 1.552 1.045 0 C-N-CA 126.516 1.926 . . . . 0.0 113.101 -179.961 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 93.0 m -63.59 157.59 64.79 Favored Pre-proline 0 CA--C 1.549 0.937 0 C-N-CA 126.083 1.753 . . . . 0.0 112.739 178.496 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -64.89 155.02 70.14 Favored 'Trans proline' 0 CA--C 1.537 0.671 0 C-N-CA 123.281 2.654 . . . . 0.0 112.803 -179.871 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 19.5 ptpt -59.75 -25.59 64.99 Favored 'General case' 0 N--CA 1.48 1.074 0 C-N-CA 125.707 1.603 . . . . 0.0 114.497 178.029 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 8.9 tp -57.11 144.47 9.34 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.473 0 C-N-CA 127.089 2.155 . . . . 0.0 113.212 -178.68 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 23.8 tp -119.66 108.24 14.21 Favored 'General case' 0 CA--C 1.535 0.402 0 C-N-CA 126.708 2.003 . . . . 0.0 108.292 -178.283 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 39.5 ttpt -128.95 79.03 75.34 Favored Pre-proline 0 CA--C 1.54 0.576 0 C-N-CA 126.38 1.872 . . . . 0.0 108.511 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -73.68 90.34 0.94 Allowed 'Trans proline' 0 CA--C 1.539 0.742 0 C-N-CA 123.72 2.947 . . . . 0.0 111.909 -171.442 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 1.1 t -83.56 161.26 3.38 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 C-N-CA 124.421 1.089 . . . . 0.0 111.03 -177.56 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 46.3 t -72.44 111.59 7.76 Favored 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 124.342 1.057 . . . . 0.0 109.839 170.448 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -65.51 146.01 49.25 Favored Glycine 0 CA--C 1.532 1.118 0 C-N-CA 123.778 0.704 . . . . 0.0 112.422 177.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 82.7 p -61.39 -29.86 70.19 Favored 'General case' 0 N--CA 1.476 0.865 0 N-CA-C 113.935 1.087 . . . . 0.0 113.935 -174.072 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 31.8 t70 -84.98 -8.19 58.84 Favored 'General case' 0 CA--C 1.551 0.993 0 C-N-CA 125.964 1.706 . . . . 0.0 113.894 176.92 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 107.51 1.04 34.96 Favored Glycine 0 CA--C 1.536 1.386 0 C-N-CA 126.504 2.002 . . . . 0.0 114.674 -178.623 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 22.1 mtm180 -90.32 -172.21 3.37 Favored 'General case' 0 N--CA 1.479 0.988 0 C-N-CA 126.355 1.862 . . . . 0.0 112.387 -177.269 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 23.0 m -128.8 135.26 48.91 Favored 'General case' 0 N--CA 1.479 1.01 0 C-N-CA 125.487 1.515 . . . . 0.0 110.492 -178.274 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 81.8 m-85 -135.94 150.39 49.27 Favored 'General case' 0 N--CA 1.474 0.74 0 C-N-CA 125.055 1.342 . . . . 0.0 111.488 -177.573 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.31 -45.08 89.52 Favored 'General case' 0 CA--C 1.543 0.683 0 N-CA-C 113.929 1.085 . . . . 0.0 113.929 -165.242 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 27.0 p30 -157.74 178.62 10.05 Favored 'General case' 0 CA--C 1.549 0.932 0 C-N-CA 125.927 1.691 . . . . 0.0 111.124 170.298 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 89.0 p -60.54 -29.69 69.29 Favored 'General case' 0 N--CA 1.478 0.973 0 N-CA-C 114.015 1.117 . . . . 0.0 114.015 179.052 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 45.4 t -61.66 -57.93 10.05 Favored 'General case' 0 N--CA 1.465 0.312 0 C-N-CA 124.24 1.016 . . . . 0.0 111.704 176.888 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 7.6 tp -59.75 -37.89 73.38 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.819 0 N-CA-C 112.062 0.393 . . . . 0.0 112.062 -179.878 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -57.3 -55.96 28.02 Favored 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 124.199 1.0 . . . . 0.0 111.583 173.967 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 70.4 mtp85 -61.23 -40.63 94.73 Favored 'General case' 0 N--CA 1.475 0.809 0 N-CA-C 113.297 0.851 . . . . 0.0 113.297 178.341 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -65.41 -36.35 83.68 Favored 'General case' 0 CA--C 1.546 0.819 0 N-CA-C 112.57 0.582 . . . . 0.0 112.57 177.132 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 25.9 t-20 -72.37 -47.53 48.68 Favored 'General case' 0 CA--C 1.546 0.815 0 C-N-CA 124.798 1.239 . . . . 0.0 113.003 175.926 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 135.8 29.5 0.36 Allowed Glycine 0 CA--C 1.538 1.53 0 C-N-CA 124.911 1.243 . . . . 0.0 115.469 -178.437 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 34.6 t -127.87 152.32 35.8 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.464 0 C-N-CA 127.416 2.286 . . . . 0.0 108.645 -176.992 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 58.2 m -141.72 160.06 40.95 Favored 'General case' 0 N--CA 1.476 0.838 0 C-N-CA 125.878 1.671 . . . . 0.0 112.302 -179.343 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 16.3 mt -113.17 -12.84 11.64 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.108 0 C-N-CA 125.102 1.361 . . . . 0.0 111.828 -175.067 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -58.21 -26.06 62.38 Favored 'General case' 0 N--CA 1.482 1.157 0 C-N-CA 125.699 1.6 . . . . 0.0 114.255 176.25 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 20.8 m -63.59 -49.74 72.15 Favored 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 125.654 1.582 . . . . 0.0 112.349 179.114 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -156.93 133.68 10.14 Favored 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 125.912 1.685 . . . . 0.0 111.511 175.086 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.82 -64.24 0.48 Allowed Glycine 0 CA--C 1.531 1.081 0 C-N-CA 124.985 1.279 . . . . 0.0 112.504 -178.41 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 95.6 p -150.43 165.71 32.33 Favored 'General case' 0 N--CA 1.473 0.694 0 C-N-CA 125.089 1.356 . . . . 0.0 113.018 178.312 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 13.2 p -149.38 66.17 8.29 Favored Pre-proline 0 CA--C 1.553 1.085 0 C-N-CA 125.495 1.518 . . . . 0.0 112.045 175.626 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -70.83 103.86 1.4 Allowed 'Trans proline' 0 CA--C 1.542 0.911 0 C-N-CA 123.875 3.05 . . . . 0.0 112.387 -177.179 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 16.1 m -61.21 139.16 58.19 Favored 'General case' 0 N--CA 1.477 0.887 0 C-N-CA 125.252 1.421 . . . . 0.0 111.976 178.207 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -166.1 165.21 38.02 Favored Glycine 0 CA--C 1.535 1.321 0 C-N-CA 125.059 1.314 . . . . 0.0 112.75 172.819 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 19.9 tt . . . . . 0 C--O 1.252 1.228 0 C-N-CA 126.571 1.948 . . . . 0.0 112.184 -179.596 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 18.8 ptpt . . . . . 0 N--CA 1.492 1.638 0 N-CA-C 111.6 0.222 . . . . 0.0 111.6 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 4.0 mppt? -114.35 130.71 56.69 Favored 'General case' 0 N--CA 1.478 0.968 0 C-N-CA 125.711 1.604 . . . . 0.0 110.248 172.9 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 33.2 t -136.36 128.21 44.16 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.942 0 C-N-CA 125.922 1.689 . . . . 0.0 109.481 179.153 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 4.7 t -124.99 -4.92 7.45 Favored 'General case' 0 CA--C 1.548 0.87 0 C-N-CA 124.726 1.211 . . . . 0.0 114.111 -178.118 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . 49.34 30.73 3.39 Favored 'General case' 0 CA--C 1.549 0.921 0 C-N-CA 127.018 2.127 . . . . 0.0 115.603 178.421 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 58.0 m -61.8 151.29 79.76 Favored Pre-proline 0 CA--C 1.547 0.828 0 C-N-CA 124.368 1.067 . . . . 0.0 112.379 177.141 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -75.1 -4.13 14.93 Favored 'Trans proline' 0 CA--C 1.543 0.955 0 C-N-CA 124.135 3.223 . . . . 0.0 115.735 -168.769 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 37.8 mmtm 58.86 6.93 0.7 Allowed 'General case' 0 N--CA 1.481 1.093 0 C-N-CA 128.247 2.619 . . . . 0.0 116.299 179.839 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 11.2 tp -51.76 142.47 4.27 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.631 0 C-N-CA 126.698 1.999 . . . . 0.0 112.329 178.436 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 4.5 tt -78.46 89.99 4.45 Favored 'General case' 0 CA--C 1.545 0.772 0 C-N-CA 127.209 2.204 . . . . 0.0 110.907 -177.706 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 3.8 ttmp? -143.83 74.83 16.34 Favored Pre-proline 0 N--CA 1.477 0.897 0 C-N-CA 124.992 1.317 . . . . 0.0 111.843 178.33 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -67.8 91.1 0.36 Allowed 'Trans proline' 0 CA--C 1.54 0.809 0 C-N-CA 124.347 3.364 . . . . 0.0 112.754 -175.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 5.7 m -87.27 143.08 12.05 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 C-N-CA 126.32 1.848 . . . . 0.0 112.101 179.652 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 47.3 t -63.7 119.82 10.65 Favored 'General case' 0 CA--C 1.542 0.653 0 C-N-CA 124.125 0.97 . . . . 0.0 110.988 172.475 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -92.23 154.79 22.53 Favored Glycine 0 CA--C 1.533 1.17 0 C-N-CA 124.597 1.094 . . . . 0.0 112.861 177.911 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 7.5 t -61.74 -27.26 68.6 Favored 'General case' 0 N--CA 1.475 0.781 0 N-CA-C 114.463 1.283 . . . . 0.0 114.463 -173.943 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 10.5 t0 -76.52 -10.25 59.25 Favored 'General case' 0 CA--C 1.547 0.841 0 N-CA-C 113.69 0.996 . . . . 0.0 113.69 176.216 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 105.09 -10.11 47.3 Favored Glycine 0 CA--C 1.536 1.354 0 C-N-CA 126.586 2.041 . . . . 0.0 114.048 178.21 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 5.9 ptp85 -82.31 -171.13 3.27 Favored 'General case' 0 N--CA 1.473 0.706 0 C-N-CA 126.067 1.747 . . . . 0.0 112.723 173.365 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 11.5 t -123.34 157.62 32.86 Favored 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 125.595 1.558 . . . . 0.0 111.688 174.307 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -137.51 148.53 46.08 Favored 'General case' 0 N--CA 1.471 0.6 0 C-N-CA 126.263 1.825 . . . . 0.0 110.917 -179.9 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -60.28 -36.86 78.8 Favored 'General case' 0 CA--C 1.543 0.673 0 N-CA-C 114.049 1.129 . . . . 0.0 114.049 -164.277 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 12.4 p30 -156.89 177.54 11.39 Favored 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 126.443 1.897 . . . . 0.0 111.848 168.889 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 27.6 t -58.73 -38.95 79.49 Favored 'General case' 0 N--CA 1.472 0.637 0 O-C-N 121.345 -0.847 . . . . 0.0 113.099 176.486 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 20.0 t -60.14 -55.94 27.66 Favored 'General case' 0 N--CA 1.468 0.47 0 O-C-N 121.493 -0.755 . . . . 0.0 111.806 -179.886 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 7.4 tt -59.4 -38.71 76.42 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.698 0 CA-C-O 118.996 -0.526 . . . . 0.0 112.292 178.437 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -59.61 -53.6 56.12 Favored 'General case' 0 CA--C 1.543 0.684 0 CA-C-N 119.132 0.878 . . . . 0.0 111.904 174.814 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 5.7 mtp-105 -57.41 -44.07 84.27 Favored 'General case' 0 N--CA 1.477 0.884 0 C-N-CA 124.824 1.25 . . . . 0.0 112.3 178.034 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -71.51 -34.0 69.71 Favored 'General case' 0 CA--C 1.544 0.737 0 N-CA-C 113.448 0.907 . . . . 0.0 113.448 178.748 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 28.8 t-20 -66.85 -40.39 87.91 Favored 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 124.277 1.031 . . . . 0.0 112.541 174.056 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 135.29 22.59 0.63 Allowed Glycine 0 CA--C 1.538 1.471 0 C-N-CA 125.051 1.31 . . . . 0.0 115.896 176.366 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 40.4 t -128.26 149.54 33.2 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.525 0 C-N-CA 126.26 1.824 . . . . 0.0 109.866 -174.556 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 58.8 m -121.92 171.81 8.66 Favored 'General case' 0 N--CA 1.475 0.78 0 C-N-CA 126.857 2.063 . . . . 0.0 112.063 -176.702 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -138.82 108.37 4.07 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.447 0 C-N-CA 125.513 1.525 . . . . 0.0 108.92 -176.37 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 47.6 mmtm -58.32 -39.08 78.45 Favored 'General case' 0 N--CA 1.478 0.957 0 C-N-CA 125.808 1.643 . . . . 0.0 112.729 177.719 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER 55.43 24.02 6.33 Favored 'General case' 0 N--CA 1.478 0.951 0 C-N-CA 126.746 2.018 . . . . 0.0 114.928 176.024 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 33.8 tt0 -59.79 -33.81 72.21 Favored 'General case' 0 N--CA 1.474 0.765 0 C-N-CA 125.858 1.663 . . . . 0.0 113.8 -171.98 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -89.37 -2.53 76.66 Favored Glycine 0 CA--C 1.537 1.448 0 C-N-CA 124.975 1.274 . . . . 0.0 115.218 179.233 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 44.4 m -89.05 173.59 8.37 Favored 'General case' 0 N--CA 1.472 0.657 0 C-N-CA 125.161 1.384 . . . . 0.0 113.404 -173.933 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 73.7 m -125.15 70.92 62.45 Favored Pre-proline 0 CA--C 1.549 0.904 0 C-N-CA 126.103 1.761 . . . . 0.0 111.225 174.676 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 76.6 Cg_endo -70.83 157.79 57.34 Favored 'Trans proline' 0 CA--C 1.541 0.851 0 C-N-CA 123.077 2.518 . . . . 0.0 112.465 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 6.3 t -108.2 -12.58 15.07 Favored 'General case' 0 N--CA 1.481 1.114 0 C-N-CA 125.051 1.34 . . . . 0.0 113.724 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -110.58 -59.84 0.49 Allowed Glycine 0 CA--C 1.535 1.286 0 C-N-CA 125.585 1.564 . . . . 0.0 114.349 -176.557 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 19.5 tt . . . . . 0 C--O 1.253 1.264 0 C-N-CA 126.608 1.963 . . . . 0.0 112.619 -173.433 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.723 0 N-CA-C 111.781 0.289 . . . . 0.0 111.781 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 57.0 mtpt -126.52 171.73 10.82 Favored 'General case' 0 N--CA 1.482 1.17 0 C-N-CA 126.47 1.908 . . . . 0.0 111.12 173.683 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 49.2 t -142.85 141.49 27.05 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.17 0 C-N-CA 126.725 2.01 . . . . 0.0 109.258 176.121 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 10.9 t -67.61 123.89 21.72 Favored 'General case' 0 CA--C 1.544 0.746 0 C-N-CA 123.324 0.65 . . . . 0.0 111.83 176.212 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -74.04 32.36 0.08 Allowed 'General case' 0 CA--C 1.554 1.128 0 C-N-CA 126.588 1.955 . . . . 0.0 115.668 -172.654 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 62.8 m -64.25 152.65 87.9 Favored Pre-proline 0 CA--C 1.549 0.926 0 C-N-CA 124.907 1.283 . . . . 0.0 113.67 179.275 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 89.1 Cg_endo -72.6 153.86 54.71 Favored 'Trans proline' 0 C--N 1.352 0.742 0 C-N-CA 123.359 2.706 . . . . 0.0 112.326 176.581 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 57.3 mtmt -76.38 -1.93 29.33 Favored 'General case' 0 N--CA 1.48 1.053 0 C-N-CA 125.708 1.603 . . . . 0.0 114.685 -179.361 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 46.9 mm -51.18 120.59 1.34 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.715 0 C-N-CA 126.145 1.778 . . . . 0.0 111.181 174.716 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 54.9 tp -84.71 102.27 12.85 Favored 'General case' 0 CA--C 1.539 0.546 0 C-N-CA 127.401 2.28 . . . . 0.0 109.614 177.935 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 20.8 tptp -147.07 91.94 5.04 Favored Pre-proline 0 N--CA 1.471 0.582 0 C-N-CA 124.098 0.959 . . . . 0.0 110.753 166.432 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -64.47 137.89 57.35 Favored 'Trans proline' 0 N--CA 1.456 -0.689 0 C-N-CA 121.191 1.261 . . . . 0.0 111.024 172.266 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 8.7 m -140.79 159.09 23.98 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.361 0 C-N-CA 127.373 2.269 . . . . 0.0 110.845 -179.346 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 37.6 t -72.78 149.52 43.58 Favored 'General case' 0 CA--C 1.545 0.763 0 C-N-CA 123.822 0.849 . . . . 0.0 111.785 171.973 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -123.76 156.21 17.93 Favored Glycine 0 CA--C 1.535 1.325 0 C-N-CA 125.859 1.695 . . . . 0.0 112.544 169.974 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 14.6 t -51.53 -40.64 60.05 Favored 'General case' 0 N--CA 1.478 0.966 0 C-N-CA 126.059 1.744 . . . . 0.0 115.431 -166.119 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 13.9 m-20 -71.1 -5.86 34.79 Favored 'General case' 0 CA--C 1.548 0.879 0 N-CA-C 114.863 1.431 . . . . 0.0 114.863 -179.193 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 86.83 61.32 1.61 Allowed Glycine 0 CA--C 1.527 0.805 0 C-N-CA 125.107 1.337 . . . . 0.0 110.592 -173.387 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 89.5 mmt-85 -142.18 168.29 20.09 Favored 'General case' 0 N--CA 1.472 0.671 0 C-N-CA 127.36 2.264 . . . . 0.0 111.103 -172.806 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 6.6 p -132.14 145.23 51.24 Favored 'General case' 0 C--O 1.235 0.322 0 C-N-CA 126.301 1.84 . . . . 0.0 111.089 172.455 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 92.8 m-85 -141.63 157.04 45.59 Favored 'General case' 0 N--CA 1.471 0.62 0 C-N-CA 125.604 1.561 . . . . 0.0 111.454 -179.461 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.69 -32.89 74.77 Favored 'General case' 0 CA--C 1.545 0.788 0 N-CA-C 114.451 1.278 . . . . 0.0 114.451 -165.222 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 60.5 t30 -149.37 168.13 24.24 Favored 'General case' 0 CA--C 1.544 0.747 0 C-N-CA 125.558 1.543 . . . . 0.0 111.17 171.26 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 34.6 p -57.19 -42.63 81.56 Favored 'General case' 0 N--CA 1.472 0.653 0 C-N-CA 124.769 1.228 . . . . 0.0 113.106 175.216 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 38.1 t -56.51 -55.76 29.68 Favored 'General case' 0 CA--C 1.533 0.292 0 C-N-CA 124.376 1.07 . . . . 0.0 112.11 177.507 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.8 tt -62.21 -35.25 68.08 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.672 0 CA-C-O 118.684 -0.674 . . . . 0.0 112.407 -177.679 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -57.82 -53.43 58.27 Favored 'General case' 0 CA--C 1.54 0.563 0 CA-C-N 119.288 0.949 . . . . 0.0 111.443 173.516 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -56.38 -49.78 73.47 Favored 'General case' 0 N--CA 1.474 0.768 0 C-N-CA 125.042 1.337 . . . . 0.0 111.282 176.124 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -63.7 -39.84 95.29 Favored 'General case' 0 CA--C 1.541 0.622 0 C-N-CA 123.786 0.834 . . . . 0.0 113.089 -177.68 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 88.8 m-20 -66.27 -33.44 75.74 Favored 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 124.86 1.264 . . . . 0.0 112.79 174.458 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 130.17 17.21 1.64 Allowed Glycine 0 CA--C 1.536 1.369 0 N-CA-C 116.389 1.316 . . . . 0.0 116.389 171.618 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 7.4 t -118.63 132.97 66.96 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.666 0 CA-C-N 119.629 1.714 . . . . 0.0 110.608 -178.229 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 38.5 m -78.54 164.69 24.48 Favored 'General case' 0 C--N 1.322 -0.597 0 C-N-CA 126.826 2.05 . . . . 0.0 112.714 -179.583 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -134.36 98.8 2.51 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.525 0 C-N-CA 125.873 1.669 . . . . 0.0 109.1 -178.959 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -87.93 -13.74 41.06 Favored 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 125.849 1.66 . . . . 0.0 113.405 -179.723 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 22.7 t -84.88 119.59 25.51 Favored 'General case' 0 CA--C 1.532 0.273 0 C-N-CA 125.954 1.701 . . . . 0.0 110.935 173.608 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 8.2 tp10 -63.43 -15.08 56.6 Favored 'General case' 0 CA--C 1.551 1.015 0 C-N-CA 125.478 1.511 . . . . 0.0 113.169 169.844 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -78.22 58.43 4.01 Favored Glycine 0 CA--C 1.536 1.366 0 C-N-CA 126.135 1.826 . . . . 0.0 113.79 178.434 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 71.6 p -140.2 168.46 19.75 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 126.299 1.84 . . . . 0.0 112.491 179.681 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 1.9 m -65.1 159.16 67.28 Favored Pre-proline 0 CA--C 1.549 0.909 0 C-N-CA 123.575 0.75 . . . . 0.0 112.792 174.036 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -68.8 164.88 31.68 Favored 'Trans proline' 0 CA--C 1.541 0.836 0 C-N-CA 123.182 2.588 . . . . 0.0 112.462 175.945 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 20.7 m -137.49 143.82 41.9 Favored 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 125.521 1.528 . . . . 0.0 110.651 -175.691 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -81.75 -171.4 45.71 Favored Glycine 0 CA--C 1.538 1.496 0 C-N-CA 125.138 1.351 . . . . 0.0 114.044 178.179 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 4.6 mp . . . . . 0 C--O 1.252 1.227 0 C-N-CA 126.728 2.011 . . . . 0.0 110.191 179.068 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 68.4 mttm . . . . . 0 N--CA 1.492 1.654 0 N-CA-C 110.537 -0.171 . . . . 0.0 110.537 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 37.7 ttpt -72.38 94.74 1.66 Allowed 'General case' 0 N--CA 1.48 1.037 0 C-N-CA 125.224 1.41 . . . . 0.0 111.31 175.776 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 13.8 p -143.41 147.1 20.59 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.028 0 C-N-CA 125.043 1.337 . . . . 0.0 112.304 179.737 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 3.2 m -66.8 113.25 4.74 Favored 'General case' 0 CA--C 1.548 0.884 0 C-N-CA 125.515 1.526 . . . . 0.0 110.377 173.77 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -75.89 58.45 1.15 Allowed 'General case' 0 CA--C 1.554 1.1 0 C-N-CA 124.798 1.239 . . . . 0.0 113.24 -179.519 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 76.3 m -69.75 159.32 84.39 Favored Pre-proline 0 CA--C 1.553 1.082 0 C-N-CA 126.048 1.739 . . . . 0.0 113.746 -177.413 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -71.06 165.44 32.39 Favored 'Trans proline' 0 CA--C 1.542 0.877 0 C-N-CA 123.497 2.798 . . . . 0.0 113.407 179.141 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 7.9 ptpp? -68.35 -27.56 66.36 Favored 'General case' 0 N--CA 1.482 1.161 0 C-N-CA 125.072 1.349 . . . . 0.0 114.613 175.501 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 34.9 mm -60.08 161.88 1.24 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.83 0 C-N-CA 128.162 2.585 . . . . 0.0 111.294 176.295 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 20.1 tp -141.98 101.89 4.03 Favored 'General case' 0 CA--C 1.537 0.472 0 C-N-CA 126.257 1.823 . . . . 0.0 109.879 -170.646 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -115.52 84.92 12.77 Favored Pre-proline 0 N--CA 1.474 0.726 0 C-N-CA 126.096 1.759 . . . . 0.0 109.42 175.399 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 93.7 Cg_endo -74.52 81.14 2.14 Favored 'Trans proline' 0 CA--C 1.541 0.848 0 C-N-CA 124.043 3.162 . . . . 0.0 111.717 -176.616 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 9.0 m -85.84 164.24 2.48 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 C-N-CA 127.195 2.198 . . . . 0.0 113.003 -175.938 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 30.1 p -68.29 173.97 4.37 Favored 'General case' 0 CA--C 1.549 0.933 0 C-N-CA 124.231 1.012 . . . . 0.0 112.294 159.289 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -148.48 155.98 26.66 Favored Glycine 0 CA--C 1.532 1.132 0 C-N-CA 125.691 1.615 . . . . 0.0 111.392 173.712 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 19.0 t -57.09 -35.55 69.54 Favored 'General case' 0 N--CA 1.476 0.872 0 N-CA-C 115.144 1.535 . . . . 0.0 115.144 -163.138 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 31.5 t70 -71.86 -9.1 57.84 Favored 'General case' 0 CA--C 1.551 1.008 0 N-CA-C 114.415 1.265 . . . . 0.0 114.415 179.305 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 106.84 12.58 23.94 Favored Glycine 0 CA--C 1.535 1.286 0 C-N-CA 126.063 1.792 . . . . 0.0 114.073 179.35 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 31.2 mtm180 -120.99 134.46 55.3 Favored 'General case' 0 N--CA 1.476 0.844 0 C-N-CA 126.225 1.81 . . . . 0.0 111.181 -171.542 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 18.0 p -75.23 151.55 38.41 Favored 'General case' 0 N--CA 1.471 0.597 0 C-N-CA 124.622 1.169 . . . . 0.0 112.614 177.927 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 76.5 m-85 -139.69 149.03 43.19 Favored 'General case' 0 N--CA 1.471 0.592 0 C-N-CA 125.434 1.494 . . . . 0.0 112.93 -179.87 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -69.74 -33.72 72.84 Favored 'General case' 0 CA--C 1.545 0.76 0 N-CA-C 113.902 1.075 . . . . 0.0 113.902 -165.895 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . 0.463 ' H ' HG22 ' A' ' 26' ' ' ILE . 14.7 m-20 -145.87 170.85 15.76 Favored 'General case' 0 CA--C 1.543 0.703 0 C-N-CA 125.813 1.645 . . . . 0.0 110.946 166.116 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 40.7 p -59.46 -35.55 74.27 Favored 'General case' 0 N--CA 1.473 0.722 0 O-C-N 121.368 -0.832 . . . . 0.0 112.45 165.824 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 43.5 t -52.87 -63.33 1.18 Allowed 'General case' 0 CA--C 1.533 0.316 0 C-N-CA 126.01 1.724 . . . . 0.0 112.369 174.064 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.463 HG22 ' H ' ' A' ' 23' ' ' ASN . 9.1 tp -58.38 -37.3 62.85 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.788 0 N-CA-C 112.592 0.59 . . . . 0.0 112.592 -178.583 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -59.94 -54.59 44.32 Favored 'General case' 0 CA--C 1.544 0.716 0 CA-C-N 118.697 0.68 . . . . 0.0 111.836 173.961 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 25.4 mmm180 -61.57 -39.98 93.09 Favored 'General case' 0 N--CA 1.478 0.975 0 C-N-CA 124.707 1.203 . . . . 0.0 113.207 177.933 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 9.2 t -62.15 -43.92 97.76 Favored 'General case' 0 CA--C 1.544 0.729 0 C-N-CA 124.832 1.253 . . . . 0.0 111.644 175.128 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 28.7 t-20 -68.79 -46.62 68.21 Favored 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 124.837 1.255 . . . . 0.0 113.179 178.263 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 136.11 26.42 0.45 Allowed Glycine 0 CA--C 1.539 1.534 0 C-N-CA 124.787 1.184 . . . . 0.0 115.964 -179.528 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 40.1 t -124.29 156.12 31.9 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.512 0 C-N-CA 127.11 2.164 . . . . 0.0 108.607 -179.658 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 6.2 t -134.21 177.8 7.47 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 126.25 1.82 . . . . 0.0 112.216 179.143 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -141.61 107.13 1.74 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.299 0 C-N-CA 126.438 1.895 . . . . 0.0 108.869 -170.52 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 2.5 tppp? -61.67 -27.69 68.86 Favored 'General case' 0 N--CA 1.475 0.821 0 C-N-CA 124.617 1.167 . . . . 0.0 112.868 175.033 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 8.2 t -62.33 -47.12 85.66 Favored 'General case' 0 N--CA 1.472 0.644 0 C-N-CA 125.77 1.628 . . . . 0.0 113.28 179.217 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -153.48 131.15 11.52 Favored 'General case' 0 CA--C 1.542 0.661 0 C-N-CA 124.94 1.296 . . . . 0.0 112.196 179.059 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 164.57 57.44 0.02 OUTLIER Glycine 0 CA--C 1.533 1.157 0 C-N-CA 123.787 0.708 . . . . 0.0 113.647 -177.139 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 51.6 p -67.48 160.54 27.35 Favored 'General case' 0 N--CA 1.473 0.685 0 C-N-CA 124.722 1.209 . . . . 0.0 113.362 176.787 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 74.6 m -71.45 156.13 91.87 Favored Pre-proline 0 CA--C 1.549 0.94 0 C-N-CA 124.273 1.029 . . . . 0.0 112.483 176.716 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 96.2 Cg_endo -71.8 164.3 36.12 Favored 'Trans proline' 0 CA--C 1.54 0.78 0 C-N-CA 123.147 2.564 . . . . 0.0 112.357 174.011 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 38.7 p -77.22 -15.7 59.37 Favored 'General case' 0 N--CA 1.48 1.057 0 C-N-CA 124.991 1.316 . . . . 0.0 113.772 174.755 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -113.37 -157.72 12.7 Favored Glycine 0 CA--C 1.537 1.427 0 C-N-CA 127.092 2.282 . . . . 0.0 113.485 -178.76 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 4.1 mp . . . . . 0 C--O 1.253 1.265 0 C-N-CA 126.589 1.956 . . . . 0.0 110.318 178.622 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 26.1 mmmt . . . . . 0 N--CA 1.492 1.643 0 CA-C-O 120.462 0.173 . . . . 0.0 111.118 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 60.4 mttm -62.29 141.81 58.07 Favored 'General case' 0 N--CA 1.48 1.031 0 C-N-CA 125.522 1.529 . . . . 0.0 111.452 172.792 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 40.1 t -140.77 129.84 25.41 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.062 0 C-N-CA 125.789 1.635 . . . . 0.0 109.775 175.972 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 31.2 m -68.25 126.54 29.87 Favored 'General case' 0 CA--C 1.542 0.665 0 C-N-CA 124.632 1.173 . . . . 0.0 110.968 175.384 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -73.27 31.78 0.07 Allowed 'General case' 0 CA--C 1.555 1.163 0 C-N-CA 125.629 1.572 . . . . 0.0 114.37 177.777 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 60.1 m -63.32 160.76 38.6 Favored Pre-proline 0 CA--C 1.549 0.924 0 C-N-CA 126.335 1.854 . . . . 0.0 113.237 177.439 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -67.61 169.77 15.18 Favored 'Trans proline' 0 CA--C 1.541 0.872 0 C-N-CA 123.254 2.636 . . . . 0.0 112.156 170.899 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 10.1 tppt? -107.89 1.98 23.1 Favored 'General case' 0 N--CA 1.482 1.145 0 C-N-CA 125.968 1.707 . . . . 0.0 112.946 172.186 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 83.2 mt -52.24 131.76 13.88 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.762 0 C-N-CA 126.632 1.973 . . . . 0.0 110.821 179.426 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 5.2 tt -69.74 97.85 1.13 Allowed 'General case' 0 CA--C 1.542 0.652 0 C-N-CA 127.399 2.28 . . . . 0.0 111.497 -174.823 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 86.8 tttt -140.6 74.45 27.86 Favored Pre-proline 0 N--CA 1.476 0.828 0 C-N-CA 125.719 1.608 . . . . 0.0 111.101 -177.882 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -66.14 101.33 0.49 Allowed 'Trans proline' 0 CA--C 1.54 0.818 0 C-N-CA 123.956 3.104 . . . . 0.0 112.343 -178.605 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 15.9 m -127.21 159.52 37.33 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.479 0 C-N-CA 126.001 1.72 . . . . 0.0 112.859 -176.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 24.4 p -88.4 123.29 32.81 Favored 'General case' 0 CA--C 1.539 0.529 0 C-N-CA 124.358 1.063 . . . . 0.0 111.889 176.572 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -79.17 55.68 4.34 Favored Glycine 0 CA--C 1.53 0.977 0 C-N-CA 124.665 1.126 . . . . 0.0 112.117 172.673 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 3.9 t 54.81 -11.68 0.01 OUTLIER 'General case' 0 CA--C 1.55 0.979 0 C-N-CA 129.385 3.074 . . . . 0.0 117.268 -175.009 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 63.5 m-20 -95.11 -17.8 21.52 Favored 'General case' 0 N--CA 1.475 0.775 0 C-N-CA 126.041 1.736 . . . . 0.0 114.545 -179.148 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 105.66 2.99 40.36 Favored Glycine 0 CA--C 1.538 1.505 0 C-N-CA 125.498 1.523 . . . . 0.0 114.84 177.713 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 2.1 mmp_? -67.37 -177.98 0.79 Allowed 'General case' 0 N--CA 1.476 0.841 0 C-N-CA 128.541 2.736 . . . . 0.0 112.195 172.501 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 24.1 m -128.58 85.72 2.37 Favored 'General case' 0 N--CA 1.476 0.841 0 C-N-CA 124.92 1.288 . . . . 0.0 110.157 176.318 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 26.8 m-85 -76.12 154.17 35.71 Favored 'General case' 0 N--CA 1.47 0.541 0 C-N-CA 123.94 0.896 . . . . 0.0 112.252 173.389 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.15 -37.63 88.15 Favored 'General case' 0 CA--C 1.542 0.643 0 N-CA-C 113.288 0.847 . . . . 0.0 113.288 -170.447 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 14.3 p30 -152.56 179.42 8.61 Favored 'General case' 0 CA--C 1.545 0.765 0 C-N-CA 126.172 1.789 . . . . 0.0 111.968 172.283 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 9.1 p -70.67 -32.03 69.15 Favored 'General case' 0 N--CA 1.473 0.7 0 O-C-N 121.018 -1.051 . . . . 0.0 113.788 176.369 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 34.8 t -62.42 -49.99 73.27 Favored 'General case' 0 N--CA 1.469 0.484 0 C-N-CA 124.31 1.044 . . . . 0.0 112.269 178.627 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 8.5 tt -58.82 -39.77 78.1 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 N-CA-C 112.194 0.442 . . . . 0.0 112.194 179.338 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -64.88 -44.62 89.05 Favored 'General case' 0 CA--C 1.543 0.712 0 C-N-CA 124.285 1.034 . . . . 0.0 112.599 175.051 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 25.1 mmt180 -55.67 -52.5 63.64 Favored 'General case' 0 N--CA 1.478 0.941 0 C-N-CA 124.378 1.071 . . . . 0.0 111.734 170.814 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 4.9 t -63.08 -37.36 86.89 Favored 'General case' 0 CA--C 1.544 0.714 0 C-N-CA 124.13 0.972 . . . . 0.0 113.023 -178.59 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 28.4 t30 -62.66 -30.55 71.46 Favored 'General case' 0 CA--C 1.545 0.762 0 C-N-CA 124.43 1.092 . . . . 0.0 113.351 176.888 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 135.21 9.97 1.57 Allowed Glycine 0 CA--C 1.536 1.373 0 N-CA-C 116.13 1.212 . . . . 0.0 116.13 175.471 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.612 HG12 ' H ' ' A' ' 33' ' ' SER . 0.5 OUTLIER -107.51 -170.16 0.34 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.653 0 CA-C-N 119.351 1.576 . . . . 0.0 110.689 -177.242 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . 0.612 ' H ' HG12 ' A' ' 32' ' ' VAL . 27.7 m -147.91 166.96 26.07 Favored 'General case' 0 N--CA 1.471 0.599 0 C-N-CA 128.258 2.623 . . . . 0.0 110.529 174.863 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 1.1 mt -141.31 105.36 1.54 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.622 0 C-N-CA 125.069 1.347 . . . . 0.0 108.765 172.43 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -95.92 -14.66 22.93 Favored 'General case' 0 N--CA 1.481 1.081 0 C-N-CA 125.552 1.541 . . . . 0.0 113.35 176.794 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 1.5 t -78.49 31.28 0.19 Allowed 'General case' 0 N--CA 1.478 0.971 0 C-N-CA 127.382 2.273 . . . . 0.0 114.215 -176.854 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 3.3 mm-40 -61.05 159.99 10.76 Favored 'General case' 0 CA--C 1.543 0.704 0 C-N-CA 125.171 1.388 . . . . 0.0 113.635 176.863 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -75.83 -15.78 81.1 Favored Glycine 0 CA--C 1.538 1.472 0 C-N-CA 124.446 1.022 . . . . 0.0 115.077 -175.824 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 88.4 p -154.98 -178.6 7.35 Favored 'General case' 0 N--CA 1.473 0.7 0 C-N-CA 126.893 2.077 . . . . 0.0 111.061 174.79 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 73.5 m 48.37 69.66 2.56 Favored Pre-proline 0 CA--C 1.553 1.09 0 C-N-CA 126.335 1.854 . . . . 0.0 114.197 178.359 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -67.96 164.32 32.25 Favored 'Trans proline' 0 CA--C 1.54 0.811 0 C-N-CA 123.351 2.701 . . . . 0.0 112.977 -179.113 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 6.4 t -129.51 2.38 5.04 Favored 'General case' 0 N--CA 1.481 1.111 0 C-N-CA 125.189 1.396 . . . . 0.0 114.064 -172.567 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 133.62 -77.86 0.37 Allowed Glycine 0 CA--C 1.532 1.152 0 C-N-CA 125.923 1.725 . . . . 0.0 112.351 175.282 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 43.5 pt . . . . . 0 C--O 1.251 1.134 0 C-N-CA 127.102 2.161 . . . . 0.0 112.675 178.61 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 12.2 tmtt? . . . . . 0 N--CA 1.49 1.539 0 N-CA-C 110.151 -0.314 . . . . 0.0 110.151 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -141.62 162.6 35.09 Favored 'General case' 0 N--CA 1.483 1.21 0 C-N-CA 126.847 2.059 . . . . 0.0 111.138 176.978 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 41.1 t -140.27 146.73 24.2 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.099 0 C-N-CA 125.962 1.705 . . . . 0.0 110.473 -179.607 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 80.9 m -60.67 117.54 5.48 Favored 'General case' 0 CA--C 1.544 0.749 0 C-N-CA 125.559 1.544 . . . . 0.0 111.809 172.974 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -73.49 37.52 0.09 Allowed 'General case' 0 CA--C 1.556 1.175 0 C-N-CA 126.462 1.905 . . . . 0.0 114.841 -177.161 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 98.8 m -63.92 156.67 72.49 Favored Pre-proline 0 CA--C 1.55 0.956 0 C-N-CA 125.726 1.61 . . . . 0.0 113.742 -179.555 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -71.78 159.42 50.75 Favored 'Trans proline' 0 CA--C 1.54 0.811 0 C-N-CA 123.411 2.741 . . . . 0.0 113.2 -178.677 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 34.5 ttmt -86.37 -11.11 52.95 Favored 'General case' 0 N--CA 1.48 1.066 0 C-N-CA 125.786 1.634 . . . . 0.0 113.751 177.501 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 80.3 mt -55.85 146.3 5.27 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.883 0 C-N-CA 126.662 1.985 . . . . 0.0 110.444 178.862 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 11.1 mp -89.68 113.27 24.74 Favored 'General case' 0 CA--C 1.539 0.548 0 C-N-CA 124.229 1.012 . . . . 0.0 110.809 175.161 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 33.2 ttmt -135.02 75.3 61.12 Favored Pre-proline 0 CA--C 1.545 0.77 0 C-N-CA 124.874 1.27 . . . . 0.0 110.277 167.734 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 62.5 Cg_endo -68.88 86.15 0.47 Allowed 'Trans proline' 0 CA--C 1.541 0.85 0 C-N-CA 123.978 3.119 . . . . 0.0 112.535 -177.68 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 10.5 m -85.63 154.94 3.46 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.534 0 C-N-CA 126.527 1.931 . . . . 0.0 112.785 -178.391 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 46.0 t -78.2 108.49 11.55 Favored 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 124.861 1.264 . . . . 0.0 110.74 168.429 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -76.57 153.53 42.66 Favored Glycine 0 CA--C 1.531 1.079 0 C-N-CA 124.603 1.097 . . . . 0.0 113.357 174.697 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 13.5 t -58.72 -33.96 70.79 Favored 'General case' 0 N--CA 1.476 0.833 0 C-N-CA 124.595 1.158 . . . . 0.0 114.123 -172.096 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 10.4 m-20 -73.73 -3.56 29.16 Favored 'General case' 0 CA--C 1.549 0.923 0 N-CA-C 114.667 1.358 . . . . 0.0 114.667 176.359 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 95.79 18.01 33.71 Favored Glycine 0 CA--C 1.533 1.21 0 C-N-CA 125.318 1.437 . . . . 0.0 114.11 178.205 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 29.5 mtp85 -121.52 154.49 36.58 Favored 'General case' 0 N--CA 1.476 0.857 0 C-N-CA 126.164 1.786 . . . . 0.0 111.308 -173.79 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 13.5 p -87.91 146.48 25.54 Favored 'General case' 0 N--CA 1.469 0.513 0 C-N-CA 124.173 0.989 . . . . 0.0 112.185 177.162 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 97.9 m-85 -138.74 147.7 43.0 Favored 'General case' 0 N--CA 1.472 0.668 0 C-N-CA 125.327 1.451 . . . . 0.0 111.381 177.562 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.54 -32.76 74.55 Favored 'General case' 0 CA--C 1.544 0.734 0 N-CA-C 114.118 1.155 . . . . 0.0 114.118 -165.954 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 67.2 m-80 -146.2 172.84 12.85 Favored 'General case' 0 CA--C 1.543 0.688 0 C-N-CA 127.399 2.28 . . . . 0.0 110.467 168.184 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 27.7 p -63.87 -33.27 75.31 Favored 'General case' 0 N--CA 1.472 0.629 0 O-C-N 121.136 -0.977 . . . . 0.0 112.968 165.098 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 33.6 t -57.46 -55.23 37.51 Favored 'General case' 0 N--CA 1.467 0.411 0 C-N-CA 124.404 1.082 . . . . 0.0 112.623 176.029 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 6.5 tp -62.84 -31.68 53.2 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.742 0 N-CA-C 112.325 0.491 . . . . 0.0 112.325 -179.112 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -59.39 -48.8 80.27 Favored 'General case' 0 CA--C 1.542 0.658 0 O-C-N 121.482 -0.761 . . . . 0.0 111.35 170.907 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 24.0 mtp-105 -62.3 -33.61 75.0 Favored 'General case' 0 N--CA 1.479 0.992 0 C-N-CA 123.619 0.768 . . . . 0.0 113.031 175.492 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 46.9 t -62.88 -48.47 78.83 Favored 'General case' 0 CA--C 1.542 0.635 0 C-N-CA 124.302 1.041 . . . . 0.0 111.52 171.373 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 19.5 m120 -66.79 -31.6 72.35 Favored 'General case' 0 CA--C 1.546 0.822 0 C-N-CA 124.583 1.153 . . . . 0.0 113.526 178.515 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 116.86 28.81 2.36 Favored Glycine 0 CA--C 1.539 1.537 0 C-N-CA 125.602 1.572 . . . . 0.0 115.01 178.782 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 18.1 t -129.32 153.99 39.48 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.5 0 C-N-CA 127.528 2.331 . . . . 0.0 108.809 -176.335 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 68.6 m -119.73 156.07 31.25 Favored 'General case' 0 N--CA 1.474 0.761 0 C-N-CA 125.858 1.663 . . . . 0.0 112.445 179.285 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 22.0 mm -126.21 -14.02 4.16 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.114 0 C-N-CA 126.111 1.765 . . . . 0.0 112.373 -171.864 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 63.4 pttt 46.66 21.48 0.14 Allowed 'General case' 0 N--CA 1.487 1.406 0 C-N-CA 129.872 3.269 . . . . 0.0 117.96 175.78 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 19.6 t -57.53 -41.0 80.02 Favored 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 127.437 2.295 . . . . 0.0 113.683 -174.454 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 27.3 tt0 -146.18 159.91 42.67 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 124.898 1.279 . . . . 0.0 111.592 175.61 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -84.5 60.59 4.81 Favored Glycine 0 CA--C 1.532 1.15 0 C-N-CA 125.721 1.629 . . . . 0.0 113.298 -178.781 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 8.6 t -63.84 158.47 21.92 Favored 'General case' 0 N--CA 1.474 0.74 0 C-N-CA 124.325 1.05 . . . . 0.0 112.835 177.878 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 13.8 p -141.84 69.82 24.45 Favored Pre-proline 0 CA--C 1.551 1.004 0 C-N-CA 125.588 1.555 . . . . 0.0 112.235 -178.324 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_endo -70.16 162.38 42.48 Favored 'Trans proline' 0 CA--C 1.541 0.863 0 C-N-CA 123.163 2.575 . . . . 0.0 112.5 177.495 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 26.8 p -79.45 171.14 15.57 Favored 'General case' 0 N--CA 1.477 0.915 0 C-N-CA 125.215 1.406 . . . . 0.0 112.359 172.159 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 77.9 18.59 76.76 Favored Glycine 0 CA--C 1.539 1.58 0 N-CA-C 115.313 0.885 . . . . 0.0 115.313 174.573 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 20.6 tt . . . . . 0 C--O 1.255 1.345 0 C-N-CA 127.356 2.262 . . . . 0.0 112.696 -176.929 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 9.8 mtpm? . . . . . 0 N--CA 1.491 1.619 0 N-CA-C 110.307 -0.257 . . . . 0.0 110.307 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -76.65 91.17 3.41 Favored 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 125.612 1.565 . . . . 0.0 111.052 179.443 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 11.7 p -140.73 146.79 23.62 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.027 0 C-N-CA 124.959 1.304 . . . . 0.0 112.399 -177.685 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 32.9 m -94.64 91.68 6.67 Favored 'General case' 0 CA--C 1.542 0.647 0 C-N-CA 125.737 1.615 . . . . 0.0 110.81 179.712 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -75.06 54.34 0.67 Allowed 'General case' 0 CA--C 1.554 1.119 0 C-N-CA 125.525 1.53 . . . . 0.0 113.021 178.938 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 64.7 m -65.22 152.19 92.23 Favored Pre-proline 0 CA--C 1.552 1.023 0 C-N-CA 125.437 1.495 . . . . 0.0 112.893 -177.901 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -72.03 151.99 56.56 Favored 'Trans proline' 0 CA--C 1.539 0.763 0 C-N-CA 122.957 2.438 . . . . 0.0 112.57 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 32.3 mmtp -72.49 -21.67 61.17 Favored 'General case' 0 N--CA 1.479 1.014 0 C-N-CA 125.232 1.413 . . . . 0.0 113.605 174.664 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.473 ' H ' HD12 ' A' ' 9' ' ' ILE . 4.9 mp -67.8 127.26 29.17 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.548 0 C-N-CA 125.508 1.523 . . . . 0.0 110.198 178.879 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 2.0 pt? -68.55 131.41 45.19 Favored 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 124.912 1.285 . . . . 0.0 111.6 173.72 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 37.0 ttmt -152.08 64.86 5.91 Favored Pre-proline 0 N--CA 1.474 0.745 0 C-N-CA 124.323 1.049 . . . . 0.0 111.114 175.181 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -66.85 153.04 79.29 Favored 'Trans proline' 0 CA--C 1.536 0.619 0 C-N-CA 122.552 2.168 . . . . 0.0 112.199 -176.049 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 18.4 t -134.84 -68.91 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.059 0 C-N-CA 123.695 0.798 . . . . 0.0 112.071 -173.818 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 31.1 p -143.18 -173.9 4.05 Favored 'General case' 0 CA--C 1.544 0.72 0 C-N-CA 126.355 1.862 . . . . 0.0 112.156 -173.812 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -163.75 87.57 0.1 Allowed Glycine 0 CA--C 1.528 0.882 0 C-N-CA 124.098 0.856 . . . . 0.0 114.126 -175.543 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 11.4 t -55.7 -38.17 69.35 Favored 'General case' 0 N--CA 1.478 0.969 0 C-N-CA 124.132 0.973 . . . . 0.0 113.261 176.781 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 54.6 m-20 -78.39 -5.69 53.04 Favored 'General case' 0 N--CA 1.478 0.942 0 C-N-CA 125.141 1.376 . . . . 0.0 113.953 174.541 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 93.86 9.93 59.29 Favored Glycine 0 CA--C 1.537 1.467 0 C-N-CA 125.532 1.539 . . . . 0.0 114.321 -174.018 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 13.5 ptp180 -122.19 135.86 54.83 Favored 'General case' 0 N--CA 1.477 0.898 0 C-N-CA 126.738 2.015 . . . . 0.0 112.21 -177.03 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.1 p -66.64 110.84 3.36 Favored 'General case' 0 N--CA 1.474 0.728 0 C-N-CA 125.347 1.459 . . . . 0.0 111.783 175.657 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 44.6 m-85 -76.86 154.37 33.87 Favored 'General case' 0 N--CA 1.472 0.636 0 O-C-N 121.628 -0.67 . . . . 0.0 111.829 174.794 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.96 -43.83 82.1 Favored 'General case' 0 CA--C 1.542 0.662 0 N-CA-C 113.238 0.829 . . . . 0.0 113.238 -169.416 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 21.2 p30 -160.98 178.68 9.13 Favored 'General case' 0 CA--C 1.548 0.866 0 C-N-CA 126.755 2.022 . . . . 0.0 111.569 173.487 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 16.2 m -63.36 -27.62 69.44 Favored 'General case' 0 N--CA 1.475 0.815 0 O-C-N 120.625 -1.297 . . . . 0.0 113.913 179.833 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 38.6 t -63.1 -56.41 17.07 Favored 'General case' 0 CA--C 1.532 0.257 0 C-N-CA 124.708 1.203 . . . . 0.0 111.555 177.166 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 8.3 tp -59.17 -35.24 56.54 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.87 0 N-CA-C 112.54 0.571 . . . . 0.0 112.54 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -59.3 -57.83 11.31 Favored 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 123.937 0.895 . . . . 0.0 111.993 175.332 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 73.6 mtp180 -60.56 -38.92 86.13 Favored 'General case' 0 N--CA 1.479 1.001 0 N-CA-C 113.058 0.762 . . . . 0.0 113.058 176.561 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 47.7 t -59.83 -50.38 74.04 Favored 'General case' 0 CA--C 1.542 0.646 0 C-N-CA 124.422 1.089 . . . . 0.0 112.179 176.048 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 63.3 t30 -69.95 -40.26 75.56 Favored 'General case' 0 CA--C 1.545 0.767 0 C-N-CA 125.01 1.324 . . . . 0.0 112.925 -176.911 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 129.26 30.2 0.68 Allowed Glycine 0 CA--C 1.536 1.375 0 C-N-CA 124.676 1.131 . . . . 0.0 115.161 178.369 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -120.14 178.49 2.49 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.545 0 C-N-CA 126.943 2.097 . . . . 0.0 110.037 -176.411 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 83.8 p -138.04 159.69 41.34 Favored 'General case' 0 N--CA 1.476 0.854 0 C-N-CA 124.843 1.257 . . . . 0.0 113.466 -178.135 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 16.0 mm -87.53 -23.5 6.56 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.965 0 C-N-CA 124.545 1.138 . . . . 0.0 112.509 -175.003 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 8.3 tptm -68.69 -3.04 10.61 Favored 'General case' 0 N--CA 1.477 0.913 0 C-N-CA 127.102 2.161 . . . . 0.0 114.292 178.921 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 18.6 t -51.27 -41.84 60.69 Favored 'General case' 0 N--CA 1.473 0.686 0 C-N-CA 127.014 2.126 . . . . 0.0 113.591 179.998 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 7.4 tp10 -153.02 -52.71 0.11 Allowed 'General case' 0 N--CA 1.474 0.74 0 C-N-CA 124.365 1.066 . . . . 0.0 111.476 173.099 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -76.82 65.81 2.85 Favored Glycine 0 CA--C 1.533 1.196 0 C-N-CA 125.615 1.578 . . . . 0.0 113.474 -179.661 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 25.7 t -57.76 119.1 6.06 Favored 'General case' 0 N--CA 1.47 0.552 0 C-N-CA 125.462 1.505 . . . . 0.0 111.83 175.493 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 93.7 m -119.07 159.22 45.81 Favored Pre-proline 0 CA--C 1.549 0.906 0 C-N-CA 125.928 1.691 . . . . 0.0 111.787 -179.239 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -72.8 95.56 0.82 Allowed 'Trans proline' 0 CA--C 1.542 0.91 0 C-N-CA 123.672 2.914 . . . . 0.0 112.057 178.244 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 27.9 m -57.94 130.66 47.56 Favored 'General case' 0 N--CA 1.476 0.869 0 C-N-CA 125.695 1.598 . . . . 0.0 111.773 177.112 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -78.42 -69.95 1.35 Allowed Glycine 0 CA--C 1.536 1.365 0 C-N-CA 124.634 1.111 . . . . 0.0 113.696 -177.068 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 21.3 tt . . . . . 0 C--O 1.252 1.198 0 C-N-CA 126.863 2.065 . . . . 0.0 112.251 -178.301 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 65.8 mttm . . . . . 0 N--CA 1.493 1.719 0 CA-C-O 120.834 0.349 . . . . 0.0 110.593 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 9.5 mtmp? -97.05 104.09 16.08 Favored 'General case' 0 N--CA 1.482 1.161 0 C-N-CA 125.109 1.363 . . . . 0.0 110.818 -178.833 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 40.9 t -129.62 140.28 49.49 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.065 0 C-N-CA 125.841 1.656 . . . . 0.0 110.029 -178.867 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 8.5 t -66.37 118.07 9.51 Favored 'General case' 0 CA--C 1.543 0.676 0 C-N-CA 124.401 1.08 . . . . 0.0 112.805 -174.787 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -75.24 32.4 0.1 Allowed 'General case' 0 CA--C 1.553 1.077 0 C-N-CA 126.873 2.069 . . . . 0.0 115.214 -174.132 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 58.4 m -62.96 157.48 60.75 Favored Pre-proline 0 CA--C 1.549 0.912 0 C-N-CA 124.851 1.26 . . . . 0.0 113.15 176.062 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 97.1 Cg_endo -70.58 172.13 14.03 Favored 'Trans proline' 0 CA--C 1.54 0.799 0 C-N-CA 123.419 2.746 . . . . 0.0 112.176 173.141 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 29.9 mtpp -121.05 3.09 10.47 Favored 'General case' 0 N--CA 1.481 1.112 0 C-N-CA 126.2 1.8 . . . . 0.0 114.011 179.765 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -53.0 138.63 12.0 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.785 0 C-N-CA 126.366 1.867 . . . . 0.0 112.347 179.649 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 3.2 tt -70.69 77.61 0.6 Allowed 'General case' 0 CA--C 1.547 0.849 0 C-N-CA 126.72 2.008 . . . . 0.0 111.382 -178.773 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 25.7 tptp -140.15 68.86 34.42 Favored Pre-proline 0 N--CA 1.473 0.722 0 C-N-CA 125.875 1.67 . . . . 0.0 110.893 179.6 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -64.86 148.55 89.98 Favored 'Trans proline' 0 CA--C 1.534 0.524 0 C-N-CA 122.326 2.017 . . . . 0.0 111.868 -178.676 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 1.7 t -137.75 161.0 33.8 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.804 0 C-N-CA 125.542 1.537 . . . . 0.0 109.99 -177.501 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 21.6 p -73.35 130.64 40.61 Favored 'General case' 0 CA--C 1.543 0.683 0 C-N-CA 124.582 1.153 . . . . 0.0 111.669 176.1 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -110.59 159.96 13.57 Favored Glycine 0 CA--C 1.535 1.325 0 C-N-CA 125.135 1.35 . . . . 0.0 112.026 170.729 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 56.6 p -63.53 -30.68 71.76 Favored 'General case' 0 N--CA 1.475 0.781 0 N-CA-C 114.28 1.215 . . . . 0.0 114.28 -172.822 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 17.0 t70 -77.17 -20.37 55.55 Favored 'General case' 0 N--CA 1.477 0.906 0 C-N-CA 124.437 1.095 . . . . 0.0 113.69 177.078 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 106.34 1.27 38.05 Favored Glycine 0 CA--C 1.537 1.411 0 C-N-CA 126.876 2.179 . . . . 0.0 114.789 176.325 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 56.2 mtt180 -85.78 156.21 20.69 Favored 'General case' 0 N--CA 1.476 0.866 0 C-N-CA 125.221 1.408 . . . . 0.0 112.974 -173.688 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 9.6 p -81.58 126.67 32.0 Favored 'General case' 0 N--CA 1.467 0.418 0 C-N-CA 125.959 1.703 . . . . 0.0 111.319 169.799 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 86.1 m-85 -126.13 159.28 33.3 Favored 'General case' 0 N--CA 1.47 0.566 0 C-N-CA 125.71 1.604 . . . . 0.0 110.789 171.99 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -62.57 -42.39 99.52 Favored 'General case' 0 CA--C 1.543 0.701 0 N-CA-C 113.078 0.77 . . . . 0.0 113.078 -168.381 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 14.2 p30 -155.47 178.36 10.32 Favored 'General case' 0 CA--C 1.545 0.78 0 C-N-CA 126.179 1.792 . . . . 0.0 112.258 173.56 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 33.1 t -62.48 -38.25 89.11 Favored 'General case' 0 N--CA 1.473 0.696 0 O-C-N 121.148 -0.97 . . . . 0.0 113.088 178.904 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 24.6 t -59.18 -57.64 12.15 Favored 'General case' 0 N--CA 1.467 0.377 0 C-N-CA 123.974 0.91 . . . . 0.0 111.25 179.749 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 8.4 tt -57.68 -39.45 70.26 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.618 0 N-CA-C 111.783 0.29 . . . . 0.0 111.783 -179.074 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -65.65 -45.73 81.87 Favored 'General case' 0 CA--C 1.542 0.663 0 C-N-CA 123.561 0.745 . . . . 0.0 112.42 179.411 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 16.7 ttp180 -62.87 -44.93 94.8 Favored 'General case' 0 N--CA 1.474 0.728 0 O-C-N 121.372 -0.83 . . . . 0.0 112.198 174.318 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -65.59 -32.54 74.18 Favored 'General case' 0 CA--C 1.545 0.756 0 N-CA-C 113.173 0.805 . . . . 0.0 113.173 177.67 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 51.9 t30 -65.7 -44.06 87.28 Favored 'General case' 0 CA--C 1.544 0.719 0 C-N-CA 124.698 1.199 . . . . 0.0 112.591 173.574 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 159.35 1.29 0.07 OUTLIER Glycine 0 CA--C 1.537 1.409 0 N-CA-C 117.519 1.767 . . . . 0.0 117.519 175.098 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -90.65 178.18 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.453 0 CA-C-N 119.823 1.812 . . . . 0.0 112.036 -176.288 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 66.1 m -133.03 108.36 8.82 Favored 'General case' 0 N--CA 1.477 0.881 0 C-N-CA 125.918 1.687 . . . . 0.0 111.986 177.995 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 16.4 mt -117.43 -34.05 1.77 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.3 0 C-N-CA 125.065 1.346 . . . . 0.0 112.377 178.899 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 9.2 tptm -69.49 -16.74 63.52 Favored 'General case' 0 N--CA 1.479 0.988 0 C-N-CA 125.568 1.547 . . . . 0.0 113.702 179.643 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 13.1 p -66.79 97.44 0.47 Allowed 'General case' 0 CA--C 1.538 0.501 0 C-N-CA 126.727 2.011 . . . . 0.0 111.704 167.877 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 26.8 tt0 -62.39 168.99 3.15 Favored 'General case' 0 CA--C 1.551 0.993 0 C-N-CA 125.077 1.351 . . . . 0.0 112.175 172.457 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -69.1 -9.73 60.77 Favored Glycine 0 CA--C 1.54 1.638 0 C-N-CA 124.74 1.162 . . . . 0.0 115.797 -177.863 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 63.2 p -70.4 162.47 28.59 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 125.009 1.324 . . . . 0.0 112.743 170.341 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 71.7 m -133.38 71.24 76.47 Favored Pre-proline 0 CA--C 1.547 0.856 0 C-N-CA 124.913 1.285 . . . . 0.0 111.301 179.078 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 93.3 Cg_endo -72.65 163.06 39.58 Favored 'Trans proline' 0 CA--C 1.54 0.815 0 C-N-CA 123.168 2.579 . . . . 0.0 112.542 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 6.5 t -75.77 -14.84 60.32 Favored 'General case' 0 N--CA 1.48 1.065 0 N-CA-C 113.903 1.075 . . . . 0.0 113.903 178.764 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -171.56 -82.97 0.05 OUTLIER Glycine 0 CA--C 1.534 1.254 0 C-N-CA 124.468 1.032 . . . . 0.0 113.301 176.13 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 21.4 tt . . . . . 0 C--O 1.254 1.314 0 C-N-CA 126.127 1.771 . . . . 0.0 113.668 179.894 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 64.2 mttm . . . . . 0 N--CA 1.496 1.863 0 N-CA-C 113.67 0.989 . . . . 0.0 113.67 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -119.8 90.38 3.32 Favored 'General case' 0 N--CA 1.483 1.192 0 O-C-N 120.12 -1.613 . . . . 0.0 110.673 179.126 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 46.3 t -137.35 132.89 46.27 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.953 0 C-N-CA 126.255 1.822 . . . . 0.0 109.746 179.179 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 64.3 m -67.78 126.03 28.12 Favored 'General case' 0 CA--C 1.542 0.637 0 C-N-CA 123.846 0.858 . . . . 0.0 111.517 175.423 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -73.8 42.88 0.14 Allowed 'General case' 0 CA--C 1.554 1.115 0 C-N-CA 125.928 1.691 . . . . 0.0 113.96 179.093 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 56.4 m -60.52 153.56 60.26 Favored Pre-proline 0 CA--C 1.55 0.955 0 C-N-CA 125.254 1.422 . . . . 0.0 113.125 177.908 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 88.3 Cg_endo -71.74 158.15 53.88 Favored 'Trans proline' 0 CA--C 1.539 0.735 0 C-N-CA 123.146 2.564 . . . . 0.0 112.309 179.568 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 1.4 mptm? -73.31 -8.56 56.36 Favored 'General case' 0 N--CA 1.48 1.039 0 C-N-CA 125.469 1.508 . . . . 0.0 113.88 179.631 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 51.1 mm -52.95 125.46 7.01 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.668 0 C-N-CA 126.442 1.897 . . . . 0.0 111.498 177.233 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 50.3 tp -95.35 100.44 12.21 Favored 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 127.339 2.256 . . . . 0.0 109.033 176.382 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 29.4 ttmt -146.76 82.34 8.69 Favored Pre-proline 0 N--CA 1.472 0.655 0 C-N-CA 124.565 1.146 . . . . 0.0 110.66 171.22 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 70.2 Cg_endo -68.69 148.32 71.56 Favored 'Trans proline' 0 N--CA 1.459 -0.549 0 C-N-CA 121.805 1.67 . . . . 0.0 110.926 177.543 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 1.4 t -138.41 160.52 31.59 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.752 0 C-N-CA 124.879 1.271 . . . . 0.0 109.966 -179.12 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 49.8 t -75.88 96.34 3.69 Favored 'General case' 0 CA--C 1.54 0.585 0 C-N-CA 124.334 1.054 . . . . 0.0 110.097 173.0 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -62.78 153.3 44.64 Favored Glycine 0 CA--C 1.534 1.265 0 C-N-CA 123.427 0.537 . . . . 0.0 112.113 174.084 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 21.1 t -53.93 -36.09 62.4 Favored 'General case' 0 N--CA 1.477 0.887 0 C-N-CA 125.256 1.422 . . . . 0.0 114.315 -171.51 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 17.8 m-20 -78.67 -2.77 40.77 Favored 'General case' 0 CA--C 1.55 0.945 0 C-N-CA 125.276 1.43 . . . . 0.0 114.589 178.781 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 92.96 37.27 5.76 Favored Glycine 0 CA--C 1.535 1.295 0 C-N-CA 125.503 1.525 . . . . 0.0 113.321 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 13.3 mmm180 -129.52 125.46 36.37 Favored 'General case' 0 N--CA 1.477 0.911 0 C-N-CA 126.604 1.962 . . . . 0.0 111.025 -166.125 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 2.8 p -83.74 90.35 7.3 Favored 'General case' 0 N--CA 1.474 0.746 0 C-N-CA 125.6 1.56 . . . . 0.0 112.074 177.292 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -77.34 154.9 32.36 Favored 'General case' 0 N--CA 1.473 0.691 0 C-N-CA 124.385 1.074 . . . . 0.0 111.851 172.348 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -67.69 -40.82 84.35 Favored 'General case' 0 CA--C 1.545 0.779 0 N-CA-C 113.458 0.91 . . . . 0.0 113.458 -168.705 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 62.1 t30 -144.77 172.27 13.24 Favored 'General case' 0 CA--C 1.548 0.885 0 C-N-CA 125.171 1.388 . . . . 0.0 110.898 169.955 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 88.3 p -62.07 -34.52 76.43 Favored 'General case' 0 N--CA 1.472 0.66 0 O-C-N 120.574 -1.329 . . . . 0.0 113.317 176.365 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 35.4 t -59.72 -57.41 13.03 Favored 'General case' 0 N--CA 1.467 0.414 0 C-N-CA 124.604 1.162 . . . . 0.0 112.669 177.341 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 7.6 tp -58.21 -34.1 48.82 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 CA-C-O 119.06 -0.495 . . . . 0.0 112.286 179.591 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -58.29 -53.6 56.49 Favored 'General case' 0 CA--C 1.544 0.734 0 CA-C-N 118.929 0.786 . . . . 0.0 111.934 172.986 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -58.98 -46.05 89.06 Favored 'General case' 0 N--CA 1.48 1.032 0 N-CA-C 112.666 0.617 . . . . 0.0 112.666 175.338 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -65.3 -32.58 74.31 Favored 'General case' 0 CA--C 1.545 0.776 0 N-CA-C 113.301 0.852 . . . . 0.0 113.301 -179.948 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 25.6 t-20 -71.61 -49.03 44.07 Favored 'General case' 0 CA--C 1.543 0.701 0 C-N-CA 124.758 1.223 . . . . 0.0 112.62 173.86 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 145.47 21.18 0.14 Allowed Glycine 0 CA--C 1.537 1.46 0 N-CA-C 116.813 1.485 . . . . 0.0 116.813 178.965 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 21.7 t -127.48 150.05 33.0 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.607 0 C-N-CA 126.067 1.747 . . . . 0.0 109.548 -176.966 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 80.0 p -124.42 138.69 54.33 Favored 'General case' 0 N--CA 1.47 0.542 0 C-N-CA 126.157 1.783 . . . . 0.0 112.129 -179.499 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 23.5 mm -91.66 -18.93 7.18 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.917 0 C-N-CA 124.961 1.304 . . . . 0.0 111.854 -179.03 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 10.0 mtpm? -83.38 15.21 3.11 Favored 'General case' 0 N--CA 1.482 1.132 0 C-N-CA 128.276 2.631 . . . . 0.0 113.543 173.135 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 8.2 p -68.77 61.56 0.1 Allowed 'General case' 0 N--CA 1.476 0.851 0 C-N-CA 128.464 2.706 . . . . 0.0 114.314 179.919 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 57.6 mm-40 -80.17 165.76 22.11 Favored 'General case' 0 CA--C 1.547 0.828 0 C-N-CA 126.784 2.034 . . . . 0.0 112.766 176.163 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -154.9 41.04 0.61 Allowed Glycine 0 CA--C 1.534 1.271 0 C-N-CA 125.185 1.374 . . . . 0.0 113.615 -177.206 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 13.4 t -129.73 168.95 15.74 Favored 'General case' 0 N--CA 1.473 0.722 0 C-N-CA 126.084 1.754 . . . . 0.0 111.822 -179.725 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 81.8 m 37.13 68.68 1.5 Allowed Pre-proline 0 CA--C 1.552 1.024 0 C-N-CA 127.818 2.447 . . . . 0.0 114.036 -177.448 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -63.48 140.0 73.62 Favored 'Trans proline' 0 CA--C 1.538 0.692 0 C-N-CA 123.056 2.504 . . . . 0.0 111.696 -176.983 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 78.0 p -67.64 162.04 24.47 Favored 'General case' 0 N--CA 1.477 0.9 0 C-N-CA 123.849 0.86 . . . . 0.0 112.676 -178.398 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -170.94 175.39 44.66 Favored Glycine 0 CA--C 1.534 1.237 0 C-N-CA 124.435 1.017 . . . . 0.0 113.553 -178.331 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 17.5 tt . . . . . 0 C--O 1.254 1.341 0 C-N-CA 126.317 1.847 . . . . 0.0 113.416 178.466 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 56.0 mttp . . . . . 0 N--CA 1.49 1.565 0 N-CA-C 109.692 -0.485 . . . . 0.0 109.692 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -142.84 168.41 19.79 Favored 'General case' 0 N--CA 1.484 1.23 0 C-N-CA 125.713 1.605 . . . . 0.0 112.8 -177.298 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 11.7 p -148.63 151.83 12.85 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.093 0 C-N-CA 125.301 1.44 . . . . 0.0 112.184 -178.159 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 60.1 m -77.93 97.51 5.34 Favored 'General case' 0 CA--C 1.545 0.762 0 C-N-CA 126.017 1.727 . . . . 0.0 111.69 177.408 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -75.3 67.6 1.92 Allowed 'General case' 0 CA--C 1.551 1.006 0 C-N-CA 125.56 1.544 . . . . 0.0 113.091 179.802 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 72.8 m -68.92 155.57 93.16 Favored Pre-proline 0 CA--C 1.552 1.027 0 C-N-CA 124.882 1.273 . . . . 0.0 113.586 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 90.4 Cg_endo -74.11 168.01 25.81 Favored 'Trans proline' 0 CA--C 1.541 0.849 0 C-N-CA 123.591 2.861 . . . . 0.0 113.173 179.38 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -76.59 -3.23 36.56 Favored 'General case' 0 N--CA 1.482 1.155 0 C-N-CA 125.619 1.567 . . . . 0.0 114.447 177.927 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 85.6 mt -55.69 151.42 2.22 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.899 0 C-N-CA 126.868 2.067 . . . . 0.0 110.744 174.555 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 50.8 tp -136.9 93.49 2.85 Favored 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 125.914 1.686 . . . . 0.0 109.401 -175.538 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 16.7 mmtm -135.21 82.1 42.44 Favored Pre-proline 0 N--CA 1.475 0.779 0 C-N-CA 125.828 1.651 . . . . 0.0 110.129 174.307 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 65.0 Cg_endo -69.83 91.17 0.52 Allowed 'Trans proline' 0 CA--C 1.54 0.805 0 C-N-CA 123.809 3.006 . . . . 0.0 112.061 -177.238 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 5.0 m -87.11 157.87 3.19 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.522 0 C-N-CA 126.723 2.009 . . . . 0.0 112.882 -177.356 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 45.0 t -68.23 143.29 55.36 Favored 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 124.05 0.94 . . . . 0.0 111.064 171.366 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -111.72 148.97 18.1 Favored Glycine 0 CA--C 1.532 1.108 0 C-N-CA 125.472 1.51 . . . . 0.0 112.786 177.803 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 68.9 m -59.58 -22.81 62.29 Favored 'General case' 0 N--CA 1.477 0.878 0 N-CA-C 115.564 1.69 . . . . 0.0 115.564 -170.498 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 33.4 t70 -77.89 -10.74 59.73 Favored 'General case' 0 CA--C 1.549 0.929 0 C-N-CA 124.904 1.282 . . . . 0.0 114.15 175.238 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 98.39 31.85 6.3 Favored Glycine 0 CA--C 1.536 1.391 0 C-N-CA 125.422 1.487 . . . . 0.0 113.111 -172.097 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 15.3 mmp_? -121.91 -175.0 3.01 Favored 'General case' 0 N--CA 1.478 0.969 0 C-N-CA 127.743 2.417 . . . . 0.0 111.281 -169.734 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 9.3 t -136.84 143.95 43.36 Favored 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 125.191 1.396 . . . . 0.0 111.427 173.007 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 85.4 m-85 -142.39 147.94 37.04 Favored 'General case' 0 N--CA 1.473 0.705 0 C-N-CA 125.22 1.408 . . . . 0.0 112.217 -175.713 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -61.14 -44.81 96.74 Favored 'General case' 0 CA--C 1.542 0.667 0 N-CA-C 114.003 1.112 . . . . 0.0 114.003 -164.608 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 65.6 m-80 -146.85 175.06 10.93 Favored 'General case' 0 CA--C 1.548 0.886 0 C-N-CA 126.461 1.904 . . . . 0.0 110.633 167.576 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 20.0 m -57.76 -30.09 65.33 Favored 'General case' 0 N--CA 1.477 0.903 0 O-C-N 120.945 -1.097 . . . . 0.0 113.599 171.666 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 46.7 t -58.56 -61.1 2.85 Favored 'General case' 0 N--CA 1.466 0.368 0 C-N-CA 124.964 1.306 . . . . 0.0 112.312 175.557 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 8.5 tp -62.56 -33.3 58.85 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.744 0 N-CA-C 112.039 0.385 . . . . 0.0 112.039 179.995 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -57.41 -54.51 46.0 Favored 'General case' 0 CA--C 1.542 0.661 0 C-N-CA 123.348 0.659 . . . . 0.0 111.556 171.56 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 5.5 mtp85 -58.95 -40.22 84.03 Favored 'General case' 0 N--CA 1.48 1.031 0 N-CA-C 113.243 0.831 . . . . 0.0 113.243 174.907 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 33.0 t -59.95 -46.64 88.77 Favored 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 124.517 1.127 . . . . 0.0 111.628 177.17 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 95.4 m-20 -69.15 -48.07 63.31 Favored 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 125.546 1.538 . . . . 0.0 112.786 179.116 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 129.6 39.84 0.28 Allowed Glycine 0 CA--C 1.536 1.36 0 C-N-CA 125.212 1.387 . . . . 0.0 114.652 -176.867 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 44.7 t -133.25 158.18 42.94 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.597 0 C-N-CA 126.938 2.095 . . . . 0.0 108.494 174.528 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 42.7 t -123.57 143.29 50.3 Favored 'General case' 0 N--CA 1.47 0.572 0 C-N-CA 125.545 1.538 . . . . 0.0 111.937 175.492 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 17.1 mm -100.76 -15.58 7.52 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.79 0 C-N-CA 126.034 1.734 . . . . 0.0 111.331 175.889 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 10.7 mmmm -101.7 -24.13 14.13 Favored 'General case' 0 N--CA 1.479 0.984 0 C-N-CA 126.642 1.977 . . . . 0.0 113.877 -177.359 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 1.4 t 55.26 32.53 18.78 Favored 'General case' 0 N--CA 1.478 0.953 0 C-N-CA 126.024 1.73 . . . . 0.0 114.647 178.396 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 14.3 mm-40 -65.52 -13.3 58.61 Favored 'General case' 0 N--CA 1.477 0.911 0 C-N-CA 125.852 1.661 . . . . 0.0 114.735 178.828 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 149.23 2.85 0.31 Allowed Glycine 0 CA--C 1.538 1.496 0 C-N-CA 124.875 1.226 . . . . 0.0 116.032 178.121 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 12.1 m -59.11 -33.51 70.94 Favored 'General case' 0 N--CA 1.475 0.799 0 C-N-CA 125.457 1.503 . . . . 0.0 114.927 -172.302 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 83.9 m 30.64 66.56 0.85 Allowed Pre-proline 0 CA--C 1.555 1.157 0 C-N-CA 128.345 2.658 . . . . 0.0 114.956 177.723 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo -68.56 116.33 4.35 Favored 'Trans proline' 0 CA--C 1.539 0.733 0 C-N-CA 123.666 2.911 . . . . 0.0 112.979 -171.444 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 24.1 p -76.08 -45.96 31.41 Favored 'General case' 0 N--CA 1.476 0.845 0 C-N-CA 125.629 1.571 . . . . 0.0 113.614 -178.437 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 151.57 -126.59 2.11 Favored Glycine 0 CA--C 1.535 1.324 0 C-N-CA 125.366 1.46 . . . . 0.0 112.744 -176.648 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 34.6 pt . . . . . 0 C--O 1.254 1.308 0 C-N-CA 126.091 1.757 . . . . 0.0 114.082 177.978 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 83.4 tttt . . . . . 0 N--CA 1.491 1.575 0 N-CA-C 110.416 -0.216 . . . . 0.0 110.416 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 1.9 mptp? -71.9 142.56 49.51 Favored 'General case' 0 N--CA 1.481 1.09 0 C-N-CA 124.111 0.964 . . . . 0.0 110.733 173.717 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 13.7 p -149.86 145.26 17.48 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.917 0 C-N-CA 124.939 1.296 . . . . 0.0 111.564 179.285 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 57.2 m -107.88 -18.86 13.7 Favored 'General case' 0 N--CA 1.476 0.839 0 C-N-CA 125.095 1.358 . . . . 0.0 113.6 179.481 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . 50.07 26.32 2.04 Favored 'General case' 0 CA--C 1.552 1.023 0 C-N-CA 127.254 2.222 . . . . 0.0 115.285 -171.032 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 61.9 m -70.22 160.72 79.8 Favored Pre-proline 0 CA--C 1.548 0.869 0 C-N-CA 125.363 1.465 . . . . 0.0 112.922 177.157 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -67.58 167.59 20.48 Favored 'Trans proline' 0 CA--C 1.54 0.798 0 C-N-CA 123.295 2.663 . . . . 0.0 112.231 169.736 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 10.2 mtpm? -112.53 1.38 15.83 Favored 'General case' 0 N--CA 1.48 1.059 0 C-N-CA 126.282 1.833 . . . . 0.0 113.28 173.672 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 48.9 mm -55.93 133.03 19.99 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.593 0 C-N-CA 126.386 1.874 . . . . 0.0 111.082 178.587 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 5.4 tt -69.87 96.0 0.97 Allowed 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 127.771 2.428 . . . . 0.0 111.08 -176.723 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 34.7 ttpt -144.45 73.97 15.53 Favored Pre-proline 0 CA--C 1.546 0.801 0 C-N-CA 124.467 1.107 . . . . 0.0 111.901 -179.427 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -68.21 89.43 0.39 Allowed 'Trans proline' 0 CA--C 1.538 0.708 0 C-N-CA 124.188 3.259 . . . . 0.0 112.922 -175.996 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 16.3 m -73.73 160.24 5.36 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.412 0 C-N-CA 126.084 1.754 . . . . 0.0 112.244 175.273 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 16.5 t -69.36 165.95 19.65 Favored 'General case' 0 CA--C 1.549 0.908 0 C-N-CA 123.625 0.77 . . . . 0.0 111.141 166.998 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -143.6 134.55 5.9 Favored Glycine 0 CA--C 1.53 0.973 0 C-N-CA 124.778 1.18 . . . . 0.0 112.151 177.783 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 63.7 m -57.22 -24.48 54.9 Favored 'General case' 0 N--CA 1.477 0.886 0 C-N-CA 125.847 1.659 . . . . 0.0 114.906 -176.993 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -83.29 -4.58 58.58 Favored 'General case' 0 CA--C 1.548 0.887 0 C-N-CA 125.775 1.63 . . . . 0.0 113.955 176.985 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 94.65 20.21 29.8 Favored Glycine 0 CA--C 1.535 1.311 0 C-N-CA 125.38 1.467 . . . . 0.0 114.284 179.111 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 43.7 mtt180 -121.01 178.18 4.83 Favored 'General case' 0 N--CA 1.477 0.908 0 C-N-CA 126.169 1.788 . . . . 0.0 112.536 -173.88 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 31.8 m -128.35 142.64 51.06 Favored 'General case' 0 N--CA 1.477 0.9 0 C-N-CA 126.107 1.763 . . . . 0.0 110.049 -179.584 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 86.8 m-85 -135.57 155.64 50.15 Favored 'General case' 0 N--CA 1.471 0.588 0 C-N-CA 125.171 1.388 . . . . 0.0 111.651 -175.438 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -61.66 -38.63 88.46 Favored 'General case' 0 CA--C 1.544 0.742 0 N-CA-C 113.212 0.819 . . . . 0.0 113.212 -167.956 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 14.8 p30 -150.33 179.33 8.21 Favored 'General case' 0 CA--C 1.548 0.876 0 C-N-CA 126.213 1.805 . . . . 0.0 111.901 166.441 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 25.0 p -65.63 -34.83 79.12 Favored 'General case' 0 N--CA 1.474 0.745 0 O-C-N 121.007 -1.058 . . . . 0.0 113.755 177.298 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 34.4 t -62.93 -54.04 44.77 Favored 'General case' 0 N--CA 1.466 0.361 0 C-N-CA 124.083 0.953 . . . . 0.0 111.481 179.057 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 9.3 tp -59.0 -37.18 66.14 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.553 0 N-CA-C 112.143 0.423 . . . . 0.0 112.143 -179.277 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -63.32 -42.62 99.02 Favored 'General case' 0 CA--C 1.544 0.717 0 CA-C-N 118.851 0.75 . . . . 0.0 112.927 176.216 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 8.7 tpm_? -62.98 -41.96 99.7 Favored 'General case' 0 N--CA 1.475 0.816 0 C-N-CA 123.828 0.851 . . . . 0.0 112.278 173.82 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 7.3 t -65.06 -39.72 93.67 Favored 'General case' 0 CA--C 1.547 0.839 0 C-N-CA 123.025 0.53 . . . . 0.0 112.245 174.286 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 23.0 t-20 -63.93 -52.03 61.66 Favored 'General case' 0 CA--C 1.544 0.716 0 C-N-CA 125.82 1.648 . . . . 0.0 112.464 178.739 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 149.81 18.12 0.08 OUTLIER Glycine 0 CA--C 1.537 1.436 0 N-CA-C 117.344 1.698 . . . . 0.0 117.344 179.095 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 14.5 t -124.43 144.38 34.51 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.672 0 CA-C-N 119.98 1.89 . . . . 0.0 109.882 -176.828 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 72.3 m -89.47 128.53 35.98 Favored 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 125.805 1.642 . . . . 0.0 111.322 -179.024 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 14.3 mm -117.48 -9.33 11.99 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.23 0 C-N-CA 124.687 1.195 . . . . 0.0 112.486 -175.778 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 84.3 tttt -59.6 -33.05 70.98 Favored 'General case' 0 N--CA 1.477 0.9 0 C-N-CA 126.018 1.727 . . . . 0.0 113.409 173.707 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 18.5 t -131.48 113.4 13.64 Favored 'General case' 0 N--CA 1.468 0.446 0 C-N-CA 125.852 1.661 . . . . 0.0 110.495 -179.512 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 78.2 mm-40 -61.75 136.71 58.1 Favored 'General case' 0 N--CA 1.474 0.743 0 C-N-CA 124.698 1.199 . . . . 0.0 112.796 179.91 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -86.37 -31.85 18.15 Favored Glycine 0 CA--C 1.537 1.418 0 C-N-CA 123.912 0.768 . . . . 0.0 114.683 -179.06 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 66.2 m -76.69 93.72 3.69 Favored 'General case' 0 N--CA 1.473 0.688 0 C-N-CA 124.97 1.308 . . . . 0.0 112.045 -179.485 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 48.8 t -60.53 132.25 90.96 Favored Pre-proline 0 CA--C 1.551 1.001 0 C-N-CA 124.33 1.052 . . . . 0.0 111.607 174.979 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -71.64 161.61 44.72 Favored 'Trans proline' 0 CA--C 1.542 0.913 0 C-N-CA 123.125 2.55 . . . . 0.0 112.652 178.656 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 34.5 m -127.29 -37.42 2.04 Favored 'General case' 0 N--CA 1.483 1.202 0 C-N-CA 124.965 1.306 . . . . 0.0 112.912 -175.559 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 172.94 -168.08 41.05 Favored Glycine 0 CA--C 1.534 1.219 0 C-N-CA 125.03 1.3 . . . . 0.0 112.72 -173.177 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 11.2 tp . . . . . 0 C--O 1.254 1.301 0 C-N-CA 126.41 1.884 . . . . 0.0 112.98 -179.877 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.489 1.512 0 CA-C-O 120.491 0.186 . . . . 0.0 111.172 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -79.76 74.86 6.45 Favored 'General case' 0 N--CA 1.482 1.127 0 C-N-CA 125.204 1.402 . . . . 0.0 111.738 179.087 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 24.7 t -137.34 123.82 28.31 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.999 0 C-N-CA 125.486 1.515 . . . . 0.0 110.588 179.91 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 22.4 m -71.14 114.37 9.13 Favored 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 125.285 1.434 . . . . 0.0 110.447 173.426 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -72.84 35.88 0.07 Allowed 'General case' 0 CA--C 1.556 1.195 0 C-N-CA 125.702 1.601 . . . . 0.0 114.321 178.257 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 63.8 m -64.85 159.03 66.45 Favored Pre-proline 0 CA--C 1.549 0.932 0 C-N-CA 126.499 1.92 . . . . 0.0 113.934 -178.232 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -70.81 158.96 54.15 Favored 'Trans proline' 0 C--N 1.352 0.736 0 C-N-CA 123.293 2.662 . . . . 0.0 112.785 -179.64 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 48.3 tttm -71.54 -21.17 61.94 Favored 'General case' 0 N--CA 1.478 0.953 0 C-N-CA 125.272 1.429 . . . . 0.0 113.397 176.401 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 43.7 mm -57.32 130.61 20.45 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.652 0 C-N-CA 126.257 1.823 . . . . 0.0 110.994 -179.651 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.416 HD23 ' H ' ' A' ' 10' ' ' LEU . 2.0 pt? -93.05 133.95 35.68 Favored 'General case' 0 CA--C 1.539 0.548 0 C-N-CA 125.312 1.445 . . . . 0.0 111.981 176.426 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 54.2 mttm -144.17 81.39 11.56 Favored Pre-proline 0 N--CA 1.471 0.611 0 C-N-CA 126.87 2.068 . . . . 0.0 109.236 166.748 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -71.53 85.03 0.93 Allowed 'Trans proline' 0 CA--C 1.539 0.729 0 C-N-CA 123.522 2.815 . . . . 0.0 111.915 178.836 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 35.2 m -110.96 166.72 5.37 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.344 0 C-N-CA 126.987 2.115 . . . . 0.0 112.609 -176.877 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 24.4 p -76.38 130.82 38.61 Favored 'General case' 0 CA--C 1.544 0.717 0 C-N-CA 124.124 0.97 . . . . 0.0 111.961 176.338 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -89.29 160.14 29.15 Favored Glycine 0 CA--C 1.534 1.255 0 C-N-CA 124.925 1.25 . . . . 0.0 111.974 168.239 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 91.2 p -59.39 -26.19 64.91 Favored 'General case' 0 N--CA 1.476 0.873 0 N-CA-C 115.252 1.575 . . . . 0.0 115.252 -171.928 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 32.2 m-20 -81.56 -2.77 51.18 Favored 'General case' 0 CA--C 1.547 0.858 0 C-N-CA 125.321 1.448 . . . . 0.0 114.451 176.585 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 89.59 31.4 11.48 Favored Glycine 0 CA--C 1.536 1.387 0 C-N-CA 124.772 1.177 . . . . 0.0 113.089 -176.285 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 42.9 mmm-85 -114.68 172.24 7.16 Favored 'General case' 0 N--CA 1.477 0.877 0 C-N-CA 127.808 2.443 . . . . 0.0 111.022 -170.873 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 31.7 m -128.68 133.53 48.23 Favored 'General case' 0 N--CA 1.481 1.086 0 C-N-CA 124.717 1.207 . . . . 0.0 110.748 178.921 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 87.3 m-85 -135.73 156.15 49.28 Favored 'General case' 0 N--CA 1.473 0.682 0 C-N-CA 125.186 1.394 . . . . 0.0 112.155 -178.106 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.99 -40.76 95.44 Favored 'General case' 0 CA--C 1.543 0.689 0 N-CA-C 113.499 0.926 . . . . 0.0 113.499 -166.965 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . 0.438 ' H ' HG22 ' A' ' 26' ' ' ILE . 28.7 p30 -148.4 179.7 7.59 Favored 'General case' 0 CA--C 1.547 0.847 0 C-N-CA 125.326 1.45 . . . . 0.0 112.194 164.813 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 44.6 p -62.64 -34.12 76.42 Favored 'General case' 0 N--CA 1.474 0.76 0 C-N-CA 124.228 1.011 . . . . 0.0 113.531 176.772 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 47.3 t -62.39 -55.1 31.08 Favored 'General case' 0 N--CA 1.465 0.276 0 C-N-CA 124.321 1.049 . . . . 0.0 111.917 178.093 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.438 HG22 ' H ' ' A' ' 23' ' ' ASN . 9.3 tp -61.26 -35.71 67.87 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.611 0 N-CA-C 112.25 0.463 . . . . 0.0 112.25 179.576 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -58.99 -51.37 70.38 Favored 'General case' 0 CA--C 1.544 0.73 0 C-N-CA 123.698 0.799 . . . . 0.0 111.885 172.499 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 77.5 mtp85 -57.92 -45.55 86.36 Favored 'General case' 0 N--CA 1.477 0.925 0 C-N-CA 124.644 1.177 . . . . 0.0 112.772 174.85 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 6.7 t -62.48 -40.83 97.95 Favored 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 123.766 0.826 . . . . 0.0 112.275 177.139 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 43.9 t30 -67.67 -42.04 82.79 Favored 'General case' 0 CA--C 1.543 0.681 0 C-N-CA 125.026 1.33 . . . . 0.0 113.245 178.32 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 134.43 23.79 0.64 Allowed Glycine 0 CA--C 1.538 1.476 0 N-CA-C 116.046 1.178 . . . . 0.0 116.046 178.013 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 38.0 t -125.01 154.47 33.06 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.448 0 C-N-CA 126.835 2.054 . . . . 0.0 108.379 -178.147 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 91.3 p -135.79 166.97 22.05 Favored 'General case' 0 N--CA 1.472 0.646 0 C-N-CA 124.618 1.167 . . . . 0.0 112.875 175.918 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 2.0 mt -125.98 -8.71 5.38 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.04 0 C-N-CA 124.862 1.265 . . . . 0.0 112.006 -172.193 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 25.7 pttm -60.46 -30.78 69.88 Favored 'General case' 0 N--CA 1.479 0.981 0 C-N-CA 126.366 1.866 . . . . 0.0 113.584 174.291 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 33.8 m -83.62 83.19 7.99 Favored 'General case' 0 N--CA 1.468 0.467 0 C-N-CA 126.263 1.825 . . . . 0.0 110.551 -179.559 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 16.9 pt-20 -130.01 163.45 26.45 Favored 'General case' 0 CA--C 1.543 0.709 0 C-N-CA 125.949 1.7 . . . . 0.0 112.657 -177.049 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -91.67 -27.89 15.87 Favored Glycine 0 CA--C 1.537 1.418 0 C-N-CA 123.953 0.787 . . . . 0.0 115.037 -173.848 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 25.6 p -85.05 166.37 16.75 Favored 'General case' 0 N--CA 1.473 0.676 0 C-N-CA 125.209 1.403 . . . . 0.0 113.127 177.365 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 48.6 t -65.6 127.98 93.45 Favored Pre-proline 0 CA--C 1.55 0.96 0 C-N-CA 123.91 0.884 . . . . 0.0 111.593 176.917 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -71.34 94.08 0.67 Allowed 'Trans proline' 0 CA--C 1.543 0.945 0 C-N-CA 123.886 3.057 . . . . 0.0 112.211 -178.089 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 8.6 m -138.6 147.26 42.75 Favored 'General case' 0 N--CA 1.48 1.032 0 C-N-CA 126.029 1.732 . . . . 0.0 110.86 -177.441 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 143.7 -62.28 0.5 Allowed Glycine 0 CA--C 1.532 1.154 0 C-N-CA 124.891 1.234 . . . . 0.0 113.63 171.452 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 21.1 tt . . . . . 0 C--O 1.252 1.204 0 C-N-CA 126.954 2.102 . . . . 0.0 112.273 -178.011 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.636 0 N-CA-C 111.622 0.231 . . . . 0.0 111.622 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 48.5 tttm 51.05 47.46 24.82 Favored 'General case' 0 N--CA 1.484 1.241 0 C-N-CA 127.084 2.154 . . . . 0.0 113.586 178.912 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 12.8 p -142.41 144.93 24.18 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.966 0 C-N-CA 126.047 1.739 . . . . 0.0 111.69 -179.414 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 81.0 m -80.92 110.27 16.29 Favored 'General case' 0 CA--C 1.544 0.736 0 C-N-CA 125.584 1.554 . . . . 0.0 110.782 175.736 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -74.95 68.62 1.82 Allowed 'General case' 0 CA--C 1.549 0.935 0 C-N-CA 125.686 1.595 . . . . 0.0 113.17 -177.672 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 62.6 m -69.05 154.89 94.57 Favored Pre-proline 0 CA--C 1.549 0.909 0 C-N-CA 124.536 1.134 . . . . 0.0 113.431 -179.404 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -68.5 152.77 74.82 Favored 'Trans proline' 0 CA--C 1.54 0.811 0 C-N-CA 123.201 2.601 . . . . 0.0 111.854 172.637 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 15.2 ptmt -63.86 -26.03 68.43 Favored 'General case' 0 N--CA 1.479 1.023 0 C-N-CA 125.685 1.594 . . . . 0.0 114.678 177.571 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 9.5 tt -57.78 158.32 1.35 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.614 0 C-N-CA 126.673 1.989 . . . . 0.0 112.301 176.079 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 16.8 tp -126.96 114.78 18.29 Favored 'General case' 0 CA--C 1.538 0.487 0 C-N-CA 126.433 1.893 . . . . 0.0 108.518 -178.07 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 31.1 mmmt -127.61 80.18 72.29 Favored Pre-proline 0 N--CA 1.473 0.716 0 C-N-CA 126.125 1.77 . . . . 0.0 109.792 -176.362 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -72.78 84.28 1.27 Allowed 'Trans proline' 0 CA--C 1.541 0.83 0 C-N-CA 124.274 3.316 . . . . 0.0 112.402 -175.427 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 14.4 m -73.78 164.76 3.41 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.598 0 C-N-CA 126.883 2.073 . . . . 0.0 112.832 177.556 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 10.0 t -79.79 -5.21 54.92 Favored 'General case' 0 CA--C 1.551 0.995 0 C-N-CA 124.539 1.135 . . . . 0.0 113.983 174.406 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 57.29 -155.19 18.24 Favored Glycine 0 CA--C 1.539 1.548 0 C-N-CA 125.338 1.447 . . . . 0.0 113.984 179.211 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 38.0 m -121.22 -20.54 6.7 Favored 'General case' 0 N--CA 1.475 0.776 0 C-N-CA 124.94 1.296 . . . . 0.0 114.223 174.454 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -80.81 -13.88 58.56 Favored 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 124.252 1.021 . . . . 0.0 113.102 171.703 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 98.51 -14.91 61.71 Favored Glycine 0 CA--C 1.537 1.456 0 C-N-CA 126.782 2.134 . . . . 0.0 114.008 -177.945 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 9.8 ptm180 -77.96 168.83 19.28 Favored 'General case' 0 N--CA 1.474 0.747 0 C-N-CA 125.378 1.471 . . . . 0.0 112.279 168.269 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 54.7 m -95.22 149.36 21.4 Favored 'General case' 0 N--CA 1.475 0.779 0 C-N-CA 124.452 1.101 . . . . 0.0 111.708 174.823 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 56.1 m-85 -131.63 151.99 51.18 Favored 'General case' 0 N--CA 1.47 0.562 0 C-N-CA 126.249 1.819 . . . . 0.0 110.676 173.797 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.89 -40.54 87.79 Favored 'General case' 0 CA--C 1.544 0.713 0 N-CA-C 113.273 0.842 . . . . 0.0 113.273 -169.855 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . 0.41 ' H ' HG22 ' A' ' 26' ' ' ILE . 16.5 m120 -144.61 170.96 15.07 Favored 'General case' 0 CA--C 1.545 0.786 0 C-N-CA 126.29 1.836 . . . . 0.0 110.954 174.894 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 28.4 p -61.41 -32.06 72.0 Favored 'General case' 0 N--CA 1.475 0.797 0 C-N-CA 124.152 0.981 . . . . 0.0 112.618 162.073 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 42.3 t -54.84 -64.25 0.89 Allowed 'General case' 0 CA--C 1.535 0.374 0 C-N-CA 125.699 1.599 . . . . 0.0 112.366 173.264 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.41 HG22 ' H ' ' A' ' 23' ' ' ASN . 13.6 tt -58.54 -35.62 55.6 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.812 0 N-CA-C 112.211 0.449 . . . . 0.0 112.211 -178.021 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -59.07 -56.63 19.72 Favored 'General case' 0 CA--C 1.541 0.617 0 C-N-CA 123.5 0.72 . . . . 0.0 111.505 174.671 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 69.6 mtm180 -64.55 -37.5 87.77 Favored 'General case' 0 N--CA 1.479 0.977 0 N-CA-C 113.209 0.818 . . . . 0.0 113.209 179.009 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 35.9 t -58.35 -45.25 88.54 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 125.233 1.413 . . . . 0.0 111.833 172.695 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 23.0 t-20 -71.57 -48.84 45.73 Favored 'General case' 0 CA--C 1.546 0.816 0 C-N-CA 125.03 1.332 . . . . 0.0 112.79 179.911 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 144.7 23.43 0.14 Allowed Glycine 0 CA--C 1.54 1.629 0 N-CA-C 116.523 1.369 . . . . 0.0 116.523 179.765 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 18.4 t -130.88 151.56 36.12 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.603 0 C-N-CA 126.637 1.975 . . . . 0.0 109.179 -174.789 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 95.0 p -144.91 124.81 13.45 Favored 'General case' 0 N--CA 1.47 0.562 0 C-N-CA 125.106 1.362 . . . . 0.0 112.108 -179.724 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 6.3 mt -63.57 -20.88 27.23 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.149 0 C-N-CA 124.306 1.042 . . . . 0.0 112.132 -178.805 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -67.29 -16.1 64.08 Favored 'General case' 0 N--CA 1.475 0.813 0 C-N-CA 126.808 2.043 . . . . 0.0 113.254 173.014 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 1.1 t 61.93 20.21 11.33 Favored 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 126.402 1.881 . . . . 0.0 114.768 -179.372 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -147.59 166.41 27.45 Favored 'General case' 0 CA--C 1.541 0.622 0 C-N-CA 124.913 1.285 . . . . 0.0 113.298 -178.391 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -80.0 52.5 4.25 Favored Glycine 0 CA--C 1.534 1.252 0 C-N-CA 125.581 1.562 . . . . 0.0 113.794 -179.581 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 10.8 t -72.44 88.68 1.22 Allowed 'General case' 0 CA--C 1.54 0.594 0 C-N-CA 124.851 1.261 . . . . 0.0 111.128 176.802 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 17.7 t 40.87 75.02 0.64 Allowed Pre-proline 0 CA--C 1.556 1.177 0 C-N-CA 127.884 2.474 . . . . 0.0 114.358 -175.398 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 74.9 Cg_endo -72.35 89.16 0.82 Allowed 'Trans proline' 0 CA--C 1.543 0.962 0 C-N-CA 124.174 3.249 . . . . 0.0 112.605 -177.318 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 22.1 p -71.75 102.12 2.74 Favored 'General case' 0 N--CA 1.475 0.791 0 C-N-CA 126.074 1.75 . . . . 0.0 112.307 176.911 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 97.39 114.1 3.18 Favored Glycine 0 CA--C 1.535 1.313 0 C-N-CA 124.848 1.213 . . . . 0.0 113.1 176.673 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 27.6 mm . . . . . 0 C--O 1.254 1.309 0 C-N-CA 126.025 1.73 . . . . 0.0 111.391 177.304 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 62.8 pttt . . . . . 0 N--CA 1.491 1.611 0 N-CA-C 111.606 0.224 . . . . 0.0 111.606 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 8.8 mtmp? 48.21 46.74 19.82 Favored 'General case' 0 N--CA 1.487 1.401 0 C-N-CA 126.983 2.113 . . . . 0.0 113.975 -179.027 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 11.1 p -138.8 142.53 34.16 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.003 0 C-N-CA 125.002 1.321 . . . . 0.0 112.046 -179.036 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 61.2 m -82.05 100.41 9.72 Favored 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 125.494 1.518 . . . . 0.0 110.832 177.266 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -73.99 52.89 0.45 Allowed 'General case' 0 CA--C 1.554 1.123 0 C-N-CA 125.612 1.565 . . . . 0.0 113.131 177.36 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 92.8 m -62.86 157.03 62.98 Favored Pre-proline 0 CA--C 1.551 1.001 0 C-N-CA 125.791 1.636 . . . . 0.0 113.232 178.977 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -71.82 167.7 25.87 Favored 'Trans proline' 0 CA--C 1.542 0.881 0 C-N-CA 123.29 2.66 . . . . 0.0 113.283 -177.24 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 61.7 mtpt -66.46 -16.8 64.39 Favored 'General case' 0 N--CA 1.481 1.088 0 C-N-CA 126.033 1.733 . . . . 0.0 114.097 176.171 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 79.8 mt -58.47 136.36 21.96 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.722 0 C-N-CA 126.489 1.916 . . . . 0.0 110.24 178.064 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.9 pt? -130.98 26.42 4.93 Favored 'General case' 0 CA--C 1.546 0.816 0 C-N-CA 125.416 1.487 . . . . 0.0 113.951 -178.48 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 26.4 mmtp -52.59 107.22 0.79 Allowed Pre-proline 0 N--CA 1.477 0.893 0 C-N-CA 126.516 1.926 . . . . 0.0 111.553 175.182 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 91.6 Cg_endo -73.61 87.76 1.08 Allowed 'Trans proline' 0 CA--C 1.539 0.729 0 C-N-CA 123.526 2.818 . . . . 0.0 112.01 -173.816 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 13.6 m -73.8 157.85 6.17 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.459 0 C-N-CA 125.636 1.574 . . . . 0.0 112.297 179.246 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 30.3 p -63.44 165.2 8.1 Favored 'General case' 0 CA--C 1.544 0.741 0 C-N-CA 123.412 0.685 . . . . 0.0 111.835 165.637 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -133.97 143.29 14.93 Favored Glycine 0 CA--C 1.527 0.798 0 C-N-CA 125.058 1.313 . . . . 0.0 111.972 179.999 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 55.6 m -65.08 -15.82 62.79 Favored 'General case' 0 N--CA 1.473 0.706 0 C-N-CA 125.362 1.465 . . . . 0.0 114.913 -174.598 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 42.0 m-20 -95.32 5.78 50.78 Favored 'General case' 0 CA--C 1.553 1.082 0 C-N-CA 125.972 1.709 . . . . 0.0 113.514 171.955 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 88.91 24.81 31.27 Favored Glycine 0 N--CA 1.473 1.108 0 C-N-CA 125.05 1.309 . . . . 0.0 114.157 179.921 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 24.0 mtp85 -120.47 -170.53 2.0 Favored 'General case' 0 N--CA 1.481 1.098 0 C-N-CA 126.297 1.839 . . . . 0.0 112.348 -171.409 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 41.2 m -134.42 139.04 45.27 Favored 'General case' 0 N--CA 1.478 0.964 0 C-N-CA 125.952 1.701 . . . . 0.0 110.37 -179.34 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 65.6 m-85 -134.3 159.4 41.09 Favored 'General case' 0 N--CA 1.473 0.694 0 C-N-CA 124.921 1.288 . . . . 0.0 111.603 179.036 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -63.97 -40.53 96.6 Favored 'General case' 0 CA--C 1.543 0.682 0 N-CA-C 112.92 0.711 . . . . 0.0 112.92 -168.075 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 28.5 p30 -154.77 -178.39 7.17 Favored 'General case' 0 CA--C 1.551 0.991 0 C-N-CA 125.314 1.445 . . . . 0.0 111.635 168.877 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 83.4 p -73.12 -16.79 61.45 Favored 'General case' 0 N--CA 1.48 1.046 0 N-CA-C 114.753 1.39 . . . . 0.0 114.753 177.843 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 38.8 t -76.6 -56.06 4.95 Favored 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 124.77 1.228 . . . . 0.0 111.136 173.861 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 7.7 tp -57.85 -34.63 48.77 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.859 0 C-N-CA 123.528 0.731 . . . . 0.0 112.406 179.115 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -55.24 -53.35 57.17 Favored 'General case' 0 CA--C 1.541 0.627 0 C-N-CA 123.885 0.874 . . . . 0.0 111.484 172.967 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 81.3 mtm180 -67.02 -37.42 84.13 Favored 'General case' 0 N--CA 1.475 0.786 0 C-N-CA 125.031 1.332 . . . . 0.0 113.49 178.317 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 42.5 t -57.22 -47.0 82.43 Favored 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 124.325 1.05 . . . . 0.0 111.599 170.844 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 63.6 t30 -70.96 -49.84 41.09 Favored 'General case' 0 CA--C 1.546 0.797 0 C-N-CA 125.502 1.521 . . . . 0.0 112.961 -178.172 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 145.42 23.22 0.12 Allowed Glycine 0 CA--C 1.539 1.561 0 N-CA-C 116.792 1.477 . . . . 0.0 116.792 178.663 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 19.3 t -125.55 150.84 31.06 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.613 0 C-N-CA 126.714 2.006 . . . . 0.0 108.839 -178.069 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 32.5 t -144.61 118.54 9.35 Favored 'General case' 0 N--CA 1.472 0.666 0 C-N-CA 124.907 1.283 . . . . 0.0 112.698 179.197 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.471 ' H ' HD12 ' A' ' 34' ' ' ILE . 0.7 OUTLIER -86.51 13.12 0.96 Allowed 'Isoleucine or valine' 0 CA--C 1.555 1.16 0 C-N-CA 126.789 2.035 . . . . 0.0 111.469 -178.638 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 1.1 mptm? 60.99 5.13 0.92 Allowed 'General case' 0 N--CA 1.487 1.392 0 C-N-CA 128.728 2.811 . . . . 0.0 115.433 -174.978 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 7.5 t -67.98 -21.23 65.07 Favored 'General case' 0 N--CA 1.474 0.727 0 C-N-CA 125.181 1.393 . . . . 0.0 114.58 -178.45 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 14.1 tt0 -144.62 162.12 37.45 Favored 'General case' 0 CA--C 1.548 0.87 0 C-N-CA 124.659 1.184 . . . . 0.0 111.546 177.021 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -79.54 47.92 3.34 Favored Glycine 0 CA--C 1.536 1.392 0 C-N-CA 125.711 1.624 . . . . 0.0 116.044 -166.077 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 21.3 t -78.18 -59.74 2.66 Favored 'General case' 0 N--CA 1.475 0.784 0 C-N-CA 124.617 1.167 . . . . 0.0 112.661 -179.361 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 13.2 p -143.14 70.39 18.26 Favored Pre-proline 0 CA--C 1.551 1.005 0 C-N-CA 125.234 1.414 . . . . 0.0 111.869 -178.363 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 79.3 Cg_endo -70.11 162.34 42.62 Favored 'Trans proline' 0 CA--C 1.543 0.95 0 C-N-CA 123.173 2.582 . . . . 0.0 112.544 178.475 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 21.3 m -130.0 77.67 1.8 Allowed 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 125.287 1.435 . . . . 0.0 109.959 -178.922 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -84.28 71.68 2.94 Favored Glycine 0 CA--C 1.533 1.187 0 C-N-CA 125.154 1.359 . . . . 0.0 113.476 -175.296 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 54.2 mt . . . . . 0 C--O 1.254 1.311 0 C-N-CA 126.171 1.789 . . . . 0.0 111.085 176.172 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 74.6 tttt . . . . . 0 N--CA 1.492 1.648 0 N-CA-C 111.503 0.186 . . . . 0.0 111.503 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 10.4 ptpp? -166.15 167.31 16.37 Favored 'General case' 0 N--CA 1.487 1.388 0 C-N-CA 127.17 2.188 . . . . 0.0 111.122 167.923 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 45.8 t -139.77 133.08 36.34 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.042 0 C-N-CA 125.675 1.59 . . . . 0.0 110.172 177.51 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 4.9 m -68.99 104.05 2.0 Allowed 'General case' 0 CA--C 1.547 0.843 0 C-N-CA 124.686 1.194 . . . . 0.0 109.888 171.139 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -74.44 51.19 0.44 Allowed 'General case' 0 CA--C 1.554 1.101 0 C-N-CA 125.571 1.549 . . . . 0.0 113.58 -177.588 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 81.2 m -71.5 156.07 91.88 Favored Pre-proline 0 CA--C 1.548 0.885 0 C-N-CA 125.624 1.569 . . . . 0.0 114.039 -172.704 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -68.93 158.83 56.34 Favored 'Trans proline' 0 CA--C 1.54 0.814 0 C-N-CA 123.63 2.887 . . . . 0.0 113.213 177.979 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 64.8 mttm -69.98 -14.02 62.5 Favored 'General case' 0 N--CA 1.481 1.093 0 C-N-CA 126.399 1.88 . . . . 0.0 114.142 177.813 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 10.3 tp -62.41 146.49 12.42 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 C-N-CA 126.438 1.895 . . . . 0.0 113.446 -177.114 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 62.7 tp -116.8 88.36 2.88 Favored 'General case' 0 CA--C 1.539 0.544 0 C-N-CA 127.138 2.175 . . . . 0.0 108.881 -175.677 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 13.1 mmmm -134.38 74.12 67.28 Favored Pre-proline 0 N--CA 1.474 0.739 0 C-N-CA 126.519 1.928 . . . . 0.0 109.179 175.536 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -67.21 120.02 7.07 Favored 'Trans proline' 0 CA--C 1.536 0.611 0 C-N-CA 122.929 2.419 . . . . 0.0 111.12 -175.732 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -107.51 155.75 8.17 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.747 0 C-N-CA 124.929 1.291 . . . . 0.0 110.961 -175.8 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 8.8 p -81.98 106.33 13.81 Favored 'General case' 0 CA--C 1.545 0.754 0 C-N-CA 125.792 1.637 . . . . 0.0 110.813 171.582 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -69.11 154.07 53.11 Favored Glycine 0 CA--C 1.534 1.272 0 O-C-N 121.45 -0.781 . . . . 0.0 112.085 172.063 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 73.2 m -61.69 -18.71 60.73 Favored 'General case' 0 N--CA 1.479 0.982 0 N-CA-C 116.084 1.883 . . . . 0.0 116.084 -168.854 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 31.8 t70 -82.14 -11.29 58.82 Favored 'General case' 0 CA--C 1.548 0.902 0 N-CA-C 114.105 1.15 . . . . 0.0 114.105 175.252 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 107.42 6.13 33.73 Favored Glycine 0 CA--C 1.536 1.377 0 C-N-CA 126.3 1.905 . . . . 0.0 114.418 -179.452 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 40.2 mtp180 -104.39 138.55 40.63 Favored 'General case' 0 N--CA 1.475 0.798 0 C-N-CA 126.073 1.749 . . . . 0.0 111.211 -175.139 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 8.1 p -77.91 141.9 38.75 Favored 'General case' 0 N--CA 1.47 0.55 0 C-N-CA 123.901 0.88 . . . . 0.0 112.39 175.961 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 92.8 m-85 -135.49 144.05 46.16 Favored 'General case' 0 N--CA 1.472 0.666 0 C-N-CA 125.437 1.495 . . . . 0.0 111.742 175.786 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -60.33 -40.98 92.56 Favored 'General case' 0 CA--C 1.543 0.688 0 N-CA-C 114.145 1.165 . . . . 0.0 114.145 -163.402 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 14.1 p30 -155.3 174.28 15.44 Favored 'General case' 0 CA--C 1.55 0.971 0 C-N-CA 126.282 1.833 . . . . 0.0 110.175 163.818 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 73.8 p -60.82 -25.98 66.99 Favored 'General case' 0 N--CA 1.48 1.037 0 N-CA-C 114.391 1.256 . . . . 0.0 114.391 -175.883 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 48.7 t -57.91 -62.25 1.94 Allowed 'General case' 0 CA--C 1.532 0.277 0 C-N-CA 124.923 1.289 . . . . 0.0 111.742 172.344 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 6.4 tt -59.91 -36.09 64.61 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.773 0 N-CA-C 112.289 0.477 . . . . 0.0 112.289 -177.336 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -58.26 -58.18 9.61 Favored 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 124.179 0.992 . . . . 0.0 111.518 174.589 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 65.2 mtm180 -64.17 -36.06 82.82 Favored 'General case' 0 N--CA 1.477 0.881 0 N-CA-C 113.271 0.841 . . . . 0.0 113.271 179.417 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 6.6 t -61.93 -42.97 99.71 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 124.009 0.924 . . . . 0.0 111.631 174.197 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 26.9 t-20 -69.37 -49.08 58.82 Favored 'General case' 0 CA--C 1.546 0.792 0 C-N-CA 124.851 1.26 . . . . 0.0 112.68 176.679 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 139.52 24.38 0.3 Allowed Glycine 0 CA--C 1.539 1.568 0 N-CA-C 116.16 1.224 . . . . 0.0 116.16 179.595 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 32.5 t -129.74 153.23 38.52 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.636 0 C-N-CA 126.373 1.869 . . . . 0.0 109.385 -177.927 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 68.9 m -134.41 170.48 15.67 Favored 'General case' 0 N--CA 1.47 0.575 0 C-N-CA 126.312 1.845 . . . . 0.0 112.099 -179.582 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 1.9 mp -118.01 3.34 7.28 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.1 0 C-N-CA 126.414 1.886 . . . . 0.0 111.443 -178.924 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 28.0 tptp -49.72 -61.88 1.87 Allowed 'General case' 0 N--CA 1.479 1.017 0 C-N-CA 127.044 2.137 . . . . 0.0 112.96 -178.904 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 13.4 t -156.29 129.75 8.22 Favored 'General case' 0 N--CA 1.466 0.328 0 C-N-CA 125.737 1.615 . . . . 0.0 110.054 -179.533 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 44.4 mt-10 -68.04 168.74 11.35 Favored 'General case' 0 CA--C 1.547 0.834 0 C-N-CA 124.857 1.263 . . . . 0.0 113.175 -179.444 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -69.12 -12.24 65.17 Favored Glycine 0 CA--C 1.54 1.642 0 N-CA-C 115.63 1.012 . . . . 0.0 115.63 -178.771 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 89.1 p -147.97 165.27 31.22 Favored 'General case' 0 N--CA 1.473 0.715 0 C-N-CA 126.069 1.748 . . . . 0.0 112.064 174.197 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 10.8 p -147.9 72.67 11.37 Favored Pre-proline 0 CA--C 1.551 1.017 0 C-N-CA 125.044 1.338 . . . . 0.0 112.052 178.589 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_endo -76.1 84.48 1.81 Allowed 'Trans proline' 0 CA--C 1.545 1.039 0 C-N-CA 123.811 3.007 . . . . 0.0 112.177 -179.551 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 2.0 m -74.27 43.12 0.17 Allowed 'General case' 0 N--CA 1.485 1.281 0 C-N-CA 126.701 2.0 . . . . 0.0 112.651 176.899 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 82.92 142.98 4.75 Favored Glycine 0 CA--C 1.537 1.422 0 C-N-CA 126.545 2.021 . . . . 0.0 113.034 -171.172 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 37.9 pt . . . . . 0 C--O 1.252 1.203 0 C-N-CA 127.447 2.299 . . . . 0.0 112.593 179.67 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 60.2 mtpt . . . . . 0 N--CA 1.494 1.738 0 CA-C-O 119.731 -0.176 . . . . 0.0 110.82 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 59.5 pttt 48.29 26.2 1.04 Allowed 'General case' 0 N--CA 1.49 1.568 0 C-N-CA 128.682 2.793 . . . . 0.0 117.27 179.236 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 25.0 t -77.63 124.13 35.5 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.853 0 C-N-CA 124.531 1.132 . . . . 0.0 111.049 -179.185 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 61.8 m -115.3 4.11 14.37 Favored 'General case' 0 CA--C 1.551 0.999 0 C-N-CA 126.351 1.861 . . . . 0.0 113.248 174.897 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . 54.41 30.85 13.46 Favored 'General case' 0 CA--C 1.551 1.002 0 C-N-CA 127.795 2.438 . . . . 0.0 114.408 -170.016 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 64.1 m -64.42 156.83 75.15 Favored Pre-proline 0 CA--C 1.55 0.958 0 C-N-CA 125.388 1.475 . . . . 0.0 113.387 177.321 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 95.3 Cg_endo -74.18 165.18 32.55 Favored 'Trans proline' 0 CA--C 1.542 0.894 0 C-N-CA 123.419 2.746 . . . . 0.0 113.522 -174.682 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 73.9 mmtt -78.87 -0.26 29.98 Favored 'General case' 0 N--CA 1.482 1.146 0 C-N-CA 126.28 1.832 . . . . 0.0 114.746 178.632 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 50.8 mm -56.86 157.97 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.766 0 C-N-CA 126.696 1.998 . . . . 0.0 111.146 170.536 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 51.5 tp -135.7 92.71 2.85 Favored 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 126.515 1.926 . . . . 0.0 108.583 -178.857 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . . . . . . . . . 53.5 tptt -139.2 80.77 22.43 Favored Pre-proline 0 N--CA 1.471 0.595 0 C-N-CA 125.327 1.451 . . . . 0.0 110.124 174.186 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 62.1 Cg_endo -68.92 146.92 66.99 Favored 'Trans proline' 0 CA--C 1.537 0.67 0 C-N-CA 121.919 1.746 . . . . 0.0 111.102 177.68 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 1.4 t -137.08 159.81 36.41 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.977 0 C-N-CA 124.933 1.293 . . . . 0.0 110.518 -176.589 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 29.9 p -85.83 -7.47 58.71 Favored 'General case' 0 CA--C 1.547 0.828 0 C-N-CA 125.85 1.66 . . . . 0.0 114.764 -174.487 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 56.86 -178.38 0.78 Allowed Glycine 0 CA--C 1.537 1.442 0 C-N-CA 127.136 2.303 . . . . 0.0 116.447 177.274 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 11.2 t -79.46 -36.36 38.93 Favored 'General case' 0 CA--C 1.543 0.692 0 C-N-CA 123.653 0.781 . . . . 0.0 112.166 170.732 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -75.63 -12.22 60.17 Favored 'General case' 0 CA--C 1.548 0.877 0 C-N-CA 125.441 1.497 . . . . 0.0 114.596 -177.857 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 92.26 7.44 63.79 Favored Glycine 0 CA--C 1.536 1.373 0 C-N-CA 125.745 1.641 . . . . 0.0 114.723 176.13 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' ARG . . . . . . . . . . . . . 38.3 mtt180 -95.84 -178.08 4.25 Favored 'General case' 0 N--CA 1.477 0.902 0 C-N-CA 126.353 1.861 . . . . 0.0 112.172 -177.046 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 47.3 m -122.24 128.19 50.84 Favored 'General case' 0 N--CA 1.476 0.85 0 C-N-CA 124.573 1.149 . . . . 0.0 110.505 179.32 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 56.4 m-85 -131.85 156.34 46.24 Favored 'General case' 0 N--CA 1.47 0.566 0 C-N-CA 125.491 1.517 . . . . 0.0 111.483 179.243 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.19 -43.83 85.7 Favored 'General case' 0 CA--C 1.544 0.748 0 N-CA-C 113.307 0.854 . . . . 0.0 113.307 -169.197 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 70.6 m-80 -139.66 175.9 9.18 Favored 'General case' 0 CA--C 1.544 0.729 0 C-N-CA 125.739 1.616 . . . . 0.0 111.557 171.184 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 42.4 t -61.34 -40.44 94.25 Favored 'General case' 0 N--CA 1.473 0.723 0 O-C-N 121.339 -0.851 . . . . 0.0 112.199 167.018 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 46.0 t -53.49 -57.42 10.76 Favored 'General case' 0 N--CA 1.467 0.398 0 C-N-CA 125.095 1.358 . . . . 0.0 112.795 -179.782 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 10.8 tp -59.97 -39.37 80.01 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.694 0 C-N-CA 122.791 0.436 . . . . 0.0 112.108 -179.099 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -68.76 -40.15 79.88 Favored 'General case' 0 CA--C 1.542 0.635 0 O-C-N 121.525 -0.735 . . . . 0.0 112.386 178.2 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 20.8 tpt180 -68.85 -35.66 77.2 Favored 'General case' 0 N--CA 1.472 0.654 0 C-N-CA 124.57 1.148 . . . . 0.0 112.691 176.107 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 47.8 t -59.45 -49.29 78.37 Favored 'General case' 0 CA--C 1.542 0.648 0 C-N-CA 125.059 1.344 . . . . 0.0 111.083 167.479 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' ASN . . . . . . . . . . . . . 25.9 t-20 -62.97 -45.35 92.83 Favored 'General case' 0 CA--C 1.546 0.796 0 C-N-CA 124.814 1.246 . . . . 0.0 113.324 -179.535 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 143.66 17.22 0.24 Allowed Glycine 0 CA--C 1.54 1.614 0 N-CA-C 117.191 1.636 . . . . 0.0 117.191 175.386 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 21.7 t -115.7 144.15 23.98 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.704 0 CA-C-N 119.882 1.841 . . . . 0.0 110.232 -176.27 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' SER . . . . . . . . . . . . . 23.0 t -91.11 126.84 36.32 Favored 'General case' 0 N--CA 1.472 0.65 0 C-N-CA 126.48 1.912 . . . . 0.0 111.525 176.041 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . 22.8 mm -116.65 -23.02 4.15 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.991 0 C-N-CA 125.08 1.352 . . . . 0.0 112.686 -174.655 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 26.5 mmmt -65.46 -21.08 66.61 Favored 'General case' 0 N--CA 1.48 1.027 0 C-N-CA 126.183 1.793 . . . . 0.0 113.72 173.548 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 1.7 t -76.11 9.55 2.44 Favored 'General case' 0 N--CA 1.476 0.868 0 C-N-CA 126.336 1.854 . . . . 0.0 114.982 -177.669 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 37.5 tp10 -48.85 -40.77 30.77 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 126.942 2.097 . . . . 0.0 115.179 -176.568 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -156.23 55.54 0.4 Allowed Glycine 0 CA--C 1.53 0.975 0 C-N-CA 124.098 0.856 . . . . 0.0 113.616 -174.77 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 43.0 m -64.05 -30.28 71.37 Favored 'General case' 0 N--CA 1.475 0.819 0 C-N-CA 124.618 1.167 . . . . 0.0 114.021 179.902 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' CYS . . . . . . . . . . . . . 38.2 t -149.29 83.07 6.69 Favored Pre-proline 0 CA--C 1.551 0.997 0 C-N-CA 125.448 1.499 . . . . 0.0 111.07 175.661 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 95.1 Cg_endo -75.9 170.4 20.22 Favored 'Trans proline' 0 CA--C 1.542 0.909 0 C-N-CA 123.423 2.748 . . . . 0.0 112.37 178.9 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 6.2 t -70.6 171.86 9.58 Favored 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 123.94 0.896 . . . . 0.0 112.456 170.716 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -92.66 -110.63 1.91 Allowed Glycine 0 CA--C 1.535 1.296 0 C-N-CA 125.486 1.517 . . . . 0.0 112.919 -179.135 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . . . . . . . . . 33.9 pt . . . . . 0 C--O 1.252 1.217 0 C-N-CA 125.874 1.67 . . . . 0.0 113.748 177.705 . . . . . . . . 0 0 . 1 stop_ save_